WO2009058314A1 - Enantioselective process for preparing a substituted alkanoic acid - Google Patents

Enantioselective process for preparing a substituted alkanoic acid Download PDF

Info

Publication number
WO2009058314A1
WO2009058314A1 PCT/US2008/012294 US2008012294W WO2009058314A1 WO 2009058314 A1 WO2009058314 A1 WO 2009058314A1 US 2008012294 W US2008012294 W US 2008012294W WO 2009058314 A1 WO2009058314 A1 WO 2009058314A1
Authority
WO
WIPO (PCT)
Prior art keywords
bophoz
cod
tetrahydro
phanephos
compound
Prior art date
Application number
PCT/US2008/012294
Other languages
French (fr)
Inventor
William A. Kinney
Christopher A. Teleha
Shyamali Ghosh
Bruce E. Maryanoff
Original Assignee
Janssen Pharmaceutica, N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica, N.V. filed Critical Janssen Pharmaceutica, N.V.
Priority to CA2703876A priority Critical patent/CA2703876A1/en
Priority to EP08846194.2A priority patent/EP2217569B1/en
Priority to ES08846194.2T priority patent/ES2474165T3/en
Priority to JP2010532054A priority patent/JP2011519340A/en
Publication of WO2009058314A1 publication Critical patent/WO2009058314A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/22—Organic complexes
    • B01J31/2204—Organic complexes the ligands containing oxygen or sulfur as complexing atoms
    • B01J31/2208—Oxygen, e.g. acetylacetonates
    • B01J31/2213—At least two complexing oxygen atoms present in an at least bidentate or bridging ligand
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B01J31/2404—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
    • B01J31/2409—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring with more than one complexing phosphine-P atom
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B01J31/2495—Ligands comprising a phosphine-P atom and one or more further complexing phosphorus atoms covered by groups B01J31/1845 - B01J31/1885, e.g. phosphine/phosphinate or phospholyl/phosphonate ligands
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/60—Reduction reactions, e.g. hydrogenation
    • B01J2231/64—Reductions in general of organic substrates, e.g. hydride reductions or hydrogenations
    • B01J2231/641—Hydrogenation of organic substrates, i.e. H2 or H-transfer hydrogenations, e.g. Fischer-Tropsch processes
    • B01J2231/645—Hydrogenation of organic substrates, i.e. H2 or H-transfer hydrogenations, e.g. Fischer-Tropsch processes of C=C or C-C triple bonds
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/02—Compositional aspects of complexes used, e.g. polynuclearity
    • B01J2531/0261—Complexes comprising ligands with non-tetrahedral chirality
    • B01J2531/0263—Planar chiral ligands, e.g. derived from donor-substituted paracyclophanes and metallocenes or from substituted arenes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/02—Compositional aspects of complexes used, e.g. polynuclearity
    • B01J2531/0261—Complexes comprising ligands with non-tetrahedral chirality
    • B01J2531/0266—Axially chiral or atropisomeric ligands, e.g. bulky biaryls such as donor-substituted binaphthalenes, e.g. "BINAP" or "BINOL"
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80—Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82—Metals of the platinum group
    • B01J2531/821—Ruthenium
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80—Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82—Metals of the platinum group
    • B01J2531/822—Rhodium
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80—Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82—Metals of the platinum group
    • B01J2531/827—Iridium

Definitions

  • the present invention is directed to a process for enantioselectively preparing substituted alkanoic acid integrin antagonist compounds. More particularly, the process is directed to an enantioselective synthesis of a substituted piperidine alkanoic acid dual ⁇ v ⁇ 3 / ⁇ v ⁇ 5 integrin antagonist.
  • the present invention is directed to an asymmetric hydrogenation process for preparing a compound of Formula (I) and Formula (11) and intermediates thereof:
  • R 2 , W, Z and q are as defined herein, wherein ⁇ represents a chiral carbon chain atom and, wherein ⁇ represents a chiral carbon ring member atom.
  • Formula (III) Formula (IV) were described in De Corte BL, Kinney WA, Liu L, Ghosh S, Brunner L, Hoekstra WJ, Santulli RJ, Tuman RW, Baker J, Burns C, Proost JC, Tounge BA, Damiano BP, Maryanoff BE, Johnson DL and Galemmo RA Jr., Bioorg. Med. Chem. Lett., 2004, 14, 5227; and, disclosed in United States Patent Publications US2004/0077684 and US2004/0224986, referred to therein as compound of Formula (I) and Formula (II), each of which is incorporated herein by reference in their entirety and for all purposes.
  • United States Patent Publication US2004/0077684 and U.S. Patent Publication US2004/0224986 describe racemic and stereoisomeric compounds of Formula (HI) and Formula (IV). Such compounds may be asymmetrically prepared using the instant process to provide stereoisomeric compounds representative of compounds of Formula (1) and Formula (II) of the present invention.
  • the present invention is further directed to an asymmetric hydrogenation process for preparing a compound of Formula (Ia) and intermediates thereof:
  • Formula (Ia) is referred to herein as (3S,3'S>4-[l-(3-5,6,7,8-tetrahydro-[l ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-3-( l ,2,3,4-tetrahydro-quinolin-3-yl)-butyric acid.
  • the compound of Formula (Ia) was referred to therein as an isomer Compound 19-4 of 1 ,2,3,4-tetrahydro- ⁇ -[[ 1 -[ 1 -oxo-3-(5,6,7,8-tetrahydro- 1 ,8- naphthyridin-2-yl)propyl]-4-piperidinyl]methyl]-3-quinolinepropanoic acid.
  • the compound of Formula (Ia) was synthesized as disclosed in Scheme E (alternatively, as in Scheme F) and Example 15 of same.
  • the process of the present invention is an efficient and stereoselective enantiomeric and diastereomeric hydrogenation which improves conversion and enantiomeric excess of the desired product by optimized reaction conditions for compounds of Formula (I), Formula (II) and Formula (Ia) and intermediates thereof by improving control of geometric isomer formation by stereoselective olefin reduction and substantially avoiding isomer separation using sequential chiral column chromatography.
  • the process of the present invention provides improved conversion and enantiomeric and diastereomeric excess of a desired enantiomer of a compound of Formula (I), Formula (II), Formula (Ia) and intermediates thereof.
  • W is selected from the group consisting of -C 0 . 6 alkyl(R ⁇ ), -C
  • Ri is selected from the group consisting of hydrogen, -N(R 4 ):, -N(R 4 )(R 5 ), -N(R 4 )(R 6 ),
  • . 8 alkyl(R 7 ) and -C( N-R 4 )-N(R 4 )-SO 2 -N(R 4 ) 2 ;
  • R 4 is selected from the group consisting of hydrogen and -C
  • R 6 is selected from the group consisting of -cycloalkyl(Rs), -heterocyclyl(Rs), -aryl(R 8 ) and -heteroaryl(Rs);
  • R 7 is one to two substituents independently selected from the group consisting of hydrogen, -C
  • R 8 is selected from the group consisting of hydrogen, -C
  • R 9 is selected from the group consisting of hydrogen, -C
  • R 2 is selected from the group consisting of -cycloalkyl(R 8 ), -heterocyclyl(R 8 ), -aryl(R 8 ) and -heteroaryl(R 8 ), wherein ⁇ represents a chiral carbon ring member atom of -cycloalkyl(R 8 ) and -heterocyclyl(Rs); q is 0, 1 , 2 or 3; and
  • Z is selected from the group consisting of hydroxy and -O-Ci.galkyl; comprising the steps of:
  • Scheme A Step 1 reacting a Compound Al, wherein PG is a C
  • Step 2. optionally converting Compound A2 or Compound A3, each wherein Z is hydroxy, to a Compound A2 or Compound A3, each wherein Z is -O-C
  • Step 4 when any of Compound A4, Compound A5, Compound A6 or Compound A7, wherein Z is hydroxy, are present, converting each such compound into the corresponding Compound A4, Compound A5, Compound A6 or Compound A7, wherein Z is -O-Ci-salkyl;
  • Step 5 separating each of Compound A2, Compound A3, Compound A4, Compound A5, Compound A6 and Compound A7, each wherein Z is -O-C
  • Step 7 reacting the compound selected from Compound A8 to Compound A13, each 15 wherein Z is -O-Cuealkyl, with a Compound A14 to provide a corresponding compound respectively selected from Compound A15 to a Compound A20 of Formula (I): A8, ( ⁇ R) isomer
  • Step 8 converting the compound selected from Compound A15 to Compound A20, each wherein Z is -0-C ⁇ -salkyl, to a corresponding Compound A15 to Compound A20, each wherein Z is hydroxy, of Formula (I).
  • the process described herein above optionally further comprises the step of:
  • Step 5a dehydrogenating Compound A7, wherein Z is -O-C ⁇ _salkyl and Ri is selected from -cycloalkyl(Rs) or -heterocyclyl(Rs), to Compound A3, wherein Z is -0-C ⁇ -salkyl and R: is selected from -aryl(R 8 ) or -heteroaryl(Rg), dehydrogenated from the corresponding -cycloalkyl(Rs) or -heterocyclyl(Rs), respectively, of Compound A7, and then repeating Step 3 using said
  • An Example 1 of the invention includes a process wherein the first hydrogen source is selected from gaseous hydrogen or an excess of formic acid.
  • An Example 2 of the invention includes a process wherein the first ligand-metal complex consists essentially of a first ligand conjugated with a first metal adduct, wherein the first ligand is selected from the group consisting of ( ⁇ )-PhanePhos,
  • An Example 3 of the invention includes a process wherein the first ligand metal complex is selected from the group consisting of (./?)-An-Phanephos/[Rh(COD)]BF 4 ,
  • An Example 4 of the invention includes a process wherein the first solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA, THF, toluene, EtOAc, 2- propanol and DMF and mixtures thereof.
  • An Example 5 of the invention includes a process wherein the optional first additive is selected from the group consisting of AcOH, Et 3 N, HBF 4 , HBF 4 etherate, HCI, HCI etherate, CF 3 COOH, CH 3 COOH and TsOH, and, when present, is in an amount up to about 1 .2 Eq.
  • An Example 6 of the invention includes a process wherein the first temperature is in a range of from about 25 0 C to about 90 0 C, or is in a range of from about 50 0 C to about 90 0 C.
  • An Example 7 of the invention includes a process wherein the first pressure is in a range of from about 3 bar to about 30 bar, or is in a range of from about 25 bar to about 30 bar.
  • An Example 8 of the invention includes a process wherein, when Z is hydroxy for
  • the first ligand is selected from the group consisting of ( ⁇ )-Xyl-PhanePhos, (Sj-Xyl-PhanePhos, ( ⁇ -PhanePhos, (Sj-PhanePhos, ( ⁇ -An-PhanePhos,
  • the first metal adduct is selected from the group consisting Of [Rh(COD) 2 ]BF 4 , [Rh(COD) 2 ]OTf, [Rh(ethylene) 2 CI] 2 , [Rh(ethylene) 2 (acac)], [Rh(CO) 2 (acac)] ;
  • the first temperature is in a range of from about 25 0 C to about 70 0 C
  • the first pressure is in a range of from about 3 bar to about 30 bar.
  • An Example 9 of the invention includes a process wherein, when Z is hydroxy for Compound Al, the first ligand-metal complex is selected from the group consisting of (/?>An-PhanePhos/[Rh(COD)]BF 4 , ( ⁇ )-Me-BoPhoz&[Ir(COD)CI] 2 , ( ⁇ j-MeOXyl-PhanePhos/[Rh(COD)]BF 4 , 0*?J-PhanePhos/[Rh(COD)]BF 4 , (#;-PhanePhos&[Rh(COD) 2 ]OTf, ( ⁇ -PhanePhos/[RuCI 2 (DMF) 2 ], (7?;-Tol-Binap/[RuCl(p-cymene)]Cl, (i?;-Xyl-PhanePhos&[Ru(COD)(CF 3 COO) 2 ] 2 , ( ⁇ -Xyl
  • An Example 10 of the invention includes a process wherein, when Z is hydroxy for Compound Al, the first ligand is selected from the group consisting of (7?)-Xyl-PhanePhos,
  • An Example 11 of the invention includes a process wherein, when Z is hydroxy for Compound Al, the first ligand is selected from the group consisting of ( ⁇ )-Xyl-PhanePhos,
  • An Example 12 of the invention includes a process wherein, when Z is hydroxy for Compound Al, the first ligand is selected from the group consisting of ( ⁇ )-Me-BoPhoz and
  • the first metal adduct is [Ir(COD)CI] 2
  • the first solvent is selected from the group consisting of THF, DCE and EtOAc
  • the first temperature is in a range of from about 65 0 C to about 70 0 C
  • the first pressure is in a range of from about 25 bar to about 30 bar.
  • An Example 13 of the invention includes a process wherein, when Z is hydroxy for Compound Al, the first ligand is selected from the group consisting of ( ⁇ )-PhanePhos , (S)-PhanePhos,
  • the first metal adduct is selected from the group consisting Of [Rh(COD) 2 ]BF 4 ,
  • the first solvent is MeOH
  • the first temperature is from about 25 0 C to about 60 0 C
  • the first pressure is from about 3 bar to about 30 bar.
  • An Example 14 of the invention includes a process wherein, when Z is hydroxy for Compound Al, the first ligand is selected from the group consisting of ( ⁇ )-PhanePhos , (5)-PhanePhos, ( ⁇ )-An-PhanePhos, (5)-An-PhanePhos, ( ⁇ )-Xyl-PhanePhos, (S)-Xyl-PhanePhos,
  • the first metal adduct is selected from the group consisting of [Ru(COD)(CF3COO)2] 2 ,
  • the first solvent is selected from the group consisting of MeOH, EtOH, IPA, DCE, THF, toluene, EtOAc, DMF and mixtures thereof
  • the optional first additive is selected from the group consisting of AcOH, CF3CO2H and
  • the first temperature is in a range of from about 40 0 C to about 70 0 C
  • the first pressure is in a range of from about 3 bar to about 30 bar.
  • An Example 15 of the invention includes a process wherein, when Z is hydroxy for Compound Al, the first ligand is ( ⁇ )-XylPhanePhos, the first metal adduct is selected from the group consisting Of [Ru(COD)(CF 3 COO ⁇ k, [Ru(COD)(CH 3 COO) 2 ], [Ru(CODXmCtHyIaIIyI) 2 ], [Ru(benzene)CI 2 ] 2 , [Ru(p-cymene)CI 2 ] 2 and [Ru(mesitylene)CI 2 ] 2 , the first solvent is selected from the group consisting of MeOH, DMF and mixtures thereof, the optional first additive is Et 3 N, the first temperature is in a range of from about 40 0 C to about 60 0 C, and the first pressure is in a range of from about 3 bar to about 30 bar.
  • the first solvent is selected from the group consisting of MeOH, DMF and mixtures thereof
  • the optional first additive is Et 3 N
  • An Example 16 of the invention includes a process wherein, when Z is hydroxy for Compound Al, the first ligand is (/?)-XylPhanePhos, the first metal adduct is selected from the group consisting of [Ru(COD)(CF 3 COO)2]2,
  • the first solvent is selected from the group consisting of MeOH, DMF and mixtures thereof, the optional first additive is AcOH, the first temperature is about 40 0 C, and the first pressure is about 10 bar.
  • An Example 17 of the invention includes a process wherein, when Z is hydroxy for Compound Al, the first ligand is (/?)-XylPhanePhos, the first metal adduct is selected from the group consisting of [Ru(COD)(CF 3 COO) 2 ] 2 ,
  • the first solvent is selected from the group consisting of MeOH, EtOH, IPA, DCE, THF, toluene, EtOAc, DMF and mixtures thereof, the first temperature is about 40 0 C, and the first pressure is about 10 bar.
  • An Example 18 of the invention includes a process wherein, when Z is hydroxy for Compound Al, the first ligand is (J?)-XylPhanePhos, the first metal adduct is [Ru(COD)(CF 3 COO) 2 J 2 , [Ru(COD)(CH 3 COO) 2 ] and [Ru(COD)(methylallyl) 2 ], the first solvent is MeOH, the first optional additive is AcOH, the first temperature is about 40 0 C, and the first pressure is about 10 bar.
  • An Example 19 of the invention includes a process wherein, when Z is hydroxy for Compound Al, the first ligand is (J?)-XylPhanePhos, the first metal adduct is [Ru(COD)(CF 3 COO) 2 J 2 , [Ru(COD)(CH 3 COO) 2 ] and [Ru(COD)(methylallyl) 2 ], the first solvent is MeOH, the first optional additive is AcOH, the first temperature is about 40 0 C
  • the first ligand is selected from the group consisting of (/?)-PhanePhos, (S)-PhanePhos, ( ⁇ )-An-PhanePhos, (S)-An-PhanePhos, ( ⁇ )-Xyl-PhanePhos, (S)-Xyl-PhanePhos, (tf)-MeOXyl-PhanePhos, (S)-MeOXyl-PhanePhos, ( ⁇ )-iPr-PhanePhos, (5)-iPr-PhanePhos, ( ⁇ ,/?)-Me-DuPhos, (S 1 S)-Me-DuPhOS, (tf)-P-Phos, (S)-P-Phos,
  • Example 20 of the invention includes a process wherein, when Z is
  • the first ligand-metal complex is selected from the group consisting of (tf)-An-Phanephos/[Rh(COD)]BF 4 ,
  • An Example 21 of the invention includes a process wherein, when Z is
  • the first ligand is selected from the group consisting of (/?)-PhanePhos, (S)-PhanePhos,
  • the first solvent is selected from the group consisting of MeOH, DCE, EtOH, toluene, EtOAc, 2-propanol, THF, and mixtures thereof
  • the optional first additive is selected from the group consisting of HBF4, AcOH and TsOH, and, when present, is in an amount up to about 1.2 Eq.
  • the first temperature is in a range of from about 50 0 C to about 90 0 C
  • the first pressure is in a range of from about 10 bar to about 30 bar.
  • An Example 22 of the invention includes a process wherein, when Z is
  • the first ligand is selected from the group consisting of ( ⁇ )-PhanePhos, (S)-PhanePhos, (S)-P-Phos, ( ⁇ )-Xyl-P-Phos, (S)-Xyl-P-Phos, W-Ph-PHOX, (tf)-iPr-PHOX, 0R)-Me-BoPhoz, (S)-Me-BoPhoz, CF 3 Ph-( ⁇ >Me-BoPhoz, CF 3 Ph-(Sj-Me-BoPhOZ, 3,4-diCl-Ph-(/?)-Me-BoPhoz,
  • the first metal adduct is selected from the group consisting of [Rh(COD) 2 ]BF 4 , [Rh(COD) 2 ]OTf, [Rh(COD)CI] 2 , [Rh(ethylene) 2 CI] 2 , [Rh(ethylene) 2
  • the first solvent is selected from the group consisting of DCE, THF, toluene, EtOAc, and mixtures thereof
  • the optional first additive is selected from the group consisting Of HBF 4 and TsOH, and, when present, is in an amount up to about 1.2 Eq.
  • the first temperature is in a range of from about 50 0 C to about 90 0 C
  • the first pressure is about 30 bar.
  • An Example 23 of the invention includes a process wherein, when Z is -O-C
  • the optional first additive is HBF 4 , and, when present, is in an amount up to about 1 .2
  • the first temperature is in a range of from about 50 0 C to about 90 0 C
  • the first pressure is from about 25 bar to about 30 bar.
  • An Example 24 of the invention includes a process wherein, when R 2 is selected from -aryl(Rs) and -heteroaryl(Rg) for Compound A2 or Compound A3, the second hydrogen source is gaseous hydrogen, the hydrogenation agent is selected from either 10% Pd/C or a second ligand-metal complex, wherein the second ligand-metal complex consists essentially of a second ligand and an
  • the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA, THF, toluene, EtOAc, 1 -BuOH and MTBE and mixtures thereof
  • the optional second additive is selected from the group consisting Of Et 3 N, ' 1Pr 2 -NH, Cy 2 NH, ( ⁇ )-Ph-ethy
  • An Example 25 of the invention includes a process wherein, when Z is hydroxy and R 2 is selected from -aryl(Rs) and -heteroaryl(R s ) for Compound A2 or Compound A3, the second ligand-metal complex is selected from the group consisting of (/?)-Me-BoPhoz&[Ir(COD)CI] 2 , ( ⁇ )-PhanePhos&[Ir(COD)CI] 2 , ( ⁇ )-P-Phos- &[lr(COD)CI] 2) (/?)-Xyl-Binap&[Ir(COD)CI] 2) (/?)-Xyl-PhanePhos&[ ] r(COD)CI]2, ( ⁇ )-Xyl-P-Phos&[Ir(COD)Cl] 2 , (5)-Me-BoPhoz&[lr(COD)CI] 2 , (S)-PhanePhos&[I
  • An Example 26 of the invention includes a process wherein, when Z is -O-Ci-salkyl and R 2 is selected from -aryl(Rs) and -heteroaryl(Rs) for Compound A2 or Compound A3, the second ligand-metal complex is selected from the group consisting of (/?)-Binol-( ⁇ )-Me-BoPhoz&[Ir(COD)CI] 2! (/?)-Et-BoPhoz&[Ir(COD)CI] 2!
  • An Example 27 of the invention includes a process wherein, when Z is hydroxy and R 2 is selected from -aryl(R 8 ) and -heteroaryl(R 8 ) for Compound A2 or Compound A3, the second ligand is selected from the group consisting of (7?)-P-Phos, (5)-P-Phos, Off)-Xyl-P-Phos, (5)-Xyl-P-Phos, (S)-ToI-P-PhOS, ( ⁇ )-Me-BoPhoz,
  • the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA,
  • the second temperature is in a range of from about 40 0 C to about 60 0 C
  • the second pressure is in a range of from about 3 bar to about 25 bar, or is in a range of from about I O bar to about 25 bar, or is in a range of from about 3 bar to about 10 bar.
  • An Example 28 of the invention includes a process wherein, when Z is -0-C ⁇ -salkyl and R ? is selected from -aryl(Rs) and -heteroaryl(R 8 ) for Compound A2 or Compound A3, the second ligand is selected from the group consisting of (7?)-Xyl-PhanePhos,
  • the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA, THF, toluene, EtOAc, 1 -BuOH and MTBE and mixtures thereof, the second temperature is in a range of from about 30 0 C to about 80 0 C, and the second pressure is in a range of from about 3 bar to about 25 bar.
  • An Example 29 of the invention includes a process wherein, when R 2 is selected from -aryl(Rs) and -heteroaryl(R 8 ) for Compound A2 or Compound A3, the second hydrogen source is gaseous hydrogen, 10% Pd/C is present in a range of weight % of from about 5% (w/vv) to about 20% (w/vv), the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA,
  • the optional second additive is selected from the group consisting Of Et 3 N, iPr 2 -NH, Cy 2 NH, (y?)-Ph-ethyl-NH 2 , (5>Ph-ethyl-NH 2 , Kl, KOH, K 2 CO 3 ,
  • the second temperature is in a range of from about 30 0 C to about 80 0 C, or is in a range of from about 40 0 C to about 60 0 C
  • the second pressure is in a range of from about 3 bar to about 25 bar, or is in a range of from about 10 bar to about 25 bar, or is in a range of from about 3 bar to about 10 bar.
  • An Example 30 of the invention includes a process wherein, when R 2 is selected from -aryl(Rs) and -heteroaryl(Rs) for Compound A2 or Compound A3, the second ligand-metal complex consists essentially of a second ligand and an
  • the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA,
  • the optional second additive is selected from the group consisting Of Et 3 N, JPr 2 -NH,
  • the second temperature is in a range of from about 30 0 C to about 80 0 C, or is in a range 15 of from about 40 0 C to about 60 0 C
  • the second pressure is in a range of from about 3 bar to about 25 bar, or is in a range of from about 10 bar to about 25 bar, or is in a range of from about 3 bar to about 10 bar.
  • An Example 31 of the invention includes a process wherein, when Z is hydroxy 0 and R 2 is selected from -aryl(R 8 ) and -heteroaryl(Rs) for Compound A2 or Compound A3, the second ligand is selected from the group consisting of ( ⁇ )-P-Phos, (5)-P-Phos, ( ⁇ )-Xyl-P-Phos, (5)-Xyl-P-Phos, (S)-Tol-P-Phos, (7?)-Me-BoPhoz, (5)-Me-BoPhoz, ( ⁇ )-Xyl-Binap and (S)-Xyl-Binap, 5 the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA,
  • Example 32 of the invention includes a process wherein, when Z is
  • -O-Ci-galkyl and R? is selected from -aryl(R 8 ) and -heteroaryl(Rg) for Compound A2 or
  • the second ligand is selected from the group consisting of (/?)-Xyl-PhanePhos, 5 ( ⁇ )-P-Phos, (S)-P-PhOS, ( ⁇ )-Xyl-P-Phos, (S)-Xyl-P-Phos, (S)-Tol-P-Phos,
  • the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA, THF, toluene, EtOAc, I -BuOH and MTBE and mixtures thereof
  • the second temperature is in a range of from about 30 0 C to about 80 0 C
  • 15 the second pressure is in a range of from about 3 bar to about 25 bar.
  • An Example 33 of the invention includes a process comprising the steps:
  • Step 1 reacting Compound Al, wherein Z is hydroxy and PG is a Ci. 4 alkoxycarbonyl protecting group such as Boc, with a first hydrogen source, a first ligand-metal complex consisting essentially of a first ligand conjugated with a first metal 0 adduct, in a first solvent in the presence of an optional first additive at a first elevated temperature and a first elevated pressure, to provide a substantially pure Compound A2 or a substantially pure Compound A3, wherein the first hydrogen source is selected from gaseous hydrogen or an excess of formic acid, the first ligand is selected from the group consisting of ( ⁇ )-Xyl-PhanePhos, 25 (S;-Xyl-PhanePhos, ( ⁇ -PhanePhos, (S;-PhanePhos, ( ⁇ -An-PhanePhos,
  • the first metal adduct is selected from the group consisting Of [Rh(COD) 2 ]BF 4 ,
  • the first solvent is selected from the group consisting of MeOH, EtOH, IPA, DCE, THF, toluene, EtOAc, DMF and mixtures thereof
  • the optional first additive is selected from the group consisting of AcOH, Et 3 N, HBF 4 ,
  • the first temperature is in a range of from about 25 0 C to about 70 0 C
  • the first pressure is in a range of from about 3 bar to about 30 bar;
  • Step 2 optionally converting Compound A2 or Compound A3, each wherein Z is hydroxy, to a Compound A2 or Compound A3, each wherein Z is -0-C ⁇ -salkyI;
  • Step 3 reacting Compound A2 or Compound A3, when R 2 is selected from -aryl(Rg) and -heteroaryl(Rs), with a second hydrogen source and a hydrogenation agent in a second solvent in the presence of an optional second additive at a second elevated temperature and a second elevated pressure to provide an isomeric mixture of a Compound A4, Compound A5, Compound A6 and Compound
  • R 2 is selected from -cycloalkyl(Rs) or -heterocyclyl(Rg), hydrogenated from the corresponding -aryl(Rg) and -heteroaryl(Rs), respectively, of Compound A2 or Compound A3, wherein the hydrogenation agent is selected from either 10% Pd/C or a second ligand-metal complex, wherein the second ligand-metal complex consists essentially of a second ligand and an [Ir(COD)CI] 2 metal adduct combined with iodine in an amount up to about 0.1 Eq., wherein 10% Pd/C is present in a range of weight % of from about 5% (w/w) to about 20% (vv/w), and wherein the second ligand is selected from the group consisting of ( ⁇ )-P-Phos,
  • the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA, THF, toluene, EtOAc and MTBE and mixtures thereof
  • the optional second additive is selected from the group consisting Of Et 3 N, iPr 2 -NH, Cy 2 NH, ( ⁇ )-Ph-ethyl-NH 2 , (S)-Ph-ethyl-NH 2 , KI, KOH, K 2 CO 3 , (/?/S)-camphorsulfonic acid and CH 3 COOH, and, when present, is in an amount up to about 1.2 E
  • An Example 34 of the invention includes a process comprising the steps: Step 1. reacting Compound Al, wherein Z is -O-C
  • C ⁇ _ 4 alkoxycarbonyl protecting group such as Boc
  • a first hydrogen source a first ligand-metal complex consisting essentially of a first ligand conjugated with a first metal adduct, in a first solvent in the presence of an optional first additive at a first elevated temperature and first elevated pressure, to provide a substantially pure Compound A2 or a substantially pure
  • Compound A3 wherein the first hydrogen source is selected from gaseous hydrogen or an excess of formic acid, the first ligand is selected from the group consisting of (7?)-PhanePhos, (5)-PhanePhos,
  • the first metal adduct is selected from the group consisting Of [Rh(COD) 2 ]BF 4 ,
  • the first solvent is selected from the group consisting of MeOH, EtOH, IPA, DCE, THF, toluene, EtOAc, DMF and mixtures thereof
  • I O the optional first additive is selected from the group consisting of AcOH, Et 3 N, HBF 4 ,
  • the first temperature is in a range of from about 25 0 C to about 70 0 C
  • the first pressure is in a range of from about 3 bar to about 30 bar
  • Step 2 reacting Compound A2 or Compound A3, when R 2 is selected from -aryl(R 8 ) and -heteroaryl(R 8 ) and Z is -O-C
  • the second ligand is selected from the group consisting of (/?)-P-Phos, (S)-P-Phos,
  • the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA, THF, toluene, EtOAc and MTBE and mixtures thereof
  • the optional second additive is selected from the group consisting Of Et 3 N, i Pr 2 -N H,
  • the second temperature is in a range of from about 40 0 C to about 60 0 C
  • the second pressure is in a range of from about 3 bar to about 25 bar, or is in a range of from about 10 bar to about 25 bar, or is in a range of from about 3 bar to about 10 bar.
  • An Example 35 of the invention includes a process comprising the steps: Step 1 . reacting Compound Al, wherein Z is hydroxy and PG is a C
  • An Example 36 of the invention includes a process wherein, when Z is hydroxy for Compound Al, the first ligand is selected from the group consisting of (7?)-Me-BoPhoz and (S)-Me-BoPhOZ, and the first metal adduct is [Ir(COD)CI] 2 .
  • An Example 37 of the invention includes a process comprising the steps: Step 1 . reacting Compound Al, wherein Z is -O-C
  • the first metal adduct is selected from the group consisting Of [Ir(COD)Cl]:
  • the first solvent is selected from the group consisting of THF, toluene, EtOAc and mixtures thereof, the first temperature is in a range of from about 25 0 C to about 70 0 C, and the first pressure is in a range of from about 3 bar to about 30 bar; and
  • Step 2 reacting Compound A2 or Compound A3, when R 2 is selected from -aryl(Rs) and -heteroaryl(Rs) and Z is -O-Ci.salkyl, by the direct addition of iodine in an amount up to about 0.1 Eq., and recharging the reaction mixture at an elevated second temperature and an elevated second pressure, wherein the second temperature is in a range of from about 30 0 C to about 80 0 C, and the second pressure is in a range of from about 3 bar to about 25 bar.
  • An Example 38 of the invention includes a process wherein, when Z is -O-Ci.salkyl for Compound Al, the first ligand is selected from the group consisting of (7?)-Me-BoPhoz and (.S)-Me-BoPhoz, and the first metal adduct is [Ir(COD)CI] 2 .
  • An Example 39 of the invention includes a Compound Al, wherein the compound is selected from the group consisting of:
  • the Greek letters “ ⁇ ” and “ ⁇ ” refer to targeted chiral carbon atoms in the compound of Formula (I) for enantioselective hydrogenation according to the process of the present invention.
  • the Greek letter “ ⁇ ” refers to asymmetric hydrogenation of the vinyl ester bond of Compound Al, for example, that is “ ⁇ ” to the chiral carbon atom, wherein the bond is hydrogenated to an R or S enantiomer, depending on the isomer of the ligand-metal complex used.
  • the Greek letter “ ⁇ ” refers to enantioselective hydrogenation of the R 2 aromatic ring system of Compound A2 or Compound A3 (wherein R 2 is selected from -aryl(Rs) and -heteroaryl(Rs)), for example, that is " ⁇ " to the chiral carbon atom, wherein the bond is hydrogenated to an isomeric mixture of Compound A4 (an ⁇ R, ⁇ R isomer), Compound A5 (an ⁇ R, ⁇ S isomer), Compound A6 (an ⁇ S, ⁇ S isomer) and Compound A7 (an ⁇ S, ⁇ R isomer) (each wherein R 2 is selected from -cycloalkyl(Rs) or
  • Scheme B represents a process for providing a desired isomer of a compound of Formula (I).
  • Step 1 reacting a Compound Bl with a first hydrogen source, a first ligand-metal complex consisting essentially of a first ligand conjugated with a first metal adduct, in a first solvent in the presence of an optional first additive at an elevated first temperature and an elevated first pressure to provide a substantially pure Compound B2 or a substantially pure Compound B3:
  • Step 2. optionally converting Compound B2 or Compound B3, each wherein Z is hydroxy, to a Compound B2 or a Compound B3, each wherein Z is -O-C
  • Step 3 optionally reacting Compound B3, when R 2 is selected from -aryl(Rs) and
  • Step 4 converting the isomeric mixture of Compound B4 and Compound B5, each when Z is hydroxy, to an isomeric mixture of Compound B4 and Compound B5, each wherein Z is -O-C
  • Step 5 separating each of Compound B4 and Compound B5, each wherein Z is -0-C ⁇ -salkyl, from the isomeric mixture;
  • Step 6 optionally dehydrogenating Compound B5, wherein Z is -O-Ci-salkyl and R 2 is selected from -cycloalkyl(Rs) or -heterocyclyl(Rg), to Compound B3, wherein Z is -O-Ci-salkyl and R 2 is selected from -aryl(R 8 ) or -heteroaryl(Rs), dehydrogenated from the corresponding -cycloalkyl(Rs) or -heterocyclyl(Rs), respectively, of Compound B5, and then repeating Step 3 using said
  • Step 7 deprotecting Compound B4, wherein Z is -O-Ci-salkyl, to provide a Compound B6:
  • Step 9 converting the Compound B7, wherein Z is -0-C ⁇ .salkyl, to a Compound B7, 5 wherein Z is hydroxy, of Formula (I).
  • An Example 40 of the invention includes a process wherein, Compound B2 is carried forward in place of Compound B3 to provide an (aR ⁇ R) isomer and an (aR, ⁇ S) isomer of Formula (1).
  • An Example 41 of the invention includes a process wherein, when Z is hydroxy I O for Compound Bl, the first ligand is selected from the group consisting of ( ⁇ )-Xyl-PhanePhos,
  • the first metal adduct is selected from the group consisting Of [Rh(COD) 2 ]BF 4 ,
  • the first temperature is in a range of from about 25 0 C to about 70 0 C
  • the first pressure is in a range of from about 3 bar to about 30 bar.
  • An Example 42 of the invention includes a process wherein, when Z is hydroxy 5 for Compound Bl, the first ligand-metal complex is selected from the group consisting of ( ⁇ >An-PhanePhos/[Rh(COD)]BF 4 , (/?)-Me-BoPhoz &[Ir(COD)CI] 2 , ( ⁇ j-MeOXyl-PhanePhos/[Rh(COD)]BF 4 , ( ⁇ >PhanePhos/[Rh(COD)]BF 4 , ( ⁇ -PhanePhos A[Rh(COD) 2 ]OTf, ( ⁇ ;-PhanePhos/[RuCl 2 (DMF) 2 ], ( ⁇ ;-Tol-Binap/[RuCI(p-cymene)]CI, ( ⁇ -Xyl-PhanePhos &[Ru(COD)(CF 3 COO) 2 ]2, ( ⁇ j-Xyl-Phane
  • the first metal adduct is selected from the group consisting Of [Rh(COD) 2 ]BF 4 , [Rh(COD) 2 ]OTf, [RU(CODKCF 3 COO) 2 J 2 , [Ru(COD)(methylallyl) 2 ], [Ru(benzene)CI 2 ] 2 and [Ir(COD)CI] 2 .
  • An Example 44 of the invention includes a process wherein, when Z is hydroxy for Compound Bl, the first ligand is selected from the group consisting of (7?)-Xyl-PhanePhos,
  • the first metal adduct is selected from the group consisting of [Rh(COD) 2 ]BF 4 ,
  • An Example 45 of the invention includes a process wherein, when Z is hydroxy for Compound Bl, the first ligand is selected from the group consisting of ( ⁇ )-Me-BoPhoz and
  • the first metal adduct is [Ir(COD)CI] 2
  • the first solvent is selected from the group consisting of THF, DCE and EtOAc
  • the first temperature is in a range of from about 65 0 C to about 70 0 C
  • the first pressure is in a range of from about 25 bar to about 30 bar.
  • An Example 46 of the invention includes a process wherein, when Z is hydroxy for Compound Bl, the first ligand is selected from the group consisting of (/?)-PhanePhos , (5)-PhanePhos,
  • the first metal adduct is selected from the group consisting of [Rh(COD) 2 ]BF 4 ,
  • An Example 47 of the invention includes a process wherein, when Z is hydroxy for Compound Bl, the first ligand is selected from the group consisting of (/?)-PhanePhos , (5)-PhanePhos, ( ⁇ )-An-PhanePhos, (5)-An-PhanePhos, (tf)-Xyl-PhanePhos, (S>Xyl-PhanePhos, (tf)-MeOXyl-PhanePhos, (S>MeOXyl-PhanePhos, (5)-iPr-PhanePhos and (/?)-iPr-PhanePhos, the first metal adduct is selected from the group consisting of [Ru(COD)(
  • the first temperature is in a range of from about 40 0 C to about 70 0 C
  • the first pressure is in a range of from about 3 bar to about 30 bar.
  • An Example 48 of the invention includes a process wherein, when Z is hydroxy for Compound Bl, the first ligand is (/?)-XylPhanePhos, the first metal adduct is selected from the group consisting Of [Ru(COD)(CF 3 COO) 2 J 2 ,
  • the first solvent is selected from the group consisting of MeOH, DMF and mixtures thereof
  • the optional first additive is Et 3 N
  • the first temperature is in a range of from about 40 0 C to about 60 0 C
  • the first pressure is in a range of from about 3 bar to about 30 bar.
  • An Example 49 of the invention includes a process wherein, when Z is hydroxy for Compound Bl, the first ligand is (/?)-XylPhanePhos, the first metal adduct is selected from the group consisting of [Ru(COD)(CF 3 COO) 2 ] 2 , [Ru(COD)(CH 3 COO) 2 ], [Ru(COD)(methylallyl) 2 ], [Ru(benzene)CI 2 ] 2 ,
  • the first solvent is selected from the group consisting of MeOH, DMF and mixtures thereof, the optional first additive is AcOH, the first temperature is about 40 0 C, and the first pressure is about 10 bar.
  • An Example 50 of the invention includes a process wherein, when Z is hydroxy for Compound Bl, the first ligand is (/?)-XylPhanePhos, the first metal adduct is selected from the group consisting of [Ru(COD)(CF 3 COO) 2 ]2, [Ru(COD)(CH 3 COO) 2 ], [Ru(COD)(methylallyl) 2 ], [Ru(benzene)CI 2 ] 2; [Ru(p-cymene)CI 2 ] 2 and [Ru(mesitylene)CI 2 ]2, the first solvent is selected from the group consisting of MeOH, EtOH, IPA, DCE, THF, toluene, EtOAc, DMF and mixtures thereof, the first temperature is about 40 0 C, and the first pressure is about 10 bar.
  • An Example 51 of the invention includes a process wherein, when Z is hydroxy for Compound Bl, the first ligand is (/?)-XylPhanePhos, the first metal adduct is [Ru(COD)(CF 3 COO) 2 J 2 , [Ru(COD)(CH 3 COO) 2 ] and
  • the first solvent is MeOH
  • the first optional additive is AcOH
  • the first temperature is about 40 0 C
  • the first pressure is about 10 bar.
  • An Example 52 of the invention includes a process wherein, when Z is -0-C ⁇ -salkyl for Compound BI, the first ligand is selected from the group consisting of (i?)-PhanePhos, (S)-PhanePhos, ( ⁇ )-An-PhanePhos, (S)-An-PhanePhos, ( ⁇ )-Xyl-PhanePhos, (S)-Xyl-PhanePhos,
  • the first metal adduct is selected from the group consisting Of [Ir(COD) 2 ]BAr F ,
  • the first solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA, THF, toluene, EtOAc, DMF, and mixtures thereof
  • the optional first additive is selected from the group consisting of Et 3 N, HBF 4 ,
  • the first temperature is in a range of from about 50 0 C to about 70 0 C
  • the first pressure is in a range of from about 10 bar to about 30 bar.
  • An Example 53 of the invention includes a process wherein, when Z is -0-C ⁇ -galkyl for Compound Bl, the first ligand-metal complex is selected from the group consisting of (/?)-An-Phanephos/[Rh(COD)]BF 4 , (/?)-Binol-(y?)-Me-BoPhoz &[Ir(C0D)CI] 2 , ( ⁇ )-Bn-BoPhoz A[Ir(COD)Cl] 2 , (tf)-iPr-BoPhoz A[Rh(COD) 2 ]OTf, ( ⁇ )-iPr-PHOX/[lr(COD)]BAr F , (7?)-iPr-PHOX/[Ir(COD)]BF 4 , (tf)-Me-BoPhoz A[Ir(COD)CI] 2 , ( ⁇ )-Me-BoPhoz
  • An Example 54 of the invention includes a process wherein, when Z is -O-Ci-galkyl for Compound Bl, the first ligand is selected from the group consisting of (/?)-PhanePhos, (S)-PhanePhos, (tf)-An-PhanePhos, ( ⁇ )-Xyl-PhanePhos, (S)-P-Phos, ( ⁇ )-Xyl-P-Phos, (S)-Xyl-P-Phos, W-Ph-PHOX, ( ⁇ )-iPr-PHOX, ( ⁇ )-Me-BoPhoz, (S)-Me-BoPhoz, CF 3 Ph-( ⁇ >Me-BoPhoz, CF 3 Ph-(S>Me-BoPhoz, 3,4-diCI-Ph-( ⁇ )-Me-BoPhoz, 3,4-diCI-Ph-(S)-Me-
  • the first metal adduct is selected from the group consisting of [Rh(COD) 2 ]BF 4 ,
  • the first solvent is selected from the group consisting of MeOH, DCE, EtOH, toluene,
  • the optional first additive is selected from the group consisting Of HBF 4 , AcOH and
  • the first temperature is in a range of from about 50 0 C to about 90 0 C
  • the first pressure is in a range of from about 10 bar to about 30 bar.
  • An Example 55 of the invention includes a process wherein, when Z is -O-C
  • the first solvent is selected from the group consisting of DCE, THF, toluene, EtOAc, and mixtures thereof
  • the optional first additive is selected from the group consisting Of HBF 4 and TsOH, and, when present, is in an amount up to about 1 .2 Eq.
  • the first temperature is in a range of from about 50 0 C to about 90 0 C
  • I O the first pressure is about 30 bar.
  • An Example 56 of the invention includes a process wherein, when Z is -O-C
  • the first metal adduct is selected from the group consisting Of [Ir(COD)CI] 2 and
  • the first solvent is selected from the group consisting of MeOH, DCE, THF, toluene,
  • the optional first additive is HBF 4 , and, when present, is in an amount up to about 1 .2
  • the first temperature is in a range of from about 50 0 C to about 90 0 C
  • the first pressure is from about 25 bar to about 30 bar.
  • An Example 57 of the invention includes a process wherein, when R 2 is selected 5 from -aryl(R 8 ) and -heteroaryl(R 8 ) for Compound B2 or Compound B3, the second hydrogen source is gaseous hydrogen, the hydrogenation agent is selected from either 10% Pd/C or a second ligand-metal complex, wherein the second ligand-metal complex consists essentially of a second ligand and an [Ir(COD)CI] 2 metal adduct combined with iodine in an amount up to about 0.1 Eq., wherein 10% Pd/C is present in a range of weight % of from about 5% weight/weight (w/vv) to about 20% (w/w), and wherein the second ligand is selected from the group consisting of (/?)-PhanePhos, (SyPhanePhos, ( ⁇ )-An-PhanePhos, (S)-An-PhanePhos, (/?)-Xyl-
  • An Example 58 of the invention includes a process wherein, when Z is hydroxy and R 2 is selected from -aryl(R 8 ) and -heteroaryl(Rg) for Compound B2 or Compound B3, the second ligand-metal complex is selected from the group consisting of (tf)-Me-BoPhoz A[Ir(COD)CI] 2 , (tf)-PhanePhos &[lr(COD)CI] 2l (tf)-P-Phos A[Ir(COD)Cl] 2 , (tf)-Xyl-Binap A[Ir(COD)CI] 2 , (tf)-Xyl-PhanePhos A[Ir(COD)CI] 2 , (tf)-Xyl-P-Phos A[Ir(COD)CI] 2 , (tf)-Xyl-P-Phos A[Ir(COD)CI] 2 , (S)
  • An Example 59 of the invention includes a process wherein, when Z is -0-C ⁇ -salkyl and R 2 is selected from -aryl(R 8 ) and -heteroaryl(Rs) for Compound B2 or Compound B3, the second ligand-metal complex is selected from the group consisting of ( ⁇ )-Binol-( ⁇ )-Me-BoPhoz A[Ir(COD)CI] 2 , (J?)-Et-BoPhoz A[Ir(COD)CI] 2 ,
  • An Example 60 of the invention includes a process wherein, when Z is hydroxy and R. 2 is selected from -aryl(Rs) and -heteroaryl(Rs) for Compound B2 or Compound B3, the second ligand is selected from the group consisting of (7?)-P-Phos, (5)-P-Phos, ( ⁇ )-Xyl-P-Phos, (S)-Xyl-P-Phos, (5)-Tol-P-Phos, (/?)-Me-BoPhoz,
  • the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA,
  • the second temperature is in a range of from about 40 0 C to about 60 0 C
  • the second pressure is in a range of from about 3 bar to about 25 bar, or is in a range of from about 10 bar to about 25 bar, or is in a range of from about 3 bar to about I O bar.
  • An Example 61 of the invention includes a process wherein, when Z is -O-Ci-galkyl and R 2 is selected from -aryl(Rs) and -heteroaryl(Rg) for Compound B2 or Compound B3, the second ligand is selected from the group consisting of (7?)-Xyl-PhanePhos,
  • the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA, THF, toluene, EtOAc, I -BuOH and MTBE and mixtures thereof, the second temperature is in a range of from about 30 0 C to about 80 0 C, and the second pressure is in a range of from about 3 bar to about 25 bar.
  • An Example 62 of the invention includes a process wherein, when R 2 is selected from -aryl(R 8 ) and -heteroaryl(R 8 ) for Compound B2 or Compound B3, the second hydrogen source is gaseous hydrogen, 10% Pd/C is present in a range of weight % of from about 5% (w/vv) to about 20% (w/w), the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA,
  • the optional second additive is selected from the group consisting of Et 3 N, iPr ⁇ -NH, Cy 2 NH, ( ⁇ )-Ph-ethyl-NH 2 , (S)-Ph-ethyl-NH 2 , Kl, KOH, K 2 CO 3 ,
  • the second temperature is in a range of from about 30 0 C to about 80 0 C, or is in a range of from about 40 0 C to about 60 0 C
  • the second pressure is in a range of from about 3 bar to about 25 bar, or is in a range of from about I O bar to about 25 bar, or is in a range of from about 3 bar to about 10 bar.
  • An Example 63 of the invention includes a process wherein, when R 2 is selected from -aryl(Rs) and -heteroaryl(Rs) for Compound B2 or Compound B3, the second ligand-metal complex consists essentially of a second ligand and an
  • the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA,
  • the optional second additive is selected from the group consisting Of Et 3 N, iPr 2 -NH,
  • the second temperature is in a range of from about 30 0 C to about 80 0 C, or is in a range of from about 40 0 C to about 60 0 C
  • the second pressure is in a range of from about 3 bar to about 25 bar, or is in a range of from about 10 bar to about 25 bar, or is in a range of from about 3 bar to about 10 bar.
  • An Example 64 of the invention includes a process wherein, when Z is hydroxy and R 2 is selected from -aryl(Rg) and -heteroaryl(Rs) for Compound B2 or Compound B3, the second ligand is selected from the group consisting of (/?)-P-Phos, (.S)-P-PhOS, ( ⁇ )-Xyl-P-Phos, (S)-Xyl-P-Phos, (S)-Tol-P-Phos, (tf)-Me-BoPhoz, (5)-Me-BoPhoz, (7?)-Xyl-Binap and (5)-Xyl-Binap, the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA,
  • Example 65 of the invention includes a process wherein, when Z is
  • R 2 is selected from -aryl(R 8 ) and -heteroaryl(R 8 ) for Compound B2 or
  • the second ligand is selected from the group consisting of ( ⁇ )-Xyl-PhanePhos, ( ⁇ )-P-Phos, (S)-P-PhOS, ( ⁇ )-Xyl-P-Phos, (S)-Xyl-P-Phos, (S)-ToI-P-PhOs,
  • the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA, THF, toluene, EtOAc, 1 -BuOH and MTBE and mixtures thereof
  • the second temperature is in a range of from about 30 0 C to about 80 0 C
  • the second pressure is in a range of from about 3 bar to about 25 bar.
  • An Example 66 of the invention includes a process comprising the steps:
  • Step 1 reacting Compound Bl, wherein Z is hydroxy, with a first hydrogen source, a first ligand-metal complex consisting essentially of a first ligand conjugated with a first metal adduct, in a first solvent in the presence of an optional first additive at a first elevated temperature and a first elevated pressure, to provide a substantially pure Compound B2 or a substantially pure Compound B3, wherein the first hydrogen source is selected from gaseous hydrogen or an excess of formic acid, the first ligand is selected from the group consisting of ( ⁇ )-Xyl-PhanePhos, (S; " -Xyl-PhanePhos, ( ⁇ >PhanePhos, (Sj-PhanePhos, (tf;-An-PhanePhos,
  • the first metal adduct is selected from the group consisting Of [Rh(COD) 2 ]BF 4 ,
  • the first solvent is selected from the group consisting of MeOH, EtOH, IPA, DCE, THF, toluene, EtOAc, DMF and mixtures thereof
  • the optional first additive is selected from the group consisting of AcOH, Et 3 N, HBF 4 ,
  • the first temperature is in a range of from about 25 0 C to about 70 0 C
  • the first pressure is in a range of from about 3 bar to about 30 bar;
  • Step 2 optionally converting Compound B2 or Compound B3, each wherein Z is hydroxy, to a Compound B2 or Compound B3, each wherein Z is I O -O-C t -galkyl;
  • Step 3 reacting Compound B2 or Compound B3, when R. 2 is selected from -aryl(Rg) and -heteroaryl(Rs), with a second hydrogen source and a hydrogenation agent in a second solvent in the presence of an optional second additive at a second elevated temperature and a second elevated pressure to provide an isomeric 15 mixture of a Compound B4 and Compound B5, wherein R? is selected from
  • the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA, 0 THF, toluene, EtOAc and MTBE and mixtures thereof
  • the optional second additive is selected from the group consisting Of Et 3 N, 1Pr 2 -NH, Cy 2 NH, ( ⁇ )-Ph-ethyl-NH 2 , (S)-Ph-ethyl-NH 2 , KI, KOH, K 2 CO 3 , (•/? ⁇ S)-camphorsulfonic acid and CH 3 COOH, and, when present, is in an amount up to about 1.2
  • An Example 67 of the invention includes a process comprising the steps: Step 1 . reacting Compound Bl, wherein Z is -O-Ci-salkyl, with a first hydrogen source, a first ligand-metal complex consisting essentially of a first ligand conjugated with a first metal adduct, in a first solvent in the presence of an optional first additive at a first elevated temperature and first elevated pressure, to provide a substantially pure Compound B2 or a substantially pure Compound B3, wherein the first hydrogen source is selected from gaseous hydrogen or an excess of formic acid, the first ligand is selected from the group consisting of (/?)-PhanePhos, (S)-PhanePhos, (7?)-An-PhanePhos, (S)-An-PhanePhos, (7?)-Xyl-PhanePhos, (5>Xyl-PhanePhos, (/?)-MeOXyl-PhanePhos, (5)-MeOX
  • the first metal adduct is selected from the group consisting of [Rh(COD) 2 ]BF 4 ,
  • the first solvent is selected from the group consisting of MeOH, EtOH, IPA, DCE, THF, toluene, EtOAc, DMF and mixtures thereof
  • the optional first additive is selected from the group consisting of AcOH, Et 3 N, HBF 4 ,
  • the first temperature is in a range of from about 25 0 C to about 70 0 C
  • the first pressure is in a range of from about 3 bar to about 30 bar; and Step 2.
  • the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA, 5 THF, toluene, EtOAc and MTBE and mixtures thereof
  • the optional second additive is selected from the group consisting of Et 3 N, 1Pr 2 -NH
  • the second temperature is in a range of from about 40 0 C to about 60 0 C
  • the second pressure is in a range of from about 3 bar to about 25 bar, or is in a range of from about 10 bar to about 25 bar, or is in a range of from about 3 bar to about 10 bar.
  • An Example 68 of the invention includes a process comprising the steps:
  • Step I reacting Compound Bl, wherein Z is hydroxy, with a first hydrogen source, a first ligand-metal complex consisting essentially of a first ligand conjugated with a first metal adduct, in a first solvent at a first temperature and a first pressure to provide a substantially pure Compound B2 or a substantially pure Compound B3, wherein 0 the first hydrogen source is selected from gaseous hydrogen or an excess of formic acid, the first ligand is selected from the group consisting of (7?)-Me-BoPhoz, (S)-Me-BoPhoz, ( ⁇ )-Xyl-P-Phos, (S)-XyI-P-PhOs, ( ⁇ )-P-Phos, (S)-P-Phos, (tf)-Et-BoPhoz, (S)-Et-BoPhOz, ( ⁇ )-iPr-BoPhoz, (S)-iPr-B
  • Step 2 reacting Compound B2 or Compound B3, when R 2 is selected from -aryl(Rs) 0 and -heteroaryl(R 8 ) and Z is hydroxy, by the direct addition of iodine in an amount up to about 0.1 Eq., and recharging the reaction mixture at an elevated second temperature and an elevated second pressure, wherein the second temperature is in a range of from about 30 0 C to about 80 0 C, and the second pressure is in a range of from about 3 bar to about 25 bar.
  • An Example 69 of the invention includes a process wherein, when Z is hydroxy for Compound Bl, the first ligand is selected from the group consisting of (7?)-Me-BoPhoz and
  • Example 70 of the invention includes a process comprising the steps:
  • Step 1 reacting Compound Bl, wherein Z is -O-C ⁇ _salkyl, with a first hydrogen source, a first ligand-metal complex consisting essentially of a first ligand conjugated with a first metal adduct, in a first solvent at a first temperature and a first pressure to provide a substantially pure Compound B2 or a substantially pure Compound B3, wherein the first hydrogen source is selected from gaseous hydrogen or an excess of formic acid, the first ligand is selected from the group consisting of (7?)-PhanePhos, (S)-PhanePhos, (7?)-An-PhanePhos, (S)-An-PhanePhos, ( ⁇ )-Xyl-PhanePhos, (S)-Xyl-PhanePhos, ( ⁇ )-MeOXyl-PhanePhos, (S>MeOXyI-PhanePhos, ( ⁇ )-iPr-PhanePhos, (S
  • the first metal adduct is selected from the group consisting Of [Ir(COD)CI] 2 ,
  • the first solvent is selected from the group consisting of THF, toluene, EtOAc and mixtures thereof, the first temperature is in a range of from about 25 0 C to about 70 0 C, and the first pressure is in a range of from about 3 bar to about 30 bar; and
  • Step 2 reacting Compound B2 or Compound B3, when R 2 is selected from -aryl(R 8 ) and -heteroaryl(Rs) and Z is -0-C ⁇ . ⁇ alkyl, by the direct addition of iodine in an amount up to about 0.1 Eq., and recharging the reaction mixture at an elevated second temperature and an elevated second pressure, wherein the second temperature is in a range of from about 30 0 C to about 80 0 C, and the second pressure is in a range of from about 3 bar to about 25 bar.
  • An Example 71 of the invention includes a process wherein, when Z is
  • the first ligand is selected from the group consisting of (/?)-Me-BoPhoz and
  • the present invention further relates to a process, as shown in Scheme C, for preparing a compound of Formula (Ia) and intermediates thereof:
  • Step 2 reacting Compound C3 with a second hydrogen source and a hydrogenation agent in a second solvent in the presence of an optional second additive at an elevated second temperature and an elevated second pressure to provide an isomeric mixture of a Compound C4 and Compound C5:
  • Step 3 separating each of Compound C4 and Compound C5 from the isomeric mixture; Step 4. optionally dehydrogenating Compound C5 to Compound C3, and then repeating Step 2 using said Compound C3 as the starting material; Step 5. deprotecting the Compound C4 to provide a Compound C6:
  • Step 6 reacting Compound C6 with a Compound C7 to provide a Compound C8:
  • Step 7 converting Compound C8 to the compound of Formula (Ia).
  • the present invention provides a process for making substantially pure Compound C2 comprising the step of: reacting a Compound Cl with a first hydrogen source, a first ligand-metal complex consisting essentially of a first ligand conjugated with a first metal adduct, in a first solvent in the presence of an optional first additive at an elevated first temperature and an elevated first pressure to provide a substantially pure Compound C2:
  • Example 72 of the invention includes a process wherein Compound C2 is carried forward in place of Compound C3 to provide an (aR ⁇ R) isomer and an ( ⁇ /?, ⁇ S) isomer of Formula (1).
  • An Example 73 of the invention includes a process for reacting Compound Cl to provide Compound C2, and a process for reacting Compound Cl to provide Compound
  • the first ligand is selected from the group consisting of (7?)-PhanePhos, (S)-PhanePhos, ( ⁇ )-An-PhanePhos, (S)-An-PhanePhos, (tf)-Xyl-PhanePhos, (S)-Xyl-PhanePhos, (7?)-MeOXyl-PhanePhos, (5)-MeOXyl-PhanePhos, (7?)-iPr-PhanePhos, (S)-iPr-PhanePhos, ( ⁇ .tf)-Me-DuPhos, (S 1 S)-Me-Du Phos, ( ⁇ )-P-Phos, (5)-P-Phos,
  • the first temperature is in a range of from about 50 0 C to about 70 0 C
  • the first pressure is in a range of from about I O bar to about 30 bar.
  • An Example 74 of the invention includes a process for reacting Compound Cl, wherein the first ligand-metal complex is selected from the group consisting of ( ⁇ )-An-Phanephos/[Rh(COD)]BF 4 , (y?)-Binol-(/?)-Me-BoPhoz &[Ir(COD)CI] 2 , (fl)-Bn-BoPhoz A[Ir(COD)CI] 2 , ( ⁇ )-iPr-BoPhoz &[Rh(COD) 2 ]OTf, (tf)-iPr-PHOX/[lr(COD)]BAr F , (/?)-iPr-PHOX/[lr(COD)]BF 4 , ( ⁇ )-Me-BoPhoz &[lr(COD)CI] 2 , (tf)-Me-BoPhoz &[Rh(CO) 2
  • the first solvent is selected from the group consisting of MeOH, DCE, EtOH, toluene, EtOAc, 2-propanol, THF, and mixtures thereof
  • the optional first additive is selected from the group consisting Of HBF 4 , AcOH and TsOH, and, when present, is in an amount up to about 1.2 Eq.
  • the first temperature is in a range of from about 50 0 C to about 90 0 C
  • the first pressure is in a range of from about 10 bar to about 30 bar.
  • An Example 76 of the invention includes a process for reacting Compound Cl, wherein the first ligand is selected from the group consisting of ( ⁇ )-PhanePhos, (S)-PhanePhos, (S)-P-Ph 0 S, ( ⁇ )-Xyl-P-Phos, (S)-Xyl-P-Phos, ( ⁇ -Ph-PHOX, (tf)-iPr-PHOX, (7?)-Me-BoPhoz, (S)-Me-BoPhoz, CF 3 Ph-(/?>Me-BoPhoz, CF 3 Ph-(S)-Me-BoPhOZ, 3,4-diCI-Ph-(7?)-Me-BoPhoz,
  • the first metal adduct is selected from the group consisting Of [Rh(COD) 2 ]BF 4 , [Rh(COD) 2 ]OTf, [Rh(COD) Cl] 2 , [Rh(ethylene) 2 CI] 2 , [Rh(ethylene)
  • the first solvent is selected from the group consisting of DCE, THF, toluene, EtOAc, and mixtures thereof
  • the optional first additive is selected from the group consisting Of HBF 4 and TsOH, and, when present, is in an amount up to about 1.2 Eq.
  • the first temperature is in a range of from about 50 0 C to about 90 0 C
  • the first pressure is about 30 bar.
  • An Example 77 of the invention includes a process for reacting Compound Cl, wherein the first ligand is selected from the group consisting of ( ⁇ )-Me-BoPhoz, (5)-Me-BoPhoz, 3,4-diCI-Ph-(tf)-Me-BoPhoz, 3,4-diCI-Ph-(5)-Me-BoPhoz, Xyl-(/?)-Me-BoPhoz, Xyl-(5)-Me-BoPhoz, (/?)-Bn-BoPhoz and (S)-Bn-BoPhoz
  • the first metal adduct is selected from the group consisting Of [Ir(COD)CI] 2 and [lr(COD) 2 ]BAr F
  • the first solvent is selected from the group consisting of MeOH, DCE, THF, toluene,
  • the optional first additive is HBF 4 , and, when present, is in an amount up to about 1 .2
  • the first temperature is in a range of from about 50 0 C to about 90 0 C
  • the first pressure is from about 25 bar to about 30 bar.
  • An Example 78 of the invention includes a process for reacting Compound C2 or Compound C3, wherein the second hydrogen source is gaseous hydrogen, the hydrogenation agent is selected from either 10% Pd/C or a second ligand-metal complex, wherein the second ligand-metal complex consists essentially of a second ligand and an
  • the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA, THF, toluene, EtOAc, 1 -BuOH and MTBE and mixtures thereof
  • the optional second additive is selected from the group consisting Of Et 3 N, JPr 2 -NH, Cy 2 NH, ( ⁇ )-Ph-e
  • An Example 79 of the invention includes a process for reacting Compound C2 or Compound C3, wherein the second ligand-metal complex is selected from the group consisting of ( ⁇ )-Binol-(/?)-Me-BoPhoz &[lr(COD)CI] 2 , ( ⁇ )-Et-BoPhoz &[lr(COD)CI] 2 , ( ⁇ )-iPr-BoPhoz &[Ir(COD)CI] 2 , ( ⁇ )-Me-BoPhoz A[Ir(COD)CI] 2 , ( ⁇ )-Ph-BoPhoz A[Ir(COD)CI] 2 , (tf)-Phenethyl-(S)-BoPhoz A[Ir(COD)CI] 2 , (tf)-Xyl-PhanePhos A[Ir(COD)CI] 2 , ( ⁇ )-Xyl
  • An Example 80 of the invention includes a process for reacting Compound C2 or
  • 10% Pd/C is present in a range of weight % of from about 5% (w/w) to about 20% (w/w), the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA,
  • the optional second additive is selected from the group consisting of Et 3 N, iPr 2 -NH,
  • the second temperature is in a range of from about 30 0 C to about 80 0 C, or is in a range of from about 40 0 C to about 60 0 C
  • the second pressure is in a range of from about 3 bar to about 25 bar, or is in a range of from about 10 bar to about 25 bar, or is in a range of from about 3 bar to about I O bar.
  • An Example 82 of the invention includes a process for reacting Compound C2 or Compound C3, wherein the second ligand-metal complex consists essentially of a second ligand and an
  • the second ligand is selected from the group consisting of (/?)-PhanePhos, (S)-PhanePhos, (/?)-An-PhanePhos, (S)-An-PhanePhos, (7?)-Xyl-PhanePhos, (S)-Xyl-PhanePhos, ( ⁇ )-MeOXyl-PhanePhos, (S)-MeOXyl-PhanePhos, (R, ⁇ )-Me-DuPhos, (S,S)-Me-DuPhos, ( ⁇ )-P-Phos, (S)-P-Phos, ( ⁇ )-Xyl-P-Phos, (S)-XyI-P-PhOS, ( ⁇ )-Tol-P-Phos, (S)-Tol-P-Phos, W-
  • the second temperature is in a range of from about 30 0 C to about 80 0 C, or is in a range of from about 40 0 C to about 60 0 C
  • the second pressure is in a range of from about 3 bar to about 25 bar, or is in a range of from about 10 bar to about 25 bar, or is in a range of from about 3 bar to about 10 bar.
  • An Example 83 of the invention includes a process for reacting Compound C2 or
  • Compound C3 wherein the second ligand is selected from the group consisting of ( ⁇ )-Xyl-PhanePhos, (tf)-P-Phos, (S)-P-PhOS, ( ⁇ )-Xyl-P-Phos, (5)-Xyl-P-Phos, (S)-Tol-P-Phos,
  • the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA,
  • the second temperature is in a range of from about 30 0 C to about 80 0 C
  • the second pressure is in a range of from about 3 bar to about 25 bar.
  • An Example 84 of the invention includes a process comprising the steps:
  • Step I reacting Compound Cl with a first hydrogen source, a first ligand-metal complex consisting essentially of a first ligand conjugated with a first metal adduct, in a first solvent in the presence of an optional first additive at a first elevated temperature and first elevated pressure, to provide a substantially pure Compound C2 or a substantially pure Compound C3, wherein the first hydrogen source is selected from gaseous hydrogen or an excess of formic acid; the first ligand is selected from the group consisting of (7?)-PhanePhos, (S)-PhanePhos, ( ⁇ )-An-PhanePhos, (S)-An-PhanePhos, ( ⁇ )-Xyl-PhanePhos, (S)-Xyl-PhanePhos,
  • the first metal adduct is selected from the group consisting Of [Rh(COD) 2 ]BF 4 , [Rh(COD) 2 ]OTf, [Rh(ethylene) 2 CI] 2 , [Rh(ethylene) 2 (acac)], [Rh(CO) 2 (acac)] s [Rh(COD)(acac)], [Ru(COD)(CF 3 COO) 2 ] 2 , [Ru(COD)(methylallyl) 2 ],
  • the first solvent is selected from the group consisting of MeOH, EtOH, IPA, DCE, THF, 5 toluene, EtOAc, DMF and mixtures thereof
  • the optional first additive is selected from the group consisting of AcOH, Et 3 N, HBF 4 ,
  • the first temperature is in a range of from about 25 0 C to about 70 0 C
  • I O the first pressure is in a range of from about 3 bar to about 30 bar;
  • Step 2 reacting Compound C3 with a second hydrogen source and a hydrogenation agent in a second solvent in the presence of an optional second additive at a second elevated temperature and a second elevated pressure to provide an isomeric mixture of Compound C4 and Compound C5, wherein 15 the second hydrogen source is gaseous hydrogen, the hydrogenation agent is selected from either 10% Pd/C or a second ligand-metal complex, wherein the second ligand-metal complex consists essentially of a second ligand and an
  • the second ligand is selected from the group consisting of (7?)-P-Phos,
  • the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA,
  • the optional second additive is selected from the group consisting Of Et 3 N, iPr 2 -NH, Cy 2 NH, ( ⁇ )-Ph-ethyl-NH 2 , (S)-Ph-ethyl-NH 2 , KI, KOH, K 2 CO 3 , (/?/S)-camphorsulfonic acid and CH 3 COOH, and, when present, is in an amount up to about 1 .2 Eq.
  • the second temperature is in a range of from about 40 0 C to about 60 0 C
  • the second pressure is in a range of from about 3 bar to about 25 bar, or is in a range of from about I O bar to about 25 bar, or is in a range of from about 3 bar to about 10 bar.
  • An Example 85 of the invention includes a process comprising the steps:
  • Step 1 reacting Compound Cl with a first hydrogen source, a first ligand-metal complex consisting essentially of a first ligand conjugated with a first metal adduct, in a first solvent at a first temperature and a first pressure to provide a substantially pure Compound C2 or a substantially pure Compound C3, wherein the first hydrogen source is selected from gaseous hydrogen or an excess of formic acid, the first ligand is selected from the group consisting of (7?)-PhanePhos, (S)-PhanePhos, (/?)-An-PhanePhos, (5)-An-PhanePhos, (tf)-Xyl-PhanePhos, (S)-Xyl-PhanePhos,
  • the first metal adduct is selected from the group consisting of [Ir(COD)CI] 2 , [Ir(COD) 2 ]BF 4 and [lr(COD) 2 ]BAr F ,
  • the first solvent is selected from the group consisting of THF, toluene, EtOAc and mixtures thereof, the first temperature is in a range of from about 25 0 C to about 70 0 C, and the first pressure is in a range of from about 3 bar to about 30 bar; and
  • Step 2 reacting Compound C2 or Compound C3 by the direct addition of iodine in an amount up to about 0.1 Eq. and recharging the reaction mixture at an elevated second temperature and an elevated second pressure, wherein the second temperature is in a range of from about 30 0 C to about 80 0 C, and the second pressure is in a range of from about 3 bar to about 25 bar.
  • An Example 86 of the invention includes a process for reacting Compound Cl, wherein the first ligand is selected from the group consisting of (/?)-Me-BoPhoz and
  • An Example 87 of the invention includes a process, according to Scheme C, for preparing a compound of Formula (Ia) and intermediates thereof, wherein the first hydrogen source is gaseous hydrogen; the first ligand-metal complex is ( ⁇ )-Me-BoPhoz A[Ir(COD)CI] 2 ; the first solvent is DCE; 0 the first temperature is about 70 0 C; the first pressure is about 25 bar; the second hydrogen source is gaseous hydrogen; and the hydrogenation agent is selected from either 10% Pd/C or a second ligand-metal complex, wherein, when the hydrogenation agent is a second ligand-metal complex selected from 5 (/?)-Me-BoPhoz &[lr(COD)CI]? combined with iodine in an amount of about 0.1
  • the second solvent is EtOAc; the second temperature is about 50 0 C; and the second pressure is about 25 bar; and, wherein, when the hydrogenation agent is selected from 10% Pd/C in an amount of about 10% (w/vv); the second solvent is IPA; the optional second additive is Et 3 N in an amount of about 0.75 Eq.; the second temperature is about 40 0 C; and, the second pressure is about 10 bar.
  • the present invention further relates to an alternative process, as shown in Scheme D, for preparing a compound of Formula (Ia) and intermediates thereof, comprising the steps of:
  • Step 1 reacting a Compound Dl with a first hydrogen source, a first ligand-metal complex consisting essentially of a first ligand conjugated with a first metal adduct, in a first solvent in the presence of an optional first additive at an elevated first temperature and an elevated first pressure to provide a substantially pure Compound D3:
  • Step 2 optionally converting the Compound D3 hydroxy group to the Compound C3 -O-C
  • Step 3 reacting Compound D3 with a second hydrogen source and a hydrogenation agent in a second solvent in the presence of an optional second additive at an elevated second temperature and an elevated second pressure to provide an isomeric mixture of a Compound D4 and Compound D5:
  • the present invention provides a process for making substantially pure Compound D2 comprising the step of: reacting a Compound Dl with a first hydrogen source, a first ligand-metal complex consisting essentially of a first ligand conjugated with a first metal adduct, in a first solvent in the presence of an optional first additive at an elevated first temperature and an elevated first pressure to provide a substantially pure Compound D2:
  • An Example 88 of the invention includes a process wherein Compound D2 is carried forward in place of Compound D3 to provide an (a.R, ⁇ 5R) isomer and an ( ⁇ i?, ⁇ S) isomer of Formula (I).
  • An Example 89 of the invention includes a process for reacting Compound Dl to provide Compound D2, and a process for reacting Compound Dl to provide Compound D3, both processes as desribed herein above, wherein the first ligand is selected from the group consisting of (/?)-Xyl-PhanePhos,
  • the first metal adduct is selected from the group consisting Of [Rh(COD) 2 ]BF 4 ,
  • the first temperature is in a range of from about 25 0 C to about 70 0 C
  • the first pressure is in a range of from about 3 bar to about 30 bar.
  • An Example 90 of the invention includes a process for reacting Compound Dl, wherein the first ligand-metal complex is selected from the group consisting of ( ⁇ -An-PhanePhos/[Rh(COD)]BF4, (tf)-Me-BoPhoz &[lr(COD)CI] 2 , ( ⁇ ;-MeOXyl-PhanePhos/[Rh(COD)]BF 4 , ( ⁇ ;-PhanePhos/[Rh(COD)]BF 4 , ( ⁇ ;-PhanePhos &[Rh(COD) 2 ]OTf s ( ⁇ -PhanePhos/[RuCl 2 (DMF) 2 ], ( ⁇ -Tol-Binap/[RuCI(p-cymene)]CI, ( ⁇ -Xyl-PhanePhos &[Ru(COD)(CF 3 COO) 2 ]2, ( ⁇ -Xyl-PhanePhos &[
  • the first metal adduct is selected from the group consisting Of [Rh(COD) 2 ]BF 4 , [Rh(COD) 2 ]OTf, [Ru(COD)(CF 3 COO) 2 ] 2 , [Ru(COD)(methylallyl) 2 ], [Ru(benzene)CI 2 ] 2 and [Ir(COD)CI] 2 .
  • An Example 92 of the invention includes a process for reacting Compound Dl, wherein the first ligand is selected from the group consisting of (7?)-Xyl-PhanePhos,
  • An Example 93 of the invention includes a process for reacting Compound Dl, wherein the first ligand is selected from the group consisting of ( ⁇ )-Me-BoPhoz and (5)-Me-BoPhoz, the first metal adduct is [Ir(COD)CI] 2 , the first solvent is selected from the group consisting of THF, DCE and EtOAc, the first temperature is in a range of from about 65 0 C to about 70 0 C, and the first pressure is in a range of from about 25 bar to about 30 bar.
  • the first ligand is selected from the group consisting of ( ⁇ )-Me-BoPhoz and (5)-Me-BoPhoz
  • the first metal adduct is [Ir(COD)CI] 2
  • the first solvent is selected from the group consisting of THF, DCE and EtOAc
  • the first temperature is in a range of from about 65 0 C to about 70 0 C
  • the first pressure
  • An Example 94 of the invention includes a process for reacting Compound Dl, wherein the first ligand is selected from the group consisting of (7?)-PhanePhos , (5)-PhanePhos,
  • the first metal adduct is selected from the group consisting Of [Rh(COD) 2 ]BF 4 , [Rh(COD) 2 ]OTf, [Rh(ethylene) 2 CI] 2 , [Rh(ethylene) 2 (acac)], [Rh(CO) 2 (acac)],
  • Example 95 of the invention includes a process for reacting Compound Dl, wherein the first ligand is selected from the group consisting of (7?)-PhanePhos , (S)-PhanePhos,
  • the first metal adduct is selected from the group consisting of [Ru(COD)(CF3COO) 2 ] 2 ,
  • the first solvent is selected from the group consisting of MeOH, EtOH, IPA, DCE, THF, toluene, EtOAc, DMF and mixtures thereof
  • the optional first additive is selected from the group consisting of AcOH, CF 3 CO 2 H and
  • the first temperature is in a range of from about 40 0 C to about 70 0 C
  • I 5 the first pressure is in a range of from about 3 bar to about 30 bar.
  • An Example 96 of the invention includes a process for reacting Compound Dl, wherein the first ligand is ( ⁇ )-XylPhanePhos, the first metal adduct is selected from the group consisting of [Ru(COD)(CF 3 COO) 2 ]T, 0 [Ru(COD)(CH 3 COO) 2 ], [Ru(COD)(methylallyl) 2 ], [Ru(benzene)CI 2 ] 2 ,
  • the first solvent is selected from the group consisting of MeOH, DMF and mixtures thereof
  • the optional first additive is Et 3 N
  • 5 the first temperature is in a range of from about 40 0 C to about 60 0 C
  • the first pressure is in a range of from about 3 bar to about 30 bar.
  • An Example 97 of the invention includes a process for reacting Compound Dl, wherein the first ligand is (tf)-XylPhanePhos, the first metal adduct is selected from the group consisting of [Ru(COD)(CF 3 COO) 2 I 2 , [Ru(COD)(CH 3 COO) 2 ], [Ru(COD)(methylallyl) 2 ], [Ru(benzene)Cl 2 ] 2; [Ru(p-cymene)Cl2]2 and [Ru(mesitylene)Cl 2 ]2, the first solvent is selected from the group consisting of MeOH, DMF and mixtures 5 thereof, the optional first additive is AcOH, the first temperature is about 40 0 C, and the first pressure is about 10 bar.
  • the first solvent is selected from the group consisting of MeOH, DMF and mixtures 5 thereof
  • the optional first additive is AcOH
  • the first temperature is about 40 0 C
  • the first pressure is about 10 bar.
  • An Example 98 of the invention includes a process for reacting Compound Dl, I O wherein the first ligand is (/?)-XylPhanePhos, the first metal adduct is selected from the group consisting of [Ru(COD)(CF3COO) 2 ] 2 ,
  • the first solvent is selected from the group consisting of MeOH, EtOH, IPA, DCE, THF, toluene, EtOAc, DMF and mixtures thereof, the first temperature is about 40 0 C and the first pressure is about 10 bar.
  • An Example 99 of the invention includes a process for reacting Compound Dl, 0 wherein the first ligand is ( ⁇ )-XylPhanePhos, the first metal adduct is [Ru(COD)(CF 3 COO) 2 ] 2; [Ru(COD)(CH 3 COO) 2 ] and
  • An Example 100 of the invention includes a process for reacting Compound D2 or Compound D3, wherein the second hydrogen source is gaseous hydrogen, the hydrogenation agent is selected from either 10% Pd/C or a second ligand-metal complex, wherein the second ligand-metal complex consists essentially of a second ligand and an [lr(COD)CI] 2 metal adduct combined with iodine in an amount up to about 0.1 Eq., wherein 10% Pd/C is present in a range of weight % of from about 5% weight/weight (w/w) to about 20% (w/w), and wherein the second ligand is selected from the group consisting of (7?)-PhanePhos, (S)-PhanePhos, ( ⁇ )-An-PhanePhos, (S
  • the optional second additive is selected from the group consisting Of Et 3 N, JPr 2 -NH,
  • the second temperature is in a range of from about 30 0 C to about 80 0 C, or is in a range of from about 40 0 C to about 60 0 C
  • the second pressure is in a range of from about 3 bar to about 25 bar, or is in a range of from about 10 bar to about 25 bar, or is in a range of from about 3 bar to about 10 bar.
  • An Example 101 of the invention includes a process for reacting Compound D2 or Compound D3, wherein the second ligand-metal complex is selected from the group consisting of (tf)-Me-BoPhoz &[lr(COD)CI] 2 , (tf)-PhanePhos &[Ir(COD)Cl] 2 , (Zf)-P-Phos &[lr(COD)CI] 2) (tf)-Xyl-Binap &[Ir(COD)CI] 2 , ( ⁇ )-Xyl-PhanePhos &[Ir(COD)CI] 2 , (tf)-Xyl-P-Phos A[Ir(COD)CI] 2 , (S)-Me-BoPhoz &[Ir(COD)CI] 2 , (S)-PhanePhos &[Ir(COD)CI] 2 , (5)-P-Phos &
  • An Example 102 of the invention includes a process for reacting Compound D2 or Compound D3, wherein the second ligand is selected from the group consisting of ( ⁇ )-P-Phos, (5)-P-Phos, ( ⁇ )-Xyl-P-Phos, (S)-Xyl-P-Phos, (S)-Tol-P-Phos, ( ⁇ )-Me-BoPhoz, (S)-Me-BoPhOZ, ( ⁇ )-Xyl-Binap and (S)-Xyl-Binap, the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA,
  • An Example 103 of the invention includes a process for reacting Compound D2 or Compound D3, wherein the second hydrogen source is gaseous hydrogen,
  • 10% Pd/C is present in a range of weight % of from about 5% (w/w) to about 20% (w/w), the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA,
  • the optional second additive is selected from the group consisting Of Et 3 N, JPr 2 -NH,
  • the second temperature is in a range of from about 30 0 C to about 80 0 C, or is in a range of from about 40 0 C to about 60 0 C
  • the second pressure is in a range of from about 3 bar to about 25 bar, or is in a range of from about I O bar to about 25 bar, or is in a range of from about 3 bar to about 10 bar.
  • An Example 104 of the invention includes a process for reacting Compound D2 or Compound D3, wherein the second ligand-metal complex consists essentially of a second ligand and an
  • the second temperature is in a range of from about 30 0 C to about 80 0 C, or is in a range of from about 40 0 C to about 60 0 C
  • the second pressure is in a range of from about 3 bar to about 25 bar, or is in a range of from about I O bar to about 25 bar, or is in a range of from about 3 bar to about 10 bar.
  • An Example 105 of the invention includes a process for reacting Compound D2 or Compound D3, wherein the second ligand is selected from the group consisting of (/?)-P-Phos, (S)-P-Phos, ( ⁇ )-Xyl-P-Phos, (S)-Xyl-P-Phos, (S)-Tol-P-Phos, (fl)-Me-BoPhoz,
  • the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA,
  • the second temperature is in a range of from about 40 0 C to about 60 0 C
  • the second pressure is in a range of from about 3 bar to about 25 bar, or is in a range of from about I O bar to about 25 bar, or is in a range of from about 3 bar to about 10 bar.
  • An Example 106 of the invention includes a process comprising the steps: Step 1. reacting Compound Dl with a first hydrogen source, a first ligand-metal complex consisting essentially of a first ligand conjugated with a first metal adduct, in a first solvent in the presence of an optional first additive at a first elevated temperature and a first elevated pressure, to provide a substantially pure Compound D2 or a substantially pure Compound D3, wherein the first hydrogen source is selected from gaseous hydrogen or an excess of formic acid, the first ligand is selected from the group consisting of (/?)-Xyl-PhanePhos,
  • the first metal adduct is selected from the group consisting of [Rh(COD) 2 ]BF 4 , [Rh(COD) 2 ]OTf, [Ru(COD)(CF 3 COO) 2 ]2, [Ru(COD)(methylallyl) 2 ], [Ru(benzene)Cl 2 ] 2 and [Ir(COD)CI] 2
  • the first solvent is selected from the group consisting of MeOH, EtOH, IPA, DCE, THF, toluene, EtOA
  • Step 3 reacting Compound D3 with a second hydrogen source and a hydrogenation agent in a second solvent in the presence of an optional second additive at an elevated second temperature and an elevated second pressure to provide an isomeric mixture of a Compound D4 and Compound D5, wherein the second hydrogen source is gaseous hydrogen, the hydrogenation agent is selected from either 10% Pd/C or a second ligand-metal complex, wherein the second ligand-metal complex consists essentially of a second ligand and an [Ir(COD)CI] 2 metal adduct combined with iodine in an amount up to about 0.1 Eq., wherein 10% Pd/C is present in a range of weight % of from about 5% (w/w) to about 20% (w/w), and wherein the second ligand is selected from the group consisting of ( ⁇ )-P-Phos,
  • the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA, THF, toluene, EtOAc and MTBE and mixtures thereof
  • the optional second additive is selected from the group consisting Of Et 3 N, iPr 2 -NH, Cy 2 NH, ( ⁇ )-Ph-ethyl-NH 2 , (5>Ph-ethy
  • An Example 107 of the invention includes a process comprising the steps: Step 1. reacting Compound Dl with a first hydrogen source, a first ligand-metal complex consisting essentially of a first ligand conjugated with a first metal adduct, in a first solvent in the presence of an optional first additive at a first elevated temperature and a first elevated pressure, to provide a substantially pure Compound D2 or a substantially pure Compound D3, wherein the first hydrogen source is selected from gaseous hydrogen or an excess of formic acid, the first ligand is selected from the group consisting of ( ⁇ )-Me-BoPhoz, (S)-Me-BoPhoz, ( ⁇ )-Xyl-P-Phos, (S)-Xyl-P-Phos, ( ⁇ )-P-Phos, (S)-P-Phos, (7?)-Et-BoPhoz, (S)-Et-BoPhOZ, ( ⁇ )-iPr-BoPh
  • Step 2 optionally converting the Compound D2 or Compound D3 hydroxy group to the Compound C2 or Compound C3 -O-C
  • Step 3 reacting Compound D3 by the direct addition of iodine in an amount up to about 0.1 Eq., and recharging the reaction mixture at an elevated second temperature and an elevated second pressure, wherein the second temperature is in a range of from about 30 0 C to about 80 0 C, and the second pressure is in a range of from about 3 bar to about 25 bar.
  • An Example 108 of the invention includes a process for reacting Compound Dl, wherein the first ligand is selected from the group consisting of (7?)-Me-BoPhoz and (S)-Me-BoPhOZ, and the first metal adduct is [Ir(COD)CI] 2 .
  • An Example 109 of the invention includes a process, according to Scheme D, for preparing a compound of Formula (Ia) and intermediates thereof, wherein the first hydrogen source is gaseous hydrogen; the first ligand-metal complex is ( ⁇ -Xyl-PhanePhos &[Ru(COD)(CF 3 COO) 2 ]2; the first solvent is MeOH; the first temperature is about 40 0 C; the first pressure is about 10 bar; the second hydrogen source is gaseous hydrogen; and the hydrogenation agent is selected from either 10% Pd/C or a second ligand-metal complex, wherein, when the hydrogenation agent is a second ligand-metal complex selected from
  • the second solvent is MeOH; the optional second additive is Et 3 N in an amount of about 0.75 Eq.; the second temperature is about 40 0 C; and, the I O second pressure is about 10 bar.
  • An Example 110 of the invention includes a process which provides an enantiomer or diastereomer of a compound of Formula (I) or a compound of Formula (II) selected from the group consisting of:
  • the amount of conversion of the starting material and the enantiomeric purity of the product was found to depend on a number of factors.
  • factors include, but are not limited to, various ligands conjugated with various metal adducts, the resulting ligand-metal complexes thus formed, the solvents used and other additives, the reaction temperature and pressure conditions and the reaction length. Alone and in combination, the influence of each of these factors was explored.
  • Scheme E illustrates a synthesis of the compound of Formula (Ia) (as described in Ghosh S, Santulli RJ, Kinney WA, DeCorte BL, Liu L, Lewis JM, Proost JC, Leo GC, Masucci J, Hageman WE, Thompson AS, Chen 1, Kawahama R, Tuman RW, Galemmo RA Jr., Johnson DL, Damiano BP and Maryanoff BE, Bioorg. Med. Chem. Lett., 2004, 14, 5937).
  • the reaction step for preparing 4-(2-oxo-2-quinolin-3-yl-ethyl)-piperidine- 1 - carboxylic acid tert-butyl ester Compound E3 uses a 3-lithioquinoline adduct as the
  • Scheme F provides a process for the stereocontrolled synthesis of (Z)-4-(3- methoxycarbonyl ⁇ -quinolin-S-yl-ally ⁇ -piperidine- l -carboxylic acid tert-butyl ester
  • An Example 111 of the invention includes a process for preparing (Z)-4-(3- methoxycarbonyl-2-quinolin-3-yl-allyl)-piperidine- l -carboxylic acid tert-butyl ester Compound Cl, comprising the steps:
  • Step 1 reacting a mixture of a Compound Fl and carbonyl diimidazole (CDI) in 5 tetrahydrofuran (THF);
  • Step 2 reacting the mixture with the potassium salt of methyl malonate and MgCb in THF to provide a Compound F2;
  • Step 3 reacting Compound F2 with trifluoromethanesulfonic anhydride (Tf 2 O) in a mixture with sodium hydride (NaH) and DIPEA in toluene to provide a (Z)- I O isomer Compound F3; and,
  • Step 4 reacting Compound F3 with quinoline-3-boronic acid and Pd(PPh 3 ) 2 CI 2
  • Scheme G illustrates the preparation of a ( lS)-(-)-camphanic acid derivative 15 Compound Gl crystalline form.
  • Compound Gl was used in a single-crystal X-ray diffraction study to confirm the absolute configuration of compounds of the present invention.
  • Ci-salkyl means a straight or branched chain hydrocarbon radical comprising from 1 to 8 carbon atoms, wherein the radical is derived by the removal of one hydrogen atom from a single carbon atom. Examples include methyl, ethyl, 1 - propyl, 2-propyl, 1 -butyl, 2-butyl, tertiary butyl (also referred to as /-butyl or / ⁇ ?/7-butyl), 1 -pentyl, 2-pentyl, 3-pentyl, 1 -hexyl, 2-hexyl, 3-hexyl and the like. Other examples include C
  • Ci-salkoxy means a straight or branched chain hydrocarbon alkyl radical of the formula -O-C
  • . 8 alkoxy is substituted on one or more available carbon chain atoms with one or more substituents where allowed by available valences.
  • aryl means monocyclic or bicyclic aromatic ring systems containing from 6 to 12 carbons in the ring. Examples include phenyl, biphenyl, naphthalene (also referred to as naphthalenyl and naphthyl), azulenyl, anthracenyl and the like. Aryl radicals may be attached to a core molecule and further substituted on any atom where allowed by available valences.
  • hetero when used as a prefix for a ring system, refers to the replacement of at least one carbon atom member in the ring system with a heteroatom selected from N, O, S, S(O), or SO 2 .
  • a hetero ring may have 1 , 2, 3, or 4 carbon atom members replaced by a nitrogen atom.
  • a ring may have 0, I , 2, or 3 nitrogen atom members and 1 oxygen or sulfur atom member.
  • up to two adjacent ring members may be heteroatoms, wherein one heteroatom is nitrogen and the other heteroatom is selected from N, S, or O.
  • heterocyclyl means a saturated or partially unsaturated monocyclic or polycyclic "hetero" ring system radical having a cycloalkyl ring as the core molecule.
  • Heterocyclyl ring systems include azetidinyl, 2H-pyrrole, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolidinyl, 1 ,3-dioxolanyl, 2-imidazolinyl (also referred to as 4,5-dihydro-l H- imidazolyl), imidazolidinyl, 2-pyrazolinyl, pyrazolidinyl, tetrazolyl, tetrazolidinyl, piperidinyl, 1 ,4-dioxanyl, morpholinyl, 1 ,4-dithianyl, thiomorpholinyl, piperazinyl, l ,4,5,6-tetrahydro-pyrimidin-2-
  • heterocyclyl also includes a benzofused-heterocyclyl ring system radical and the like, such as indolinyl (also referred to as 2,3-dihydro-indolyl), benzo[l ,3]dioxolyl (also referred to as 1 ,3-benzodioxolyl), 5,6,7,8-tetrahydro-
  • heteroaryl means an aromatic monocyclic or polycyclic heterocyclyl radical.
  • Heteroaryl ring systems include furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, I H-imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, lH-tetrazolyl, 2H-tetrazolyl, IH-[1 , 2,3]triazolyl, 2H-[ l ,2,3]triazolyI, 4H-[ l ,2,4]triazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl and the like. Heteroaryl radicals may be attached to a core molecule and further substituted on any atom where allowed by available valences.
  • heteroaryl also includes a benzofused-heteroaryl ring system radical and the like, such as indolizinyl, indolyl, indolinyl, azaindolyl, isoindolyl, benzo[b]furanyl, benzo[b]thienyl, indazolyl, azaindazolyl, benzoimidazolyl, benzothiazolyl, benzooxazolyl, benzoisoxazolyl, benzothiadiazolyl, benzotriazolyl, purinyl, 4H-quinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 1 ,8-naphthyridinyl, pteridinyl and the like.
  • Benzofused-heteroaryl radicals may be attached to a core molecule and
  • benzofused when used as a prefix for a ring system, refers to a radical formed by any monocyclic radical fused with a benzene ring; the benzofused radical may be attached to a core molecule via either ring of the bicyclic system.
  • .4alkoxycarbonyl protecting group'' means a radical of the formula: -C(O)-O-C
  • ,R 8 ) means a radical of the formula: -aryl(R
  • . 6 alkyl refers to a group of the formula:
  • form means, in reference to compounds of the present invention, such may exist as, without limitation, a salt, stereoisomer, tautomer, crystalline, polymorph, amorphous, solvate, hydrate, ester, prodrug or metabolite form.
  • the present invention encompasses all such compound forms and mixtures thereof.
  • isolated form means, in reference to compounds of the present invention, such may exist in an essentially pure state such as, without limitation, an enantiomer, a racemic mixture, a geometric isomer (such as a cis or trans stereoisomer), a mixture of geometric isomers, and the like.
  • the present invention encompasses all such compound forms and mixtures thereof.
  • Certain compounds of Formula (I), Formula (11) or Formula (Ia) may exist in various stereoisomeric or tautomeric forms and mixtures thereof.
  • the invention encompasses all such compounds, including active compounds in the form of essentially pure enantiomers, racemic mixtures and tautomers.
  • the compounds of the present invention may be present in the form of pharmaceutically acceptable salts.
  • pharmaceutically acceptable salts for use in medicines, refer to non-toxic acidic/anionic or basic/cationic salt forms.
  • Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.
  • a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.
  • suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts; and salts formed with suitable organic ligands, e.g.
  • representative pharmaceutically acceptable salts include the following: acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium, camsylate (or camphosulphonate), carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, fumarate, gluconate, glutamate, hydrabamine, hydrobromine, hydrochloride, iodide, isothionate, lactate, malate, maleate, mandelate, mesylate, nitrate, oleate, pamoate, palmitate, phosphate/diphosphate, salicylate, stearate, sulfate, succinate, tartrate, tosylate.
  • the present invention includes within its scope prodrugs of the compounds of this invention.
  • prodrugs will be functional derivatives of the compounds that are readily convertible in vivo into the required compound.
  • the term “administering” shall encompass the treatment of the various disorders described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound in vivo after administration to the patient.
  • Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.
  • the invention includes compounds of various isomers and mixtures thereof.
  • the term "isomer” refers to compounds that have the same composition and molecular weight but differ in physical and/or chemical properties. Such substances have the same number and kind of atoms but differ in structure. The structural difference may be in constitution (geometric isomers) or in an ability to rotate the plane of polarized light (stereoisomers).
  • optical isomer means isomers of identical constitution that differ only in the spatial arrangement of their groups. Optical isomers rotate the plane of polarized light in different directions.
  • optical activity means the degree to which an optical isomer rotates the plane of polarized light.
  • racemate or “racemic mixture” means an equimolar mixture of two enantiomeric species, wherein each of the isolated species rotates the plane of polarized light in the opposite direction such that the mixture is devoid of optical activity.
  • enantiomer means an isomer having a nonsuperimposable mirror image.
  • diastereomer means stereoisomers that are not enantiomers.
  • chiral means a molecule that, in a given configuration, cannot be superimposed on its mirror image. This is in contrast to achiral molecules that can be superimposed on their mirror images.
  • the invention is considered to include the tautomeric forms of all compounds of Formula (I), Formula (II) or Formula (Ia).
  • some of the compounds represented by Formula (I), Formula (II) or Formula (Ia) may be prodrugs, i.e., derivatives of a drug that possess superior delivery capabilities and therapeutic value as compared to the active drug. Prodrugs are transformed into active drugs by in vivo enzymatic or chemical processes.
  • the symbols "R” and "S” represent the configuration of groups around a stereogenic carbon atom(s) as determined by the Cahn-lngol-Prelog priority rules.
  • geometric isomer means isomers that differ in the orientation of substituent atoms in relationship to a carbon-carbon double bond, to a cycloalkyl ring, or to a bridged bicyclic system.
  • Substituent atoms (other than hydrogen) on each side of a carbon-carbon double bond may be in an E or Z configuration according to their priority. In the "E” configuration, the substituents having the highest priorities are on opposite sides in relationship to the carbon-carbon double bond. In the "Z" configuration, the substituents having the highest priorities are oriented on the same side in relationship to the carbon-carbon double bond.
  • conversion refers to the efficiency of the reduction or hydrogenation of the vinyl bond of the starting material, without consideration to the orientation or for the enantiomeric excess of the stereoisomer produced.
  • conversion or “converted” refers, when Z is hydroxy, to the alkylation of Z to provide Z is -O-C
  • Substituent atoms (other than hydrogen) attached to a ring system may be in a cis 5 or trans configuration.
  • the substituents are on the same side in relationship to the plane of the ring; in the "trans” configuration, the substituents are on opposite sides in relationship to the plane of the ring.
  • Compounds having a mixture of "cis” and “trans” species are designated "cis/trans”.
  • the compounds may, for example, be resolved into their component enantiomers by standard techniques, such as the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di-p-toluoyl-d-tartaric acid and/or (+)-di-p-toluoyl-l-tartaric acid followed by fractional crystallization and regeneration of the free base.
  • the compounds may also be 0 resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary.
  • the compounds may be resolved and percent enantiomeric excess (e.e.) determined using a chiral HPLC column.
  • catalytic amount is recognized in the art and means a substoichiometric amount or a reagent relative to a reactant. As used herein, a catalytic amount means an amount of from about 0.0001 to about 90 mole percent reagent relative to reactant, an amount of from about 0.001 to about 50 percent, an amount of from about 0.01 to about 10 percent, or an amount of from about 0.1 to about 5 percent.
  • the amount of the ligand-metal complex used can also be represented as a molar ratio of the substrate or reactant to the ligand-metal complex, and can represented by the term "S/C" or "substrate/complex.”
  • preformed ligand-metal complex is recognized in the art as any form of a conjugated or coordinated metal adduct and ligand that has been isolated in a stable form, wherein a stoichiometric ratio exists between the metal adduct and ligand.
  • the ratio of metal adduct to ligand is typically a fixed stoichiometric ratio, wherein the ligand-metal complex may be accompanied by counterions or may be present as a solvate, thus stabilizing and enabling the isolability of said complex.
  • a preformed ligand-metal complex may or may not be isolable under open atmosphere, but often is handled under an inert atmosphere using methods known in the art.
  • the preformed ligand-metal complex is typically stored for use, and then added to a solvent along with a substrate or reactant and optional additives for reaction with said substrate or reactant.
  • a preformed ligand-metal complex includes those ligand-metal complexes that may be obtained as an in situ byproduct precipitated from a reaction mixture, isolated and stored in a stable form, then subsequently used as a "preformed" ligand-metal complex in a later reaction.
  • DMF may be incorporated into the stable preformed catalyst, as in [(5)-P-Phos RuCI 2 (DMF)T], resulting from the coordination of DMF with the metal adduct during the formation of the complex.
  • a convention utilized herein to denote a preformed catalyst is the "/"denotation, used to indicate the ligand/[metal adduct].
  • Preformed catalysts not otherwise formed may also be purchased from commercial vendors.
  • Preformed catalysts disclosed and used herein include, and are not limited to, (S)-P-PhOsZ[RuCI 2 (DMF) 2 ], (S)-XyI-P-PhOsZ[RuCI 2 (DMF) 2 ], ( ⁇ )-MeBoPhoz/[RuCI 2 (DMF) 2 ], (S)-P-Phos/[Ru(benzene)CI]CI, ( ⁇ )-Xyl-P-Phos/[Ru(p-cymene)CI]CI, (S)-PhanePhos/[Rh(COD)]BF 4 , (/?)-PhanePhos/[Rh(COD)]BF 4 , (S)-P-PhosZ[Ir(COD)]CI, (S)-Xyl-P-PhosZ[Ir(COD)Cl], (/?)-iPr-PHOX/[lr
  • a synthetic method for preparing a preformed (S)-PhanePhos/[Rh(COD)]BF4 ligand-metal complex includes the coordination of an (S)-PhanePhos ligand and metal adduct [Rh(COD) 2 ]BF 4 , with loss of one (COD) group.
  • the metal adduct and ligand are typically mixed according to a stoichiometric ratio such that the combination will lead to the desired ligand-metal complex.
  • various analytical techniques are used to prove that the ligand-metal complex has indeed been formed.
  • the formation of the ligand-metal complex cannot be definitively proven.
  • the ligand-metal complex formed in situ may also typically have accompanying, stabilizing counterions or may be present as a solvate, thus stabilizing said ligand-metal complex during the reaction.
  • the ligand-metal complex formed in situ will perform in the same manner as a preformed ligand-metal complex, and have the same characteristics of a preformed ligand-metal complex, as stated above.
  • a ligand-metal complex made in situ may also be prepared in a stable solvent and stored in solution until needed.
  • a convention utilized herein to denote an "in situ” catalyst is the "&"notation, used to indicate a ligand&fmetal adduct] group.
  • metal adduct is meant to denote the convenient, weighable, stable form of a metal with its stabilizing ligands and counterions as is understood by one of ordinary skill in the art.
  • metal adducts are most stable in a dimeric form, which upon disproportionation under a prescribed set of reaction conditions, leads to a monomeric form, which is referred to herein as a "metal precursor.”
  • An example of a dimeric metal adduct is [Ru(COD)(CF 3 COO) 2 J 2 , which upon disproportionation leads to the metal precursor [Ru(COD)(CF 3 COO) 2 ]. It is understood by one of ordinary skill in the art that the stoichiometry of the disproportionation is such that 1 equivalent dimeric metal adduct provides 2 equivalents of metal precursor.
  • the reactions contemplated in the present invention include reactions that are enantioselective, diastereoselective, and/or regioselective.
  • the invention is considered to include pure enantiomers, racemic mixtures, as well as mixtures of enantiomers having 0.001 % to 99.99% enantiomeric excess.
  • an enantioselective reaction is a reaction that hydrogenates an achiral reactant to a chiral product enriched in one enantiomer. Enantioselectivity is generally quantified as "enantiomeric excess" (e.e.) defined as follows:
  • % enantiomeric exess A (ee) (% enantiomer A)-(% enantiomer B), where A and B are the enantiomers formed.
  • An enantioselective reaction yields a product with an e.e. in a range of from about 5% e.e. to about 99% e.e., or in a range of from about 30% e.e. to about 99% e.e., or in a range of from about 60% e.e. to about 99% e.e., or in a range of from about 70% e.e. to about 99% e.e., or in a range of from about 80% e.e. to about 99% e.e.
  • substantially pure means, within the scope of the present invention, an isomeric mixture which includes an enantiomerically enriched form of the enantiomer, wherein the mixture is substantially free of the opposite enantiomer.
  • substantially pure means the opposite enantiomer may be an amount in a range of about less than 25% of the mixture, about less than 10 %, about less than 5 %, about less than 2 % or about less than 1 % of the mixture.
  • An enantiomerically enriched form of the S-enantiomer isolated by HPLC from a racemic mixture may be determined according to the formula:
  • An enantiomerically enriched form of the R-enantiomer isolated by HPLC from a racemic mixture may be determined according to the formula:
  • compounds of the present invention may have at least one crystalline, polymorph or amorphous form.
  • the plurality of such forms is included in the scope of the invention.
  • some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents (e.g., organic esters such as ethanolate and the like).
  • solvates with water (i.e., hydrates) or common organic solvents (e.g., organic esters such as ethanolate and the like).
  • organic esters such as ethanolate and the like.
  • any of the processes for preparation of the compounds of the present invention it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991 .
  • the protecting groups may be removed at a convenient subsequent stage using methods known from the art.
  • the substrate Compound Cl and Compound Dl were reacted with a ligand-metal complex, wherein the ligand-metal complex consists essentially of a Iigand and a metal adduct.
  • the following examples illustrate various embodiments of the ligands, metal adducts, the ligand-metal complexes thus formed, other additives and reaction temperature and pressure conditions used in accordance with said embodiments of the present invention.
  • R b is (R/S)- l -phenyl-ethyl, R a is Ph
  • R b is ( I S)- I -naphth- 1 -yl-ethyl, R a is Ph
  • Xyl-(R/S)-Me-BoPhoz R b is Me
  • R a is 3,5-Me 2 -C 6 H 3
  • pFPh-(R/S)-Me-BoPhoz R b is Me
  • R a is 4-F-Ph
  • R b is Bn.
  • R a is 4-F-Ph
  • Binol-(R/S)-Me-BoPhoz R b is Me, R a is Binol
  • R7S iPr-Ph-PHOX.
  • R is Ph
  • R a is XyI: 3,5-Me 2 -C 6 H 3 (R)-An-Phanephos.
  • R a is 4-0Me-Ph Ligand Elements
  • (R)-Xyl-Binap Ar is 3,5-Me 2 -C 6 H 3
  • (S)-Xyl-Binap Ar is 3,5-Me 2 -C 6 H 3
  • Optical rotations were measured on a Perkin-EImer 241 polarimeter. Electrospray (ES) mass spectra were obtained on a Micromass Platform LC single quadrupole mass spectrometer in the positive mode. Elemental analysis and Karl Fischer water analysis were determined by Quantitative Technologies Inc., Whitehouse, NJ. When the percent e.e. is determined by HPLC (using Diacel ChiralPak AD-H column at 35 0 C, 1 mL/min, 80:20 eluent ratio of Hexane: IPA after derivatization to the methyl ester), the resulting standard error for percent e.e. is about 2-3 % of the HPLC peak area.
  • Representative compounds of the present invention can be synthesized in accordance with the general synthetic methods described below and are illustrated more particularly in the schemes that follow. Since the schemes are illustrations whereby intermediate and target compounds of the present invention may be prepared, the invention should not be construed as being limited by the chemical reactions and conditions expressed. Additional representative compounds and stereoisomers, racemic mixtures, diastereomers and enantiomers thereof can be synthesized using the intermediates prepared in accordance with these schemes and other materials, compounds and reagents known to those skilled in the art. All such compounds, stereoisomers, racemic mixtures, diastereomers and enantiomers thereof are intended to be encompassed within the scope of the present invention. The preparation of the various starting materials used in the schemes is well within the skill of persons versed in the art.
  • Ru Adduct Complex Hydrogenation of Compound Cl Various basic-screening, preformed Ru adduct complexes were reacted with Compound Cl (82 mg, 0.2 mmol) in a 50: 1 substrate: complex ratio in various solvents (3 mL) at a temperature of about 50 0 C, under H 2 pressure of about 360 psig (25 bar) for a period of about 16 to about 18 hours. The percent conversion and e.e. were determined by HPLC (210 nm).
  • Rh-BoPhoz Hydrogenation of Compound Cl Various Rh-BoPhoz complexes formed in situ from ligand and [Rh(COD) 2 ]OTf were reacted with Compound Cl (82 mg, 0.2 mmol) in a 50: 1 substratexomplex ratio in various solvents (3 mL) at a temperature of about 50 0 C, under H 2 pressure of about 360 psig (25 bar) for a period of about 16 to about 18 hours. The percent conversion and e.e. were determined by HPLC (210 nm). Table 2
  • the enantioselectivity obtained in aprotic solvents was improved over MeOH, even though MeOH provided improved conversion for a given complex.
  • aprotic solvents such as THF and DCE
  • the low reactivity for conversion of the substrate may be attributable to coordination of the quinoline ring nitrogen atom to the complex.
  • percent conversion obtained was improved (see Entries 1 , 5, and 6) by the use of an additive (in a range of from about 0 Eq to about 1.2 Eq) to reduce the coordinative effect of the quinoline ring nitrogen atom on the complex.
  • the improvement to conversion and enantioselectivity was achieved by the optional use of an additive to reduce the coordinative effect of the quinoline ring nitrogen atom.
  • the percent conversion e.e. were determined by HPLC (using Diacel ChiralPak 15 AD-H column at 35 0 C, 1 mL/min, 80:20 eluent ratio of Hexane: IPA after derivatization to the methyl ester).
  • Entries 5 & 6 refer to use of a ligand in combination with a metal adduct as described in Ohta T, Takaya H, Kitamura M, Nagai K and Noyori R, J. Org. Chem. 1987, 52, 3176, under reaction conditions representative of the present invention.
  • Ru metal adducts and (R,S)-Xyl-P-Phos complexes in the presence of the additive Et 3 N led to high conversion but with a low e.e.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

The present invention is directed to a process for enantioselectively preparing substituted piperidine alkanoic acid integrin antagonist compounds.

Description

ENANTIOSELECTIVE PROCESS FOR PREPARING A SUBSTITUTED ALKANOIC ACID
This U.S. nonprovisional application claims the benefit of U.S. provisional application Serial No. 61/001 ,004, filed on October 30, 2007, and of U.S. provisional application Serial No. 61/067,842, filed on February 29, 2008.
FIELD OF THE INVENTION
The present invention is directed to a process for enantioselectively preparing substituted alkanoic acid integrin antagonist compounds. More particularly, the process is directed to an enantioselective synthesis of a substituted piperidine alkanoic acid dual αvβ3/ αvβ5 integrin antagonist.
BACKGROUND OF THE INVENTION
The importance of an economically viable synthesis of single-enantiomer chiral molecules is well established and understood. In no sector is this more apparent than in the pharmaceutical industry, where one enantiomer of a chiral drug molecule may exhibit enhanced (or different) therapeutic properties over another enantiomer.
While in many cases chiral resolution often remains the method of choice for large scale production, asymmetric hydrogenation remains the most widespread catalytic alternative because of the economic and environmental benefits over older resolution technologies in which the unwanted enantiomer must be recycled or disposed of.
However, despite the inherent advantages in using asymmetric catalysis to produce single-enantiomer molecules, the process is not readily amenable to use at an industrial scale because of a number of factors: such as the ready availability of the chiral catalyst for public or licensed use in the required quantity at an affordable price, the presence of impurities in the catalyst, which can either inhibit the effectiveness of the catalyst itself or get carried into the final product where they are difficult to remove and that, there is no single ligand family, much less an individual member of a family, which leads to high enantiomer selectivity with all substrates.
Moreover, no general methodology exists, although stereoselective asymmetric hydrogenation reductions of various substrates have been extensively described (Ohta T, Miyake T, Seido N, Kumabayashi H and Takaya H, J. Org. Chem. 1995, 60, 357; Dobbs DA, Vanhessche KPM, Brazi E, Rautenstrauch V, Lenoir J-Y, Genet J-P, Wiles J, and Bergens SH, Angew. Chem., Int. Ed. Engl. 2000, 39, 1992; Menges F and Pfaltz A, Adv. Synth. Catal. 2002, 344, 40; Tang W and Zhang X, Chem. Rev. 2003, 103, 3029; Ohta T, Takaya H, Kitamura M, Nagai K and Noyori R, J. Org. Chem. 1987, 52, 3174; Liqin Q, Li Y.-M, Kwong FY, Yu W-Y, Fan Q-H and Chan ASC, Adv. Synth. Catal. 2007, 349, 517; Hayashi T, Kawamura N and Ito Y, J. Am. Chem. Soc. 1987, 109, 7876; Uemura T, Zhang X, Matsumura K, Sayo N, Kumobayashi H, Ohta T, Nozaki K and Takaya H, J. Org. Chem. 1996, 61, 5510; Tellers DM, McWilliams JC, Humphrey G, Journet M, DiMichele L, Hinksmon J, McKeown AE, Rosner T, Sun Y, and Tillyer RD, J. Am. Chem. Soc. 2006, 128, 17063; Cossy J and Belotti D, Biorg.Med.Chem.Lett 2001, / /, 1989; Blaser HU, Malan C, Pugin B, Steiner H, Spindler F and Studer M, Adv. Synth. Catal. A 2003, 345, 103 and references therein; Romero DL, Manninen PR, Han F and Romero AG, J. Org. Chem. 1999, 64, 4980-4985; United States Patent 6,465,664; and, U.S. Patent 6,787,655. There remains a need for an efficient enantiomerically and diastereomerically selective hydrogenation process for a chiral integrin antagonist with a maximum conversion to product, having the highest enantiomeric and diastereomeric excess of the desired isomer.
SUMMARY OF THE INVENTION
The present invention is directed to an asymmetric hydrogenation process for preparing a compound of Formula (I) and Formula (11) and intermediates thereof:
Figure imgf000004_0001
Formula (I) Formula (II)
wherein R2, W, Z and q are as defined herein, wherein α represents a chiral carbon chain atom and, wherein β represents a chiral carbon ring member atom.
A series of alkanoic acid dual αvβ3/ αvβs integrin antagonists of Formula (I I I) and Formula (IV):
Figure imgf000004_0002
Formula (III) Formula (IV) were described in De Corte BL, Kinney WA, Liu L, Ghosh S, Brunner L, Hoekstra WJ, Santulli RJ, Tuman RW, Baker J, Burns C, Proost JC, Tounge BA, Damiano BP, Maryanoff BE, Johnson DL and Galemmo RA Jr., Bioorg. Med. Chem. Lett., 2004, 14, 5227; and, disclosed in United States Patent Publications US2004/0077684 and US2004/0224986, referred to therein as compound of Formula (I) and Formula (II), each of which is incorporated herein by reference in their entirety and for all purposes.
Furthermore, United States Patent Publication US2004/0077684 and U.S. Patent Publication US2004/0224986 describe racemic and stereoisomeric compounds of Formula (HI) and Formula (IV). Such compounds may be asymmetrically prepared using the instant process to provide stereoisomeric compounds representative of compounds of Formula (1) and Formula (II) of the present invention.
The present invention is further directed to an asymmetric hydrogenation process for preparing a compound of Formula (Ia) and intermediates thereof:
Figure imgf000005_0001
Formula (Ia), and is referred to herein as (3S,3'S>4-[l-(3-5,6,7,8-tetrahydro-[l ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-3-( l ,2,3,4-tetrahydro-quinolin-3-yl)-butyric acid.
The compound of Formula (Ia) has been disclosed in both United States Patent Publication US2004/0077684, in U.S. Patent Publication US2004/0224986 (CIP of US2004/0077684) and in U.S. Patent Application 1 1/897484 (Continuation of US2004/0224986), which are each incorporated herein by reference in their entirety and for all purposes. The compound of Formula (Ia) was referred to therein as an isomer Compound 19-4 of 1 ,2,3,4-tetrahydro-β-[[ 1 -[ 1 -oxo-3-(5,6,7,8-tetrahydro- 1 ,8- naphthyridin-2-yl)propyl]-4-piperidinyl]methyl]-3-quinolinepropanoic acid. The compound of Formula (Ia) was synthesized as disclosed in Scheme E (alternatively, as in Scheme F) and Example 15 of same. The process of the present invention is an efficient and stereoselective enantiomeric and diastereomeric hydrogenation which improves conversion and enantiomeric excess of the desired product by optimized reaction conditions for compounds of Formula (I), Formula (II) and Formula (Ia) and intermediates thereof by improving control of geometric isomer formation by stereoselective olefin reduction and substantially avoiding isomer separation using sequential chiral column chromatography.
The process of the present invention provides improved conversion and enantiomeric and diastereomeric excess of a desired enantiomer of a compound of Formula (I), Formula (II), Formula (Ia) and intermediates thereof.
DETAILED DESCRIPTION OF THE INVENTION
The present invention, as shown in Scheme A, is directed to a process for preparing a compound of Formula (I) and Formula (II):
Figure imgf000006_0001
Formula (1) Formula (I I) wherein α represents a chiral carbon chain atom;
W is selected from the group consisting of -C0.6alkyl(Rι), -C|.6alkyl(Ria),
-Co.6alkyl-aryl(R|,R8), -Co.6alkyl-heterocyclyl(Ri,R8), -Co^alkoxy(Rι), -Co-6alkoxy-aryl(Ri,R8), and -Co-6alkoxy-heterocyclyl(R|,Rg), Ri is selected from the group consisting of hydrogen, -N(R4):, -N(R4)(R5), -N(R4)(R6),
-heterocyclyl(Rs) and -heteroaryl(R8);
Rιa is selected from the group consisting of -C(R4X=N-R4), -C(=N-R4)-N(R4)2, -C(=N-R4)-N( R4)(R6), -C(=N-R4)-N(R4)-C(=O)-R4, -C(=N-R4)-N(R4)-C(=O)-N(R4)2, -C(=N-R4)-N(R4)-CO2-R4, -C(=N-R4)-N(R4)-Sθ2-C|.8alkyl(R7) and -C(=N-R4)-N(R4)-SO2-N(R4)2;
R4 is selected from the group consisting of hydrogen and -C|.8alkyl(R7); R5 is selected from the group consisting of -Q=O)-R4, -C(=O)-N(R4)2,
-C(=0)-cycloalkyl(R8), -C(=O)-heterocyclyl(Rs), -C(=O)-aryl(R8), -C(=O)-heteroaryl(R8), -C(=O)-N(R4)-cycloalkyl(R8); -C(=O)-N(R4)-aryl(Rs), -CO2-R4, -CO2-cycloalkyl(R8), -CO2-aryl(R8); -C(R4)C=N-R4), -Q=N-R^-N(R,,),, -CC=N-R4J-N(R4)(R6), -C(=N-R4)-N(R4)-C(=O)-R4,
-C(=N-R4)-N(R4)-C(=O)-N(R4)2> -C(=N-R4)-N(R4)-CO2-R4, -C(=N-R4)-N(R4)-Sθ2-C,.8alkyl(R7), -C(=N-R4)-N(R4)-SO2-N(R4)2, -N(R4K(R4X=N-R4), -N(R4)-C(=N-R4)-N(R4)2, -N(R4)-C(=N-R4)-N(R4)(R6), -N(R4)-C(=N-R4)-N(R4)-C(=O)-R4, -N(R4)-C(=N-R4)-N(R4)-C(=O)-N(R4)2s -N(R4)-C(=N-R4)-N(R4)-CO2-R4, -N(R4)-C(=N-R4)-N(R4)-SO2-C|.salkyl(R7),
-N(R4)-C(=N-R4)-N(R4)-SO2-N(R4)2, -SO2-C|.8alkyl(R7), -SO2-N(R4),, -SO2-cycloalkyl(R8) and -SO2-aryl(R8);
R6 is selected from the group consisting of -cycloalkyl(Rs), -heterocyclyl(Rs), -aryl(R8) and -heteroaryl(Rs); R7 is one to two substituents independently selected from the group consisting of hydrogen, -C|.8alkoxy(R9), -NH2, -NH-C|.8alkyl(R9), -N(C|.8alkyl(R9))2, -C(=0)H, -C(=O)-C|.8alkyl(R9), -C(=0)-NH2, -C(=O)-NH-C,.8alkyl(R9), -C(=O)-N(C|.salkyl(R9))2, -C(=O)-NH-aryl(R10), -C(=0)-cycloalkyl(R,o), -C(=0)-heterocyclyl(Rio), -C(=O)-aryl(R,0), -C(=0)-heteroaryl(R,o), -CO2H, -CO2-C|.8alkyl(R9); -CO2-aryl(R,0), -C(=NH)-NH2, -SH, -S-C,-salkyl(R9),
-S-C|.8alkyl-S-C|.8alkyl(R9), -S-C|.8alkyl-C|.8alkoxy(R9), -S-C|.8alkyl-NH-C|.8alkyl(R9), -SO2-C,.8alkyl(R9), -SO2-NH2, -SO2-NH-C,.8alkyl(R9), -SO2-N(C|.8alkyl(R9))2, -SO2-aryl(R,0), cyano, (halo),.3; hydroxy, nitro, oxo, -cycloalkyl(Rιo), -heterocyclyl(R|0), -aryl(Rιo) and -heteroaryl(Rιo);
R8 is selected from the group consisting of hydrogen, -C|.8alkyl(R9), -C(=O)H, -C(=O)-C,.8alkyl(R9), -C(=0)-NH2, -C(=O)-NH-C,.8alkyl(R9), -C(=O)-N(C|.8alkyl(R9))2, -C(=0)-NH-aryl(R,o), -C(=0)-cycloalkyl(R,o), -C(=0)-heterocyclyl(R,o), -C(=O)-aryl(R,0), -C(=O)-heteroaryl(R,0), -CO2H, -CO2-C,.8alkyl(R9), -CO2-aryl(R,0), -C(=NH)-NH2, -SO2-C|.8alkyl(R9), -SO2-NH2, -Sθ2-NH-C|.8alkyl(R9), -SO2-N(C|.8alkyl(R9))2, -SO2-aryl(R10); -cycloalkyl(Rιo) and -aryl(Rio) when attached to a nitrogen atom; and, wherein R8 is one to four substituents independently selected from the group consisting of hydrogen, -C|.8alkyl(R9), -C|.8alkoxy(R9), -O-cycloalkyl(R|0), -O-aryl(Rιo), -C(=O)H, -C(O)-C ,.8alkyI(R9), -C(=0)-NH2) -C(O)-NH-C,.8alkyl(R9),
-C(=O)-N(C|.8alkyl(R9))2, -C(=0)-NH-aryl(Rio); -C(=0)-cycloalkyI(R,o), -C(=O)-heterocyclyl(R|0), -C(=O)-aryl(R,0); -C(=0)-heteroaryl(R,o), -CO2H, -CO2-C|.8alkyl(R9), -CO2-aryl(R|0), -C(=NH)-NH2, -SO2-Cl.8alkyl(R9), -SO2-NH2, -SO2-NH-C, .8alkyl(R9), -SO2-N(C,.8alkyl(R9))2, -SO2-aryl(R|0), -SH, -S-C|.8alkyl(R9), -S-Q.salkyl-S-Ci.salkyKRg), -S-C,.8alkyl-C|.8alkoxy(R9),
-S-C,.8alkyl-NH-C|.8alkyl(R9), -NH2, -NH-C,.8alkyl(R9), -N(C|.8alkyl(R9))2) cyano, halo, hydroxy, nitro, oxo, -cycloalkyl(Rιo), -heterocyclyl(Rιo), -aryl(Rιo) and -heteroaryl(Rιo) when attached to a carbon atom;
R9 is selected from the group consisting of hydrogen, -C|.8alkoxy, -NH2, -NH-C|.8alkyl, -N(Ci.8alkyl)2: -C(=O)H, -C(O)-NH2, -C(=O)-NH-C,.8alkyl,
-C(O)-N(C,.8alkyl)2, -CO2H, -CO2-C|.8alkyl, -SO2-C|.8alkyl, -SO2-NH2, -SO2-NH-Ci. salkyl, -SO2-N(C|_8alkyl)2, cyano, (halo)|.3, hydroxy, nitro and oxo; Rio is selected from the group consisting of hydrogen, -C|.8alkyl, -C(=O)H,
-C(O)-C,.8alkyl, -C(O)-NH2, -C(=O)-NH-C,.8alkyl, -C(O)-N(C ,.8alkyl)2, -CO2H, -CO2- C,.4alkyl, -SO2-C,.8alkyl, -SO2-NH2, -SO2-NH-C|.8alkyl and
-SO2-N(C|.8alkyl)2 when attached to a nitrogen atom; and, wherein Rio is one to four substituents independently selected from the group consisting of hydrogen, -C|.8alkyl, -C,.8alkoxy, -C(=O)H, -C(=O)-C,.8alkyl, -C(O)-NH2, -C(=O)-NH-C,.8alkyl, -C(=O)-N(C,.8alkyl)2j -CO2H, -CO2- C,.4alkyl, -SO2-C,.8alkyl, -SO2-NH2, -SO2-NH-C,.8alkyl, -SO2-N(C,.8alkyl)2, -NH2,
-NH-C|.8alkyl, -N(C|.8alkyl)2, cyano, halo, hydroxy, nitro and oxo when attached to a carbon atom; R2 is selected from the group consisting of -cycloalkyl(R8), -heterocyclyl(R8), -aryl(R8) and -heteroaryl(R8), wherein β represents a chiral carbon ring member atom of -cycloalkyl(R8) and -heterocyclyl(Rs); q is 0, 1 , 2 or 3; and
Z is selected from the group consisting of hydroxy and -O-Ci.galkyl; comprising the steps of:
Scheme A Step 1. reacting a Compound Al, wherein PG is a C|.4alkoxycarbonyl protecting group such as Boc, with a first hydrogen source, a first ligand-metal complex consisting essentially of a first ligand conjugated with a first metal adduct, in a first solvent in the presence of an optional first additive at an elevated first temperature and an elevated first pressure to provide a substantially pure Compound A2 or a substantially pure Compound A3:
Figure imgf000009_0001
Step 2. optionally converting Compound A2 or Compound A3, each wherein Z is hydroxy, to a Compound A2 or Compound A3, each wherein Z is -O-C|.8alkyl; Step 3. optionally hydrogenating Compound A2 or Compound A3, when R2 is selected from -aryl(R8) and -heteroaryl(R8), with a second hydrogen source and a hydrogenation agent, in a second solvent at an elevated second temperature and an elevated second pressure to provide an isomeric mixture of a Compound A4, Compound A5, Compound A6 and Compound A7, wherein R2 is selected from -cycloalkyl(Rs) or -heterocyclyl(Rs), hydrogenated from the corresponding -aryl(Rg) and -heteroaryl(R8), respectively, of Compound A2 or Compound A3: A2, (αR) isomer
A3, (αS) isomer *" Pr'
Figure imgf000010_0001
A5, (αR.βS) isomer A6, (αS,βS) isomer A7, (αS,βR) isomer .
Step 4. when any of Compound A4, Compound A5, Compound A6 or Compound A7, wherein Z is hydroxy, are present, converting each such compound into the corresponding Compound A4, Compound A5, Compound A6 or Compound A7, wherein Z is -O-Ci-salkyl;
Step 5. separating each of Compound A2, Compound A3, Compound A4, Compound A5, Compound A6 and Compound A7, each wherein Z is -O-C|.8alkyl, from the isomeric mixture;
I O Step 6. deprotecting the compound selected from Compound A2 to Compound A7, each wherein Z is -O-C i-salkyl, to provide a corresponding compound respectively selected from Compound A8 to a Compound A13:
A2, (αR) isomer
A3. (αS) isomer
A4, (αR.βR) isomer
A5, (αR.βS) isomer
A6, (αS.βS) isomer
Figure imgf000010_0002
A7, (αS.βR) isomer AlO, (αR.βR) isomer
Al l , (αR.βS) isomer A12, (αS,βS) isomer A13, (αS,βR) isomer .
Step 7. reacting the compound selected from Compound A8 to Compound A13, each 15 wherein Z is -O-Cuealkyl, with a Compound A14 to provide a corresponding compound respectively selected from Compound A15 to a Compound A20 of Formula (I): A8, (αR) isomer
A9, (αS) isomer
AlO, (oR,βR) isomer
Al l, (αR,βS) isomer
Figure imgf000011_0001
A12, (αS.βS) isomer A18, (αR.βS) isomer
A13, (αS.βR) isomer A19, (αS,βS) isomer
A20, (αS,βR) isomer . an(j
Step 8. converting the compound selected from Compound A15 to Compound A20, each wherein Z is -0-Cι-salkyl, to a corresponding Compound A15 to Compound A20, each wherein Z is hydroxy, of Formula (I). The process described herein above optionally further comprises the step of:
Step 5a dehydrogenating Compound A7, wherein Z is -O-Cι_salkyl and Ri is selected from -cycloalkyl(Rs) or -heterocyclyl(Rs), to Compound A3, wherein Z is -0-Cι-salkyl and R: is selected from -aryl(R8) or -heteroaryl(Rg), dehydrogenated from the corresponding -cycloalkyl(Rs) or -heterocyclyl(Rs), respectively, of Compound A7, and then repeating Step 3 using said
Compound A3 as the starting material.
An Example 1 of the invention includes a process wherein the first hydrogen source is selected from gaseous hydrogen or an excess of formic acid.
An Example 2 of the invention includes a process wherein the first ligand-metal complex consists essentially of a first ligand conjugated with a first metal adduct, wherein the first ligand is selected from the group consisting of (Λ)-PhanePhos,
(S)-PhanePhos, (Λ)-An-PhanePhos, (S)-An-PhanePhos, (tf)-Xyl-PhanePhos, (S)-Xyl-PhanePhos, (/?)-MeOXyl-PhanePhos, (S)-MeOXyl-PhanePhos, (tf)-iPr-PhanePhos, (5>iPr-PhanePhos, (7?,7?)-Me-DuPhos, (5,S)-Me-DuPhOS, (Λ)-P-Phos, (S)-P-PhOS, (Λ)-Xyl-P-Phos, (S)-Xyl-P-Phos, W-Ph-PHOX,
(S)-Ph-PHOX, (/0-iPr-PHOX, (S)-iPr-PHOX, (/?)-Me-BoPhoz, (S)-Me-BoPhoz, CF3Ph-(^-Me-BoPhOz, CF3Ph-(S;-Me-BoPhoz, (Λ)-Phenethyl-(Λ)-Me-BoPhoz, (/?)-Phenethyl-(S)-Me-BoPhoz, 3,4-diCI-Ph-(7?)-Me-BoPhoz,
I O 3,4-diCI-Ph-(S)-Me-BoPhoz, Xyl-(/?)-Me-BoPhoz, Xyl-(S)-Me-BoPhoz, (Λ)-Binol-(Λ)-Me-BoPhoz> (Λ)-Binol-(5)-Me-BoPhoz, (S)-Binol-(5)-Me-BoPhoz, (5>Binol-(/?)-Me-BoPhoz, PCy-(/?)-Me-BoPhoz, PCy-(5)-Me-BoPhoz, (Λ)-iPr-BoPhoz, (5)-iPr-BoPhoz, (Λ)-Et-BoPhoz, (S)-Et-BoPhoz, (/?)-Phenethyl-(S)-BoPhoz, (/?)-Phenethyl-(/?)-BoPhoz,
(S)-Phenethyl-(/?)-BoPhoz, (5)-Phenethyl-(5)-BoPhoz, (Λ)-Ph-BoPhoz, (S)-Ph-BoPhOZ, (Λ)-Bn-BoPhoz and (S)-Bn-BoPhoz, and wherein the first metal adduct is selected from the group consisting Of [Rh(COD)2]BF4,
[Rh(COD)2]OTf, [Rh(ethylene)2CI]2, [Rh(ethylene)2(acac)], [Rh(CO)2(acac)], [Rh(COD)CI]2, [Rh(COD)(acac)], [Ru(COD)(CF3COO)2]2,
[Ru(COD)(CH3COO)2], [Ru(COD)(methylallyl)2], [Ru(benzene)Cl2]2, [Ru(p-cymene)CI2]2, [Ru(mesitylene)CI2]2, [Ir(COD)CI]2, [Ir(COD)2]BF4 and [lr(COD)2]BArF.
An Example 3 of the invention includes a process wherein the first ligand metal complex is selected from the group consisting of (./?)-An-Phanephos/[Rh(COD)]BF4,
(Λ)-Binol-(Λ)-Me-BoPhoz&[lr(COD)CI]2, (Λ)-Bn-BoPhoz&[Ir(COD)CI]2,
(tf)-Et-BoPhoz&[Ir(COD)CI]2, (7?)-iPr-BoPhoz&[Ir(COD)Cl]2,
(7?)-iPr-BoPhoz&[Rh(COD)2]OTf, (7?)-iPr-PH0X/[lr(C0D)]BArF,
(/?)-iPr-PHOX/[Ir(COD)]BF4, (7?)-Me-BoPhoz&[Ir(COD)CI]2, (Λ)-Me-BoPhoz&[Rh(CO)2(acac)], (Λ)-Me-BoPhoz&[Rh(COD)2]OTf,
(/.)-Me-BoPhoz&[Rh(ethylene)2(acac)], (Λ)-Me-BoPhoz&[Rh(ethylene)2CI]2,
(Λ)-Me-BoPhoz/[RuCI2(DMF)2], (/?;-MeOXyl-PhanePhos/[Rh(COD)]BF4,
(Λ)-Phanephos&[Ir(COD)CI]2, W-PhanePhos/[Rh(COD)]BF4,
(Λ;-PhanePhos&[Rh(COD)2]OTf, (Λ)-Phanephos«&[Rh(ethylene)2CI]2, (Λ;-PhanePhos/[RuCl2(DMF)2], (Λ)-Ph-BoPhoz&[Ir(COD)CI]2,
(/?)-Phenethyl-(Λ)-BoPhoz&[Rh(ethylene)2CI]2,
(/?)-Phenethyl-(5)-BoPhozc&[Ir(COD)CI]2,
(7?)-Phenethyl-0S>BoPhoz&[Rh(ethylene)2Cl]2,
(7?)-Phenethyl-(S)-Me-BoPhoz&[Ir(COD)CI]2, (/?)-Ph-PHOX/[Ir(COD)]BArF, (Λ)-P-Phos&[Ir(COD)CI]2, (Λ;-Tol-Binap/[RuCI(p-cymene)]Cl, (Λ)-Xyl-Binap&[Ir(COD)CI]2, (Λ)-Xyl-PhanePhos&[Ir(COD)Cl]2, (Λ)-Xyl-Phanephos/[Rh(COD)]BF4, (Λj-Xyl-PhanePhos&[Ru(COD)(CF3COO)2]2, (Λ;-Xyl-PhanePhos&[Ru(COD)(methylallyl)2], (Λ;-Xyl-PhanePhos/[RuCl2(DMF)2], (Λ)-Xyl-P-Phos&[Ir(COD)Cl]2, (Λ)-Xyl-P-Phos&[Rh(CO)2(acac)], (/?)-Xyl-P-Phos&[Rh(ethylene)2(acac)], (/?)-Xyl-P-Phos&[Rh(ethylene)2CI]2, (Λ)-Xyl-P-Phos&[Ru(p-cymene)CI]CI, (Λ;-Xyl-P-Phos/[RuCI2(DMF)2], (Λ,/?)-MeDuPhos/[Rh(COD)]BF4, (5)-Binol-(/?)-Me-BoPhoz&[Ir(COD)Cl]2) (5)-Binol-(Λ)-Me-BoPhoz&[Rh(COD)2]OTf, (5)-Ethyl-Naphthyl-(7?)-BoPhoz&[lr(COD)CI]2, (5>>iPr-PhanePhos/[Rh(COD)]BF4, (5)-Me-BoPhoz&[lr(COD)Cl]2, (.S;-Me-BoPhoz/[RuCI2(DMF)2], (5)-PhanePhos&[lr(COD)CI]2, (S)-Phanephos/[Rh(COD)]BF4, (S;-PhanePhos/[RuCI2(DMF)2], (5)-P-Phos/[Ir(COD)CI], (S)-P-Phos&[Ir(COD)Cl]2, (S)-P-Phos/[Ru(benzene)CI]CI, (S)-P-PhOsZ[RuCI2(DMF)2], (S;-Tol-Binap/[RuCI(p-cymene)]CI, (S)-Tol-P-Phos&[Ir(COD)CI]2j (.S)-Xyl-Binap&[lr(COD)CI]2, (S)-Xyl-PhanePhos&[lr(COD)CI]2l
(5>Xyl-PhanePhos&[Rh(COD)2]OTf, (5;-Xyl-PhanePhos/[RuCI2(DMF)2], (S)-Xyl-P-Phos/[Ir(COD)Cl], (S)-Xyl-P-Phos&[Ir(COD)Cl]2, (S)-Xyl-P-Phos/[RuCI2(DMF)2], 2,4,6-F3Ph-(Λ)-Me-BoPhoz&[Ir(COD)CI]2, 3,4-diCIPh-(Λ)-Me-BoPhoz&[Ir(COD)CI]2, CF3Ph-(/f)-Me-BoPhoz&[Rh(COD)2]OTf, DPPF&[Ir(COD)Cl]2, DtBPF&[Ir(COD)CI]2, PCy-(Λ)-Me-BoPhoz&[lr(COD)CI]2, PCy-(^)-Me-BoPhoz&[Rh(COD)2]OTf, pFPh-(7?)-Bn-BoPhoz&[Ir(COD)Cl]2, pFPh-(Λ)-Et-BoPhoz&[Ir(COD)Cl]2, pFPh-(Λ)-Me-BoPhoz&[Ir(COD)Cl]2 and Xyl-(/0-Me-BoPhoz&[Ir(COD)Cl]2.
An Example 4 of the invention includes a process wherein the first solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA, THF, toluene, EtOAc, 2- propanol and DMF and mixtures thereof.
An Example 5 of the invention includes a process wherein the optional first additive is selected from the group consisting of AcOH, Et3N, HBF4, HBF4 etherate, HCI, HCI etherate, CF3COOH, CH3COOH and TsOH, and, when present, is in an amount up to about 1 .2 Eq. An Example 6 of the invention includes a process wherein the first temperature is in a range of from about 25 0C to about 90 0C, or is in a range of from about 50 0C to about 90 0C.
An Example 7 of the invention includes a process wherein the first pressure is in a range of from about 3 bar to about 30 bar, or is in a range of from about 25 bar to about 30 bar.
An Example 8 of the invention includes a process wherein, when Z is hydroxy for
Compound Al, the first ligand is selected from the group consisting of (Λ)-Xyl-PhanePhos, (Sj-Xyl-PhanePhos, (^-PhanePhos, (Sj-PhanePhos, (φ-An-PhanePhos,
(S>An-PhanePhos, (tf)-Me-BoPhoz, (S)-Me-BoPhoz,_<7?)-MeOXyl-PhanePhos, (S>MeOXyl-PhanePhos, (tf)-iPr-PhanePhos, (5>iPr-PhanePhos, PCy-(#)-Me-BoPhoz and PCy-(S)-Me-BoPhoz, the first metal adduct is selected from the group consisting Of [Rh(COD)2]BF4, [Rh(COD)2]OTf, [Rh(ethylene)2CI]2, [Rh(ethylene)2(acac)], [Rh(CO)2(acac)];
[Rh(COD)CI]2, [Rh(COD)(acac)], [Rιι(COD)(CF3COO)2]2, [RU(CODXCH3COO)2], [Ru(COD)(methylallyl)2], [Ru(benzene)CI2]2, [Ru(p-cymene)CI2]2, [Ru(mesitylene)CI2]2, [Ir(COD)CI]2, [Ir(COD)2]BF4 and [Ir(C0D)2]BArF, the first temperature is in a range of from about 25 0C to about 70 0C, and the first pressure is in a range of from about 3 bar to about 30 bar.
An Example 9 of the invention includes a process wherein, when Z is hydroxy for Compound Al, the first ligand-metal complex is selected from the group consisting of (/?>An-PhanePhos/[Rh(COD)]BF4, (Λ)-Me-BoPhoz&[Ir(COD)CI]2, (Λj-MeOXyl-PhanePhos/[Rh(COD)]BF4, 0*?J-PhanePhos/[Rh(COD)]BF4, (#;-PhanePhos&[Rh(COD)2]OTf, (φ-PhanePhos/[RuCI2(DMF)2], (7?;-Tol-Binap/[RuCl(p-cymene)]Cl, (i?;-Xyl-PhanePhos&[Ru(COD)(CF3COO)2]2, (^-Xyl-PhanePhos&[Ru(COD)(methylallyl)2], (/?;-Xyl-PhanePhos/[RuCI2(DMF)2], (y?;-Xyl-P-Phos/[RuCI2(DMF)2], (5;-iPr-PhanePhos/[Rh(COD)]BF4, (S;-Me-BoPhoz/[RuCI2(DMF)2], (5;-PhanePhos/[RuCl2(DMF)2],
(S;-Tol-Binap/[RuCI(p-cymene)]CI, (S;-Xyl-PhanePhos&[Rh(COD)2]OTf and
(S>Xyl-PhanePhos/[RuCI2(DMF)2].
An Example 10 of the invention includes a process wherein, when Z is hydroxy for Compound Al, the first ligand is selected from the group consisting of (7?)-Xyl-PhanePhos,
(Sj-Xyl-PhanePhos, (φ-PhanePhos, (Sj-PhanePhos, (/?>An-PhanePhos, (5>An-PhanePhos, (J?)-Me-BoPhoz, (5)-Me-BoPhoz, (/.)-MeOXyl-PhanePhos and (5;-MeOXyl-PhanePhos, and the first metal adduct is selected from the group consisting Of [Rh(COD)2]BF4, [Rh(COD)2]OTf, [Ru(COD)(CF3COO)Z]2, [Ru(COD)(methylallyl)2], [Ru(benzene)CI2]2 and [Ir(COD)CI]2.
An Example 11 of the invention includes a process wherein, when Z is hydroxy for Compound Al, the first ligand is selected from the group consisting of (Λ)-Xyl-PhanePhos,
(S>Xyl-PhanePhos, (φ-PhanePhos, (Sj-PhanePhos, (φ-An-PhanePhos, (S>An-PhanePhos, (Λ)-MeOXyl-PhanePhos and (5j-MeOXyl-PhanePhos, and the first metal adduct is selected from the group consisting Of [Rh(COD)2]BF4,
[Rh(COD)2]OTf, [Ru(COD)(CF3COO)2]2, [Ru(COD)(methylallyl)2] and [Ru(benzene)CI2]2.
An Example 12 of the invention includes a process wherein, when Z is hydroxy for Compound Al, the first ligand is selected from the group consisting of (Λ)-Me-BoPhoz and
(S)-Me-BoPhoz, the first metal adduct is [Ir(COD)CI]2, the first solvent is selected from the group consisting of THF, DCE and EtOAc, the first temperature is in a range of from about 65 0C to about 70 0C, and the first pressure is in a range of from about 25 bar to about 30 bar. An Example 13 of the invention includes a process wherein, when Z is hydroxy for Compound Al, the first ligand is selected from the group consisting of (Λ)-PhanePhos , (S)-PhanePhos,
(/?)-An-PhanePhos, (5)-An-PhanePhos, (tf)-Xyl-PhanePhos, (S)-Xyl-PhanePhos, (Λ)-MeOXyΙ-PhanePhos, (S>MeOXyl-PhanePhos, (5)-iPr-PhanePhos and
(tf)-iPr-PhanePhos, the first metal adduct is selected from the group consisting Of [Rh(COD)2]BF4,
[Rh(COD)2]OTf, [Rh(ethylene)2CI]2, [Rh(ethylene)2(acac)], [Rh(CO)2(acac)],
[Rh(COD)CI]2 and [Rh(COD)(acac)], the first solvent is MeOH, the first temperature is from about 25 0C to about 60 0C, and the first pressure is from about 3 bar to about 30 bar.
An Example 14 of the invention includes a process wherein, when Z is hydroxy for Compound Al, the first ligand is selected from the group consisting of (Λ)-PhanePhos , (5)-PhanePhos, (Λ)-An-PhanePhos, (5)-An-PhanePhos, (Λ)-Xyl-PhanePhos, (S)-Xyl-PhanePhos,
(Λ)-MeOXyl-PhanePhos, (S)-MeOXyl-PhanePhos, (S)-iPr-PhanePhos and
(Λ)-iPr-PhanePhos, the first metal adduct is selected from the group consisting of [Ru(COD)(CF3COO)2]2,
[RU(CODXCH3COO)2], [Ru(COD)(methylallyl)2], [Ru(benzene)Cl2]2, [Ru(p-cymene)CI2]2 and [Ru(mesitylene)CI2]2, the first solvent is selected from the group consisting of MeOH, EtOH, IPA, DCE, THF, toluene, EtOAc, DMF and mixtures thereof, and the optional first additive is selected from the group consisting of AcOH, CF3CO2H and
Et3N, the first temperature is in a range of from about 40 0C to about 70 0C, and the first pressure is in a range of from about 3 bar to about 30 bar.
An Example 15 of the invention includes a process wherein, when Z is hydroxy for Compound Al, the first ligand is (Λ)-XylPhanePhos, the first metal adduct is selected from the group consisting Of [Ru(COD)(CF3COO^k, [Ru(COD)(CH3COO)2], [Ru(CODXmCtHyIaIIyI)2], [Ru(benzene)CI2]2, [Ru(p-cymene)CI2]2 and [Ru(mesitylene)CI2]2, the first solvent is selected from the group consisting of MeOH, DMF and mixtures thereof, the optional first additive is Et3N, the first temperature is in a range of from about 40 0C to about 60 0C, and the first pressure is in a range of from about 3 bar to about 30 bar.
An Example 16 of the invention includes a process wherein, when Z is hydroxy for Compound Al, the first ligand is (/?)-XylPhanePhos, the first metal adduct is selected from the group consisting of [Ru(COD)(CF3COO)2]2,
[Ru(COD)(CH3COO)2], [Ru(COD)(methylallyl)2], [Ru(benzene)CI2]2,
[Ru(p-cymene)CI2]2 and [Ru(mesitylene)CI2]2, the first solvent is selected from the group consisting of MeOH, DMF and mixtures thereof, the optional first additive is AcOH, the first temperature is about 40 0C, and the first pressure is about 10 bar. An Example 17 of the invention includes a process wherein, when Z is hydroxy for Compound Al, the first ligand is (/?)-XylPhanePhos, the first metal adduct is selected from the group consisting of [Ru(COD)(CF3COO)2]2,
[Ru(COD)(CH3COO)2], [Ru(COD)(methylallyl)2], [Ru(benzene)CI2]2, [Ru(p-cymene)Cl2]2 and [Ru(mesitylene)Cl2]2, the first solvent is selected from the group consisting of MeOH, EtOH, IPA, DCE, THF, toluene, EtOAc, DMF and mixtures thereof, the first temperature is about 40 0C, and the first pressure is about 10 bar. An Example 18 of the invention includes a process wherein, when Z is hydroxy for Compound Al, the first ligand is (J?)-XylPhanePhos, the first metal adduct is [Ru(COD)(CF3COO)2J2, [Ru(COD)(CH3COO)2] and [Ru(COD)(methylallyl)2], the first solvent is MeOH, the first optional additive is AcOH, the first temperature is about 40 0C, and the first pressure is about 10 bar. An Example 19 of the invention includes a process wherein, when Z is
-O-C|.§alkyl for Compound Al, the first ligand is selected from the group consisting of (/?)-PhanePhos, (S)-PhanePhos, (Λ)-An-PhanePhos, (S)-An-PhanePhos, (Λ)-Xyl-PhanePhos, (S)-Xyl-PhanePhos, (tf)-MeOXyl-PhanePhos, (S)-MeOXyl-PhanePhos, (Λ)-iPr-PhanePhos, (5)-iPr-PhanePhos, (Λ,/?)-Me-DuPhos, (S1S)-Me-DuPhOS, (tf)-P-Phos, (S)-P-Phos,
(Λ)-Xyl-P-Phos, (S)-Xyl-P-Phos, W-Ph-PHOX, (S)-Ph-PHOX, (Λ)-iPr-PHOX, (S)-iPr-PHOX, (Λ)-Me-BoPhoz, (S)-Me-BoPhoz, CF3Ph-(φ-Me-BoPhυz, CF3Ph-(S;-Me-BoPhoz, (Λ)-Phenethyl-(S)-Me-BoPhoz,
3,4-diCI-Ph-(7?)-Me-BoPhoz, 3,4-diCI-Ph-(S)-Me-BoPhoz, Xyl-(i?)-Me-BoPhoz, Xyl-(S)-Me-BoPhoz, (Λ)-Binol-(Λ)-Me-BoPhoz, (Λ)-Binol-(S)-Me-BoPhoz,
(S)-Binol-(S)-Me-BoPhoz, (S)-Binol-(7?)-Me-BoPhoz, PCy-(Λ)-Me-BoPhoz, PCy-(S)-Me-BoPhoz, (Λ)-iPr-BoPhoz, (S)-iPr-BoPhoz, (Λ)-Et-BoPhoz, (S)-Et-BoPhOZ, (Λ)-Phenethyl-(S)-BoPhoz, (/?)-Phenethyl-(/?)-BoPhoz, (S)-Phenethyl-(Λ)-BoPhoz, (S)-Phenethyl-(S)-BoPhoz, (Λ)-Ph-BoPhoz, (S)-Ph-BoPhOZ, (7?)-Bn-BoPhoz and (S)-Bn-BoPhoz, the first metal adduct is selected from the group consisting of [Ir(COD)2]BArF, [Ir(COD)2]BF4, [Ir(COD)CI]2, [Rh(ethylene)2CI]2, [Rh(ethylene)2(acac)]; [Rh(COD)CI]2, and [Rh(COD)(acac)], the first solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA, THF, toluene, EtOAc, DMF, and mixtures thereof, the optional first additive is selected from the group consisting Of Et3N, HBF4,
CH3COOH and TsOH, and, when present, is in an amount up to about 1 .2 Eq., the first temperature is in a range of from about 50 0C to about 70 0C, and the first pressure is in a range of from about 10 bar to about 30 bar. An Example 20 of the invention includes a process wherein, when Z is
-O-C|.8alkyl for Compound Al, the first ligand-metal complex is selected from the group consisting of (tf)-An-Phanephos/[Rh(COD)]BF4,
(Λ)-Binol-(Λ)-Me-BoPhoz&[Ir(COD)CI]2, (Λ)-Bn-BoPhoz&[Ir(COD)Cl]2, (Λ)-iPr-BoPhoz&[Rh(COD)2]OTf, (tf)-iPr-PHOX/[Ir(COD)]BArF, (7?)-iPr-PHOX/[Ir(COD)]BF4, (Λ)-Me-BoPhoz&[Ir(COD)CI]2,
(Λ)-Me-BoPhoz&[Rh(CO)2(acac)], (Λ)-Me-BoPhoz&[Rh(COD)2]OTf, (Λ)-Me-BoPhoz&[Rh(ethylene)2(acac)], (Λ)-Me-BoPhoz&[Rh(ethylene)2CI]2, (Λ)-Me-BoPhoz/[RuCI2(DMF)2], (Λ)-Phanephos&[Ir(COD)CI]2, (Λ)-Phanephos&[Rh(ethylene)2CI]2, (Λ)-Ph-BoPhoz&[lr(COD)CI]2, (Λ)-Phenethyl-(Λ)-BoPhoz&[Rh(ethylene)2CI]2, (/?)-Phenethyl-(5)-BoPhoz&[Rh(ethylene)2Cl]2,
(/?)-Phenethyl-(5)-Me-BoPhoz&[Ir(COD)CI]2, (Λ)-Ph-PHOX/[Ir(COD)]BArF, (#)-Xyl-Phanephos/[Rh(COD)]BF4, (Λ)-Xyl-P-Phos&[Rh(CO)2(acac)], (Λ)-Xyl-P-Phos&[Rh(ethylene)2(acac)], (Λ)-Xyl-P-Phos&[Rh(ethylene)2Cl]2, (Λ)-Xyl-P-Phos/[Ru(p-cymene)CI]CI, (Λ.Λ)-MeDuPhos/[Rh(COD)]BF4,
(5)-Binol-(^)-Me-BoPhoz&[lr(COD)CI]2, (^)-BJnOl-(R)-Me-BoPhOzA[Rh(COD)2]OTf, (S)-Me-BoPhoz&[Ir(COD)CI]2, (5)-PhanePhos/[Rh(COD)]BF4, (S)-P-Phos/[Ir(COD)]CI, , (S)-P-Phos/[Ru(benzene)CI]CI, (5)-P-Phos/[RuCI2(DMF)2], (5)-Xyl-P-Phos&[Ir(COD)CI]2, (S)-Xyl-P-Phos/[Ir(COD)CI], (5)-Xyl-P-Phos/[RuCI2(DMF)2], 3,4-diCIPh-(Λ)-Me-BoPhoz&[Ir(COD)CI]2,
CF3Ph-(R)-Me-BoPhoz&[Rh(COD)2]OTf, PCy-(Λ)-Me-BoPhoz&[Ir(COD)Cl]2 and Xyl-(/?)-Me-BoPhoz&[Ir(COD)CI]2. An Example 21 of the invention includes a process wherein, when Z is
-O-Ci_8alkyl for Compound Al, the first ligand is selected from the group consisting of (/?)-PhanePhos, (S)-PhanePhos,
(tf)-An-PhanePhos, (Λ)-Xyl-PhanePhos, (S)-P-Phos, (Λ)-Xyl-P-Phos, (S)-XyI-P-PhOS, (R)-Ph-PHOX, (Λ)-iPr-PHOX, (7?)-Me-BoPhoz, (S)-Me-BoPhoz,
CF3Ph-(/?>Me-BoPhoz, CF3Ph-(S>Me-BoPhoz, 3,4-diCl-Ph-(/?)-Me-BoPhoz, 3,4-diCI-Ph-(S)-Me-BoPhoz, Xyl-(/?)-Me-BoPhoz, (Λ)-Binol-(Λ)-Me-BoPhoz, (S)-Binol-(i?)-Me-BoPhoz, (tf)-iPr-BoPhoz, (S)-iPr-BoPhoz, (Λ)-Phenethyl-(S)-BoPhoz, (/?)-Phenethyl-(/?)-BoPhoz, (/?)-Ph-BoPhoz and (/?)-Bn-BoPhoz, the first metal addiict is selected from the group consisting Of [Rh(COD)2]BF4,
[Rh(COD)2]OTf, [Rh(ethylene)2Cl]2, [Rh(ethylene)2(acac)], [Rh(CO)2(acac)]; [Ru(p-cymene)CI2]2, [Ir(COD)CI]2 and [lr(COD)]BArF, the first solvent is selected from the group consisting of MeOH, DCE, EtOH, toluene, EtOAc, 2-propanol, THF, and mixtures thereof, the optional first additive is selected from the group consisting of HBF4, AcOH and TsOH, and, when present, is in an amount up to about 1.2 Eq., the first temperature is in a range of from about 50 0C to about 90 0C, and the first pressure is in a range of from about 10 bar to about 30 bar. An Example 22 of the invention includes a process wherein, when Z is
-O-C|.8alkyl for Compound Al, the first ligand is selected from the group consisting of (Λ)-PhanePhos, (S)-PhanePhos, (S)-P-Phos, (Λ)-Xyl-P-Phos, (S)-Xyl-P-Phos, W-Ph-PHOX, (tf)-iPr-PHOX, 0R)-Me-BoPhoz, (S)-Me-BoPhoz, CF3Ph-(Λ>Me-BoPhoz, CF3Ph-(Sj-Me-BoPhOZ, 3,4-diCl-Ph-(/?)-Me-BoPhoz,
3,4-diCI-Ph-(S)-Me-BoPhoz, Xyl-(#)-Me-BoPhoz, Xyl-(S)-Me-BoPhoz, (Λ)-Binol-(7?)-Me-BoPhoz, (S)-Binol-(i?)-Me-BoPhoz, (#)-Phenethyl-(S)-BoPhoz, (/?)-Phenethyl-(7?)-BoPhoz, (fl)-Bn-BoPhoz and (S)-Bn-BoPhoz, the first metal adduct is selected from the group consisting of [Rh(COD)2]BF4, [Rh(COD)2]OTf, [Rh(COD)CI]2, [Rh(ethylene)2CI]2, [Rh(ethylene)2(acac)], [Rh(CO)2(acac)], [Ru(p-cymene)CI2]2, [Ir(COD)Cl]2, [Ir(COD)2]BF4 and
[Ir(COD)2]BArF, the first solvent is selected from the group consisting of DCE, THF, toluene, EtOAc, and mixtures thereof, the optional first additive is selected from the group consisting Of HBF4 and TsOH, and, when present, is in an amount up to about 1.2 Eq., the first temperature is in a range of from about 50 0C to about 90 0C, and the first pressure is about 30 bar.
An Example 23 of the invention includes a process wherein, when Z is -O-C|_8alkyl for Compound Al, the first ligand is selected from the group consisting of (Λ)-Me-BoPhoz, (S)-Me-BoPhoz, 3,4-diCI-Ph-(/?)-Me-BoPhoz, 3,4-diCI-Ph-(5)-Me-BoPhoz, Xyl-(/?)-Me-BoPhoz, Xyl-(5)-Me-BoPhoz, (tf)-Bn-BoPhoz and (5)-Bn-BoPhoz, the first metal addiict is selected from the group consisting of [Ir(COD)CI]2 and [lr(COD)2]BArF, the first solvent is selected from the group consisting of MeOH, DCE, THF, toluene,
EtOAc, IPA, and mixtures thereof, the optional first additive is HBF4, and, when present, is in an amount up to about 1 .2
Eq., the first temperature is in a range of from about 50 0C to about 90 0C, and the first pressure is from about 25 bar to about 30 bar.
An Example 24 of the invention includes a process wherein, when R2 is selected from -aryl(Rs) and -heteroaryl(Rg) for Compound A2 or Compound A3, the second hydrogen source is gaseous hydrogen, the hydrogenation agent is selected from either 10% Pd/C or a second ligand-metal complex, wherein the second ligand-metal complex consists essentially of a second ligand and an
[Ir(COD)CI]2 metal adduct combined with iodine in an amount up to about 0.1
Eq., wherein 10% Pd/C is present in a range of weight % of from about 5% weight/weight
(w/w) to about 20% (w/w), and wherein the second ligand is selected from the group consisting of (7?)-PhanePhos,
(S)-PhanePhos, (/?)-An-PhanePhos, (S)-An-PhanePhos, (tf)-Xyl-PhanePhos, (S)-Xyl-PhanePhos, (/?)-MeOXyl-PhanePhos, (S)-MeOXyl-PhanePhos,
(Λ)-iPr-PhanePhos, (5)-iPr-PhanePhos, (J?,/?)-Me-DuPhos, (5,S)-Me-DuPhOS, (Λ)-P-Phos, (5)-P-Phos, (Λ)-Xyl-P-Phos, (5)-Xyl-P-Phos, (Λ)-Tol-P-Phos, (S)-ToI-P-PhOS, (R)-Ph-PHOX, (S)-Ph-PHOX, (Λ)-iPr-PHOX, (S)-iPr-PHOX, (tf)-Me-BoPhoz, (S)-Me-BoPhoz, CF3Ph-(/?)-Me-BoPhoz, CF3Ph-(S;-Me-BoPhoz, (/?)-Phenethyl-(tf)-Me-BoPhoz,
(Λ)-Phenethyl-(S)-Me-BoPhoz, (S)-Ethyl-Napthyl-(/?)-Me-BoPhoz, 3,4-diCI-Ph-(Λ)-Me-BoPhoz, 3,4-diCl-Ph-(S)-Me-BoPhoz, (Λ)-2;4,6-F3Ph-(/?)-Me-BoPhoz, (Λ)-2,4,6-F3Ph-(S)-Me-BoPhoz, (S)-2,4s6-F3Ph-(5)-Me-BoPhoz, (5)-2,4,6-F3Ph-(Λ)-Me-BoPhoz, Xyl-(/?)-Me-BoPhoz, Xyl-(.S)-Me-BoPhoz, (Λ)-Binol-(Λ)-Me-BoPhoz,
(Λ)-Binol-(5)-Me-BoPhoz, (-S)-Binol-(S)-Me-BoPhoz, (S)-Binol-(Λ)-Me-BoPhoz, PCy-(/?)-Me-BoPhoz, pFPh-(/?)-Me-BoPhoz, pFPh-(S)-Me-BoPhoz, (Λ)-Et-BoPhoz, (S)-Et-BoPhOz, pFPh-(Λ)-Et-BoPhoz, pFPh-(S)-Et-BoPhoz, (Λ)-iPr-BoPhoz, (S)-iPr-BoPhoz, (Λ)-Et-BoPhoz, (S)-Et-BoPhoz, (Λ)-Phenethyl-(S)-BoPhoz, (Λ)-Phenethyl-(Λ)-BoPhoz,
(5)-Phenethyl-(Λ)-BoPhoz, (S)-Phenethyl-(S)-BoPhoz, (Λ)-Ph-BoPhoz, OS)-Ph-BoPhOz, (Λ)-Bn-BoPhoz, (5)-Bn-BoPhoz, pFPh-(Λ)-Bn-BoPhoz, pFPh-(S)-Bn-BoPhoz, (Λ)-Xyl-Binap, (5)-Xyl-Binap and DPPF, the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA, THF, toluene, EtOAc, 1 -BuOH and MTBE and mixtures thereof, the optional second additive is selected from the group consisting Of Et3N, '1Pr2-NH, Cy2NH, (Λ)-Ph-ethyl-NH2, (S)-Ph-ethyl-NH2, KI, KOH, K2CO3, (7?/S)-camphorsulfonic acid and CH3COOH, and, when present, is in an amount up to about 1 .2 Eq., the second temperature is in a range of from about 30 0C to about 80 0C, or is in a range of from about 40 0C to about 60 0C, and the second pressure is in a range of from about 3 bar to about 25 bar, or is in a range of from about 10 bar to about 25 bar, or is in a range of from about 3 bar to about 10 bar.
An Example 25 of the invention includes a process wherein, when Z is hydroxy and R2 is selected from -aryl(Rs) and -heteroaryl(Rs) for Compound A2 or Compound A3, the second ligand-metal complex is selected from the group consisting of (/?)-Me-BoPhoz&[Ir(COD)CI]2, (Λ)-PhanePhos&[Ir(COD)CI]2, (Λ)-P-Phos- &[lr(COD)CI]2) (/?)-Xyl-Binap&[Ir(COD)CI]2) (/?)-Xyl-PhanePhos&[]r(COD)CI]2, (Λ)-Xyl-P-Phos&[Ir(COD)Cl]2, (5)-Me-BoPhoz&[lr(COD)CI]2, (S)-PhanePhos&[Ir(COD)CI]2, (S)-P-Phos&[Ir(COD)CI]2,
(S)-Tol-P-Phos&[Ir(COD)CI]2, (5)-Xyl-Binap&[Ir(COD)CI]2, (S)-Xyl-PhanePhos&[Ir(COD)Cl]2 and (5)-Xyl-P-Phos&[Ir(COD)CI]2.
An Example 26 of the invention includes a process wherein, when Z is -O-Ci-salkyl and R2 is selected from -aryl(Rs) and -heteroaryl(Rs) for Compound A2 or Compound A3, the second ligand-metal complex is selected from the group consisting of (/?)-Binol-(Λ)-Me-BoPhoz&[Ir(COD)CI]2! (/?)-Et-BoPhoz&[Ir(COD)CI]2! (Λ)-iPr-BoPhoz&[Ir(COD)CI]2, (Λ)-Me-BoPhoz&[Ir(COD)CI]2, (Λ)-Ph-BoPhoz&[Ir(COD)Cl]2, (Λ)-Phenethyl-(S)-BoPhoz&[lr(COD)CI]2, (Λ)-Xyl-PhanePhos&[Ir(COD)CI]2) (Λ)-Xyl-P-Phos&[Ir(COD)Cl]2, (S)-Binol-(Λ)-Me-BoPhoz&[lr(COD)CI]2,
(5)-Ethyl-Naphthyl-(Λ)-BoPhoz&[Ir(COD)Cl]2, (5)-Me-BoPhoz&[Ir(COD)CI]2, (5)-Xyl-PhanePhos&[Ir(COD)CI]2, (S)-Xyl-P-Phos&[Ir(COD)CI]2s 2,4,6-F3Ph-(/?)-Me-BoPhoz&[lr(COD)CI]2, DPPF&[lr(COD)CI]2, DtBPF&[lr(COD)CI]2, PCy-(7?)-Me-BoPhoz&[lr(COD)CI]2, pFPh-(Λ)-Bn-BoPhoz&[Ir(COD)CI]2, pFPh-(/?)-Et-BoPhoz&[Ir(COD)CI]2, pFPh-(7?)-Me-BoPhoz&[Ir(COD)CI]2 and Xyl-(tf)-Me-BoPhoz&[Ir(COD)CI]2. An Example 27 of the invention includes a process wherein, when Z is hydroxy and R2 is selected from -aryl(R8) and -heteroaryl(R8) for Compound A2 or Compound A3, the second ligand is selected from the group consisting of (7?)-P-Phos, (5)-P-Phos, Off)-Xyl-P-Phos, (5)-Xyl-P-Phos, (S)-ToI-P-PhOS, (Λ)-Me-BoPhoz,
(S)-Me-BoPhoz, (/?)-Xyl-Binap and (S)-Xyl-Binap, the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA,
THF, toluene, EtOAc and MTBE and mixtures thereof, the second temperature is in a range of from about 40 0C to about 60 0C, and the second pressure is in a range of from about 3 bar to about 25 bar, or is in a range of from about I O bar to about 25 bar, or is in a range of from about 3 bar to about 10 bar.
An Example 28 of the invention includes a process wherein, when Z is -0-Cι-salkyl and R? is selected from -aryl(Rs) and -heteroaryl(R8) for Compound A2 or Compound A3, the second ligand is selected from the group consisting of (7?)-Xyl-PhanePhos,
(tf)-P-Phos, (S)-P-PhOS, (Λ)-Xyl-P-Phos, (S)-Xyl-P-Phos, (S)-Tol-P-Phos, (Λ)-Me-BoPhoz, (S)-Me-BoPhoz, (Λ)-Phenethyl-(S)-Me-BoPhoz, (S)-Ethyl-Napthyl-(/?)-Me-BoPhoz, (#)-2,4,6-F3Ph-(/?)-Me-BoPhoz, Xyl-(Λ)-Me-BoPhoz, (#)-Binol-(tf)-Me-BoPhoz, (S)-Binol-(tf)-Me-BoPhoz,
PCy-(Λ)-Me-BoPhoz, pFPh-(#)-Me-BoPhoz, (7?)-Et-BoPhoz, pFPh-(tf)-Et-BoPhoz, (Λ)-iPr-BoPhoz, (tf)-Ph-BoPhoz, pFPh-(tf)-Bn-BoPhoz, (Λ)-Xyl-Binap, (S^-Xyl-Binap, DtBPF and DPPF, the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA, THF, toluene, EtOAc, 1 -BuOH and MTBE and mixtures thereof, the second temperature is in a range of from about 30 0C to about 80 0C, and the second pressure is in a range of from about 3 bar to about 25 bar.
An Example 29 of the invention includes a process wherein, when R2 is selected from -aryl(Rs) and -heteroaryl(R8) for Compound A2 or Compound A3, the second hydrogen source is gaseous hydrogen, 10% Pd/C is present in a range of weight % of from about 5% (w/vv) to about 20% (w/vv), the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA,
THF, toluene, EtOAc, I -BuOH and MTBE and mixtures thereof, the optional second additive is selected from the group consisting Of Et3N, iPr2-NH, Cy2NH, (y?)-Ph-ethyl-NH2, (5>Ph-ethyl-NH2, Kl, KOH, K2CO3,
(7?/5)-camphorsulfonic acid and CH3COOH, and, when present, is in an amount up to about 1.2 Eq., the second temperature is in a range of from about 30 0C to about 80 0C, or is in a range of from about 40 0C to about 60 0C, and the second pressure is in a range of from about 3 bar to about 25 bar, or is in a range of from about 10 bar to about 25 bar, or is in a range of from about 3 bar to about 10 bar.
An Example 30 of the invention includes a process wherein, when R2 is selected from -aryl(Rs) and -heteroaryl(Rs) for Compound A2 or Compound A3, the second ligand-metal complex consists essentially of a second ligand and an
[Ir(COD)CI]2 second metal adduct combined with iodine in an amount up to about 0.1 Eq., wherein the second ligand is selected from the group consisting of (/?)-PhanePhos, (5)-PhanePhos, (tf)-An-PhanePhos, (5>An-PhanePhos, (Λ)-Xyl-PhanePhos, (S)-Xyl-PhanePhos, (/?)-MeOXyl-PhanePhos, (S>MeOXyl-PhanePhos,
(^/O-Me-DuPhos, (S1S)-Me-DuPhOS, (Λ)-P-Phos, (S)-P-Phos, (Λ)-Xyl-P-Phos, (S)-XyI-P-Ph0S, (tf)-Tol-P-Phos, (S)-Tol-P-Phos, (φ-Ph-PHOX, (S)-Ph-PHOX, (Λ)-iPr-PHOX, (S)-iPr-PHOX, (/?)-Me-BoPhoz, (S)-Me-BoPhoz, CF3Ph-(i?;-Me-BoPhoz, CF3Ph-(5>Me-BoPhoz, (Λ)-Phenethyl-(7?)-Me-BoPhoz, (/?)-Phenethyl-(S)-Me-BoPhoz, (S)-Ethyl-Napthyl-(tf)-Me-BoPhoz,
3,4-diCI-Ph-(/?)-Me-BoPhoz, 3,4-diCI-Ph-(5)-Me-BoPhoz, (Λ)-2,4,6-F3Ph-(/?)-Me-BoPhoz, (/?)-2,4,6-F3Ph-(5)-Me-BoPhoz, (S)-2,4,6-F3Ph-(5)-Me-BoPhoz, (5)-2,4,6-F3Ph-(/?)-Me-BoPhoz, Xyl-(/?)-Me-BoPhoz, Xyl-(S)-Me-BoPhoz, (/?)-Binol-(7?)-Me-BoPhoz, (7?)-Binol-(5)-Me-BoPhoz, (5)-Binol-(5)-Me-BoPhoz, (5)-Binol-(/?)-Me-BoPhoz, PCy-(/?)-Me-BoPhoz, pFPh-(Λ)-Me-BoPhoz, pFPh-(5)-Me-BoPhoz,
(Λ)-Et-BoPhoz, (S)-Et-BoPhoz, pFPh-(/?)-Et-BoPhoz, pFPh-(S)-Et-BoPhoz,
(Λ)-iPr-BoPhoz, (S)-iPr-BoPhoz, (/?)-Phenethyl-(5)-BoPhoz,
(Λ)-Phenethyl-(/?)-BoPhoz, (.S)-Phenethyl-(/?)-BoPhoz; 5 (S)-Phenethyl-(S)-BoPhoz, (y?)-Ph-BoPhoz, (5)-Ph-BoPhoz, (/?)-Bn-BoPhoz,
(5)-Bn-BoPhoz, pFPh-(/?)-Bn-BoPhoz, pFPh-(S)-Bn-BoPhoz, (Λ)-Xyl-Binap,
(S)-Xyl-Binap and DPPF, the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA,
THF, toluene, EtOAc, I -BuOH and MTBE and mixtures thereof, I O the optional second additive is selected from the group consisting Of Et3N, JPr2-NH,
Cy2NH, (Λ)-Ph-ethyl-NH2, (5)-Ph-ethyl-NH2, KI, KOH, K2CO3,
(•/?ΛS)-camphorsulfonic acid and CH3COOH, and, when present, is in an amount up to about 1 .2 Eq., the second temperature is in a range of from about 30 0C to about 80 0C, or is in a range 15 of from about 40 0C to about 60 0C, and the second pressure is in a range of from about 3 bar to about 25 bar, or is in a range of from about 10 bar to about 25 bar, or is in a range of from about 3 bar to about 10 bar.
An Example 31 of the invention includes a process wherein, when Z is hydroxy 0 and R2 is selected from -aryl(R8) and -heteroaryl(Rs) for Compound A2 or Compound A3, the second ligand is selected from the group consisting of (Λ)-P-Phos, (5)-P-Phos, (Λ)-Xyl-P-Phos, (5)-Xyl-P-Phos, (S)-Tol-P-Phos, (7?)-Me-BoPhoz, (5)-Me-BoPhoz, (Λ)-Xyl-Binap and (S)-Xyl-Binap, 5 the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA,
THF, toluene, EtOAc and MTBE and mixtures thereof, the second temperature is in a range of from about 40 0C to about 60 0C, and the second pressure is in a range of from about 3 bar to about 25 bar, or is in a range of from about I O bar to about 25 bar, or is in a range of from about 3 bar to about 10 0 bar. An Example 32 of the invention includes a process wherein, when Z is
-O-Ci-galkyl and R? is selected from -aryl(R8) and -heteroaryl(Rg) for Compound A2 or
Compound A3, the second ligand is selected from the group consisting of (/?)-Xyl-PhanePhos, 5 (Λ)-P-Phos, (S)-P-PhOS, (Λ)-Xyl-P-Phos, (S)-Xyl-P-Phos, (S)-Tol-P-Phos,
(/?)-Me-BoPhoz, (S)-Me-BoPhOZ, (Λ)-Phenethyl-(S)-Me-BoPhoz, (S)-Ethyl-Napthyl-(/?)-Me-BoPhoz, (/?)-2,4;6-F3Ph-(7?)-Me-BoPhoz, Xyl-(Λ)-Me-BoPhoz, (/?)-Binol-(/?)-Me-BoPhoz, (S)-Binol-(Λ)-Me-BoPhoz, PCy-(/?)-Me-BoPhoz, PFPh-(/?)-Me-BoPhoz, (tf)-Et-BoPhoz,
I O pFPh-(/?)-Et-BoPhoz, (Λ)-iPr-BoPhoz, (tf)-Ph-BoPhoz, pFPh-(Λ)-Bn-BoPhoz,
(Λ)-Xyl-Binap, (S)-Xyl-Binap and DPPF, the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA, THF, toluene, EtOAc, I -BuOH and MTBE and mixtures thereof, the second temperature is in a range of from about 30 0C to about 80 0C, and 15 the second pressure is in a range of from about 3 bar to about 25 bar.
An Example 33 of the invention includes a process comprising the steps:
Step 1 . reacting Compound Al, wherein Z is hydroxy and PG is a Ci.4alkoxycarbonyl protecting group such as Boc, with a first hydrogen source, a first ligand-metal complex consisting essentially of a first ligand conjugated with a first metal 0 adduct, in a first solvent in the presence of an optional first additive at a first elevated temperature and a first elevated pressure, to provide a substantially pure Compound A2 or a substantially pure Compound A3, wherein the first hydrogen source is selected from gaseous hydrogen or an excess of formic acid, the first ligand is selected from the group consisting of (Λ)-Xyl-PhanePhos, 25 (S;-Xyl-PhanePhos, (φ-PhanePhos, (S;-PhanePhos, (φ-An-PhanePhos,
(S>An-PhanePhos, (Λ)-MeOXyl-PhanePhos, (Sj-MeOXyl-PhanePhos, PCy-(Λ)-Me-BoPhoz and PCy-(S)-Me-BoPhoz, the first metal adduct is selected from the group consisting Of [Rh(COD)2]BF4,
[Rh(COD)2]OTf, [RU(CODXCF3COO)2]., [Ru(COD)(methylallyl)2], 30 [Ru(benzene)CI2]2 and [Ir(COD)CI]2, the first solvent is selected from the group consisting of MeOH, EtOH, IPA, DCE, THF, toluene, EtOAc, DMF and mixtures thereof, the optional first additive is selected from the group consisting of AcOH, Et3N, HBF4,
HBF4 etherate, HCI, HCI etherate, CF3COOH, CH3COOH and TsOH, and, when present, rs in an amount up to about 1.2 Eq., the first temperature is in a range of from about 25 0C to about 70 0C, and the first pressure is in a range of from about 3 bar to about 30 bar;
Step 2. optionally converting Compound A2 or Compound A3, each wherein Z is hydroxy, to a Compound A2 or Compound A3, each wherein Z is -0-Cι-salkyI;
Step 3. reacting Compound A2 or Compound A3, when R2 is selected from -aryl(Rg) and -heteroaryl(Rs), with a second hydrogen source and a hydrogenation agent in a second solvent in the presence of an optional second additive at a second elevated temperature and a second elevated pressure to provide an isomeric mixture of a Compound A4, Compound A5, Compound A6 and Compound
A7, wherein R2 is selected from -cycloalkyl(Rs) or -heterocyclyl(Rg), hydrogenated from the corresponding -aryl(Rg) and -heteroaryl(Rs), respectively, of Compound A2 or Compound A3, wherein the hydrogenation agent is selected from either 10% Pd/C or a second ligand-metal complex, wherein the second ligand-metal complex consists essentially of a second ligand and an [Ir(COD)CI]2 metal adduct combined with iodine in an amount up to about 0.1 Eq., wherein 10% Pd/C is present in a range of weight % of from about 5% (w/w) to about 20% (vv/w), and wherein the second ligand is selected from the group consisting of (Λ)-P-Phos,
(S)-P-PhOS, (Λ)-Xyl-P-Phos, (S)-Xyl-P-Phos, (S)-Tol-P-Phos, (7?)-Me-BoPhoz, (.S)-Me-BoPhOz, (tf)-Xyl-Binap and (5)-Xyl-Binap, the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA, THF, toluene, EtOAc and MTBE and mixtures thereof, the optional second additive is selected from the group consisting Of Et3N, iPr2-NH, Cy2NH, (Λ)-Ph-ethyl-NH2, (S)-Ph-ethyl-NH2, KI, KOH, K2CO3, (/?/S)-camphorsulfonic acid and CH3COOH, and, when present, is in an amount up to about 1.2 Eq., the second temperature is in a range of from about 40 0C to about 60 0C, and the second pressure is in a range of from about 3 bar to about 25 bar, or is in a range of from about 10 bar to about 25 bar, or is in a range of from about 3 bar to about I O bar.
An Example 34 of the invention includes a process comprising the steps: Step 1. reacting Compound Al, wherein Z is -O-C|.salkyl and PG is a
Cι_4alkoxycarbonyl protecting group such as Boc, with a first hydrogen source, a first ligand-metal complex consisting essentially of a first ligand conjugated with a first metal adduct, in a first solvent in the presence of an optional first additive at a first elevated temperature and first elevated pressure, to provide a substantially pure Compound A2 or a substantially pure
Compound A3, wherein the first hydrogen source is selected from gaseous hydrogen or an excess of formic acid, the first ligand is selected from the group consisting of (7?)-PhanePhos, (5)-PhanePhos,
(Λ)-An-PhanePhos, (S)-An-PhanePhos, (Λ)-Xyl-PhanePhos, (5)-Xyl-PhanePhos, (tf)-MeOXyl-PhanePhos, (SJ-MeOXyl-PhanePhos, (tf)-iPr-PhanePhos,
(5)-iPr-PhanePhos, (Λ.Λ)-Me-DuPhos, (S1S)-Me-DuPhOS, (Λ)-P-Phos, (5)-P-Phos, (Λ)-Xyl-P-Phos, (S)-Xyl-P-Phos, (φ-Ph-PHOX, (S)-Ph-PHOX, (tf)-iPr-PHOX, (S)-iPr-PHOX, (tf)-Me-BoPhoz, (5)-Me-BoPhoz, CF3Ph-(^-Me-BoPhOz, CF3Ph-(S>Me-BoPhoz, (Λ)-Phenethyl-(Λ)-Me-BoPhoz, (#)-Phenethyl-(S)-Me-BoPhoz, 3,4-diCI-Ph-(Λ)-Me-BoPhoz,
3,4-diCI-Ph-(5)-Me-BoPhoz, Xyl-(/?)-Me-BoPhoz, Xyl-(5)-Me-BoPhoz, (Λ)-Binol-(/?)-Me-BoPhoz, (Λ)-Binol-(S)-Me-BoPhoz, (5)-Binol-(5)-Me-BoPhoz, (S)-Binol-(7?)-Me-BoPhoz, PCy-(/?)-Me-BoPhoz, PCy-(5)-Me-BoPhoz, (Λ)-iPr-BoPhoz, (5)-iPr-BoPhoz, (/?)-Phenethyl-(S>BoPhoz, (Λ)-Phenethyl-(/?)-BoPhoz, (S)-Phenethyl-(Λ)-BoPhoz, (S)-Phenethyl-(5)-BoPhoz, (Λ)-Ph-BoPhoz, (S)-Ph-BoPhoz, (/?)-Bn-BoPhoz and
(5)-Bn-BoPhoz, the first metal adduct is selected from the group consisting Of [Rh(COD)2]BF4,
[Rh(COD)2]OTf, [Rh(ethylene)2CI]2, [Rh(ethylene)2(acac)], [Rh(C0)2(acac)], 5 [Rh(COD)(acac)], [Ru(COD)(CF3COO)2J2, [Ru(COD)(methylallyl)2];
[Ru(benzene)Cl2]2, [Ru(p-cymene)Cl2]2) [Ir(COD)CI]2, [Ir(COD)2]BF4 and
[Ir(COD)2]BArF, the first solvent is selected from the group consisting of MeOH, EtOH, IPA, DCE, THF, toluene, EtOAc, DMF and mixtures thereof, I O the optional first additive is selected from the group consisting of AcOH, Et3N, HBF4,
HBF4 etherate, HCI, HCI etherate, CF3COOH, CH3COOH and TsOH, and, when present, is in an amount up to about 1 .2 Eq., the first temperature is in a range of from about 25 0C to about 70 0C, and the first pressure is in a range of from about 3 bar to about 30 bar; and
15 Step 2. reacting Compound A2 or Compound A3, when R2 is selected from -aryl(R8) and -heteroaryl(R8) and Z is -O-C|.galkyl, with a second hydrogen source and a hydrogenation agent in a second solvent in the presence of an optional second additive at a second elevated temperature and a second elevated pressure to provide an isomeric mixture of a Compound A4, Compound A5, 0 Compound A6 and Compound A7, wherein R2 is selected from
-cycloalkyl(Rg) or -heterocyclyl(Rg), hydrogenated from the corresponding -aryl(Rs) and -heteroaryl(Rg), respectively, of Compound A2 or Compound A3, wherein the second hydrogen source is gaseous hydrogen, 5 the hydrogenation agent is selected from either 10% Pd/C or a second ligand-metal complex, the second ligand-metal complex consists essentially of a second ligand and an
[Ir(COD)CI]2 metal adduct combined with iodine in an amount up to about O. I Eq., 0 10% Pd/C is present in a range of weight % of from about 5% (vv/w) to about 20% (vv/vv), the second ligand is selected from the group consisting of (/?)-P-Phos, (S)-P-Phos,
(Λ)-Xyl-P-Phos, (S)-Xyl-P-Phos, (S)-Tol-P-Phos, (Λ)-Me-BoPhoz,
(S)-Me-BoPhOZ, (Λ)-Xyl-Binap and (S)-Xyl-Binap, the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA, THF, toluene, EtOAc and MTBE and mixtures thereof, the optional second additive is selected from the group consisting Of Et3N, i Pr2-N H,
Cy2NH, (Λ)-Ph-ethyl-NH2, (S)-Ph-ethyl-NH2, Kl, KOH, K2CO3,
(/?/S)-camphorsulfonic acid and CH3COOH, and, when present, is in an amount up to about 1 .2 Eq., the second temperature is in a range of from about 40 0C to about 60 0C, and the second pressure is in a range of from about 3 bar to about 25 bar, or is in a range of from about 10 bar to about 25 bar, or is in a range of from about 3 bar to about 10 bar.
An Example 35 of the invention includes a process comprising the steps: Step 1 . reacting Compound Al, wherein Z is hydroxy and PG is a C|.4alkoxycarbonyl protecting group such as Boc, with a first hydrogen source, a first ligand-metal complex consisting essentially of a first ligand conjugated with a first metal adduct, in a first solvent at a first temperature and a first pressure to provide a substantially pure Compound A2 or a substantially pure Compound A3, wherein the first hydrogen source is selected from gaseous hydrogen or an excess of formic acid, the first ligand is selected from the group consisting of (/?)-Me-BoPhoz, (S)-Me-BoPhoz, (tf)-Xyl-P-Phos, (S)-XyI-P-PhOS, (7?)-P-Phos, (S)-P-Phos, (/?)-Et-BoPhoz, (S)-Et-BoPhOZ, (Λ)-iPr-BoPhoz, (S)-iPr-BoPhoz, (Λ)-Bn-BoPhoz, (S)-Bn-BoPhOZ, (Λ)-Ph-BoPhoz, (S)-Ph-BoPhoz, the first metal adduct is [Ir(COD)Cl]2, [Ir(COD)2]BF4 and [Ir(COD)2]BArF, the first solvent is selected from the group consisting of THF, EtOAc and toluene, the first temperature is about 70 0C, and the first pressure is about 25 bar, and Step 2. reacting Compound A2 or Compound A3, when R2 is selected from -aryl(R8) and -heteroaryl(Rs) and Z is hydroxy, by the direct addition of iodine in an amount up to about 0.1 Eq., and recharging the reaction mixture at an elevated second temperature and an elevated second pressure, wherein the second temperature is in a range of from about 30 0C to about 80 0C, and the second pressure is in a range of from about 3 bar to about 25 bar.
An Example 36 of the invention includes a process wherein, when Z is hydroxy for Compound Al, the first ligand is selected from the group consisting of (7?)-Me-BoPhoz and (S)-Me-BoPhOZ, and the first metal adduct is [Ir(COD)CI]2.
An Example 37 of the invention includes a process comprising the steps: Step 1 . reacting Compound Al, wherein Z is -O-C|.8alkyl and PG is a C|.4alkoxycarbonyl protecting group such as Boc, with a first hydrogen source, a first ligand-metal complex consisting essentially of a first ligand conjugated with a first metal adduct, in a first solvent at a first temperature and a first pressure to provide a substantially pure Compound A2 or a substantially pure Compound A3, wherein the first hydrogen source is selected from gaseous hydrogen or an excess of formic acid, the first ligand is selected from the group consisting of (-K)-PhanePhos, (S)-PhanePhos, (Λ)-An-PhanePhos, (S)-An-PhanePhos, (Λ)-Xyl-PhanePhos, (S)-Xyl-PhanePhos,
(Λ)-MeOXyl-PhanePhos, (S)-MeOXyl-PhanePhos, (/?)-iPr-PhanePhos, (S)-iPr-PhanePhos, CR,tf)-Me-DuPhos, (S, S)-Me-Du Phos, (Λ)-P-Phos, (S)-P-Phos, (i?)-Xyl-P-Phos, (S)-Xyl-P-Phos, (tfj-Ph-PHOX, (S)-Ph-PHOX, (Λ)-iPr-PHOX, (S)-iPr-PHOX, (/?)-Me-BoPhoz, (S)-Me-BoPhoz, CF3Ph-(tf)-Me-BoPhoz, CF3Ph-(S;-Me-BoPhoz, (7?)-Phenethyl-(tf)-Me-BoPhoz,
(Λ)-Phenethyl-(S)-Me-BoPhoz, 3,4-diCl-Ph-(Λ)-Me-BoPhoz, 3,4-diCI-Ph-(S)-Me-BoPhoz, Xyl-(/?)-Me-BoPhoz, Xyl-(S)-Me-BoPhoz, (/?)-Binol-(tf)-Me-BoPhoz, (/?)-Binol-(S)-Me-BoPhoz, (S)-Binol-(S)-Me-BoPhoz, (S)-Binol-(#)-Me-BoPhoz, PCy-(#)-Me-BoPhoz, PCy-(S)-Me-BoPhoz, (Λ)-iPr-BoPhoz, (5)-iPr-BoPhoz, (J?)-Phenethyl-(S)-BoPhoz,
(Λ)-PhenethyKΛ)-BoPhoz, (S)-Phenethyl-(Λ)-BoPhoz,
(5)-Phenethyl-(5)-BoPhoz, (Λ)-Ph-BoPhoz, (S)-Ph-BoPhoz, (tf)-Bn-BoPhoz and
(S)-Bn-BoPhOz, the first metal adduct is selected from the group consisting Of [Ir(COD)Cl]:,
[Ir(COD)2]BF4 and [lr(COD)2]BArF, the first solvent is selected from the group consisting of THF, toluene, EtOAc and mixtures thereof, the first temperature is in a range of from about 25 0C to about 70 0C, and the first pressure is in a range of from about 3 bar to about 30 bar; and
Step 2. reacting Compound A2 or Compound A3, when R2 is selected from -aryl(Rs) and -heteroaryl(Rs) and Z is -O-Ci.salkyl, by the direct addition of iodine in an amount up to about 0.1 Eq., and recharging the reaction mixture at an elevated second temperature and an elevated second pressure, wherein the second temperature is in a range of from about 30 0C to about 80 0C, and the second pressure is in a range of from about 3 bar to about 25 bar.
An Example 38 of the invention includes a process wherein, when Z is -O-Ci.salkyl for Compound Al, the first ligand is selected from the group consisting of (7?)-Me-BoPhoz and (.S)-Me-BoPhoz, and the first metal adduct is [Ir(COD)CI]2.
An Example 39 of the invention includes a Compound Al, wherein the compound is selected from the group consisting of:
Cpd Names
Cl (Z)-4-(3-methoxycarbonyl-2-quinolin-3-yl-allyl)-piperidine-l -carboxylic acid tert-butyl ester, and
Dl (Z)-4-(3-carboxy-2-quinolin-3-yl-allyl)-piperidine-l -carboxylic acid tert-butyl ester.
As used throughout the various schemes presented, the Greek letters "α" and "β" refer to targeted chiral carbon atoms in the compound of Formula (I) for enantioselective hydrogenation according to the process of the present invention. The Greek letter "α" refers to asymmetric hydrogenation of the vinyl ester bond of Compound Al, for example, that is "α" to the chiral carbon atom, wherein the bond is hydrogenated to an R or S enantiomer, depending on the isomer of the ligand-metal complex used. The Greek letter "β" refers to enantioselective hydrogenation of the R2 aromatic ring system of Compound A2 or Compound A3 (wherein R2 is selected from -aryl(Rs) and -heteroaryl(Rs)), for example, that is "β" to the chiral carbon atom, wherein the bond is hydrogenated to an isomeric mixture of Compound A4 (an αR,βR isomer), Compound A5 (an αR,βS isomer), Compound A6 (an αS,βS isomer) and Compound A7 (an αS,βR isomer) (each wherein R2 is selected from -cycloalkyl(Rs) or
Figure imgf000034_0001
Alternatively, Scheme B represents a process for providing a desired isomer of a compound of Formula (I).
Scheme B
Step 1. reacting a Compound Bl with a first hydrogen source, a first ligand-metal complex consisting essentially of a first ligand conjugated with a first metal adduct, in a first solvent in the presence of an optional first additive at an elevated first temperature and an elevated first pressure to provide a substantially pure Compound B2 or a substantially pure Compound B3:
Figure imgf000034_0002
. Step 2. optionally converting Compound B2 or Compound B3, each wherein Z is hydroxy, to a Compound B2 or a Compound B3, each wherein Z is -O-C|.8alkyl;
Step 3. optionally reacting Compound B3, when R2 is selected from -aryl(Rs) and
-heteroaryl(Rs), with a second hydrogen source and a hydrogenation agent in a second solvent at an elevated second temperature and an elevated second pressure to provide an isomeric mixture of a Compound B4 and Compound B5, wherein R2 is selected from
Figure imgf000035_0001
or -heterocyclyl(R8), hydrogenated from the corresponding -aryKRg) and -heteroaryl(Rs), respectively, of Compound B3:
.
Figure imgf000035_0002
Step 4. converting the isomeric mixture of Compound B4 and Compound B5, each when Z is hydroxy, to an isomeric mixture of Compound B4 and Compound B5, each wherein Z is -O-C|.salkyl;
Step 5. separating each of Compound B4 and Compound B5, each wherein Z is -0-Cι-salkyl, from the isomeric mixture;
Step 6. optionally dehydrogenating Compound B5, wherein Z is -O-Ci-salkyl and R2 is selected from -cycloalkyl(Rs) or -heterocyclyl(Rg), to Compound B3, wherein Z is -O-Ci-salkyl and R2 is selected from -aryl(R8) or -heteroaryl(Rs), dehydrogenated from the corresponding -cycloalkyl(Rs) or -heterocyclyl(Rs), respectively, of Compound B5, and then repeating Step 3 using said
Compound B3 as the starting material;
Step 7. deprotecting Compound B4, wherein Z is -O-Ci-salkyl, to provide a Compound B6:
B4, (αS.βS) isomer ►
Figure imgf000035_0003
Step 8. reacting the Compound B6, wherein Z is -0-Cι-salkyl, with a Compound A14 to provide a Compound B7, wherein Z is -0-Cι-salkyl of Formula (I):
B6, (αS,βS) isomer
Figure imgf000036_0001
Step 9. converting the Compound B7, wherein Z is -0-Cι.salkyl, to a Compound B7, 5 wherein Z is hydroxy, of Formula (I).
An Example 40 of the invention includes a process wherein, Compound B2 is carried forward in place of Compound B3 to provide an (aRβR) isomer and an (aR,βS) isomer of Formula (1).
An Example 41 of the invention includes a process wherein, when Z is hydroxy I O for Compound Bl, the first ligand is selected from the group consisting of (Λ)-Xyl-PhanePhos,
(φ-Xyl-PhanePhos, (Λ;-PhanePhos, (SλPhanePhos, (φ-An-PhanePhos, (5;-An-PhanePhos, (Λ)-Me-BoPhoz, (5)-Me-BoPhoz,.(/?)-MeOXyl-PhanePhos, (S;-MeOXyl-PhanePhos, (tf)-iPr-PhanePhos, (S)-iPr-PhanePhos, 15 PCy-(i?)-Me-BoPhoz and PCy-(S)-Me-BoPhoz, the first metal adduct is selected from the group consisting Of [Rh(COD)2]BF4,
[Rh(COD)2]OTf, [Rh(ethylene)2CI]2, [Rh(ethylene)2(acac)], [Rh(CO)2(acac)], [Rh(COD)2CI]2, [Rh(COD)(acac)], [Rιι(COD)(CF3COO)2]2, [Ru(COD)(CH3COO)2], [Ru(COD)(methylallyl)2], [Ru(benzene)CI2]2, 0 [Ru(p-cymene)CI2]2, [Ru(mesitylene)CI2]2, [Ir(COD)CI]2, [Ir(COD)2]BF4 and
[lr(COD)2]BArF, the first temperature is in a range of from about 25 0C to about 70 0C, and the first pressure is in a range of from about 3 bar to about 30 bar.
An Example 42 of the invention includes a process wherein, when Z is hydroxy 5 for Compound Bl, the first ligand-metal complex is selected from the group consisting of (Λ>An-PhanePhos/[Rh(COD)]BF4, (/?)-Me-BoPhoz &[Ir(COD)CI]2, (Λj-MeOXyl-PhanePhos/[Rh(COD)]BF4, (Λ>PhanePhos/[Rh(COD)]BF4, (φ-PhanePhos A[Rh(COD)2]OTf, (Λ;-PhanePhos/[RuCl2(DMF)2], (Λ;-Tol-Binap/[RuCI(p-cymene)]CI, (φ-Xyl-PhanePhos &[Ru(COD)(CF3COO)2]2, (Λj-Xyl-PhanePhos &[Ru(COD)(methylallyl)2], (/?J-Xyl-PhanePhos/[RuCI2(DMF)2], W-Xyl-P-Phos/[RuCI2(DMF)2]: (S)-iPr-PhanePhos/[Rh(COD)]BF4, (5>Me-BoPhoz/[RuCI2(DMF)2], (5;-PhanePhos/[RuCI2(DMF)2], (5>Tol-Binap/[RuCIO-cymene)]CI, (5;-Xyl-PhanePhos &[Rh(COD)2]OTf and (5>Xyl-PhanePhos/[RuCl2(DMF)2]. An Example 43 of the invention includes a process wherein, when Z is hydroxy for Compound Bl, the first ligand is selected from the group consisting of (Λ)-Xyl-PhanePhos,
(φ-Xyl-PhanePhos, (φ-PhanePhos, (Sj-PhanePhos, (Λj-An-PhanePhos, (5;-An-PhanePhos, (/?)-Me-BoPhoz, (5)-Me-BoPhoz, (Λ)-MeOXyl-PhanePhos and (5^-MeOXyl-PhanePhos, and the first metal adduct is selected from the group consisting Of [Rh(COD)2]BF4, [Rh(COD)2]OTf, [RU(CODKCF3COO)2J2, [Ru(COD)(methylallyl)2], [Ru(benzene)CI2]2 and [Ir(COD)CI]2.
An Example 44 of the invention includes a process wherein, when Z is hydroxy for Compound Bl, the first ligand is selected from the group consisting of (7?)-Xyl-PhanePhos,
(Sj-Xyl-PhanePhos, (Λ>PhanePhos, rø-PhanePhos, (φ-An-PhanePhos,
(5;-An-PhanePhos, (Λ)-Me-BoPhoz, (5)-Me-BoPhoz, (Λ)-MeOXyl-PhanePhos and (5>-MeOXyl-PhanePhos, and the first metal adduct is selected from the group consisting of [Rh(COD)2]BF4,
[Rh(COD)2]OTf, [Ru(COD)(CF3COO)2]2, [Ru(COD)(methylallyl)2],
[Ru(benzene)CI2]2 and [Ir(COD)CI]2. An Example 45 of the invention includes a process wherein, when Z is hydroxy for Compound Bl, the first ligand is selected from the group consisting of (Λ)-Me-BoPhoz and
(S)-Me-BoPhOz, the first metal adduct is [Ir(COD)CI]2, the first solvent is selected from the group consisting of THF, DCE and EtOAc, the first temperature is in a range of from about 65 0C to about 70 0C, and the first pressure is in a range of from about 25 bar to about 30 bar.
An Example 46 of the invention includes a process wherein, when Z is hydroxy for Compound Bl, the first ligand is selected from the group consisting of (/?)-PhanePhos , (5)-PhanePhos,
(/?)-An-PhanePhos, (S)-An-PhanePhos, (/?)-Xyl-PhanePhos, (5)-Xyl-PhanePhos,
(/?)-MeOXyl-PhanePhos, (5)-MeOXyl-PhanePhos, (5)-iPr-PhanePhos and
(i*?)-iPr-PhanePhos, the first metal adduct is selected from the group consisting of [Rh(COD)2]BF4,
[Rh(COD)2]OTf, [Rh(ethylene)2CI]2, [Rh(ethylene)2(acac)], [Rh(CO)2(acac)],
[Rh(COD)CI]2 and [Rh(COD)(acac)], the first solvent is MeOH, the first temperature is from about 25 0C to about 60 0C, and the first pressure is from about 3 bar to about 30 bar. An Example 47 of the invention includes a process wherein, when Z is hydroxy for Compound Bl, the first ligand is selected from the group consisting of (/?)-PhanePhos , (5)-PhanePhos, (Λ)-An-PhanePhos, (5)-An-PhanePhos, (tf)-Xyl-PhanePhos, (S>Xyl-PhanePhos, (tf)-MeOXyl-PhanePhos, (S>MeOXyl-PhanePhos, (5)-iPr-PhanePhos and (/?)-iPr-PhanePhos, the first metal adduct is selected from the group consisting of [Ru(COD)(CF3COO)2J2, [Ru(COD)(CH3COO)2], [Ru(COD)(methylallyl)2], [Ru(benzene)CI2]2, [Ru(p-cymene)Cl2]2 and [Ru(mesitylene)Cl2]2, the first solvent is selected from the group consisting of MeOH, EtOH, IPA, DCE, THF, toluene, EtOAc, DMF and mixtures thereof, the optional first additive is selected from the group consisting of AcOH, CF3CO2H and
Et3N, the first temperature is in a range of from about 40 0C to about 70 0C, and the first pressure is in a range of from about 3 bar to about 30 bar. An Example 48 of the invention includes a process wherein, when Z is hydroxy for Compound Bl, the first ligand is (/?)-XylPhanePhos, the first metal adduct is selected from the group consisting Of [Ru(COD)(CF3COO)2J2,
[RU(CODXCH3COO)2], [Ru(COD)(methylallyl)2], [Ru(benzene)CI2]2, [Ru(p-cymene)CI2]2 and [Ru(mesitylene)Cl2]2, the first solvent is selected from the group consisting of MeOH, DMF and mixtures thereof, the optional first additive is Et3N, the first temperature is in a range of from about 40 0C to about 60 0C, and the first pressure is in a range of from about 3 bar to about 30 bar.
An Example 49 of the invention includes a process wherein, when Z is hydroxy for Compound Bl, the first ligand is (/?)-XylPhanePhos, the first metal adduct is selected from the group consisting of [Ru(COD)(CF3COO)2]2, [Ru(COD)(CH3COO)2], [Ru(COD)(methylallyl)2], [Ru(benzene)CI2]2,
[Ru(p-cymene)CI2]2 and [Ru(mesitylene)Cl2]2, the first solvent is selected from the group consisting of MeOH, DMF and mixtures thereof, the optional first additive is AcOH, the first temperature is about 40 0C, and the first pressure is about 10 bar.
An Example 50 of the invention includes a process wherein, when Z is hydroxy for Compound Bl, the first ligand is (/?)-XylPhanePhos, the first metal adduct is selected from the group consisting of [Ru(COD)(CF3COO)2]2, [Ru(COD)(CH3COO)2], [Ru(COD)(methylallyl)2], [Ru(benzene)CI2]2; [Ru(p-cymene)CI2]2 and [Ru(mesitylene)CI2]2, the first solvent is selected from the group consisting of MeOH, EtOH, IPA, DCE, THF, toluene, EtOAc, DMF and mixtures thereof, the first temperature is about 40 0C, and the first pressure is about 10 bar.
An Example 51 of the invention includes a process wherein, when Z is hydroxy for Compound Bl, the first ligand is (/?)-XylPhanePhos, the first metal adduct is [Ru(COD)(CF3COO)2J2, [Ru(COD)(CH3COO)2] and
[Ru(COD)(methylallyl)2], the first solvent is MeOH, and the first optional additive is AcOH, the first temperature is about 40 0C, and the first pressure is about 10 bar.
An Example 52 of the invention includes a process wherein, when Z is -0-Cι-salkyl for Compound BI, the first ligand is selected from the group consisting of (i?)-PhanePhos, (S)-PhanePhos, (Λ)-An-PhanePhos, (S)-An-PhanePhos, (Λ)-Xyl-PhanePhos, (S)-Xyl-PhanePhos,
(J?)-MeOXyl-PhanePhos, (S)-MeOXyl-PhanePhos, (Λ)-iPr-PhanePhos, (S)-iPr-PhanePhos, (tf,#)-Me-DuPhos, (S,S)-Me-DuPhos, (Λ)-P-Phos, (5)-P-Phos, (Λ)-Xyl-P-Phos, (S)-Xyl-P-Phos, W-Ph-PHOX, (S)-Ph-PHOX, (Λ)-iPr-PHOX, (S)-iPr-PHOX, (Λ)-Me-BoPhoz, (S)-Me-BoPhoz, CF3Ph-(^-Me-BoPhOZ, CF3Ph-(S;-Me-BoPhoz, (/?)-Phenethyl-(.S)-Me-BoPhoz,
3,4-diCl-Ph-(Λ)-Me-BoPhoz, 3,4-diCI-Ph-(5)-Me-BoPhoz, Xyl-(/?)-Me-BoPhoz, Xyl-(5)-Me-BoPhoz, (Λ)-Binol-(Λ)-Me-BoPhoz, (/?)-Binol-(S)-Me-BoPhoz, (5)-Binol-(5)-Me-BoPhoz, (5)-Binol-(Λ)-Me-BoPhoz, PCy-(/?)-Me-BoPhoz, PCy-(S)-Me-BoPhoz, (Λ)-iPr-BoPhoz, (S)-iPr-BoPhoz, (Λ)-Et-BoPhoz, (S)-Et-BoPhOz, (/?)-Phenethyl-(S)-BoPhoz, (/?)-Phenethyl-(7?)-BoPhoz, (S)-Phenethyl-(Λ)-BoPhoz, (S)-Phenethyl-(S)-BoPhoz, (Λ)-Ph-BoPhoz,
(.S)-Ph-BoPhOz, (/?)-Bn-BoPhoz and (S)-Bn-BoPhoz, the first metal adduct is selected from the group consisting Of [Ir(COD)2]BArF,
[Ir(COD)2]BF4, [Ir(COD)CI]2, [Rh(ethylene)2CI]2, [Rh(ethylene)2(acac)], [Rh(COD) CI]2, and [Rh(COD)(acac)], the first solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA, THF, toluene, EtOAc, DMF, and mixtures thereof, the optional first additive is selected from the group consisting of Et3N, HBF4,
CH3COOH and TsOH, and, when present, is in an amount up to about 1.2 Eq., the first temperature is in a range of from about 50 0C to about 70 0C, and the first pressure is in a range of from about 10 bar to about 30 bar.
An Example 53 of the invention includes a process wherein, when Z is -0-Cι-galkyl for Compound Bl, the first ligand-metal complex is selected from the group consisting of (/?)-An-Phanephos/[Rh(COD)]BF4, (/?)-Binol-(y?)-Me-BoPhoz &[Ir(C0D)CI]2, (Λ)-Bn-BoPhoz A[Ir(COD)Cl]2, (tf)-iPr-BoPhoz A[Rh(COD)2]OTf, (Λ)-iPr-PHOX/[lr(COD)]BArF, (7?)-iPr-PHOX/[Ir(COD)]BF4, (tf)-Me-BoPhoz A[Ir(COD)CI]2, (Λ)-Me-BoPhoz A[Rh(CO)2(acac)], (Λ)-Me-BoPhoz &[Rh(COD)2]OTf, CK)-Me-BoPhOz A[Rh(ethylene)2(acac)], (Λ)-Me-BoPhoz &[Rh(ethylene)2CI]2, (Λ)-Me-BoPhoz/[RuCI2(DMF)2], (Λ)-Phanephos A[Ir(COD)CI]2, (Λ)-Phanephos &[Rh(ethylene)2CI]2, (tf)-Ph-BoPhoz A[Ir(COD)CI]2, (Λ)-Phenethyl-(Λ)-BoPhoz &[Rh(ethylene)2CI]2, (Λ)-Phenethyl-(5)-BoPhoz &[Rh(ethylene)2CI]2, (/?)-Phenethyl-(5)-Me-BoPhoz &[Ir(COD)CI]2, (/?)-Ph-PHOX/[Ir(COD)]BArF, (7?)-Xyl-Phanephos/[Rh(COD)]BF4, (Λ)-Xyl-P-Phos A[Rh(CO)2(acac)], (Λ)-Xyl-P-Phos &[Rh(ethylene)2(acac)], (7?)-Xyl-P-Phos &[Rh(ethylene)2CI]2, (Λ)-Xyl-P-Phos/[Ru(p-cymene)CI]CI, (Λ,Λ)-MeDuPhos/[Rh(COD)]BF4,
(5)-Binol-(/?)-Me-BoPhoz A[Ir(COD)CI]2, (5)-Binol-(R)-Me-BoPhoz A[Rh(COD)2]OTf, (5)-Me-BoPhoz A[Ir(COD)CI]2, (5)-PhanePhos/[Rh(COD)]BF4, (S)-P-Phos/[lr(COD)]CI, (5)-P-PhosA[Ir(COD)CI]2, (5)-P-Phos/[Ru(benzene)CI]CI, (S)-P-Phos/[RuCI2(DMF)2], (5)-Xyl-P-Phos/[Ir(COD)]CI, (5)-XyI-P-Phos A[Ir(COD)CI]2, (_S)-Xyl-P-Phos/[RuCI2(DMF)2], 3,4-diCIPh-(Λ)-Me-BoPhoz A[Ir(COD)CI]2, CF3Ph-(R)-Me-BoPhOZ &[Rh(COD)2]OTf, PCy-(7?)-Me-BoPhoz A[Ir(COD)CI]2 and Xyl-(Λ)-Me-BoPhoz &[lr(COD)CI]2.
An Example 54 of the invention includes a process wherein, when Z is -O-Ci-galkyl for Compound Bl, the first ligand is selected from the group consisting of (/?)-PhanePhos, (S)-PhanePhos, (tf)-An-PhanePhos, (Λ)-Xyl-PhanePhos, (S)-P-Phos, (Λ)-Xyl-P-Phos, (S)-Xyl-P-Phos, W-Ph-PHOX, (Λ)-iPr-PHOX, (Λ)-Me-BoPhoz, (S)-Me-BoPhoz, CF3Ph-(Λ>Me-BoPhoz, CF3Ph-(S>Me-BoPhoz, 3,4-diCI-Ph-(Λ)-Me-BoPhoz, 3,4-diCI-Ph-(S)-Me-BoPhoz, Xyl-(Λ)-Me-BoPhoz, (/?)-Binol-(Λ)-Me-BoPhoz, (S)-Binol-(Λ)-Me-BoPhoz, (Z?)-iPr-BoPhoz, (S)-iPr-BoPhoz,
(Λ)-Phenethyl-(S)-BoPhoz, (Λ)-Phenethyl-(/.)-BoPhoz, (Λ)-Ph-BoPhoz and (Λ)-Bn-BoPhoz, the first metal adduct is selected from the group consisting of [Rh(COD)2]BF4,
[Rh(COD)2]OTf, [Rh(ethylene)2CI]2, [Rh(ethylene)2(acac)], [Rh(CO)2(acac)J, [Ru(p-cymene)CI2]2, [Ir(COD)CI]2 and [lr(COD)2]BArF, the first solvent is selected from the group consisting of MeOH, DCE, EtOH, toluene,
EtOAc, 2-propanol, THF, and mixtures thereof, the optional first additive is selected from the group consisting Of HBF4, AcOH and
TsOH, and, when present, is in an amount up to about 1.2 Eq., the first temperature is in a range of from about 50 0C to about 90 0C, and the first pressure is in a range of from about 10 bar to about 30 bar.
An Example 55 of the invention includes a process wherein, when Z is -O-C|.8alkyl for Compound Bl, the first ligand is selected from the group consisting of (Λ)-PhanePhos, (S)-PhanePhos, (5)-P-Phos, (Λ)-Xyl-P-Phos, (S)-Xyl-P-Phos, W-Ph-PHOX, (Λ)-iPr-PHOX,
(Λ)-Me-BoPhoz, (S)-Me-BoPhoz, CF3Ph-W-Me-BoPhOZ, CF3Ph-(S)-Me-BoPh0Z, 3,4-diCI-Ph-(tf)-Me-BoPhoz, 3,4-diCI-Ph-(S)-Me-BoPhoz, Xyl-(/?)-Me-BoPhoz, Xyl-(S)-Me-BoPhoz, (Λ)-Binol-(/?)-Me-BoPhoz, (S)-BInOl-(^)-Me-BoPhOZ, (/?)-Phenethyl-(S)-BoPhoz, (7?)-Phenethyl-(/?)-BoPhoz, (/?)-Bn-BoPhoz and (S)-Bn-BoPhoz, the first metal adduct is selected from the group consisting Of [Rh(COD)2]BF4,
[Rh(COD)2]OTf, [Rh(COD)CI]2, [Rh(ethylene)2CI]2, [Rh(ethylene)2(acac)]s [Rh(CO)2(acac)], [Ru(p-cymene)CI2]2, [Ir(COD)CI]2, [Ir(COD)2]BF4 and [lr(COD)2]BArF,
5 the first solvent is selected from the group consisting of DCE, THF, toluene, EtOAc, and mixtures thereof, the optional first additive is selected from the group consisting Of HBF4 and TsOH, and, when present, is in an amount up to about 1 .2 Eq., the first temperature is in a range of from about 50 0C to about 90 0C, and I O the first pressure is about 30 bar.
An Example 56 of the invention includes a process wherein, when Z is -O-C|.8alkyl for Compound Bl, the first ligand is selected from the group consisting of (/?)-Me-BoPhoz, (S)-Me-BoPhOZ,
3,4-diCI-Ph-(Λ)-Me-BoPhoz, 3,4-diCI-Ph-(5)-Me-BoPhoz, Xyl-(Λ)-Me-BoPhoz, 1 5 XyI-(S)-Me-BoPhOZ, (j"?)-Bn-BoPhoz and (S)-Bn-BoPhoz, the first metal adduct is selected from the group consisting Of [Ir(COD)CI]2 and
[lr(COD)2]BArF, the first solvent is selected from the group consisting of MeOH, DCE, THF, toluene,
EtOAc, I PA, and mixtures thereof, 0 the optional first additive is HBF4, and, when present, is in an amount up to about 1 .2
Eq., the first temperature is in a range of from about 50 0C to about 90 0C, and the first pressure is from about 25 bar to about 30 bar.
An Example 57 of the invention includes a process wherein, when R2 is selected 5 from -aryl(R8) and -heteroaryl(R8) for Compound B2 or Compound B3, the second hydrogen source is gaseous hydrogen, the hydrogenation agent is selected from either 10% Pd/C or a second ligand-metal complex, wherein the second ligand-metal complex consists essentially of a second ligand and an [Ir(COD)CI]2 metal adduct combined with iodine in an amount up to about 0.1 Eq., wherein 10% Pd/C is present in a range of weight % of from about 5% weight/weight (w/vv) to about 20% (w/w), and wherein the second ligand is selected from the group consisting of (/?)-PhanePhos, (SyPhanePhos, (Λ)-An-PhanePhos, (S)-An-PhanePhos, (/?)-Xyl-PhanePhos, (S)-Xyl-PhanePhos, (7?)-MeOXyl-PhanePhos, (S)-MeOXyl-PhanePhos, (/?)-iPr-PhanePhos, (S)-iPr-PhanePhos, (/..φ-Me-DuPhos, (5,S)-Me-DuPhOS, (Λ)-P-Phos, (S)-P-PhOs, (Λ)-Xyl-P-Phos, (S)-Xyl-P-Phos, (Λ)-Tol-P-Phos,
(S)-Tol-P-Phos, W-Ph-PHOX, (S)-Ph-PHOX, (Λ)-iPr-PHOX, (S)-iPr-PHOX, (Λ)-Me-BoPhoz, (S)-Me-BoPhoz, CF3Ph-(/?)-Me-BoPhoz, CF3Ph-(S;-Me-BoPhoz, (Λ)-Phenethyl-(Λ)-Me-BoPhoz, (/?)-Phenethyl-(5)-Me-BoPhoz, (S)-Ethyl-Napthyl-(j|?)-Me-BoPhoz, 3,4-diCI-Ph-(Λ)-Me-BoPhoz, 3,4-diCI-Ph-(S)-Me-BoPhoz,
(Λ)-2,4s6-F3Ph-(/?)-Me-BoPhoz, (Λ)-2,4,6-F3Ph-(.S)-Me-BoPhoz, (S)-2,4,6-F3Ph-(S)-Me-BoPhoz, (S)-2,4,6-F3Ph-(tf)-Me-BoPhoz, Xyl-(Λ)-Me-BoPhoz, Xyl-(S)-Me-BoPhoz, (/?)-Binol-(7?)-Me-BoPhoz, (/?)-Binol-(S)-Me-BoPhoz, (S)-Binol-(S)-Me-BoPhoz, (S)-B inol-(tf)-Me-BoPhoz, PCy-(7?)-Me-BoPhoz, pFPh-(Λ)-Me-BoPhoz, pFPh-(S)-Me-BoPhoz,
(Λ)-Et-BoPhoz, (S)-Et-BoPhOZ, pFPh-(7?)-Et-BoPhoz, pFPh-(S)-Et-BoPhoz, (/?)-iPr-BoPhoz, (S)-iPr-BoPhoz, (Λ)-Et-BoPhoz, (S)-Et-BoPhoz, (/?)-Phenethyl-(S)-BoPhoz, (/?)-Phenethyl-(/?)-BoPhoz, (S)-Phenethyl-(/?)-BoPhoz, (S)-Phenethyl-(S)-BoPhoz, (/?)-Ph-BoPhoz, (S)-Ph-BoPhoz, (fl)-Bn-BoPhoz, (S)-Bn-BoPhoz, pFPh-(7?)-Bn-BoPhoz, pFPh-(S)-Bn-BoPhoz, (i?)-Xyl-Binap, (S)-Xyl-Binap and DPPF, the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA, THF, toluene, EtOAc, 1 -BuOH and MTBE and mixtures thereof, the optional second additive is selected from the group consisting Of Et3N, iPn-NH, Cy2NH, (/?)-Ph-ethyl-NH2, (S)-Ph-ethyl-NH2, Kl, KOH, K2CO3, (/?/5)-camphorsulfonic acid and CH3COOH, and, when present, is in an amount up to about 1 .2 Eq., the second temperature is in a range of from about 30 0C to about 80 0C, or is in a range of from about 40 0C to about 60 0C, and the second pressure is in a range of from about 3 bar to about 25 bar, or is in a range of from about 10 bar to about 25 bar, or is in a range of from about 3 bar to about 10 bar.
An Example 58 of the invention includes a process wherein, when Z is hydroxy and R2 is selected from -aryl(R8) and -heteroaryl(Rg) for Compound B2 or Compound B3, the second ligand-metal complex is selected from the group consisting of (tf)-Me-BoPhoz A[Ir(COD)CI]2, (tf)-PhanePhos &[lr(COD)CI]2l (tf)-P-Phos A[Ir(COD)Cl]2, (tf)-Xyl-Binap A[Ir(COD)CI]2, (tf)-Xyl-PhanePhos A[Ir(COD)CI]2, (tf)-Xyl-P-Phos A[Ir(COD)CI]2, (S)-Me-BoPhoz A[Ir(COD)Cl]2, (S)-PhanePhos A[Ir(COD)CI]2, (S)-P-PhOsA[Ir(COD)CI]2, (S)-Tol-P-PhosA[Ir(COD)CI]2, (S)-Xyl-Binap A[Ir(COD)Cl]2, (S)-Xyl-PhanePhos A[Ir(COD)CI]2 and (S)-Xyl-P-Phos A[Ir(COD)CI]2.
An Example 59 of the invention includes a process wherein, when Z is -0-Cι-salkyl and R2 is selected from -aryl(R8) and -heteroaryl(Rs) for Compound B2 or Compound B3, the second ligand-metal complex is selected from the group consisting of (Λ)-Binol-(Λ)-Me-BoPhoz A[Ir(COD)CI]2, (J?)-Et-BoPhoz A[Ir(COD)CI]2,
(tf)-iPr-BoPhoz A[Ir(COD)CI]2, (Λ)-Me-BoPhoz A[Ir(COD)CI]2, (tf)-Ph-BoPhoz A[Ir(COD)CI]2, (Λ)-Phenethyl-(S)-BoPhoz A[Ir(COD)CI]2, (tf)-Xyl-PhanePhos A[Ir(COD)CI]2, (Λ)-Xyl-P-Phos A[Ir(COD)CI]2, (S)-Binol-(tf)-Me-BoPhoz A[Ir(COD)CI]2, (S)-Ethyl-Naphthyl-(Λ)-BoPhoz A[Ir(COD)CI]2, (S)-Me-BoPhoz A[Ir(COD)CI]2, (5)-Xyl-PhanePhos A[Ir(COD)Cl]2, (S)-Xyl-P-Phos A[Ir(COD)CI]2, 2,4,6-F3Ph-(/?)-Me-BoPhoz A[Ir(COD)Cl]2, DPPF A[Ir(COD)CI]2, DtBPF A[Ir(COD)CI]2, PCy-(#)-Me-BoPhoz A[Ir(COD)CI]2, pFPh-(/?)-Bn-BoPhoz A[Ir(COD)CI]2, pFPh-(/?)-Et-BoPhoz A[Ir(COD)CI]2, pFPh-(/?)-Me-BoPhoz A[Ir(COD)CI]2 and Xyl-(/?)-Me-BoPhoz A[Ir(COD)CI]2. An Example 60 of the invention includes a process wherein, when Z is hydroxy and R.2 is selected from -aryl(Rs) and -heteroaryl(Rs) for Compound B2 or Compound B3, the second ligand is selected from the group consisting of (7?)-P-Phos, (5)-P-Phos, (Λ)-Xyl-P-Phos, (S)-Xyl-P-Phos, (5)-Tol-P-Phos, (/?)-Me-BoPhoz,
(S)-Me-BoPhoz, (Λ)-Xyl-Binap and (5)-Xyl-Binap, the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA,
THF, toluene, EtOAc and MTBE and mixtures thereof, the second temperature is in a range of from about 40 0C to about 60 0C, and the second pressure is in a range of from about 3 bar to about 25 bar, or is in a range of from about 10 bar to about 25 bar, or is in a range of from about 3 bar to about I O bar.
An Example 61 of the invention includes a process wherein, when Z is -O-Ci-galkyl and R2 is selected from -aryl(Rs) and -heteroaryl(Rg) for Compound B2 or Compound B3, the second ligand is selected from the group consisting of (7?)-Xyl-PhanePhos,
(Λ)-P-Phos, OS)-P-PhOS, (Λ)-Xyl-P-Phos, (S)-Xyl-P-Phos, (5)-Tol-P-Phos, (TJ)-Me-BoPhOZ, (S")-Me-BoPhoz, (/?)-Phenethyl-(S)-Me-BoPhoz, (S)-Ethyl-Napthyl-(#)-Me-BoPhoz, (Λ)-2,4,6-F3Ph-(Λ)-Me-BoPhoz, Xyl-(/?)-Me-BoPhoz, (Λ)-Binol-(Λ)-Me-BoPhoz, (S)-Binol-(Λ)-Me-BoPhoz,
PCy-(Λ)-Me-BoPhoz, pFPh-(/?)-Me-BoPhoz, (tf)-Et-BoPhoz, pFPh-(#)-Et-BoPhoz, (Λ)-iPr-BoPhoz, (tf)-Ph-BoPhoz, pFPh-(Λ)-Bn-BoPhoz, (Λ)-Xyl-Binap, (S)-Xyl-Binap, DtBPF and DPPF, the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA, THF, toluene, EtOAc, I -BuOH and MTBE and mixtures thereof, the second temperature is in a range of from about 30 0C to about 80 0C, and the second pressure is in a range of from about 3 bar to about 25 bar.
An Example 62 of the invention includes a process wherein, when R2 is selected from -aryl(R8) and -heteroaryl(R8) for Compound B2 or Compound B3, the second hydrogen source is gaseous hydrogen, 10% Pd/C is present in a range of weight % of from about 5% (w/vv) to about 20% (w/w), the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA,
THF, toluene, EtOAc, I -BuOH and MTBE and mixtures thereof, the optional second additive is selected from the group consisting of Et3N, iPr^-NH, Cy2NH, (Λ)-Ph-ethyl-NH2, (S)-Ph-ethyl-NH2, Kl, KOH, K2CO3,
(7?/S)-camphorsulfonic acid and CH3COOH, and, when present, is in an amount up to about 1.2 Eq., the second temperature is in a range of from about 30 0C to about 80 0C, or is in a range of from about 40 0C to about 60 0C, and the second pressure is in a range of from about 3 bar to about 25 bar, or is in a range of from about I O bar to about 25 bar, or is in a range of from about 3 bar to about 10 bar.
An Example 63 of the invention includes a process wherein, when R2 is selected from -aryl(Rs) and -heteroaryl(Rs) for Compound B2 or Compound B3, the second ligand-metal complex consists essentially of a second ligand and an
[Ir(COD)CI]2 second metal adduct combined with iodine in an amount up to about 0.1 Eq., wherein the second ligand is selected from the group consisting of (/?)-PhanePhos, (5)-PhanePhos, (/?)-An-PhanePhos, (5>An-PhanePhos, (Λ)-Xyl-PhanePhos, (5)-Xyl-PhanePhos, (/?)-MeOXyl-PhanePhos, (S)-MeOXyl-PhanePhos,
(R, R)-Me-Du Phos, (S.S)-Me-DuPhos, (Λ)-P-Phos, (5)-P-Phos, (Λ)-Xyl-P-Phos, (S)-XyI-P-PhOs, (Λ)-Tol-P-Phos, (S)-Tol-P-Phos, W-Ph-PHOX, (S)-Ph-PHOX, (Λ)-iPr-PHOX, (5)-iPr-PHOX, (Λ)-Me-BoPhoz, (S)-Me-BoPhoz, CF3Ph-(/?;-Me-BoPhoz, CF3Ph-(5;-Me-BoPhoz, (Λ)-Phenethyl-(Λ)-Me-BoPhoz, (/?)-Phenethyl-(5)-Me-BoPhoz, (S)-Ethyl-Napthyl-(/?)-Me-BoPhoz,
3,4-diCI-Ph-(fl)-Me-BoPhoz, 3,4-diCI-Ph-(5)-Me-BoPhoz, (Λ)-2,4,6-F3Ph-(Λ)-Me-BoPhoz, (Λ)-2,4,6-F3Ph-(S)-Me-BoPhoz, (5)-2,4,6-F3Ph-(5)-Me-BoPhoz, (51-2,4,6-F3Ph-(ZJ)-Me-BoPhOz, Xyl-(Λ)-Me-BoPhoz, Xyl-(5)-Me-BoPhoz, (Λ)-Binol-(Λ)-Me-BoPhoz, (Λ)-Binol-(5)-Me-BoPhoz, (5)-Binol-(S)-Me-BoPhoz, (S)-Binol-(Λ)-Me-BoPhoz, PCy-(tf)-Me-BoPhoz, pFPh-(/?)-Me-BoPhoz, PFPh-(.S)-Me-BoPhoz,
(Λ)-Et-BoPhoz, (S)-Et-BoPhoz, pFPh-(Λ)-Et-BoPhoz, pFPh-(5)-Et-BoPhoz,
(Λ)-iPr-BoPhoz, (S>iPr-BoPhoz, (Λ)-Phenethyl-(5)-BoPhoz,
(Λ)-Phenethyl-(Λ)-BoPhoz, (S)-Phenethyl-(Λ)-BoPhoz, (S)-Phenethyl-(S)-BoPhoz, (tf)-Ph-BoPhoz, (5)-Ph-BoPhoz, (Λ)-Bn-BoPhoz,
(5)-Bn-BoPhoz, pFPh-(7?)-Bn-BoPhoz; pFPh-(S)-Bn-BoPhoz, (Λ)-Xyl-Binap,
(S)-Xyl-Binap and DPPF, the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA,
THF, toluene, EtOAc, 1 -BuOH and MTBE and mixtures thereof, the optional second additive is selected from the group consisting Of Et3N, iPr2-NH,
Cy2NH, (Λ)-Ph-ethyl-NH2, (S)-Ph-ethyl-NH2, KI, KOH, K2CO3,
(/?/5)-camphorsulfonic acid and CH3COOH, and, when present, is in an amount up to about 1 .2 Eq., the second temperature is in a range of from about 30 0C to about 80 0C, or is in a range of from about 40 0C to about 60 0C, and the second pressure is in a range of from about 3 bar to about 25 bar, or is in a range of from about 10 bar to about 25 bar, or is in a range of from about 3 bar to about 10 bar.
An Example 64 of the invention includes a process wherein, when Z is hydroxy and R2 is selected from -aryl(Rg) and -heteroaryl(Rs) for Compound B2 or Compound B3, the second ligand is selected from the group consisting of (/?)-P-Phos, (.S)-P-PhOS, (Λ)-Xyl-P-Phos, (S)-Xyl-P-Phos, (S)-Tol-P-Phos, (tf)-Me-BoPhoz, (5)-Me-BoPhoz, (7?)-Xyl-Binap and (5)-Xyl-Binap, the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA,
THF, toluene, EtOAc and MTBE and mixtures thereof, the second temperature is in a range of from about 40 0C to about 60 0C, and the second pressure is in a range of from about 3 bar to about 25 bar, or is in a range of from about 10 bar to about 25 bar, or is in a range of from about 3 bar to about 10 bar. An Example 65 of the invention includes a process wherein, when Z is
-O-Ci-salkyl and R2 is selected from -aryl(R8) and -heteroaryl(R8) for Compound B2 or
Compound B3, the second ligand is selected from the group consisting of (Λ)-Xyl-PhanePhos, (Λ)-P-Phos, (S)-P-PhOS, (Λ)-Xyl-P-Phos, (S)-Xyl-P-Phos, (S)-ToI-P-PhOs,
(Λ)-Me-BoPhoz; (S)-Me-BoPhoz, (Λ)-Phenethyl-(S)-Me-BoPhoz, (S)-Ethyl-Napthyl-(tf)-Me-BoPhoz, (/?)-2,4,6-F3Ph-(/?)-Me-BoPhoz, Xyl-(Λ)-Me-BoPhoz, (Λ)-Binol-(Λ)-Me-BoPhoz, (S)-Binol-(7?)-Me-BoPhoz, PCy-(#)-Me-BoPhoz, pFPh-(/?)-Me-BoPhoz, (Λ)-Et-BoPhoz, pFPh-(/?)-Et-BoPhoz, (Z?)-iPr-BoPhoz, (7?)-Ph-BoPhoz, pFPh-(#)-Bn-BoPhoz,
(Λ)-Xyl-Binap, (S)-Xyl-Binap and DPPF, the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA, THF, toluene, EtOAc, 1 -BuOH and MTBE and mixtures thereof, the second temperature is in a range of from about 30 0C to about 80 0C, and the second pressure is in a range of from about 3 bar to about 25 bar.
An Example 66 of the invention includes a process comprising the steps:
Step 1 . reacting Compound Bl, wherein Z is hydroxy, with a first hydrogen source, a first ligand-metal complex consisting essentially of a first ligand conjugated with a first metal adduct, in a first solvent in the presence of an optional first additive at a first elevated temperature and a first elevated pressure, to provide a substantially pure Compound B2 or a substantially pure Compound B3, wherein the first hydrogen source is selected from gaseous hydrogen or an excess of formic acid, the first ligand is selected from the group consisting of (Λ)-Xyl-PhanePhos, (S;" -Xyl-PhanePhos, (Λ>PhanePhos, (Sj-PhanePhos, (tf;-An-PhanePhos,
(S>An-PhanePhos, (Λ)-MeOXyl-PhanePhos, (S^-MeOXyl-PhanePhos, PCy-(Λ)-Me-BoPhoz and PCy-(S)-Me-BoPhoz, the first metal adduct is selected from the group consisting Of [Rh(COD)2]BF4,
[Rh(COD)2]OTf, [Ru(COD)(CF3COO)2I2, [Ru(COD)(methylallyl)2], [Ru(benzene)CI2]2 and [Ir(COD)CI]2, the first solvent is selected from the group consisting of MeOH, EtOH, IPA, DCE, THF, toluene, EtOAc, DMF and mixtures thereof, the optional first additive is selected from the group consisting of AcOH, Et3N, HBF4,
HBF4 etherate, HCI, HCI etherate, CF3COOH, CH3COOH and TsOH, and, when 5 present, is in an amount up to about 1.2 Eq., the first temperature is in a range of from about 25 0C to about 70 0C, and the first pressure is in a range of from about 3 bar to about 30 bar;
Step 2. optionally converting Compound B2 or Compound B3, each wherein Z is hydroxy, to a Compound B2 or Compound B3, each wherein Z is I O -O-Ct-galkyl;
Step 3. reacting Compound B2 or Compound B3, when R.2 is selected from -aryl(Rg) and -heteroaryl(Rs), with a second hydrogen source and a hydrogenation agent in a second solvent in the presence of an optional second additive at a second elevated temperature and a second elevated pressure to provide an isomeric 15 mixture of a Compound B4 and Compound B5, wherein R? is selected from
-cycloalkyl(Rg) or -heterocyclyl(Rg), hydrogenated from the corresponding -aryl(R8) and -heteroaryl(Rg), respectively, of Compound B2 or Compound B3, wherein the hydrogenation agent is selected from either 10% Pd/C or a second ligand-metal 0 complex, wherein the second ligand-metal complex consists essentially of a second ligand and an [Ir(COD)CI]? metal adduct combined with iodine in an amount up to about O. I Eq., wherein 10% Pd/C is present in a range of weight % of from about 5% (vv/vv) to about 5 20% (w/w), and wherein the second ligand is selected from the group consisting of (/?)-P-Phos,
(S)-P-Phos, (Λ)-Xyl-P-Phos, (S)-Xyl-P-Phos, (S)-Tol-P-Phos, (Λ)-Me-BoPhoz, (S)-Me-BoPhOZ, (Λ)-Xyl-Binap and (S)-Xyl-Binap, the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA, 0 THF, toluene, EtOAc and MTBE and mixtures thereof, the optional second additive is selected from the group consisting Of Et3N, 1Pr2-NH, Cy2NH, (Λ)-Ph-ethyl-NH2, (S)-Ph-ethyl-NH2, KI, KOH, K2CO3, (•/?ΛS)-camphorsulfonic acid and CH3COOH, and, when present, is in an amount up to about 1.2 Eq., the second temperature is in a range of from about 40 0C to about 60 0C, and the second pressure is in a range of from about 3 bar to about 25 bar, or is in a range of from about I O bar to about 25 bar, or is in a range of from about 3 bar to about I O bar.
An Example 67 of the invention includes a process comprising the steps: Step 1 . reacting Compound Bl, wherein Z is -O-Ci-salkyl, with a first hydrogen source, a first ligand-metal complex consisting essentially of a first ligand conjugated with a first metal adduct, in a first solvent in the presence of an optional first additive at a first elevated temperature and first elevated pressure, to provide a substantially pure Compound B2 or a substantially pure Compound B3, wherein the first hydrogen source is selected from gaseous hydrogen or an excess of formic acid, the first ligand is selected from the group consisting of (/?)-PhanePhos, (S)-PhanePhos, (7?)-An-PhanePhos, (S)-An-PhanePhos, (7?)-Xyl-PhanePhos, (5>Xyl-PhanePhos, (/?)-MeOXyl-PhanePhos, (5)-MeOXyl-PhanePhos, (j?)-iPr-PhanePhos, (S>iPr-PhanePhos, (#,/?)-Me-DuPhos, (S,S)-Me-DuPhos, (fl)-P-Phos, (S>P-Phos,
(/?)-Xyl-P-Phos, (S)-XyI-P-Ph0S, OK)-Ph-PHOX, (S)-Ph-PHOX, (tf)-iPr-PHOX, (S>iPr-PHOX, (Λ)-Me-BoPhoz, (S>Me-BoPhoz, CF3Ph-(tfJ-Me-BoPhoz, CF3Ph-(S>Me-BoPhoz, (#)-Phenethyl-(/?)-Me-BoPhoz, (/?)-Phenethyl-(S>Me-BoPhoz, 3,4-diCl-Ph-(#)-Me-BoPhoz, 3,4-diCI-Ph-(S)-Me-BoPhoz, Xyl-(y?)-Me-BoPhoz, Xyl-(S)-Me-BoPhoz,
(/?)-Binol-(/?)-Me-BoPhoz, (#)-Binol-(S>Me-BoPhoz, (S)-Binol-(S)-Me-BoPhoz, (S>Binol-(/?)-Me-BoPhoz, PCy-(/?)-Me-BoPhoz, PCy-(S>Me-BoPhoz, (Λ)-iPr-BoPhoz, (S)-iPr-BoPhoz, (7?)-Phenethyl-(S)-BoPhoz, (Λ)-Phenethyl-(/?)-BoPhoz, (S>Phenethyl-(Λ)-BoPhoz, (S)-Phenethyl-(5)-BoPhoz, (Λ)-Ph-BoPhoz, (S)-Ph-BoPhoz, (Λ)-Bn-BoPhoz and
(S)-Bn-BoPhoz, the first metal adduct is selected from the group consisting of [Rh(COD)2]BF4,
[Rh(COD)2]OTf, [Rh(ethylene)2CI]2; [Rh(ethylene)2(acac)], [Rh(CO)2(acac)], [Rh(COD)(acac)], [Ru(COD)(CF3COO)2]2; [Ru(COD)(methylallyl)2],
[Ru(benzene)CI2]2, [Ru(p-cymene)CI2]2: [Ir(COD)CI]2, [Ir(COD)2]BF4 and
[Ir(COD)2]BArF, the first solvent is selected from the group consisting of MeOH, EtOH, IPA, DCE, THF, toluene, EtOAc, DMF and mixtures thereof, the optional first additive is selected from the group consisting of AcOH, Et3N, HBF4,
HBF4 etherate, HCI, HCl etherate, CF3COOH, CH3COOH and TsOH, and, when present, is in an amount up to about 1.2 Eq., the first temperature is in a range of from about 25 0C to about 70 0C, and the first pressure is in a range of from about 3 bar to about 30 bar; and Step 2. reacting Compound B2 or Compound B3, when Ri is selected from -aryl(Rs) and -heteroaryl(Rs) and Z is -0-Cι-salkyl, with a second hydrogen source and a hydrogenation agent in a second solvent in the presence of an optional second additive at a second elevated temperature and a second elevated pressure to provide an isomeric mixture of a Compound B4 and Compound B5, wherein R2 is selected from -cycloalkyl(Rg) or -heterocyclyl(Rg), hydrogenated from the corresponding -aryl(Rg) and -heteroaryl(Rg), respectively, of Compound B2 or Compound B3, wherein the second hydrogen source is gaseous hydrogen, the hydrogenation agent is selected from either 10% Pd/C or a second ligand-metal complex, the second ligand-metal complex consists essentially of a second ligand and an
[Ir(COD)CI]? metal adduct combined with iodine in an amount up to about O. I Eq., 10% Pd/C is present in a range of weight % of from about 5% (w/w) to about 20% (w/w), the second ligand is selected from the group consisting of (/?)-P-Phos, (S)-P-Phos,
(Λ)-Xyl-P-Phos, (S)-Xyl-P-Phos, (S)-Tol-P-Phos, (tf)-Me-BoPhoz,
(S)-Me-BoPhoz, (Λ)-Xyl-Binap and (S)-Xyl-Binap, the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA, 5 THF, toluene, EtOAc and MTBE and mixtures thereof, the optional second additive is selected from the group consisting of Et3N, 1Pr2-NH,
Cy2NH, (/?)-Ph-ethyl-NH2, (S)-Ph-ethyl-NH2, Kl, KOH, K2CO3,
(7?/5)-camphorsulfonic acid and CH3COOH, and, when present, is in an amount up to about 1 .2 Eq., I O the second temperature is in a range of from about 40 0C to about 60 0C, and the second pressure is in a range of from about 3 bar to about 25 bar, or is in a range of from about 10 bar to about 25 bar, or is in a range of from about 3 bar to about 10 bar.
An Example 68 of the invention includes a process comprising the steps:
15 Step I . reacting Compound Bl, wherein Z is hydroxy, with a first hydrogen source, a first ligand-metal complex consisting essentially of a first ligand conjugated with a first metal adduct, in a first solvent at a first temperature and a first pressure to provide a substantially pure Compound B2 or a substantially pure Compound B3, wherein 0 the first hydrogen source is selected from gaseous hydrogen or an excess of formic acid, the first ligand is selected from the group consisting of (7?)-Me-BoPhoz, (S)-Me-BoPhoz, (Λ)-Xyl-P-Phos, (S)-XyI-P-PhOs, (Λ)-P-Phos, (S)-P-Phos, (tf)-Et-BoPhoz, (S)-Et-BoPhOz, (Λ)-iPr-BoPhoz, (S)-iPr-BoPhoz, (Λ)-Bn-BoPhoz, (5)-Bn-BoPhoz, (/?)-Ph-BoPhoz, (S)-Ph-BoPhoz, 5 the first metal adduct is [Ir(COD)Cl]2, [Ir(COD)2]BF4 and [Ir(COD)2]BArF, the first solvent is selected from the group consisting of THF, EtOAc and toluene, the first temperature is about 70 0C, and the first pressure is about 25 bar, and
Step 2. reacting Compound B2 or Compound B3, when R2 is selected from -aryl(Rs) 0 and -heteroaryl(R8) and Z is hydroxy, by the direct addition of iodine in an amount up to about 0.1 Eq., and recharging the reaction mixture at an elevated second temperature and an elevated second pressure, wherein the second temperature is in a range of from about 30 0C to about 80 0C, and the second pressure is in a range of from about 3 bar to about 25 bar. An Example 69 of the invention includes a process wherein, when Z is hydroxy for Compound Bl, the first ligand is selected from the group consisting of (7?)-Me-BoPhoz and
(S)-Me-BoPhOz, and the first metal adduct is [Ir(COD)CI]2. An Example 70 of the invention includes a process comprising the steps:
Step 1 . reacting Compound Bl, wherein Z is -O-Cι_salkyl, with a first hydrogen source, a first ligand-metal complex consisting essentially of a first ligand conjugated with a first metal adduct, in a first solvent at a first temperature and a first pressure to provide a substantially pure Compound B2 or a substantially pure Compound B3, wherein the first hydrogen source is selected from gaseous hydrogen or an excess of formic acid, the first ligand is selected from the group consisting of (7?)-PhanePhos, (S)-PhanePhos, (7?)-An-PhanePhos, (S)-An-PhanePhos, (Λ)-Xyl-PhanePhos, (S)-Xyl-PhanePhos, (Λ)-MeOXyl-PhanePhos, (S>MeOXyI-PhanePhos, (Λ)-iPr-PhanePhos, (S)-iPr-PhanePhos, (tf,/?)-Me-DuPhos, (S1S)-Me-DuPhOS, (Λ)-P-Phos, (S>P-Phos,
(Λ)-Xyl-P-Phos, (S)-Xyl-P-Phos, (φ-Ph-PHOX, (S)-Ph-PHOX, (fl)-iPr-PHOX, (SyiPr-PHOX, (tf)-Me-BoPhoz, (S)-Me-BoPhoz, CF3Ph-(/?;-Me-BoPhoz, CF3Ph-(5>Me-BoPhoz, (Λ)-Phenethyl-(Λ)-Me-BoPhoz, (/?)-Phenethyl-(S)-Me-BoPhoz, 3,4-diCI-Ph-(/?)-Me-BoPhoz, 3,4-diCI-Ph-(S)-Me-BoPhoz, Xyl-(/?)-Me-BoPhoz, Xyl-(S)-Me-BoPhoz,
(Λ)-Binol-(/?)-Me-BoPhoz, (Λ)-Binol-(S)-Me-BoPhoz, (S)-Binol-(S)-Me-BoPhoz, (S)-Binol-(/?)-Me-BoPhoz, PCy-(/?)-Me-BoPhoz, PCy-(S>Me-BoPhoz, (j"?)-iPr-BoPhoz, (S)-iPr-BoPhoz, (#)-Phenethyl-(S)-BoPhoz, (£)-Phenethyl-(/?)-BoPhoz, (S)-Phenethyl-(#)-BoPhoz, (5)-Phenethyl-(5)-BoPhoz, (7?)-Ph-BoPhoz, (S)-Ph-BoPhoz, (Λ)-Bn-BoPhoz and
(5)-Bn-BoPhoz, the first metal adduct is selected from the group consisting Of [Ir(COD)CI]2,
[Ir(COD)2]BF4 and [lr(COD)2]BArF, the first solvent is selected from the group consisting of THF, toluene, EtOAc and mixtures thereof, the first temperature is in a range of from about 25 0C to about 70 0C, and the first pressure is in a range of from about 3 bar to about 30 bar; and
Step 2. reacting Compound B2 or Compound B3, when R2 is selected from -aryl(R8) and -heteroaryl(Rs) and Z is -0-Cι.βalkyl, by the direct addition of iodine in an amount up to about 0.1 Eq., and recharging the reaction mixture at an elevated second temperature and an elevated second pressure, wherein the second temperature is in a range of from about 300C to about 800C, and the second pressure is in a range of from about 3 bar to about 25 bar. An Example 71 of the invention includes a process wherein, when Z is
-O-Ci-salkyl for Compound Bl, the first ligand is selected from the group consisting of (/?)-Me-BoPhoz and
(5)-Me-BoPhoz, and the first metal adduct is [Ir(COD)CI]2.
The present invention further relates to a process, as shown in Scheme C, for preparing a compound of Formula (Ia) and intermediates thereof:
Figure imgf000056_0001
Formula (Ia) comprising the steps of:
Scheme C Step I . reacting a Compound Cl with a first hydrogen source, a first ligand-metal complex consisting essentially of a first ligand conjugated with a first metal adduct, in a first solvent in the presence of an optional first additive at an elevated first temperature and an elevated first pressure to provide a substantially pure Compound C3:
Figure imgf000056_0002
Step 2. reacting Compound C3 with a second hydrogen source and a hydrogenation agent in a second solvent in the presence of an optional second additive at an elevated second temperature and an elevated second pressure to provide an isomeric mixture of a Compound C4 and Compound C5:
Figure imgf000057_0001
Step 3. separating each of Compound C4 and Compound C5 from the isomeric mixture; Step 4. optionally dehydrogenating Compound C5 to Compound C3, and then repeating Step 2 using said Compound C3 as the starting material; Step 5. deprotecting the Compound C4 to provide a Compound C6:
C4, (αS.βS) isomer
Figure imgf000057_0002
Step 6. reacting Compound C6 with a Compound C7 to provide a Compound C8:
Figure imgf000057_0003
Step 7. converting Compound C8 to the compound of Formula (Ia).
The present invention provides a process for making substantially pure Compound C2 comprising the step of: reacting a Compound Cl with a first hydrogen source, a first ligand-metal complex consisting essentially of a first ligand conjugated with a first metal adduct, in a first solvent in the presence of an optional first additive at an elevated first temperature and an elevated first pressure to provide a substantially pure Compound C2:
Figure imgf000058_0001
5 An Example 72 of the invention includes a process wherein Compound C2 is carried forward in place of Compound C3 to provide an (aRβR) isomer and an (α/?,βS) isomer of Formula (1).
An Example 73 of the invention includes a process for reacting Compound Cl to provide Compound C2, and a process for reacting Compound Cl to provide Compound
I O C3, both processes as desribed herein above, wherein the first ligand is selected from the group consisting of (7?)-PhanePhos, (S)-PhanePhos, (Λ)-An-PhanePhos, (S)-An-PhanePhos, (tf)-Xyl-PhanePhos, (S)-Xyl-PhanePhos, (7?)-MeOXyl-PhanePhos, (5)-MeOXyl-PhanePhos, (7?)-iPr-PhanePhos, (S)-iPr-PhanePhos, (Λ.tf)-Me-DuPhos, (S1S)-Me-Du Phos, (Λ)-P-Phos, (5)-P-Phos,
15 (Λ)-Xyl-P-Phos, (S)-Xyl-P-Phos, (φ-Ph-PHOX, (S)-Ph-PHOX, (Λ)-iPr-PHOX,
(S)-iPr-PHOX, (Λ)-Me-B oPhoz, (S)-Me-BoPhoz, CF3Ph-(^-Me-BoPhoz, CF3Ph-(Sj-Me-BoPhOZ, (Λ)-Phenethyl-(S)-Me-BoPhoz,
3,4-diCI-Ph-(i?)-Me-BoPhoz, 3,4-diCl-Ph-(S)-Me-BoPhoz; Xyl-(7?)-Me-BoPhoz, Xyl-(S)-Me-BoPhoz, (Λ)-Binol-(Λ)-Me-BoPhoz, (Λ)-Binol-(S)-Me-BoPhoz, 0 (S)-Binol-(S)-Me-BoPhoz, (S)-Binol-(/?)-Me-BoPhoz, PCy-(Λ)-Me-BoPhoz,
PCy-(S)-Me-BoPhOZ, (Z?)-iPr-BoPhoz, (S)-iPr-BoPhoz, (fl)-Et-BoPhoz, (S)-Et-BoPhOZ, (/?)-Phenethyl-(S)-BoPhoz, (y?)-Phenethyl-(7?)-BoPhoz, (S)-Phenethyl-(/?)-BoPhoz, (S)-Phenethyl-(S)-BoPhoz, (Λ)-Ph-BoPhoz, (Sj-Ph-BoPhoz, (tf)-Bn-BoPhoz and (S)-Bn-BoPhoz, the first metal adduct is selected from the group consisting of [lr(COD)2]BArF, [Ir(COD)2]BF4, [Ir(COD)CI]2, [Rh(ethylene)2CI]2, [Rh(ethylene)2(acac)]; [Rh(COD)CI]2, and [Rh(COD)(acac)], the first solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA, THF, toluene, EtOAc, DMF, and mixtures thereof, the optional first additive is selected from the group consisting of Et}N, HBF4,
CH3COOH and TsOH, and, when present, is in an amount up to about 1 .2 Eq., the first temperature is in a range of from about 50 0C to about 70 0C, and the first pressure is in a range of from about I O bar to about 30 bar. An Example 74 of the invention includes a process for reacting Compound Cl, wherein the first ligand-metal complex is selected from the group consisting of (Λ)-An-Phanephos/[Rh(COD)]BF4, (y?)-Binol-(/?)-Me-BoPhoz &[Ir(COD)CI]2, (fl)-Bn-BoPhoz A[Ir(COD)CI]2, (Λ)-iPr-BoPhoz &[Rh(COD)2]OTf, (tf)-iPr-PHOX/[lr(COD)]BArF, (/?)-iPr-PHOX/[lr(COD)]BF4, (Λ)-Me-BoPhoz &[lr(COD)CI]2, (tf)-Me-BoPhoz &[Rh(CO)2(acac)], (Λ)-Me-BoPhoz A[Rh(COD)2]OTf, (tf)-Me-BoPhoz &[Rh(ethylene)2(acac)], (tf)-Me-BoPhoz &[Rh(ethylene)2CI]2, (7?)-Me-BoPhoz/[RuCI2(DMF)2], (Λ)-Phanephos A[Ir(COD)CI]2, (Λ)-Phanephos A[Rh(ethylene)2CI]2, (tf)-Ph-BoPhoz A[Ir(COD)CI]2, (/?)-Phenethyl-(J?)-BoPhoz &[Rh(ethylene)2CI]2, (7?)-Phenethyl-(S)-BoPhoz A[Rh(ethylene)2CI]2, (/?)-Phenethyl-(S)-Me-BoPhoz A[Ir(COD)CI]2, (tf)-Ph-PHOX/[Ir(COD)]BArF,
(Λ)-Xyl-Phanephos/[Rh(COD)]BF4, (Λ)-Xyl-P-Phos A[Rh(CO)2(acac)], (Λ)-Xyl-P-Phos A[Rh(ethylene)2(acac)], (Λ)-Xyl-P-Phos &[Rh(ethylene)2CI]2, (Λ)-Xyl-P-Phos/[Ru(p-cymene)CI]CI, (Λ.Λ)-MeDuPhos/[Rh(COD)]BF4, (5)-Binol-(/?)-Me-BoPhoz A[Ir(COD)CI]2, (S)-Binol-(R)-Me-BoPhoz A[Rh(COD)2]OTf, (S)-Me-BoPhOZ A[Ir(COD)CI]2, (.S)-PhanePhos/[Rh(COD)]BF4, (S>P-Phos /[Ir(COD)]CI, (5)-P-Phos A[Ir(COD)CI]2, (S)-P-Phos/[Ru(benzene)CI]CI, (5)-P-Phos/[RuCI2(DMF)2], (S)-XyI-P-PhOsZ[Ir(COD)]CI1 (S)-XyI-P-PhOS A[Ir(COD)Cl]2, (S)-Xyl-P-Phos/[RuCI2(DMF)2], 3,4-diCIPh-(/?)-Me-BoPhoz A[Ir(COD)Cl]2, CF3Ph-(R)-Me-BoPhoz A[Rh(COD)2]OTf, PCy-(tf)-Me-BoPhoz A[Ir(COD)Cl]2 and Xyl-(/?)-Me-BoPhoz A[Ir(COD)Cl]2. An Example 75 of the invention includes a process for reacting Compound Cl, wherein the first ligand is selected from the group consisting of (/?)-PhanePhos, (5)-PhanePhos,
(Λ)-An-PhanePhos, (7?)-Xyl-PhanePhos, (S)-P-Phos, (Λ)-Xyl-P-Phos, (S)-Xyl-P-Phos, (φ-Ph-PHOX, (tf)-iPr-PHOX, (fl)-Me-BoPhoz, (S)-Me-BoPhoz,
CF3Ph-(/?j-Me-BoPhoz, CF3Ph-(S>Me-BoPhoz, 3,4-diCI-Ph-(/?)-Me-BoPhoz, 3,4-diCI-Ph-(S>Me-BoPhoz, Xyl-(Λ)-Me-BoPhoz, (/?)-Binol-(/?)-Me-BoPhoz, (S)-Binol-(/?)-Me-BoPhoz, (/?)-iPr-BoPhoz, (S)-iPr-BoPhoz, (/?)-Phenethyl-(S)-BoPhoz, (/?)-Phenethyl-(tf)-BoPhoz, (Λ)-Ph-BoPhoz and (Λ)-Bn-BoPhoz, the first metal adduct is selected from the group consisting of [Rh(COD)2]BF4,
[RJi(COD)2]OTf, [Rh(ethylene)2CI]2, [Rh(ethylene)2(acac)]; [Rh(CO)2(acac)], [Ru(p-cymene)Cl2]2, [Ir(COD)CI]2 and [lr(COD)2]BArF, the first solvent is selected from the group consisting of MeOH, DCE, EtOH, toluene, EtOAc, 2-propanol, THF, and mixtures thereof, the optional first additive is selected from the group consisting Of HBF4, AcOH and TsOH, and, when present, is in an amount up to about 1.2 Eq., the first temperature is in a range of from about 50 0C to about 90 0C, and the first pressure is in a range of from about 10 bar to about 30 bar. An Example 76 of the invention includes a process for reacting Compound Cl, wherein the first ligand is selected from the group consisting of (Λ)-PhanePhos, (S)-PhanePhos, (S)-P-Ph0S, (Λ)-Xyl-P-Phos, (S)-Xyl-P-Phos, (φ-Ph-PHOX, (tf)-iPr-PHOX, (7?)-Me-BoPhoz, (S)-Me-BoPhoz, CF3Ph-(/?>Me-BoPhoz, CF3Ph-(S)-Me-BoPhOZ, 3,4-diCI-Ph-(7?)-Me-BoPhoz,
3,4-diCI-Ph-(S)-Me-BoPhoz, Xyl-(7?)-Me-BoPhoz, Xyl-(S)-Me-BoPhoz, (/?)-Binol-(tf)-Me-BoPhoz, (S)-Binol-(Λ)-Me-BoPhoz, (#)-Phenethyl-(S)-BoPhoz, (Λ)-Phenethyl-(Λ)-BoPhoz, (tf)-Bn-BoPhoz and (S)-Bn-BoPhoz, the first metal adduct is selected from the group consisting Of [Rh(COD)2]BF4, [Rh(COD)2]OTf, [Rh(COD) Cl]2, [Rh(ethylene)2CI]2, [Rh(ethylene)2(acac)]; [Rh(CO)2(acac)], [Ru(p-cymene)CI2]2, [Ir(COD)CI]2, [Ir(COD)2]BF4 and
[Ir(COD)2]BArF, the first solvent is selected from the group consisting of DCE, THF, toluene, EtOAc, and mixtures thereof, the optional first additive is selected from the group consisting Of HBF4 and TsOH, and, when present, is in an amount up to about 1.2 Eq., the first temperature is in a range of from about 50 0C to about 90 0C, and the first pressure is about 30 bar.
An Example 77 of the invention includes a process for reacting Compound Cl, wherein the first ligand is selected from the group consisting of (Λ)-Me-BoPhoz, (5)-Me-BoPhoz, 3,4-diCI-Ph-(tf)-Me-BoPhoz, 3,4-diCI-Ph-(5)-Me-BoPhoz, Xyl-(/?)-Me-BoPhoz, Xyl-(5)-Me-BoPhoz, (/?)-Bn-BoPhoz and (S)-Bn-BoPhoz, the first metal adduct is selected from the group consisting Of [Ir(COD)CI]2 and [lr(COD)2]BArF, the first solvent is selected from the group consisting of MeOH, DCE, THF, toluene,
EtOAc, IPA, and mixtures thereof, the optional first additive is HBF4, and, when present, is in an amount up to about 1 .2
Eq., the first temperature is in a range of from about 50 0C to about 90 0C, and the first pressure is from about 25 bar to about 30 bar.
An Example 78 of the invention includes a process for reacting Compound C2 or Compound C3, wherein the second hydrogen source is gaseous hydrogen, the hydrogenation agent is selected from either 10% Pd/C or a second ligand-metal complex, wherein the second ligand-metal complex consists essentially of a second ligand and an
[Ir(COD)CI]2 metal adduct combined with iodine in an amount up to about 0.1
Eq., wherein 10% Pd/C is present in a range of weight % of from about 5% weight/weight
(w/w) to about 20% (w/vv), and wherein the second ligand is selected from the group consisting of (7?)-PhanePhos,
(S)-PhanePhos, (Λ)-An-PhanePhos, (S)-An-PhanePhos, <7?)-Xyl-PhanePhos, (S)-Xyl-PhanePhos, (/?)-MeOXyl-PhanePhos, (S)-MeOXyl-PhanePhos,
(/?)-iPr-PhanePhos, (S)-iPr-PhanePhos, (7?,/?)-Me-DuPhos, (S,S)-Me-DuPhos, (Λ)-P-Phos, (S)-P-PhOS, (Λ)-Xyl-P-Phos, (S)-Xyl-P-Phos, (Λ)-Tol-P-Phos, (5)-Tol-P-Phos, (tfj-Ph-PHOX, (S)-Ph-PHOX, (Λ)-iPr-PHOX, (S)-iPr-PHOX, (tf)-Me-BoPhoz, (S)-Me-BoPhoz, CF3Ph-(/?)-Me-BoPhoz, CF3Ph-(S)-Me-BoPhOZ, (#)-Phenethyl-(/?)-Me-BoPhoz,
(tf)-Phenethyl-(S)-Me-BoPhoz, (S)-Ethyl-Napthyl-(/?)-Me-BoPhoz, 3,4-diCI-Ph-(/?)-Me-BoPhoz; 3,4-diCI-Ph-(S)-Me-BoPhoz, (Λ)-2,4,6-F3Ph-(Λ)-Me-BoPhoz,
Figure imgf000062_0001
(S)-2,4,6-F3Ph-(S)-Me-BoPhoz, (S)-2,4,6-F3Ph-(Λ)-Me-BoPhoz, Xyl-(Λ)-Me-BoPhoz, Xyl-(S)-Me-BoPhoz, (Λ)-Binol-(7?)-Me-BoPhoz,
(Λ)-Binol-(S)-Me-BoPhoz, (S)-Binol-(S)-Me-BoPhoz, (S)-Binol-(Λ)-Me-BoPhoz, PCy-(tf)-Me-BoPhoz, pFPh-(7?)-Me-BoPhoz, PFPh-(S)-Me-BoPhoz, (/?)-Et-BoPhoz, (S)-Et-BoPhOZ, pFPh-(Λ)-Et-BoPhoz, pFPh-(S)-Et-BoPhoz, (y?)-iPr-BoPhoz, (S)-iPr-BoPhoz, (Λ)-Et-BoPhoz, (S)-Et-BoPhoz, (/?)-Phenethyl-(S)-BoPhoz, (/?)-Phenethyl-(/?)-BoPhoz,
(S)-Phenethyl-(Λ)-BoPhoz, (S)-Phenethyl-(S)-BoPhoz, (/?)-Ph-BoPhoz, (S)-Ph-BoPhOz, (/?)-Bn-BoPhoz, (S)-Bn-BoPhoz, pFPh-(Λ)-Bn-BoPhoz, pFPh-(S)-Bn-BoPhoz, (Λ)-Xyl-Binap, (S)-Xyl-Binap and DPPF, the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA, THF, toluene, EtOAc, 1 -BuOH and MTBE and mixtures thereof, the optional second additive is selected from the group consisting Of Et3N, JPr2-NH, Cy2NH, (Λ)-Ph-ethyl-NH2, (S)-Ph-ethyl-NH2, Kl, KOH, K2CO3, (Λ/S)-camphorsulfonic acid and CH3COOH, and, when present, is in an amount up to about 1.2 Eq., the second temperature is in a range of from about 30 0C to about 80 0C, or is in a range of from about 40 0C to about 60 0C, and the second pressure is in a range of from about 3 bar to about 25 bar, or is in a range of from about I O bar to about 25 bar, or is in a range of from about 3 bar to about I O bar.
An Example 79 of the invention includes a process for reacting Compound C2 or Compound C3, wherein the second ligand-metal complex is selected from the group consisting of (Λ)-Binol-(/?)-Me-BoPhoz &[lr(COD)CI]2, (Λ)-Et-BoPhoz &[lr(COD)CI]2, (Λ)-iPr-BoPhoz &[Ir(COD)CI]2, (Λ)-Me-BoPhoz A[Ir(COD)CI]2, (Λ)-Ph-BoPhoz A[Ir(COD)CI]2, (tf)-Phenethyl-(S)-BoPhoz A[Ir(COD)CI]2, (tf)-Xyl-PhanePhos A[Ir(COD)CI]2, (Λ)-Xyl-P-Phos A[Ir(COD)CI]2, (S)-Binol-(Λ)-Me-BoPhoz A[Ir(COD)CI]2, (S)-Ethyl-Naphthyl-(/?)-BoPhoz A[Ir(COD)CI]2, (S)-Me-BoPhoz
A[Ir(COD)CI]2, (S)-Xyl-PhanePhos A[Ir(COD)CI]2, (S)-Xyl-P-Phos A[Ir(COD)CI]2, 2,4;6-F3Ph-(tf)-Me-BoPhoz A[Ir(COD)CI]2, DPPF A[Ir(COD)CI]2, DtBPF A[Ir(COD)CI]2, PCy-(Λ)-Me-BoPhoz A[Ir(COD)CI]2, pFPh-(/?)-Bn-BoPhoz A[Ir(COD)CI]2, pFPh-(#)-Et-BoPhoz A[Ir(COD)CI]2, pFPh-(/?)-Me-BoPhoz A[Ir(COD)CI]2 and Xyl-(/?)-Me-BoPhoz A[Ir(COD)CI]2.
An Example 80 of the invention includes a process for reacting Compound C2 or
Compound C3, wherein the second ligand is selected from the group consisting of (Λ)-Xyl-PhanePhos,
(Λ)-P-Phos, (S)-P-PhOS, (Λ)-Xyl-P-Phos, (S)-Xyl-P-Phos, (S)-Tol-P-Phos, (/?)-Me-BoPhoz, (S)-Me-BoPhoz, (/?)-Phenethyl-(5)-Me-BoPhoz,
(5)-Ethyl-Napthyl-(Λ)-Me-BoPhoz, (Λ)-2,4,6-F3Ph-(/?)-Me-BoPhoz, Xyl-(Λ)-Me-BoPhoz, (Λ)-Binol-(Λ)-Me-BoPhoz, (S)-Binol-(Λ)-Me-BoPhoz, PCy-(/?)-Me-BoPhoz, pFPh-(/?)-Me-BoPhoz, (7?)-Et-BoPhoz, pFPh-(/?)-Et-BoPhoz, (Λ)-iPr-BoPhoz, (/?)-Ph-BoPhoz, pFPh-(/?)-Bn-BoPhoz, (Λ)-Xyl-Binap, (S)-Xyl-Binap, DtBPF and DPPF, the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA, THF, toluene, EtOAc, 1 -BuOH and MTBE and mixtures thereof, the second temperature is in a range of from about 30 0C to about 80 0C, and the second pressure is in a range of from about 3 bar to about 25 bar. An Example 81 of the invention includes a process for reacting Compound C2 or Compound C3, wherein the second hydrogen source is gaseous hydrogen,
10% Pd/C is present in a range of weight % of from about 5% (w/w) to about 20% (w/w), the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA,
THF, toluene, EtOAc, 1 -BuOH and MTBE and mixtures thereof, the optional second additive is selected from the group consisting of Et3N, iPr2-NH,
Cy2NH, (Λ)-Ph-ethyl-NH2, (S)-Ph-ethyl-NH2> Kl, KOH, K2CO3,
(/?/S)-camphorsulfonic acid and CH3COOH, and, when present, is in an amount up to about 1 .2 Eq., the second temperature is in a range of from about 30 0C to about 80 0C, or is in a range of from about 40 0C to about 60 0C, and the second pressure is in a range of from about 3 bar to about 25 bar, or is in a range of from about 10 bar to about 25 bar, or is in a range of from about 3 bar to about I O bar.
An Example 82 of the invention includes a process for reacting Compound C2 or Compound C3, wherein the second ligand-metal complex consists essentially of a second ligand and an
[Ir(COD)CI]? second metal adduct combined with iodine in an amount up to about 0. 1 Eq., wherein the second ligand is selected from the group consisting of (/?)-PhanePhos, (S)-PhanePhos, (/?)-An-PhanePhos, (S)-An-PhanePhos, (7?)-Xyl-PhanePhos, (S)-Xyl-PhanePhos, (Λ)-MeOXyl-PhanePhos, (S)-MeOXyl-PhanePhos, (R, Λ)-Me-DuPhos, (S,S)-Me-DuPhos, (Λ)-P-Phos, (S)-P-Phos, (Λ)-Xyl-P-Phos, (S)-XyI-P-PhOS, (Λ)-Tol-P-Phos, (S)-Tol-P-Phos, W-Ph-PHOX, (S)-Ph-PHOX,
(tf)-iPr-PHOX, (S)-iPr-PHOX, (/?)-Me-BoPhoz, (S)-Me-BoPhoz, CF3Ph-W-Me-BoPhOz, CF3Ph-(S;-Me-BoPhoz, (Λ)-Phenethyl-(/?)-Me-BoPhoz, (tf)-Phenethyl-(S)-Me-BoPhoz, (S)-Ethyl-Napthyl-(tf)-Me-BoPhoz, 3,4-diCI-Ph-(tf)-Me-BoPhoz, 3,4-diCI-Ph-(S)-Me-BoPhoz, (fl)-2,4,6-F3Ph-(/?)-Me-BoPhoz, (#)-2,4,6-F3Ph-(S)-Me-BoPhoz, (5>2,4,6-F3Ph-(S>Me-BoPhoz, (S>2,4,6-F3Ph-(/?)-Me-BoPhoz, Xyl-(Λ)-Me-BoPhoz, Xyl-(S)-Me-BoPhoz, (Λ)-Binol-(Λ)-Me-BoPhoz, (/?)-Binol-(S)-Me-BoPhoz, (5)-Binol-(5)-Me-BoPhoz, (5)-Binol-(Λ)-Me-BoPhoz, PCy-(i?)-Me-BoPhoz, pFPh-(/?)-Me-BoPhoz, pFPh-(S>Me-BoPhoz, (Λ)-Et-BoPhoz, (5)-Et-BoPhoz, pFPh-(tf)-Et-BoPhoz, pFPh-(S)-Et-BoPhoz,
(/?)-iPr-BoPhoz, (5)-iPr-BoPhoz, (Λ)-Phenethyl-(S)-BoPhoz, (/?)-Phenethyl-(/?)-BoPhoz, (5)-Phenethyl-(/?)-BoPhoz, (S)-Phenethyl-(S)-BoPhoz, (7?)-Ph-BoPhoz, (S)-Ph-BoPhoz, (/?)-Bn-BoPhoz, (S)-Bn-BoPhoz, pFPh-(/?)-Bn-BoPhoz, pFPh-(S>Bn-BoPhoz, (Λ)-Xyl-Binap, (S)-Xyl-Binap and DPPF, the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA, THF, toluene, EtOAc, 1 -BuOH and MTBE and mixtures thereof, the optional second additive is selected from the group consisting Of Et3N, JPr2-NH,
Cy2NH, (Λ)-Ph-ethyl-NH2, (S)-Ph-ethyl-NH2, Kl, KOH, K2CO3, (j"?/5)-camphorsulfonic acid and CH3COOH, and, when present, is in an amount up to about 1 .2 Eq., the second temperature is in a range of from about 30 0C to about 80 0C, or is in a range of from about 40 0C to about 60 0C, and the second pressure is in a range of from about 3 bar to about 25 bar, or is in a range of from about 10 bar to about 25 bar, or is in a range of from about 3 bar to about 10 bar.
An Example 83 of the invention includes a process for reacting Compound C2 or
Compound C3, wherein the second ligand is selected from the group consisting of (Λ)-Xyl-PhanePhos, (tf)-P-Phos, (S)-P-PhOS, (Λ)-Xyl-P-Phos, (5)-Xyl-P-Phos, (S)-Tol-P-Phos,
(tf)-Me-BoPhoz, (5)-Me-BoPhoz, (/?)-Phenethyl-(5)-Me-BoPhoz, (S)-Ethyl-Napthyl-(/?)-Me-BoPhoz, (#)-2,4,6-F3Ph-(/?)-Me-BoPhoz, Xyl-(7?)-Me-BoPhoz, (Λ)-Binol-(Λ)-Me-BoPhoz, (S)-Binol-(/?)-Me-BoPhoz, PCy-(/?)-Me-BoPhoz, pFPh-(tf)-Me-BoPhoz, (Λ)-Et-BoPhoz, pFPh-(/?)-Et-BoPhoz, (Λ)-iPr-BoPhoz, (Λ)-Ph-BoPhoz, pFPh-(V?)-Bn-BoPhoz,
(Λ)-Xyl-Binap, (S)-Xyl-Binap and DPPF, the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA,
THF, toluene, EtOAc, 1 -BuOH and MTBE and mixtures thereof, the second temperature is in a range of from about 30 0C to about 80 0C, and the second pressure is in a range of from about 3 bar to about 25 bar.
An Example 84 of the invention includes a process comprising the steps:
Step I . reacting Compound Cl with a first hydrogen source, a first ligand-metal complex consisting essentially of a first ligand conjugated with a first metal adduct, in a first solvent in the presence of an optional first additive at a first elevated temperature and first elevated pressure, to provide a substantially pure Compound C2 or a substantially pure Compound C3, wherein the first hydrogen source is selected from gaseous hydrogen or an excess of formic acid; the first ligand is selected from the group consisting of (7?)-PhanePhos, (S)-PhanePhos, (Λ)-An-PhanePhos, (S)-An-PhanePhos, (Λ)-Xyl-PhanePhos, (S)-Xyl-PhanePhos,
(fl)-MeOXyl-PhanePhos, (S)-MeOXyl-PhanePhos, (Λ)-iPr-PhanePhos, (S)-iPr-PhanePhos, (7?,/?)-Me-DuPhos, (5,S)-Me-DuPhOS, (Λ)-P-Phos, (S)-P-Phos, (Λ)-Xyl-P-Phos, (S)-XyI-P-PhOS, (tfj-Ph-PHOX, (S)-Ph-PHOX, (Λ)-iPr-PHOX, (S)-iPr-PHOX, (/?)-Me-BoPhoz, (S)-Me-BoPhoz, CF3Ph-(/?>Me-BoPhoz, CF3Ph-(S>Me-BoPhoz, (Λ)-Phenethyl-(Λ)-Me-BoPhoz,
(#)-Phenethyl-(S)-Me-BoPhoz, 3,4-diCI-Ph-(tf)-Me-BoPhoz, 3,4-diCI-Ph-(S)-Me-BoPhoz, Xyl-(7?)-Me-BoPhoz, Xyl-(S)-Me-BoPhoz, (/?)-Binol-(tf)-Me-BoPhoz, (Λ)-Binol-(S)-Me-BoPhoz, (S)-Binol-(S)-Me-BoPhoz, (S)-Binol-(/?)-Me-BoPhoz, PCy-(7?)-Me-BoPhoz, PCy-(S)-Me-BoPhoz, (Z?)-iPr-BoPhoz, (S)-iPr-BoPhoz, (Λ)-Phenethyl-(S)-BoPhoz,
(/?)-Phenethyl-(Λ)-BoPhoz, (S)-Phenethyl-(Λ)-BoPhoz,
(S)-Phenethyl-(S)-BoPhoz, (/?)-Ph-BoPhoz, (S)-Ph-BoPhoz, (Λ)-Bn-BoPhoz and (S)-Bn-BoPhOZ, the first metal adduct is selected from the group consisting Of [Rh(COD)2]BF4, [Rh(COD)2]OTf, [Rh(ethylene)2CI]2, [Rh(ethylene)2(acac)], [Rh(CO)2(acac)]s [Rh(COD)(acac)], [Ru(COD)(CF3COO)2]2, [Ru(COD)(methylallyl)2],
[Ru(benzene)Cl2]2! [Ru(p-cymene)CI2]2) [Ir(COD)CI]2, [Ir(COD)2]BF4 and
[lr(COD)2]BArF, the first solvent is selected from the group consisting of MeOH, EtOH, IPA, DCE, THF, 5 toluene, EtOAc, DMF and mixtures thereof, the optional first additive is selected from the group consisting of AcOH, Et3N, HBF4,
HBF4 etherate, HCI, HCI etherate, CF3COOH, CH3COOH and TsOH, and, when present, is in an amount up to about 1.2 Eq., the first temperature is in a range of from about 25 0C to about 70 0C, and I O the first pressure is in a range of from about 3 bar to about 30 bar; and
Step 2. reacting Compound C3 with a second hydrogen source and a hydrogenation agent in a second solvent in the presence of an optional second additive at a second elevated temperature and a second elevated pressure to provide an isomeric mixture of Compound C4 and Compound C5, wherein 15 the second hydrogen source is gaseous hydrogen, the hydrogenation agent is selected from either 10% Pd/C or a second ligand-metal complex, wherein the second ligand-metal complex consists essentially of a second ligand and an
[Ir(COD)CI]2 metal adduct combined with iodine in an amount up to about 0.1 0 Eq., wherein 10% Pd/C is present in a range of weight % of from about 5% (w/w) to about
20% (w/vv), and wherein the second ligand is selected from the group consisting of (7?)-P-Phos,
(.S)-P-PhOS, (Λ)-Xyl-P-Phos, (S>Xyl-P-Phos, (5)-Tol-P-Phos, (tf)-Me-BoPhoz, 5 (S)-Me-BoPhOZ, (Λ)-Xyl-Binap and (S)-Xyl-Binap, the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA,
THF, toluene, EtOAc and MTBE and mixtures thereof, the optional second additive is selected from the group consisting Of Et3N, iPr2-NH, Cy2NH, (Λ)-Ph-ethyl-NH2, (S)-Ph-ethyl-NH2, KI, KOH, K2CO3, (/?/S)-camphorsulfonic acid and CH3COOH, and, when present, is in an amount up to about 1 .2 Eq., the second temperature is in a range of from about 40 0C to about 60 0C, and the second pressure is in a range of from about 3 bar to about 25 bar, or is in a range of from about I O bar to about 25 bar, or is in a range of from about 3 bar to about 10 bar.
An Example 85 of the invention includes a process comprising the steps:
Step 1 . reacting Compound Cl with a first hydrogen source, a first ligand-metal complex consisting essentially of a first ligand conjugated with a first metal adduct, in a first solvent at a first temperature and a first pressure to provide a substantially pure Compound C2 or a substantially pure Compound C3, wherein the first hydrogen source is selected from gaseous hydrogen or an excess of formic acid, the first ligand is selected from the group consisting of (7?)-PhanePhos, (S)-PhanePhos, (/?)-An-PhanePhos, (5)-An-PhanePhos, (tf)-Xyl-PhanePhos, (S)-Xyl-PhanePhos,
(7?)-MeOXyl-PhanePhos, (S)-MeOXyl-PhanePhos, (7?)-iPr-PhanePhos, (S)-iPr-PhanePhos, (/?,Λ)-Me-DuPhos, (S,S)-Me-DuPhos, (Λ)-P-Phos, (5)-P-Phos, (Λ)-Xyl-P-Phos, (S)-Xyl-P-Phos, (φ-Ph-PHOX, (S)-Ph-PHOX, (Λ)-iPr-PHOX, (S)-iPr-PHOX, (Λ)-Me-BoPhoz, (S)-Me-BoPhoz, CF3Ph-(φ-Me-BoPhoz, CF3Ph-0S;-Me-BoPhoz, (Λ)-Phenethyl-(#)-Me-BoPhoz,
(Λ)-Phenethyl-(S)-Me-BoPhozs 3,4-diCI-Ph-(/?)-Me-BoPhoz, 3,4-diCI-Ph-(S)-Me-BoPhoz, Xyl-(/?)-Me-BoPhoz, Xyl-(S)-Me-BoPhoz, (Λ)-Binol-(Λ)-Me-BoPhoz, (/?)-Binol-(5)-Me-BoPhoz, (5)-Binol-(5)-Me-BoPhoz, (S)-Binol-(7?)-Me-BoPhoz, PCy-(Λ)-Me-BoPhoz, PCy-(5)-Me-BoPhoz, (tf)-iPr-BoPhoz, (5)-iPr-BoPhoz, (/?)-Phenethyl-(5)-BoPhoz,
(/?)-Phenethyl-(Λ)-BoPhoz, (5)-Phenethyl-(/?)-BoPhoz,
(S)-Phenethyl-(5)-BoPhoz, (Λ)-Ph-BoPhoz, (5)-Ph-BoPhoz, (Λ)-Bn-BoPhoz and (S)-Bn-BoPhOz, the first metal adduct is selected from the group consisting of [Ir(COD)CI]2, [Ir(COD)2]BF4 and [lr(COD)2]BArF,
61 the first solvent is selected from the group consisting of THF, toluene, EtOAc and mixtures thereof, the first temperature is in a range of from about 25 0C to about 70 0C, and the first pressure is in a range of from about 3 bar to about 30 bar; and
5 Step 2. reacting Compound C2 or Compound C3 by the direct addition of iodine in an amount up to about 0.1 Eq. and recharging the reaction mixture at an elevated second temperature and an elevated second pressure, wherein the second temperature is in a range of from about 30 0C to about 80 0C, and the second pressure is in a range of from about 3 bar to about 25 bar.
I O An Example 86 of the invention includes a process for reacting Compound Cl, wherein the first ligand is selected from the group consisting of (/?)-Me-BoPhoz and
(.S)-Me-BoPhOz, and the first metal adduct is [Ir(COD)CI]2.
15 An Example 87 of the invention includes a process, according to Scheme C, for preparing a compound of Formula (Ia) and intermediates thereof, wherein the first hydrogen source is gaseous hydrogen; the first ligand-metal complex is (Λ)-Me-BoPhoz A[Ir(COD)CI]2; the first solvent is DCE; 0 the first temperature is about 70 0C; the first pressure is about 25 bar; the second hydrogen source is gaseous hydrogen; and the hydrogenation agent is selected from either 10% Pd/C or a second ligand-metal complex, wherein, when the hydrogenation agent is a second ligand-metal complex selected from 5 (/?)-Me-BoPhoz &[lr(COD)CI]? combined with iodine in an amount of about 0.1
Eq., then the second solvent is EtOAc; the second temperature is about 50 0C; and the second pressure is about 25 bar; and, wherein, when the hydrogenation agent is selected from 10% Pd/C in an amount of about 10% (w/vv); the second solvent is IPA; the optional second additive is Et3N in an amount of about 0.75 Eq.; the second temperature is about 40 0C; and, the second pressure is about 10 bar.
The present invention further relates to an alternative process, as shown in Scheme D, for preparing a compound of Formula (Ia) and intermediates thereof, comprising the steps of:
Scheme D
Step 1 . reacting a Compound Dl with a first hydrogen source, a first ligand-metal complex consisting essentially of a first ligand conjugated with a first metal adduct, in a first solvent in the presence of an optional first additive at an elevated first temperature and an elevated first pressure to provide a substantially pure Compound D3:
Figure imgf000070_0001
Step 2. optionally converting the Compound D3 hydroxy group to the Compound C3 -O-C|.8alkyl group, and carrying forward Compound C3 according to Step 2 of Scheme C;
Step 3. reacting Compound D3 with a second hydrogen source and a hydrogenation agent in a second solvent in the presence of an optional second additive at an elevated second temperature and an elevated second pressure to provide an isomeric mixture of a Compound D4 and Compound D5:
Figure imgf000070_0002
D4, (αS,βS) isomer D5, (αS,βR) isomer and Step 4. converting the hydroxy group in the isomeric mixture of Compound D4 and Compound D5 to an -0-Cι-salkyl group to provide an isomeric mixture of Compound C4 and Compound C5; and carrying forward the isomeric mixture of Compound C4 and Compound C5 according to Step 3 of Scheme C.
The present invention provides a process for making substantially pure Compound D2 comprising the step of: reacting a Compound Dl with a first hydrogen source, a first ligand-metal complex consisting essentially of a first ligand conjugated with a first metal adduct, in a first solvent in the presence of an optional first additive at an elevated first temperature and an elevated first pressure to provide a substantially pure Compound D2:
Figure imgf000071_0001
An Example 88 of the invention includes a process wherein Compound D2 is carried forward in place of Compound D3 to provide an (a.R,\5R) isomer and an (αi?,βS) isomer of Formula (I).
An Example 89 of the invention includes a process for reacting Compound Dl to provide Compound D2, and a process for reacting Compound Dl to provide Compound D3, both processes as desribed herein above, wherein the first ligand is selected from the group consisting of (/?)-Xyl-PhanePhos,
(S;-Xyl-PhanePhos, (φ-PhanePhos, rø-PhanePhos, (φ-An-PhanePhos, (S>An-PhanePhos, (/?)-Me-BoPhoz, (5)-Me-BoPhoz,.(/?)-MeOXyl-PhanePhos, (S;-MeOXyl-PhanePhos; (/?)-iPr-PhanePhos, (5)-iPr-PhanePhos, PCy-(Λ)-Me-BoPhoz and PCy-(S)-Me-BoPhoz, the first metal adduct is selected from the group consisting Of [Rh(COD)2]BF4,
[Rh(COD)2]OTf, [Rh(ethylene)2CI]2; [Rh(ethylene)2(acac)], [Rh(CO)2(acac)], [Rh(COD)CI]2, [Rh(COD)(acac)], [Ru(COD)(CF3COO)2]2, [Ru(COD)(CH3COO)2], [Ru(COD)(methylallyl)2], [Ru(benzene)CI2]2; [Ru(p-cymene)CI2]2, [Ru(mesitylene)Cl2]2, [Ir(COD)CI]2, [Ir(COD)2]BF4 and
[Ir(COD)2]BArF) the first temperature is in a range of from about 25 0C to about 70 0C, and the first pressure is in a range of from about 3 bar to about 30 bar.
An Example 90 of the invention includes a process for reacting Compound Dl, wherein the first ligand-metal complex is selected from the group consisting of (φ-An-PhanePhos/[Rh(COD)]BF4, (tf)-Me-BoPhoz &[lr(COD)CI]2, (Λ;-MeOXyl-PhanePhos/[Rh(COD)]BF4, (Λ;-PhanePhos/[Rh(COD)]BF4, (Λ;-PhanePhos &[Rh(COD)2]OTfs (φ-PhanePhos/[RuCl2(DMF)2], (φ-Tol-Binap/[RuCI(p-cymene)]CI, (φ-Xyl-PhanePhos &[Ru(COD)(CF3COO)2]2, (φ-Xyl-PhanePhos &[Ru(COD)(methylallyl)2], (Λ;-Xyl-PhanePhos/[RuCI2(DMF)2], (Λ;-Xyl-P-Phos/[RuCI2(DMF)2], (5;-iPr-PhanePhos/[Rh(COD)]BF4s (5;-Me-BoPhoz/[RuCI2(DMF)2], (5>PhanePhos/[RuCI2(DMF)2], (S^Tol-Binap/tRuCIO-cymeneJlCI^S^-Xyl-PhanePhos A[Rh(COD)2]OTf and (S>Xyl-PhanePhos/[RuCI2(DMF)2]. An Example 91 of the invention includes a process for reacting Compound Dl, wherein the first ligand is selected from the group consisting of (/?)-Xyl-PhanePhos,
(5>Xyl-PhanePhos, (φ-PhanePhos, (S;-PhanePhos, (Λ>An-PhanePhos, (5>-An-PhanePhos, (Λ)-Me-BoPhoz, (5)-Me-BoPhoz, (Λ)-MeOXyl-PhanePhos and (Sj-MeOXyl-PhanePhos, and
the first metal adduct is selected from the group consisting Of [Rh(COD)2]BF4, [Rh(COD)2]OTf, [Ru(COD)(CF3COO)2]2, [Ru(COD)(methylallyl)2], [Ru(benzene)CI2]2 and [Ir(COD)CI]2. An Example 92 of the invention includes a process for reacting Compound Dl, wherein the first ligand is selected from the group consisting of (7?)-Xyl-PhanePhos,
(S>Xyl-PhanePhos, (/?>PhanePhos, (Sj-PhanePhos, (/?>An-PhanePhos, (Sj-An-PhanePhos, (tf)-Me-BoPhoz, (5)-Me-BoPhoz, (Λ)-MeOXyl-PhanePhos and (SMvleOXyl-PhanePhos, and the first metal adduct is selected from the group consisting of [Rh(COD)2]BF4,
[Rh(COD)2]OTf, [Ru(COD)(CF3COO)2]2; [Ru(COD)(methylallyl)2],
[Ru(benzene)CI2]2 and [Ir(COD)CI]2. An Example 93 of the invention includes a process for reacting Compound Dl, wherein the first ligand is selected from the group consisting of (Λ)-Me-BoPhoz and (5)-Me-BoPhoz, the first metal adduct is [Ir(COD)CI]2, the first solvent is selected from the group consisting of THF, DCE and EtOAc, the first temperature is in a range of from about 65 0C to about 70 0C, and the first pressure is in a range of from about 25 bar to about 30 bar.
An Example 94 of the invention includes a process for reacting Compound Dl, wherein the first ligand is selected from the group consisting of (7?)-PhanePhos , (5)-PhanePhos,
(7?)-An-PhanePhos, (5>An-PhanePhos, (/?)-Xyl-PhanePhos, (S)-Xyl-PhanePhos,
(7?)-MeOXyl-PhanePhos, (5)-MeOXyl-PhanePhos, (5)-iPr-PhanePhos and
(tf)-iPr-PhanePhos, the first metal adduct is selected from the group consisting Of [Rh(COD)2]BF4, [Rh(COD)2]OTf, [Rh(ethylene)2CI]2, [Rh(ethylene)2(acac)], [Rh(CO)2(acac)],
[Rh(COD)CI]2 and [Rh(COD)(acac)], the first solvent is MeOH, the first temperature is from about 25 0C to about 60 0C, and the first pressure is from about 3 bar to about 30 bar. An Example 95 of the invention includes a process for reacting Compound Dl, wherein the first ligand is selected from the group consisting of (7?)-PhanePhos , (S)-PhanePhos,
(7?)-An-PhanePhos, (S)-An-PhanePhos, (tf)-Xyl-PhanePhos, (S>Xyl-PhanePhos, 5 (/?)-MeOXyl-PhanePhos, (S)-MeOXyl-PhanePhos, (S)-iPr-PhanePhos and
(/?)-iPr-PhanePhos, the first metal adduct is selected from the group consisting of [Ru(COD)(CF3COO)2]2,
[Ru(COD)(CH3COO)2], [Ru(COD)(methylallyl)2], [Ru(benzene)CI2]2,
[Ru(p-cymene)CI2]2 and [Ru(mesitylene)CI2]?, I O the first solvent is selected from the group consisting of MeOH, EtOH, IPA, DCE, THF, toluene, EtOAc, DMF and mixtures thereof, the optional first additive is selected from the group consisting of AcOH, CF3CO2H and
Et3N, the first temperature is in a range of from about 40 0C to about 70 0C, and I 5 the first pressure is in a range of from about 3 bar to about 30 bar.
An Example 96 of the invention includes a process for reacting Compound Dl, wherein the first ligand is (Λ)-XylPhanePhos, the first metal adduct is selected from the group consisting of [Ru(COD)(CF3COO)2]T, 0 [Ru(COD)(CH3COO)2], [Ru(COD)(methylallyl)2], [Ru(benzene)CI2]2,
[Ru(p-cymene)Cl2]2 and [Ru(mesitylene)Cl2]2, the first solvent is selected from the group consisting of MeOH, DMF and mixtures thereof, the optional first additive is Et3N, 5 the first temperature is in a range of from about 40 0C to about 60 0C, and the first pressure is in a range of from about 3 bar to about 30 bar.
An Example 97 of the invention includes a process for reacting Compound Dl, wherein the first ligand is (tf)-XylPhanePhos, the first metal adduct is selected from the group consisting of [Ru(COD)(CF3COO)2I2, [Ru(COD)(CH3COO)2], [Ru(COD)(methylallyl)2], [Ru(benzene)Cl2]2; [Ru(p-cymene)Cl2]2 and [Ru(mesitylene)Cl2]2, the first solvent is selected from the group consisting of MeOH, DMF and mixtures 5 thereof, the optional first additive is AcOH, the first temperature is about 40 0C, and the first pressure is about 10 bar.
An Example 98 of the invention includes a process for reacting Compound Dl, I O wherein the first ligand is (/?)-XylPhanePhos, the first metal adduct is selected from the group consisting of [Ru(COD)(CF3COO)2]2,
[Ru(COD)(CH3COO)2], [Ru(COD)(methylallyl)2], [Ru(benzene)CI2]2,
[Ru(p-cymene)CI2]2 and [Ru(mesitylene)CI2]2, 15 the first solvent is selected from the group consisting of MeOH, EtOH, IPA, DCE, THF, toluene, EtOAc, DMF and mixtures thereof, the first temperature is about 40 0C and the first pressure is about 10 bar.
An Example 99 of the invention includes a process for reacting Compound Dl, 0 wherein the first ligand is (Λ)-XylPhanePhos, the first metal adduct is [Ru(COD)(CF3COO)2]2; [Ru(COD)(CH3COO)2] and
[Ru(COD)(methylallyl)2], the first solvent is MeOH, 5 the first optional additive is AcOH, the first temperature is about 40 0C, and the first pressure is about I O bar. An Example 100 of the invention includes a process for reacting Compound D2 or Compound D3, wherein the second hydrogen source is gaseous hydrogen, the hydrogenation agent is selected from either 10% Pd/C or a second ligand-metal complex, wherein the second ligand-metal complex consists essentially of a second ligand and an [lr(COD)CI]2 metal adduct combined with iodine in an amount up to about 0.1 Eq., wherein 10% Pd/C is present in a range of weight % of from about 5% weight/weight (w/w) to about 20% (w/w), and wherein the second ligand is selected from the group consisting of (7?)-PhanePhos, (S)-PhanePhos, (Λ)-An-PhanePhos, (S)-An-PhanePhos, (tf)-Xyl-PhanePhos, (S)-Xyl-PhanePhos, (tf)-MeOXyl-PhanePhos, (S)-MeOXyl-PhanePhos, (7?)-iPr-PhanePhos, (S)-iPr-PhanePhos, (Λ,Λ)-Me-DuPhos, (S, S)-Me-Du Phos, CK)-P-Phos, (S)-P-PhOS, (Λ)-Xyl-P-Phos, (S)-Xyl-P-Phos, (Λ)-Tol-P-Phos,
OS)-ToI-P-PhOs, (φ-Ph-PHOX, (S)-Ph-PHOX, (Λ)-iPr-PHOX, (S)-iPr-PHOX, (Λ)-Me-BoPhoz, (S)-Me-BoPhoz, CF3Ph-(/?)-Me-BoPhoz, CF3Ph-(S>Me-BoPhoz, (/?)-Phenethyl-(tf)-Me-BoPhoz, (Λ)-Phenethyl-(S)-Me-BoPhoz, (S)-Ethyl-Napthyl-(7?)-Me-BoPhoz, 3,4-diCI-Ph-(/?)-Me-BoPhoz, 3,4-diCI-Ph-(S)-Me-BoPhoz,
(Λ)-2,4,6-F3Ph-(/?)-Me-BoPhoz, (/?)-2,4,6-F3Ph-(S)-Me-BoPhoz, (S)-2,4,6-F3Ph-(S)-Me-BoPhoz, (S)-2,4,6-F3Ph-(Λ)-Me-BoPhoz, Xyl-(Λ)-Me-BoPhoz, Xyl-(S)-Me-BoPhoz, (Λ)-Binol-(Λ)-Me-BoPhoz, (Λ)-Binol-(S)-Me-BoPhoz, (S)-Binol-(S)-Me-BoPhoz, (S)-B inol-(/?)-Me-BoPhoz, PCy-(Λ)-Me-BoPhoz, pFPh-(Λ)-Me-BoPhoz, pFPh-(S)-Me-BoPhoz,
(Λ)-Et-BoPhoz, (S)-Et-BoPhoz, pFPh-(/?)-Et-BoPhoz, pFPh-(S)-Et-BoPhoz, (Λ)-iPr-BoPhoz, (S)-iPr-BoPhoz, (7?)-Et-BoPhoz, (S)-Et-BoPhoz, (/?)-Phenethyl-(S)-BoPhoz, (Λ)-Phenethyl-(/.)-BoPhoz, (S)-Phenethyl-(/?)-BoPhoz, (S)-Phenethyl-(S)-BoPhoz, (Λ)-Ph-BoPhoz, (S)-Ph-BoPhOz, (tf)-Bn-BoPhoz, (S)-Bn-BoPhoz, pFPh-(/?)-Bn-BoPhoz, pFPh-(S)-Bn-BoPhoz, (Λ)-Xyl-Binap, (S)-Xyl-Binap and DPPF, the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA,
THF, toluene, EtOAc, 1 -BuOH and MTBE and mixtures thereof, the optional second additive is selected from the group consisting Of Et3N, JPr2-NH,
Cy2NH, (Λ)-Ph-ethyl-NH2, (S)-Ph-ethyl-NH2, KI, KOH, K2CO3, (i?/5)-camphorsulfonic acid and CH3COOH, and, when present, is in an amount up to about 1.2 Eq., the second temperature is in a range of from about 30 0C to about 80 0C, or is in a range of from about 40 0C to about 60 0C, and the second pressure is in a range of from about 3 bar to about 25 bar, or is in a range of from about 10 bar to about 25 bar, or is in a range of from about 3 bar to about 10 bar.
An Example 101 of the invention includes a process for reacting Compound D2 or Compound D3, wherein the second ligand-metal complex is selected from the group consisting of (tf)-Me-BoPhoz &[lr(COD)CI]2, (tf)-PhanePhos &[Ir(COD)Cl]2, (Zf)-P-Phos &[lr(COD)CI]2) (tf)-Xyl-Binap &[Ir(COD)CI]2, (Λ)-Xyl-PhanePhos &[Ir(COD)CI]2, (tf)-Xyl-P-Phos A[Ir(COD)CI]2, (S)-Me-BoPhoz &[Ir(COD)CI]2, (S)-PhanePhos &[Ir(COD)CI]2, (5)-P-Phos &[Ir(COD)Cl]2, (5)-Tol-P-Phos A[Ir(COD)CI]2, (S)-Xyl-Binap A[Ir(COD)CI]2, (S)-Xyl-PhanePhos A[Ir(COD)CI]2 and (S)-Xyl-P-Phos A[Ir(COD)Cl]2. An Example 102 of the invention includes a process for reacting Compound D2 or Compound D3, wherein the second ligand is selected from the group consisting of (Λ)-P-Phos, (5)-P-Phos, (Λ)-Xyl-P-Phos, (S)-Xyl-P-Phos, (S)-Tol-P-Phos, (Λ)-Me-BoPhoz, (S)-Me-BoPhOZ, (Λ)-Xyl-Binap and (S)-Xyl-Binap, the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA,
THF, toluene, EtOAc and MTBE and mixtures thereof, the second temperature is in a range of from about 40 0C to about 60 0C, and the second pressure is in a range of from about 3 bar to about 25 bar, or is in a range of from about 10 bar to about 25 bar, or is in a range of from about 3 bar to about 10 bar. An Example 103 of the invention includes a process for reacting Compound D2 or Compound D3, wherein the second hydrogen source is gaseous hydrogen,
10% Pd/C is present in a range of weight % of from about 5% (w/w) to about 20% (w/w), the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA,
THF, toluene, EtOAc, 1 -BuOH and MTBE and mixtures thereof, the optional second additive is selected from the group consisting Of Et3N, JPr2-NH,
Cy2NH, (Λ)-Ph-ethyl-NH2, (S)-Ph-ethyl-NH2, Kl, KOH, K2CO3,
(7?/5)-camphorsulfonic acid and CH3COOH, and, when present, is in an amount up to about 1.2 Eq., the second temperature is in a range of from about 30 0C to about 80 0C, or is in a range of from about 40 0C to about 60 0C, and the second pressure is in a range of from about 3 bar to about 25 bar, or is in a range of from about I O bar to about 25 bar, or is in a range of from about 3 bar to about 10 bar.
An Example 104 of the invention includes a process for reacting Compound D2 or Compound D3, wherein the second ligand-metal complex consists essentially of a second ligand and an
[Ir(COD)CI]2 second metal adduct combined with iodine in an amount up to about 0.1 Eq., wherein the second ligand is selected from the group consisting of (/?)-PhanePhos, (5)-PhanePhos, (7?)-An-PhanePhos, (S)-An-PhanePhos, (/?)-Xyl-PhanePhos, OS)-Xyl-PhanePhos, (Λ)-MeOXyl-PhanePhos, (S)-MeOXyl-PhanePhos, (Λ,7?)-Me-DuPhos, (S.S)-Me-DuPhos, (Λ)-P-Phos, (S)-P-Phos, (Λ)-Xyl-P-Phos, (S)-XyI-P-PhOS, (Λ)-Tol-P-Phos, (S>Tol-P-Phos, (Λj-Ph-PHOX, (S)-Ph-PHOX,
(tf)-iPr-PHOX, (S)-iPr-PHOX, (tf)-Me-BoPhoz, (S)-Me-BoPhoz, CF3Ph-(Λ>Me-BoPhoz, CF3Ph-(S';-Me-BoPhoz, (Λ)-Phenethyl-(Λ)-Me-BoPhoz, (/?)-Phenethyl-(S)-Me-BoPhoz, (S)-Ethyl-Napthyl-(/?)-Me-BoPhoz, 3,4-diCI-Ph-(/?)-Me-BoPhoz, 3,4-diCI-Ph-(S)-Me-BoPhoz, (tf)-2,4,6-F3Ph-(/?)-Me-BoPhoz, (tf)-2,4,6-F3Ph-(S)-Me-BoPhoz, (S)-2,4,6-F3Ph-(S)-Me-BoPhoz, (S)-2,4,6-F3Ph-(/?)-Me-BoPhoz, Xyl-(Λ)-Me-BoPhoz, Xyl-(5)-Me-BoPhoz, (Λ)-Binol-(Λ)-Me-BoPhoz, (/?)-Binol-(5)-Me-BoPhoz, (5)-Binol-(5)-Me-BoPhoz, (5)-Binol-(Λ)-Me-BoPhoz, PCy-(#)-Me-BoPhoz, pFPh-(Λ)-Me-BoPhoz, pFPh-(S)-Me-BoPhoz, (Λ)-Et-BoPhoz, (S)-Et-BoPhOZ, pFPh-(fl)-Et-BoPhoz, pFPh-(S)-Et-BoPhoz,
(/?)-iPr-BoPhoz, (S)-iPr-BoPhoz, (/?)-Phenethyl-(S)-BoPhoz, (tf)-Phenethyl-(/?)-BoPhoz, (S)-Phenethyl-(/?)-BoPhoz, (S)-Phenethyl-(S)-BoPhoz, (Λ)-Ph-BoPhoz, (S)-Ph-BoPhoz, (Λ)-Bn-BoPhoz, (S)-Bn-BoPhoz, pFPh-(/?)-Bn-BoPhoz, pFPh-(S)-Bn-BoPhoz, (Λ)-Xyl-Binap, (S)-Xyl-Binap and DPPF, the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA, THF, toluene, EtOAc, I -BuOH and MTBE and mixtures thereof, the optional second additive is selected from the group consisting Of Et3N, iPn-NH,
Cy2NH, (Λ)-Ph-ethyl-NH2, (S)-Ph-ethyl-NH2, KI, KOH, K2CO3, (/?/S)-camphorsulfonic acid and CH3COOH, and, when present, is in an amount up to about 1 .2 Eq., the second temperature is in a range of from about 30 0C to about 80 0C, or is in a range of from about 40 0C to about 60 0C, and the second pressure is in a range of from about 3 bar to about 25 bar, or is in a range of from about I O bar to about 25 bar, or is in a range of from about 3 bar to about 10 bar.
An Example 105 of the invention includes a process for reacting Compound D2 or Compound D3, wherein the second ligand is selected from the group consisting of (/?)-P-Phos, (S)-P-Phos, (Λ)-Xyl-P-Phos, (S)-Xyl-P-Phos, (S)-Tol-P-Phos, (fl)-Me-BoPhoz,
(S)-Me-BoPhOz, (7?)-Xyl-Binap and (S)-Xyl-Binap, the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA,
THF, toluene, EtOAc and MTBE and mixtures thereof, the second temperature is in a range of from about 40 0C to about 60 0C, and the second pressure is in a range of from about 3 bar to about 25 bar, or is in a range of from about I O bar to about 25 bar, or is in a range of from about 3 bar to about 10 bar.
An Example 106 of the invention includes a process comprising the steps: Step 1. reacting Compound Dl with a first hydrogen source, a first ligand-metal complex consisting essentially of a first ligand conjugated with a first metal adduct, in a first solvent in the presence of an optional first additive at a first elevated temperature and a first elevated pressure, to provide a substantially pure Compound D2 or a substantially pure Compound D3, wherein the first hydrogen source is selected from gaseous hydrogen or an excess of formic acid, the first ligand is selected from the group consisting of (/?)-Xyl-PhanePhos,
(S;-Xyl-PhanePhos, (φ-PhanePhos, (5^-PhanePhos, (φ-An-PhanePhos, (S;-An-PhanePhos, (Λ)-MeOXyl-PhanePhos, (Sj-MeOXyl-PhanePhos, PCy-(/?)-Me-BoPhoz and PCy-(5)-Me-BoPhoz, the first metal adduct is selected from the group consisting of [Rh(COD)2]BF4, [Rh(COD)2]OTf, [Ru(COD)(CF3COO)2]2, [Ru(COD)(methylallyl)2], [Ru(benzene)Cl2]2 and [Ir(COD)CI]2, the first solvent is selected from the group consisting of MeOH, EtOH, IPA, DCE, THF, toluene, EtOAc, DMF and mixtures thereof, the optional first additive is selected from the group consisting of AcOH, Et3N, HBF4, HBF4 etherate, HCI, HCI etherate, CF3COOH, CH3COOH and TsOH, and, when present, is in an amount up to about 1.2 Eq., the first temperature is in a range of from about 25 0C to about 70 0C and the first pressure is in a range of from about 3 bar to about 30 bar; Step 2. optionally converting the Compound D2 or Compound D3 hydroxy group to the Compound C2 or Compound C3 -O-Ci.8alkyl group, and carrying forward Compound C2 or Compound C3 according to Step 2 of Scheme C; and
Step 3. reacting Compound D3 with a second hydrogen source and a hydrogenation agent in a second solvent in the presence of an optional second additive at an elevated second temperature and an elevated second pressure to provide an isomeric mixture of a Compound D4 and Compound D5, wherein the second hydrogen source is gaseous hydrogen, the hydrogenation agent is selected from either 10% Pd/C or a second ligand-metal complex, wherein the second ligand-metal complex consists essentially of a second ligand and an [Ir(COD)CI]2 metal adduct combined with iodine in an amount up to about 0.1 Eq., wherein 10% Pd/C is present in a range of weight % of from about 5% (w/w) to about 20% (w/w), and wherein the second ligand is selected from the group consisting of (Λ)-P-Phos,
(S)-P-PhOS, (Λ)-Xyl-P-Phos, (S)-Xyl-P-Phos, (5)-Tol-P-Phos, (/?)-Me-BoPhoz, (S)-Me-BoPhOz, (Λ)-Xyl-Binap and (5)-Xyl-Binap, the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA, THF, toluene, EtOAc and MTBE and mixtures thereof, the optional second additive is selected from the group consisting Of Et3N, iPr2-NH, Cy2NH, (Λ)-Ph-ethyl-NH2, (5>Ph-ethyl-NH2, KI, KOH, K2CO3, (Λ/S)-camphorsulfonic acid and CH3COOH, and, when present, is in an amount up to about 1.2 Eq., the second temperature is in a range of from about 40 0C to about 60 0C, and the second pressure is in a range of from about 3 bar to about 25 bar, or is in a range of from about 10 bar to about 25 bar, or is in a range of from about 3 bar to about 10 bar.
An Example 107 of the invention includes a process comprising the steps: Step 1. reacting Compound Dl with a first hydrogen source, a first ligand-metal complex consisting essentially of a first ligand conjugated with a first metal adduct, in a first solvent in the presence of an optional first additive at a first elevated temperature and a first elevated pressure, to provide a substantially pure Compound D2 or a substantially pure Compound D3, wherein the first hydrogen source is selected from gaseous hydrogen or an excess of formic acid, the first ligand is selected from the group consisting of (Λ)-Me-BoPhoz, (S)-Me-BoPhoz, (Λ)-Xyl-P-Phos, (S)-Xyl-P-Phos, (Λ)-P-Phos, (S)-P-Phos, (7?)-Et-BoPhoz, (S)-Et-BoPhOZ, (Λ)-iPr-BoPhoz, (S)-iPr-BoPhoz, (tf)-Bn-BoPhoz, (S)-Bn-BoPhoz, (Λ)-Ph-BoPhoz, (S)-Ph-BoPhOZ, the first metal adduct is [Ir(COD)CI]2, [Ir(COD)2]BF4 and [lr(COD)2]BArF, the first solvent is selected from the group consisting of THF, EtOAc and toluene, the first temperature is about 70 0C, and the first pressure is about 25 bar, and
Step 2. optionally converting the Compound D2 or Compound D3 hydroxy group to the Compound C2 or Compound C3 -O-C |.8alky! group, and carrying forward
Compound C2 or Compound C3 according to Step 2 of Scheme C;
Step 3. reacting Compound D3 by the direct addition of iodine in an amount up to about 0.1 Eq., and recharging the reaction mixture at an elevated second temperature and an elevated second pressure, wherein the second temperature is in a range of from about 30 0C to about 80 0C, and the second pressure is in a range of from about 3 bar to about 25 bar.
An Example 108 of the invention includes a process for reacting Compound Dl, wherein the first ligand is selected from the group consisting of (7?)-Me-BoPhoz and (S)-Me-BoPhOZ, and the first metal adduct is [Ir(COD)CI]2.
An Example 109 of the invention includes a process, according to Scheme D, for preparing a compound of Formula (Ia) and intermediates thereof, wherein the first hydrogen source is gaseous hydrogen; the first ligand-metal complex is (φ-Xyl-PhanePhos &[Ru(COD)(CF3COO)2]2; the first solvent is MeOH; the first temperature is about 40 0C; the first pressure is about 10 bar; the second hydrogen source is gaseous hydrogen; and the hydrogenation agent is selected from either 10% Pd/C or a second ligand-metal complex, wherein, when the hydrogenation agent is a second ligand-metal complex selected from
(/?)-Me-BoPhoz A[Ir(COD)CI]2 combined with iodine in an amount of about 0.1 5 Eq., then the second solvent is EtOAc; the second temperature is about 50 0C; and the second pressure is about 25 bar; and, wherein, when the hydrogenation agent is selected from 10% Pd/C in an amount of about
10% (w/w); the second solvent is MeOH; the optional second additive is Et3N in an amount of about 0.75 Eq.; the second temperature is about 40 0C; and, the I O second pressure is about 10 bar.
An Example 110 of the invention includes a process which provides an enantiomer or diastereomer of a compound of Formula (I) or a compound of Formula (II) selected from the group consisting of:
Cpd Names
1 β-[ l -[[3-[( 1 ,4,5, 6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]phenyl]acetyl]-4- piperidinyl]-3-quinolinepropanoic acid,
2 3-( l -{2-[3-(5-hydroxy-l ,4,5,6-tetrahydro-pyrimidin-2-ylamino)-phenyl]- acetyl}-piperidin-4-yl)-3-quinolin-3-yl-propionic acid methyl ester,
3 β-[ 1 -[ 1 -oxo-4-(5,6,7,8-tetrahydro-l ,8-naphthyridin-2-yl)butyl]-4-piperidinyl]- 3-quinolinepropanoic acid,
4 3-quinolin-3-yl-3-[l -(4-5,6,7, 8-tetrahydro-[ l ,8]naphthyridin-2-yl-butyryl)- piperidin-4-yl]-propionic acid methyl ester,
5 3-[ I -(4-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl-butyryl)-piperidin-4-yl]-3- ( 1 ,2,3,4-tetrahydro-quinolin-3-yl)-propionic acid,
6 (3tf*,3\S*)-3-[ 1 -(4-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl-butyryl)- piperidin-4-yl]-3-(l ,2,3,4-tetrahydro-quinolin-3-yl)-propionic acid,
7 (3R*,yR*)-3-[ 1 -(4-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl-butyryl)- piperidin-4-yl]-3-(l ,2,3,4-tetrahydro-quinolin-3-yl)-propionic acid,
8 (35*,3'/?*)-3-[ l -(4-5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2-yl-butyryl)- piperidin-4-yl]-3-( l ,2,3,4-tetrahydro-quinolin-3-yl)-propionic acid,
9 (35*,3'5*)-3-[ l -(4-5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2-yl-butyryl)-piperidin- 4-yl]-3-(l ,2,3,4-tetrahydro-quinolin-3-yl)-propionic acid, Cpd Names
10 3-[ I -(4-5,6,7, 8-tetrahydro-[l ,8]naphthyridin-2-yl-butyryl)-piperidin-4-yl]-3- ( l ,2,3,4-tetrahydro-quinolin-3-yl)-propionic acid methyl ester,
1 1 β-[2-[ I -[3-[( 1 ,4,5,6-tetrahydro-2-pyrimidinyl)amino]benzoyl]-4- piperidinyl]ethyl]-3-pyridinepropanoic acid,
12 3-pyridin-3-yl-5-{ l -[3-(l ,4,5,6-tetrahydro-pyrimidin-2-ylamino)-benzoyl]- piperidin-4-yl}-pentanoic acid methyl ester,
13 β-[2-[l -[3-[(l,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]-4- piperidinyl]ethyl]-3-pyridinepropanoic acid,
14 5-{ l -[3-(5-hydroxy-l ,4,5,6-tetrahydro-pyrimidin-2-ylamino)-benzoyl]- piperidin-4-yl}-3-pyridin-3-yl-pentanoic acid methyl ester,
15 β-[2-[ I -[ I -oxo-3-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2-y l)propyl]-4- piperidinyl]ethyl]-3-pyridinepropanoic acid,
16 3-pyridin-3-yl-5-[ 1 -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl-propionyl)- piperidin-4-yl]-pentanoic acid methyl ester,
17 β-[2-[ I -[ 1 -oxo-4-(2-pyridinylamino)butyl]-4-piperidinyl]ethyl]-3- pyridinepropanoic acid,
18 3-pyridin-3-yl-5-{ 1 -[4-(pyridin-2-ylamino)-butyryl]-piperidin-4-yl}-pentanoic acid methyl ester,
19 6-methoxy-β-[2-[ I -[3-[( 1 ,4,5,6-tetrahydro-5-hydroxy-2- pyrimidinyl)amino]benzoyl]-4-piperidinyl]ethyl]-3-pyridinepropanoic acid,
20 5-{ I -[3-(5-hydroxy- 1 ,4,5,6-tetrahydro-pyrimidin-2-ylamino)-benzoyl]- piperidin-4-yl }-3-(6-methoxy-pyridin-3-yl)-pentanoic acid methyl ester,
21 β-( l ,3-benzodioxol-5-yl)-l -[ l-oxo-3-(5,6,7,8-tetrahydro-l ,8-naphthyridin-2- yl)propyl]-4-piperidinebutanoic acid,
22 3-benzo[ 1 ,3]dioxol-5-yl-4-[ 1 -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid methyl ester,
23 β-[2-[ I -[3-[( 1 ,4,5,6-tetrahydro-2-pyrimidinyl)amino]benzoyl]-4- piperidinyl]ethyl]-3-quinolinepropanoic acid,
24 3-quinolin-3-yl-5-{ I -[3-( 1 ,4,5,6-tetrahydro-pyrimidin-2-ylamino)-benzoyl]- piperidin-4-yl }-pentanoic acid methyl ester,
25 l -[ l -oxo-3-(5,6,7,8-tetrahydro-l ,8-naphthyridin-2-yl)propyl]-β-phenyl-4- piperidinebutanoic acid,
26 3-phenyl-4-[ l -(3-5,6,7,8-tetrahydro-[l ,8]naphthyridin-2-yl-propionyl)- piperidin-4-yl]-butyric acid methyl ester,
27 β-( 1 ,3-benzodioxol-5-yl)- 1 -[ 1 -oxo-3-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2- yl)propyl]-4-piperidinepropanoic acid, Cpd Names
28 3-benzo[ 1 ,3]dioxol-5-yl-3-[ 1 -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-propionic acid methyl ester,
29 β-( 1 ,3-benzodioxoI-5-yl)- 1 -[ 1 -oxo-4-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2- yl)butyl]-4-piperidinepropanoic acid,
30 3-benzo[ 1 ,3]dioxol-5-yl-3-[ 1 -(4-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl- butyryl)-piperidin-4-yl]-propionic acid methyl ester,
31 P^l ^-benzodioxol-S-yO- l -tCSAV^-tetrahydro-US-naphthyridin^-yOacetyl]- 4-piperidinepropanoic acid,
32 S-benzop
Figure imgf000085_0001
acetyl)-piperidin-4-yl]-propionic acid methyl ester,
33 6-methoxy-β-[ 1 -[ 1 -oxo-4-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2-yl)butyl]-4- piperidinyl]-3-pyridinepropanoic acid,
34 3-(6-methoxy-pyridin-3-yl)-3-[ I -(4-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl- butyryl)-piperidin-4-yl]-propionic acid methyl ester,
35 3-(2-methyl-l ,4,5,6-tetrahydro-pyrimidin-5-yl)-4-[ l -(3-5,6,7,8-tetrahydro- [ 1 ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-butyric acid,
36 3-(2-methyl-1 ,4;5,6-tetrahydro-pyrimidin-5-yl)-4-[ l -(3-5,6,7, 8-tetrahydro- [ l ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-butyric acid methyl ester,
37 4-[ I -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-3- ( l ,2,3,4-tetrahydro-quinolin-3-yl)-butyric acid,
38 (3Λ,3'/?)-4-[ l -(3-5,6,7,8-tetrahydro-[l ,8]naphthyridin-2-yl-propionyl)- piperidin-4-yl]-3-( l ,2,3,4-tetrahydro-quinolin-3-yl)-butyric acid,
39 (3y?,3'/?)-4-[ l -(3-5,6,7,8-tetrahydro-[] ,8]naphthyridin-2-yl-propionyl)- piperidin-4-yl]-3-( l ,2,3,4-tetrahydro-quinolin-3-yl)-butyric acid methyl ester,
40 (3J?,3'S)-4-[ I -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl-propionyl)- piperidin-4-yl]-3-( 1 ,2,3,4-tetrahydro-quinolin-3-yl)-butyric acid,
41 (3#,3'S)-4-[ I -(3-5,6,7, 8-tetrahydro-[ l ,8]naphthyridin-2-yl-propionyl)- piperidin-4-yl]-3-(l ,2,3,4-tetrahydro-quinolin-3-yl)-butyric acid methyl ester,
42 (35,3'/?)-4-[ ] -(3-5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2-yl-propionyl)- piperidin-4-yl]-3-( 1 ,2,3,4-tetrahydro-quinolin-3-yl)-butyric acid,
43 (35,3'7?)-4-[ l -(3-5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2-yl-propionyl)- piperidin-4-yl]-3-( l ,2,3,4-tetrahydro-quinolin-3-yl)-butyric acid methyl ester,
(Ia) (35,3'5)-4-[ l -(3-5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2-yl-propionyl)-piperidin- 4-yl]-3-( 1 ,2,3,4-tetrahydro-quinolin-3-yl)-butyric acid,
44 (35,3'5)-4-[ 1 -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl-propionyl)-piperidin- 4-yl]-3-( l ,2,3,4-tetrahydro-quinolin-3-yl)-butyric acid methyl ester, Cpd Names
45 4-[ 1 -(3-5,6, 7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-3- ( l ,2,3,4-tetrahydro-quinolin-3-yl)-butyric acid methyl ester,
46 β-( 1 ,3-benzodioxol-5-yl)- 1 -[ ! -oxo-3-(5,6,7,8-tetrahydro- 1 ,8-naphthyrid in-2- yl)propyl]-4-piperidinepentanoic acid,
47 3-benzo[ 1 ,3]dioxol-5-yl-5-[ 1 -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-pentanoic acid methyl ester,
48 6-methoxy-β-[2-[ 1 -[ 1 -oxo-3-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2-yl)propyl]- 4-piperidinyl]ethyl]-3-pyridinepropanoic acid,
49 3-(6-methoxy-pyridin-3-yl)-5-[ 1 -(3-5,6,7, 8-tetrahydro-[ 1 ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-pentanoic acid methyl ester,
50 (35*)-3-(6-methoxy-pyridin-3-yl)-5-[ 1 -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin- 2-yl-propionyl)-piperidin-4-yl]-pentanoic acid,
51 (3/?*)-3-(6-methoxy-pyridin-3-yl)-5-[ l -(3-5,6,7,8-tetrahydro-[l ,8]naphthyridin- 2-yl-propionyl)-piperidin-4-yl]-pentanoic acid,
52 β-[2-[ 1 -[ 1 -oxo-4-(2-pyridinylamino)butyl]-4-piperidinyl]ethyl]-3- quinolinepropanoic acid,
53 5- ( l -[4-(pyridin-2-ylamino)-butyryl]-piperidin-4-yl }-3-quinolin-3-yl-pentanoic acid methyl ester,
54 β-( l ,3-benzodioxol-5-yl)-l -[ l -oxo-4-(2-pyridinylamino)bιιtyl]-4- piperidinepentanoic acid,
55 3-benzo[ 1 ,3]dioxol-5-yl-5-{ 1 -[4-(pyridin-2-ylamino)-butyryl]-piperidin-4-yl }- pentanoic acid methyl ester,
56 β-( l ,3-benzodioxol-5-yl)-l -[1 -oxo-4-(2-pyridinylamino)butyl]-4- piperidinepropanoic acid,
57 3-benzo[ l ,3]dioxol-5-yl-3-{ l -[4-(pyridin-2-ylamino)-butyryl]-piperidin-4-yl}- propionic acid methyl ester,
58 6-methoxy-β-[2-[ 1 -[ 1 -oxo-4-(2-pyridinylamino)butyl]-4-piperidinyl]ethyl]-3- pyridinepropanoic acid,
59 3-(6-methoxy-pyridin-3-yl)-5-{ 1 -[4-(pyridin-2-ylamino)-butyryl]-piperidin-4- yl}-pentanoic acid methyl ester,
60 β-( 1 ,3-benzodioxol-5-yl)- 1 -[ 1 -oxo-4-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2- yl)butyl]-4-piperidinebutanoic acid,
61 3-benzo[ 1 ,3]dioxol-5-yl-4-[ I -(4-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl- butyryl)-piperidin-4-yl]-butyric acid methyl ester,
62 β.( 1 ,3-benzodioxol-5-yl)- 1 -[3-[( 1 ,4,5,6-tetrahydro-5-hydroxy-2- pyrimidinyl)amino]benzoyl]-4-piperidinebutanoic acid, Cpd Names
63 3-benzo[ l ,3]dioxol-5-yl-4-{ l -[3-(5-hydroxy-l ,4,5,6-tetrahydro-pyrimidin-2- ylamino)-benzoyl]-piperidin-4-yl}-butyric acid methyl ester,
64 6-methoxy-β-[[ 1 -[ 1 -oxo-3-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2-yl)propyl]-4- piperidinyl]methyl]-3-pyridinepropanoic acid,
65 3-(6-methoxy-pyridin-3-yl)-4-[ l -(3-5,6,7,8-tetrahydro-[l ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid methyl ester,
66 (3Λ*)-3-(6-methoxy-pyridin-3-yl)-4-[ 1 -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin- 2-yl-propionyl)-piperidin-4-yl]-butyric acid,
67 (3S*)-3-(6-methoxy-pyridin-3-yl)-4-[ 1 -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin- 2-yl-propionyl)-piperidin-4-yl]-butyric acid,
68 β-[[ 1 -[ 1 -oxo-4-(5,6,7,8-tetrahydro- 1 ,8-naphthyrid in-2-y l)butyl]-4- piperidinyl]methyl]-3-quinolinepropanoic acid,
69 3-quinolin-3-yl-4-[ I -(4-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl-butyryl)- piperidin-4-yl]-butyric acid methyl ester,
70 β-(3-fluorophenyl)-l -[ l -oxo-3-(5,6,7,8-tetrahydro-l ,8-naphthyridin-2- yl)propyl]-4-piperidinebutanoic acid,
71 3-(3-fluoro-phenyl)-4-[l -(3-5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid methyl ester,
72 (3/?*)-3-(3-fluoro-phenyl)-4-[ 1 -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid,
73 (3S*)-3-(3-fluoro-phenyl)-4-[ 1 -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid,
74 β-(3-fluorophenyl)-l -[1 -oxo-4-(5,6,7,8-tetrahydro-l ,8-naphthyridin-2-yl)butyl]- 4-piperidinebutanoic acid,
75 3-(3-fluoro-phenyl)-4-[l -(4-5,6,7, 8-tetrahydro-[ l ,8]naphthyridin-2-yl-butyryl)- piperidin-4-yl]-butyric acid methyl ester,
76 β-[[ 1 -[ 1 -oxo-3-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2-yl)propy l]-4- piperidinyl]methyl]-3-quinolinepropanoic acid,
77 3-quinolin-3-yl-4-[l-(3-5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2-yl-propionyl)- piperidin-4-yl]-butyric acid methyl ester,
78 β-(4-fluorophenyl)- 1 -[ 1 -oxo-3-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2- yl)propyl]-4-piperidinebutanoic acid,
79 3-(4-fIuoro-phenyl)-4-[l -(3-5,6,7, 8-tetrahydro-[l ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid methyl ester,
80 β-(4-fluorophenyl)- l -[l -oxo-4-(5,6,7,8-tetrahydro-l ,8-naphthyridin-2-yl)butyl]- 4-piperidinebutanoic acid, Cpd Names
81 3-(4-fluoro-phenyl)-4-[ l-(4-5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2-yl-butyryl)- piperidin-4-yl]-butyric acid methyl ester,
82 2-methy l-β-[[ 1 -[ 1 -oxo-3-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2-yl)propyl]-4- piperidinyl]methyl]-5-pyrimidinepropanoic acid,
83 3-(2-methyl-pyrimidin-5-yl)-4-[ I -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid methyl ester,
84 β-(2,3-dihydro-6-benzofuranyl)- 1 -[ 1 -oxo-3-(5,6,7,8-tetrahydro- 1 ,8- naphthyridin-2-yl)propyl]-4-piperidinebutanoic acid,
85 3-(2,3-dihydro-benzofuran-6-yl)-4-[ 1 -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin- 2-yl-propionyl)-piperidin-4-yl]-butyric acid methyl ester,
86 (3S*)-3-(2,3-dihydro-benzofuran-6-yl)-4-[ 1 -(3-5,6,7,8-tetrahydro- [ 1 ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-butyric acid,
87 (3/?*)-3-(2,3-dihydro-benzofuran-6-yl)-4-[l -(3-5,6,7;8-tetrahydro- [ 1 ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-butyric acid,
88 β-(3,5-difluorophenyl)-l -[l -oxo-3-(5,6,7,8-tetrahydro- l ,8-naphthyridin-2- yl)propyl]-4-piperidinebutanoic acid, 89 3-(3:5-dinuoro-phenyl)-4-[ ] -(3-5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid methyl ester,
90 β-(3,5-difluorophenyl)- 1 -[ 1 -oxo-4-(5,6,7,8-tetrahydro-1 ,8-naphthyridin-2- yl)butyl]-4-piperidinebutanoic acid,
91 3-(3,5-difluoro-phenyl)-4-[l -(4-5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2-yl- butyryl)-piperidin-4-yl]-butyric acid methyl ester,
92 I -[] -oxo-3-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2-y l)propy l]-β-[3- (trifluoromethyl)phenyl]-4-piperidinebutanoic acid,
93 4-[ l -(3-5,6,7,8-tetrahydro-[l ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-3- (3-trifluoromethyl-phenyl)-butyric acid methyl ester,
94 l -[ l -oxo-3-(5,6,7,8-tetrahydro-l ,8-naphthyridin-2-yl)propyl]-β-[4- (trifluoromethoxy)phenyl]-4-piperidinebutanoic acid,
95 4-[ 1 -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-3- (4-trifluoromethoxy-phenyl)-butyric acid methyl ester,
96 β-(2-fluoro[ 1 , 1 '-biphenyl]-4-yl)- 1 -[ 1 -oxo-3-(5,6,7,8-tetrahydro- 1 ,8- naphthyridin-2-yl)propyl]-4-piperidinebutanoic acid,
97 3-(2-fluoro-biphenyl-4-yl)-4-[l -(3-5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid methyl ester,
98 β-(3-fluoro-4-methoxyphenyl)-l -[ l -oxo-3-(5,6,7,8-tetrahydro-l ,8-naphthyridin- 2-yl)propyl]-4-piperidinebutanoic acid, Cpd Names
99 3-(3-fluoro-4-methoxy-phenyl)-4-[ 1 -(3-5,6,7;8-tetrahydro-[ 1 ,8]naphthyridin-2- yl-propionyl)-piperidin-4-yl]-butyric acid methyl ester,
100 I -[ 1 -oxo-3-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2-yl)propyl]-β-(4- phenoxyphenyl)-4-piperidinebutanoic acid,
101 3-(4-phenoxy-pheny l)-4-[ 1 -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid methyl ester,
102 β.[[ 1.[ 1 -oxo-3-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2-yl)propyl]-4- piperidinyl]methyl]-4-isoquinolinepropanoic acid,
103 3-isoquinolin-4-yl-4-[ l -(3-5,6,7,8-tetrahydro-[l ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid methyl ester,
104 β-[[ 1 -[ l -oxo-3-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2-yl)propy l]-4- piperidinyl]methyl]-3-pyridinepropanoic acid,
105 3-pyridin-3-yl-4-[ 1 -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl-propionyl)- piperidin-4-yl]-butyric acid methyl ester,
106 β-(2,3-dihydro-5-benzofuranyl)- 1 -[ 1 -oxo-3-(5,6,7,8-tetrahydro- 1 ,8- naphthyridin-2-yl)propyl]-4-piperidinebutanoic acid,
107 . 3-(2,3-dihydro-benzofuran-5-yl)-4-[ 1 -(3-5,6,7;8-tetrahydro-[ 1 ,8]naphthyridin-
2-yl-propionyl)-piperidin-4-yl]-butyric acid methyl ester,
108 2,4-dimethoxy-β-[[ I -[ I -oxo-3-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2- yl)propyl]-4-piperidinyl]methyl]-5-pyrimidinepropanoic acid,
109 3-(2,4-dimethoxy-pyrimidin-5-yl)-4-[ l -(3-5,6,7, 8-tetrahydro-[] ,8]naphthyridin- 2-yl-propionyl)-piperidin-4-yl]-butyric acid methyl ester,
1 10 2-methoxy-β-[[ 1 -[ 1 -oxo-3-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2-yl)propyl]-4- piperidinyl]methyl]-5-pyrimidinepropanoic acid,
1 1 1 3-(2-methoxy-pyrimidin-5-yl)-4-[l -(3-5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2- yl-propionyl)-piperidin-4-yl]-butyric acid methyl ester,
1 12 β-[2-[ l -[3-[(l ,4,5,6-tetrahydro-5-hydroxy-2-pyπmidinyl)arnino]benzoyl]-4- piperidinyl]ethyl]-3-quinolinepropanoic acid,
1 13 5-{ l -[3-(5-hydroxy-l ,4,5,6-tetrahydro-pyrimidin-2-ylamino)-benzoyl]- piperidin-4-yl}-3-quinolin-3-yl-pentanoic acid methyl ester,
1 14 β-[2-[ l -[3-[(3,4,5,6-tetrahydro-2-pyridinyl)amino]benzoyl]-4- piperidinyl]ethyl]-3-quinolinepropanoic acid,
1 15 3-quinolin-3-yl-5-{ l -[3-(3,4,5,6-tetrahydro-pyridin-2-ylamino)-benzoyl]- piperidin-4-yl}-pentanoic acid methyl ester,
1 16 β-[2-[ 1 -[ 1 -oxo-3-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2-yl)propyl]-4- piperidinyl]ethyl]-3-quinolinepropanoic acid, Cpd Names
1 17 3-quinolin-3-yl-5-[ 1 -(3-5,6,7, 8-tetrahydro-[ 1 ,8]naphthyridin-2-yl-propionyl)- piperidin-4-yl]-pentanoic acid methyl ester,
1 18 β-[2-[ 1 -[ 1 -oxo-3-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2-yl)propyl]-4- piperidinyl]ethyl]-3-quinolinepropanoic acid,
1 19 3-quinolin-3-yl-5-[ I -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl-propionyl)- piperidin-4-yl]-pentanoic acid methyl ester,
120 β-(l ,3-benzodioxol-5-yl)-l -[3-[(3,4,5,6-tetrahydro-2-pyridinyl)amino]benzoyl]- 4-piperidinepentanoic acid,
121 3-benzo[ 1 ,3]dioxol-5-yl-5-{ 1 -[3-(3,4,5,6-tetrahydro-pyridin-2-ylamino)- benzoyl]-piperidin-4-yl}-pentanoic acid methyl ester,
122 β-( 1 ,3-benzodioxol-5-yl)- 1 -[3-[( 1 ,4,5,6-tetrahydro-5-hydroxy-2- pyrimidinyl)amino]benzoyl]-4-piperidinepentanoic acid,
123 3-benzo[ 1 ,3]dioxol-5-yl-5-{ 1 -[3-(5-hydroxy- 1 ,4,5,6-tetrahydro-pyrimidin-2- ylamino)-benzoyl]-piperidin-4-yl}-pentanoic acid methyl ester,
124 β^ l ^-benzodioxol-S-yO-l -^S^J.S-tetrahydro-Uδ-naphthyridin^-yOacetyl]- 4-piperidinepentanoic acid,
125 3-benzo[ 1 ,3]dioxol-5-yl-5-[ 1 -(2-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl- acetyl)-piperidin-4-yl]-pentanoic acid methyl ester,
126 β-(2-naphthalenyl)- 1 -[ I -oxo-3-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2- yl)propyl]-4-piperidinebutanoic acid,
127 3-naphthalen-2-yl-4-[ I -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl-propionyl)- piperidin-4-yl]-butyric acid methyl ester,
128 (3S*)-3-naphthalen-2-yl-4-[ l-(3-5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid,
129 (3/?*)-3-naphthalen-2-yl-4-[ 1 -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid,
130 3-[ I -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-4- (5,6,7,8-tetrahydro-quinolin-3-yl)-butyric acid,
131 3-[ 1 -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-4- (5,6,7,8-tetrahydro-quinolin-3-yl)-butyric acid methyl ester,
132 5,6,7, 8-tetrahydro-β-[ I -[ I -oxo-4-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2- yl)butyl]-4-piperidinyl]-3-quinolinepropanoic acid,
133 5,6,7,8-tetrahydro-β-[ I -[ 1 -oxo-4-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2- yl)butyl]-4-piperidinyl]-3-quinolinepropanoic acid,
134 5,6,7,8-tetrahydro-β-[ I -[ 1 -oxo-4-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2- yl)butyl]-4-piperidinyl]-3-quinolinepropanoic acid, Cpd Names
135 3-[ 1 -(4-5,6;7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl-butyryl)-piperidin-4-yl]-3- (5,6,7,8-tetrahydro-quinolin-3-yl)-propionic acid methyl ester,
136 3-(3-methoxy-phenyl)-4-[ 1 -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid,
137 3-(3-methoxy-phenyl)-4-[ 1 -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid methyl ester,
138 3-(4-methoxy-phenyl)-4-[ l -(3-5,6,7, 8-tetrahydro-[ 1 , 8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid,
139 3-(4-methoxy-phenyl)-4-[ 1 -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid methyl ester,
140 3-(tetrahydro-furan-3-yl)-4-[ l -(3-5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid,
141 3-(tetrahydro-furan-3-yl)-4-[ 1 -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid methyl ester,
142 4-[l -(3-5,6,7,8-tetrahydro-[l ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-3- thiophen-2-yl-butyric acid,
143 4-[ 1 -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-3- thiophen-2-yl-butyric acid methyl ester,
144 3-(2,3-dihydro-benzo[ l ,4]dioxin-6-yl)-4-[ l -(3-5,6,7,8-tetrahydro- [ 1 ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-butyric acid,
145 3-(2,3-dihydro-benzo[l ,4]dioxin-6-yl)-4-[ l -(3-5,6,7, 8-tetrahydro- [ l ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-butyric acid methyl ester,
146 3-(3-methylsulfanyl-phenyl)-4-[l -(3-5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid,
147 3-(3-methylsulfanyl-phenyl)-4-[l -(3-5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid methyl ester,
148 N-methy 1- 1 ,2,3,4-tetrahydro-β-[[ 1 -[ 1 -oxo-3-(5,6,7,8-tetrahydro- 1 ,8- naphthyridin-2-yl)propyl]-4-piperidinyl]methyl]-3-quinolinepropanoic acid,
149 3-( 1 -methyl-1 ,2,3,4-tetrahydro-quinolin-3-yl)-4-[ I -(3-5,6,7, 8-tetrahydro- [ l ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-butyric acid methyl ester,
150 3-(3-dimethylamino-phenyl)-4-[ I -(3-5,6,7, 8-tetrahydro-[ 1 ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid,
151 3-(3-dimethylamino-phenyl)-4-[ 1 -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid methyl ester,
152 3-(4-hydroxy-3-methoxy-phenyl)-4-[ 1 -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin- 2-yl-propionyl)-piperidin-4-yl]-butyric acid, Cpd Names
153 3-(4-hydroxy-3-methoxy-phenyl)-4-[ l -(3-5,6,7,8-tetrahydro-[ l ,8]naphthyridin- 2-yl-propionyl)-piperidin-4-yl]-butyric acid methyl ester,
154 (35*)-3-(4-hydroxy-3-methoxy-phenyl)-4-[ 1 -(3-5,6,7, 8-tetrahydro- [l ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-butyric acid,
155 4-{ l -[3-(4,5-dihydro-l H-imidazol-2-ylarnino)-benzoyl]-piperidin-4-yl}-3-(3- fluoro-phenyl)-butyric acid,
156 4-{ l -[3-(4,5-dihydro-I H-imidazol-2-ylamino)-benzoyl]-piperidin-4-yl}-3-(3- fluoro-phenyl)-butyric acid methyl ester,
157 3-(3-ethylamino-phenyl)-4-[l -(3-5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid,
158 3-(3-ethylamino-phenyl)-4-[l-(3-5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid methyl ester,
159 3-(3-methy lamino-pheny l)-4-[ 1 -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid,
160 3-(3-methylamino-phenyl)-4-[l-(3-5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid methyl ester,
161 3-(2,3-dihydro-benzofuran-6-yl)-3-[l -(4-5,6,7, 8-tetrahydro-[l ,8]naphthyridin- - 2-yl-butyryl)-piperidin-4-yl]-propionic acid,
162 3-(2,3-dihydro-benzofuran-6-yl)-3-[ l -(4-5,6,7, 8-tetrahydro-[ l ,8]naphthyridin- 2-yl-butyryl)-piperidin-4-yl]-propionic acid methyl ester,
163 3-(3-fluoro-phenyl)-4-{ 1 -[3-(5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl)- propyl]-piperidin-4-y I } -butyric acid,
164 3-(3-fluoro-phenyl)-4-{ l -[3-(5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2-yl)- propyl]-piperidin-4-yl}-butyric acid methyl ester,
165 3-(2,3-dihydro-benzofuran-6-yl)-3-[ 1 -4-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2- yl)butyl]-4-piperidinyl]-propanoic acid,
166 3-(2,3-dihydro-benzofuran-6-yl)-3-[l -4-(5,6,7,8-tetrahydro- ] ,8-naphthyridin-2- yl)butyl]-4-piperidinyl]-propanoic acid methyl ester,
167 3-{4-[2-(2-bromo-ethoxy)-ethoxy]-3-methoxy-phenyl}-4-[l -(3-5,6,7, 8- tetrahydro-[l ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-butyric acid,
168 3-{4-[2-(2-bromo-ethoxy)-ethoxy]-3-methoxy-phenyl}-4-[l -(3-5,6,7, 8- tetrahydro-[ 1 ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-butyric acid methyl ester,
169 3-{4-[2-(2-acetylsulfanyl-ethoxy)-ethoxy]-3-methoxy-phenyl}-4-[l -(3-5,6,7, 8- tetrahydro-[ 1 ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-butyric acid, Cpd Names
170 3-{4-[2-(2-acetylsulfanyl-ethoxy)-ethoxy]-3-methoxy-phenyl}-4-[ I -(3-5,6,7,8- tetrahydro-[ 1 ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-butyric acid methyl ester,
171 3-{4-[2-(2-mercapto-ethoxy)-ethoxy]-3-methoxy-phenyl}-4-[ l -(3-5,6,7, 8- tetrahydro-[ 1 ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-butyric acid,
172 3-{4-[2-(2-mercapto-ethoxy)-ethoxy]-3-methoxy-phenyl}-4-[ I -(3-5,6,7,8- tetrahydro-[ 1 ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-butyric acid methyl ester,
173 3-(4-{2-[2-(2-chloro-ethoxy)-ethoxy]-ethoxy}-3-methoxy-phenyl)-4-[l -(3- 5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-butyric acid,
174 3-(4-{2-[2-(2-chloro-ethoxy)-ethoxy]-ethoxy }-3-methoxy-phenyl)-4-[ 1 -(3- 5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-butyric acid methyl ester,
175 3-(4-{2-[2-(2-mercapto-ethoxy)-ethoxy]-ethoxy}-3-methoxy-phenyl)-4-[ 1 -(3- 5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-butyric acid,
176 3-(4-{2-[2-(2-mercapto-ethoxy)-ethoxy]-ethoxy}-3-methoxy-phenyl)-4-[ 1 -(3- 5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-butyric acid methyl ester,
177 3-(4-{2-[2-(2-acetylsuifanyl-ethoxy)-ethoxy]-ethoxy}-3-methoxy-phenyl)-4-[ l- (3-5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-butyric acid methyl ester, and
178 3-(4-{2-[2-(2-acetylsulfanyl-ethoxy)-ethoxy]-ethoxy}-3-methoxy-phenyl)-4-[ l - (3-5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-butyric acid.
The foregoing Schemes are offered by way of illustration; the invention should not be construed as being limited by the chemical reactions and conditions expressed. The methods for preparing the various starting materials used in the Schemes are within the skill of persons versed in the art. Discussion of the Problem
In the asymmetric homogeneous reaction of the present invention, the amount of conversion of the starting material and the enantiomeric purity of the product was found to depend on a number of factors. Such factors include, but are not limited to, various ligands conjugated with various metal adducts, the resulting ligand-metal complexes thus formed, the solvents used and other additives, the reaction temperature and pressure conditions and the reaction length. Alone and in combination, the influence of each of these factors was explored.
Scheme E illustrates a synthesis of the compound of Formula (Ia) (as described in Ghosh S, Santulli RJ, Kinney WA, DeCorte BL, Liu L, Lewis JM, Proost JC, Leo GC, Masucci J, Hageman WE, Thompson AS, Chen 1, Kawahama R, Tuman RW, Galemmo RA Jr., Johnson DL, Damiano BP and Maryanoff BE, Bioorg. Med. Chem. Lett., 2004, 14, 5937).
Scheme E
Figure imgf000094_0001
I O E3, Ra = 3-quinolinyl
Figure imgf000094_0002
E4, (aR) E-isomer E5, (aS) E-isomer
Figure imgf000094_0003
The reaction step for preparing 4-(2-oxo-2-quinolin-3-yl-ethyl)-piperidine- 1 - carboxylic acid tert-butyl ester Compound E3 uses a 3-lithioquinoline adduct as the
15 reagent and an excess of n-BuLi and 3-bromoquinoline with a low reaction temperature over a period of time. Additionally, the generation of the product as a mixture of geometric isomers Compound Cl (Z-isomer) and Compound E4 (£-isomer) by the Horner-Emmons reaction results in a mixed isomer ratio.
The hydrogenation of the mixture of Compound Cl and Compound E4 yields a product as an equal mixture of four diastereomers, Compound C2, Compound C3, Compound E4 and Compound E5 and requires two subsequent separations by sequential chiral column chromatography.
Scheme F provides a process for the stereocontrolled synthesis of (Z)-4-(3- methoxycarbonyl^-quinolin-S-yl-ally^-piperidine- l -carboxylic acid tert-butyl ester
I O Compound Cl starting from acid Compound Fl via Compound F2 and vinyl triflate Compound F3 (see, Romero DL, Manninen PR, Han F and Romero AG, J. Org. Chem. 1999, 64, 4980-4985, for an alternative method for controlling stereoisomeric orientation using a triflate anhydride).
Scheme F
Figure imgf000095_0001
An Example 111 of the invention includes a process for preparing (Z)-4-(3- methoxycarbonyl-2-quinolin-3-yl-allyl)-piperidine- l -carboxylic acid tert-butyl ester Compound Cl, comprising the steps:
Step 1. reacting a mixture of a Compound Fl and carbonyl diimidazole (CDI) in 5 tetrahydrofuran (THF);
Step 2. reacting the mixture with the potassium salt of methyl malonate and MgCb in THF to provide a Compound F2;
Step 3. reacting Compound F2 with trifluoromethanesulfonic anhydride (Tf2O) in a mixture with sodium hydride (NaH) and DIPEA in toluene to provide a (Z)- I O isomer Compound F3; and,
Step 4. reacting Compound F3 with quinoline-3-boronic acid and Pd(PPh3)2CI2
(bistriphenylphosphine palladium dichloride) in a mixture with 2 M Na2CO3 in THF to provide Compound Cl.
Scheme G illustrates the preparation of a ( lS)-(-)-camphanic acid derivative 15 Compound Gl crystalline form. Compound Gl was used in a single-crystal X-ray diffraction study to confirm the absolute configuration of compounds of the present invention.
Figure imgf000096_0001
0 Enantioselective reductions of stereo-defined unsaturated esters have been described where an unsaturated ester was reacted with copper hydride [(PPh3)CuH]6 (Stryker's reagent) in the presence of a catalytic amount of a chiral ligand of the (R,S)- JosiPhos series in a solvent to provide a stereoselective product (Lipshutz BH, Servesko JM and Taft BR, J. Am. Chem. Soc. 2004, 126, 8352). Hydrogenation reactions of an unsaturated ester using a (Λ)-Tol-Binap ligand provided a chiral compound (Hughes G, Kimura M and Buchwald SL, J. Am. Chem. Soc. 2003, 125, 1 1253; United States Patents 6,465,664 and 6,787,655) Although the literature describes such enantioselective reductions of unsaturated esters and acids, a more efficient synthetic route is needed.
Compound Definitions
As used herein, with reference to substituents, the term "independently" means that when more than one of such substituent is possible, such substituents may be the same or different from each other.
The term "Ci-salkyl" means a straight or branched chain hydrocarbon radical comprising from 1 to 8 carbon atoms, wherein the radical is derived by the removal of one hydrogen atom from a single carbon atom. Examples include methyl, ethyl, 1 - propyl, 2-propyl, 1 -butyl, 2-butyl, tertiary butyl (also referred to as /-butyl or /<?/7-butyl), 1 -pentyl, 2-pentyl, 3-pentyl, 1 -hexyl, 2-hexyl, 3-hexyl and the like. Other examples include C|.4alkyl groups. Ci-salkyl is substituted on one or more available carbon chain atoms with one or more substituents where allowed by available valences.
The term "Ci-salkoxy" means a straight or branched chain hydrocarbon alkyl radical of the formula -O-C|.8alkyl, comprising from 1 to 8 carbon atoms. Examples include methoxy, ethoxy, propoxy and the like. Other examples include C|.4alkoxy.
C|.8alkoxy is substituted on one or more available carbon chain atoms with one or more substituents where allowed by available valences.
The term "aryl" means monocyclic or bicyclic aromatic ring systems containing from 6 to 12 carbons in the ring. Examples include phenyl, biphenyl, naphthalene (also referred to as naphthalenyl and naphthyl), azulenyl, anthracenyl and the like. Aryl radicals may be attached to a core molecule and further substituted on any atom where allowed by available valences. The term "hetero," when used as a prefix for a ring system, refers to the replacement of at least one carbon atom member in the ring system with a heteroatom selected from N, O, S, S(O), or SO2. A hetero ring may have 1 , 2, 3, or 4 carbon atom members replaced by a nitrogen atom. Alternatively, a ring may have 0, I , 2, or 3 nitrogen atom members and 1 oxygen or sulfur atom member. Alternatively, up to two adjacent ring members may be heteroatoms, wherein one heteroatom is nitrogen and the other heteroatom is selected from N, S, or O.
The term "heterocyclyl" means a saturated or partially unsaturated monocyclic or polycyclic "hetero" ring system radical having a cycloalkyl ring as the core molecule. Heterocyclyl ring systems include azetidinyl, 2H-pyrrole, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolidinyl, 1 ,3-dioxolanyl, 2-imidazolinyl (also referred to as 4,5-dihydro-l H- imidazolyl), imidazolidinyl, 2-pyrazolinyl, pyrazolidinyl, tetrazolyl, tetrazolidinyl, piperidinyl, 1 ,4-dioxanyl, morpholinyl, 1 ,4-dithianyl, thiomorpholinyl, piperazinyl, l ,4,5,6-tetrahydro-pyrimidin-2-yl, azepanyl, hexahydro-l ,4-diazepinyl, hexahydro- 1 ,4- oxazepanyl, tetrahydro-furanyl, tetrahydro-thienyl, tetrahydro-pyranyl, tetrahydro- pyridazinyl and the like. Heterocyclyl radicals may be attached to a core molecule and further substituted on any atom where allowed by available valences.
The term "heterocyclyl" also includes a benzofused-heterocyclyl ring system radical and the like, such as indolinyl (also referred to as 2,3-dihydro-indolyl), benzo[l ,3]dioxolyl (also referred to as 1 ,3-benzodioxolyl), 5,6,7,8-tetrahydro-
[l ,8]naphthyridin-2-yl, l ,2,3,4-tetrahydro-quinolin-3-yl, 2,3-dihydro-l ,4-benzodioxinyl, 2,3-dihydro-benzofuranyl, 1 ,2-dihydro-phthalazinyl and the like. Benzofused- heterocyclyl radicals may be attached to a core molecule and further substituted on any atom where allowed by available valences. The term "heteroaryl" means an aromatic monocyclic or polycyclic heterocyclyl radical. Heteroaryl ring systems include furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, I H-imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, lH-tetrazolyl, 2H-tetrazolyl, IH-[1 , 2,3]triazolyl, 2H-[ l ,2,3]triazolyI, 4H-[ l ,2,4]triazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl and the like. Heteroaryl radicals may be attached to a core molecule and further substituted on any atom where allowed by available valences.
The term "heteroaryl" also includes a benzofused-heteroaryl ring system radical and the like, such as indolizinyl, indolyl, indolinyl, azaindolyl, isoindolyl, benzo[b]furanyl, benzo[b]thienyl, indazolyl, azaindazolyl, benzoimidazolyl, benzothiazolyl, benzooxazolyl, benzoisoxazolyl, benzothiadiazolyl, benzotriazolyl, purinyl, 4H-quinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 1 ,8-naphthyridinyl, pteridinyl and the like. Benzofused-heteroaryl radicals may be attached to a core molecule and further substituted on any atom where allowed by available valences.
The term "benzofused," when used as a prefix for a ring system, refers to a radical formed by any monocyclic radical fused with a benzene ring; the benzofused radical may be attached to a core molecule via either ring of the bicyclic system.
The term "C|.4alkoxycarbonyl protecting group'' means a radical of the formula: -C(O)-O-C|.4alkyl.
The term "'-Co-όalkyKRi)" means a radical of the formula: -(Ri) or -C|.6alkyl-(R|).
The term "-Co-6alkyl-aryl(R|,R8)" means a radical of the formula: -aryl(R|,R8) or -C|.6alkyl-aryl(R|,Rs).
In general, under standard nomenclature rules used throughout this disclosure, the terminal portion of the designated side chain is described first followed by the adjacent functionality toward the point of attachment.
Thus, for example, a "phenyl-C|.6alkyl-amino-carbonyl-C|.6alkyl" substituent refers to a group of the formula:
Figure imgf000099_0001
It is intended that the definition of any substituent or variable at a particular location in a molecule be independent of its definitions elsewhere in that molecule. It is understood that substituents and substitution patterns on the compounds of this invention can be selected by one of ordinary skill in the art to provide compounds that are chemically stable and that can be readily synthesized by techniques known in the art as well as those methods set forth herein. Compound Forms
The term "form" means, in reference to compounds of the present invention, such may exist as, without limitation, a salt, stereoisomer, tautomer, crystalline, polymorph, amorphous, solvate, hydrate, ester, prodrug or metabolite form. The present invention encompasses all such compound forms and mixtures thereof. The term "isolated form" means, in reference to compounds of the present invention, such may exist in an essentially pure state such as, without limitation, an enantiomer, a racemic mixture, a geometric isomer (such as a cis or trans stereoisomer), a mixture of geometric isomers, and the like. The present invention encompasses all such compound forms and mixtures thereof., Certain compounds of Formula (I), Formula (11) or Formula (Ia) may exist in various stereoisomeric or tautomeric forms and mixtures thereof. The invention encompasses all such compounds, including active compounds in the form of essentially pure enantiomers, racemic mixtures and tautomers.
The compounds of the present invention may be present in the form of pharmaceutically acceptable salts. For use in medicines, the "pharmaceutically acceptable salts" of the compounds of this invention refer to non-toxic acidic/anionic or basic/cationic salt forms.
Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid. Furthermore, when the compounds of the present invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts; and salts formed with suitable organic ligands, e.g. quaternary ammonium salts. Thus, representative pharmaceutically acceptable salts include the following: acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium, camsylate (or camphosulphonate), carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, fumarate, gluconate, glutamate, hydrabamine, hydrobromine, hydrochloride, iodide, isothionate, lactate, malate, maleate, mandelate, mesylate, nitrate, oleate, pamoate, palmitate, phosphate/diphosphate, salicylate, stearate, sulfate, succinate, tartrate, tosylate.
The present invention includes within its scope prodrugs of the compounds of this invention. In general, such prodrugs will be functional derivatives of the compounds that are readily convertible in vivo into the required compound. Thus, in the methods of treatment of the present invention, the term "administering" shall encompass the treatment of the various disorders described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound in vivo after administration to the patient. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.
The invention includes compounds of various isomers and mixtures thereof. The term "isomer" refers to compounds that have the same composition and molecular weight but differ in physical and/or chemical properties. Such substances have the same number and kind of atoms but differ in structure. The structural difference may be in constitution (geometric isomers) or in an ability to rotate the plane of polarized light (stereoisomers).
The term "optical isomer" means isomers of identical constitution that differ only in the spatial arrangement of their groups. Optical isomers rotate the plane of polarized light in different directions. The term "optical activity" means the degree to which an optical isomer rotates the plane of polarized light. The term "racemate" or "racemic mixture" means an equimolar mixture of two enantiomeric species, wherein each of the isolated species rotates the plane of polarized light in the opposite direction such that the mixture is devoid of optical activity.
The term "enantiomer" means an isomer having a nonsuperimposable mirror image. The term "diastereomer" means stereoisomers that are not enantiomers.
The term "chiral" means a molecule that, in a given configuration, cannot be superimposed on its mirror image. This is in contrast to achiral molecules that can be superimposed on their mirror images.
The invention is considered to include the tautomeric forms of all compounds of Formula (I), Formula (II) or Formula (Ia). In addition, some of the compounds represented by Formula (I), Formula (II) or Formula (Ia) may be prodrugs, i.e., derivatives of a drug that possess superior delivery capabilities and therapeutic value as compared to the active drug. Prodrugs are transformed into active drugs by in vivo enzymatic or chemical processes. The symbols "R" and "S" represent the configuration of groups around a stereogenic carbon atom(s) as determined by the Cahn-lngol-Prelog priority rules.
The term "geometric isomer" means isomers that differ in the orientation of substituent atoms in relationship to a carbon-carbon double bond, to a cycloalkyl ring, or to a bridged bicyclic system. Substituent atoms (other than hydrogen) on each side of a carbon-carbon double bond may be in an E or Z configuration according to their priority. In the "E" configuration, the substituents having the highest priorities are on opposite sides in relationship to the carbon-carbon double bond. In the "Z" configuration, the substituents having the highest priorities are oriented on the same side in relationship to the carbon-carbon double bond. The term "conversion" refers to the efficiency of the reduction or hydrogenation of the vinyl bond of the starting material, without consideration to the orientation or for the enantiomeric excess of the stereoisomer produced. The term "converting" or "converted" refers, when Z is hydroxy, to the alkylation of Z to provide Z is -O-C|.8alkyl; and, conversely, when Z is -O-Ci.salkyl, to the dealkylation of Z to provide Z is hydroxy.
Substituent atoms (other than hydrogen) attached to a ring system may be in a cis 5 or trans configuration. In the "cis" configuration, the substituents are on the same side in relationship to the plane of the ring; in the "trans" configuration, the substituents are on opposite sides in relationship to the plane of the ring. Compounds having a mixture of "cis" and "trans" species are designated "cis/trans".
The isomeric descriptors ("R," "S," "E," and "Z") indicate atom configurations I O relative to a core molecule and are intended to be used as defined in the literature.
Where the processes for the preparation of the compounds according to the invention give rise to mixture of stereoisomers, it may be desirable to separate these isomers by conventional techniques such as preparative chromatography. The compounds may be prepared in racemic form, or individual enantiomers may be prepared
15 either by enantiospecific synthesis or by resolution. The compounds may, for example, be resolved into their component enantiomers by standard techniques, such as the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di-p-toluoyl-d-tartaric acid and/or (+)-di-p-toluoyl-l-tartaric acid followed by fractional crystallization and regeneration of the free base. The compounds may also be 0 resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary. Alternatively, the compounds may be resolved and percent enantiomeric excess (e.e.) determined using a chiral HPLC column.
The term "catalytic amount" is recognized in the art and means a substoichiometric amount or a reagent relative to a reactant. As used herein, a catalytic amount means an amount of from about 0.0001 to about 90 mole percent reagent relative to reactant, an amount of from about 0.001 to about 50 percent, an amount of from about 0.01 to about 10 percent, or an amount of from about 0.1 to about 5 percent.
Additionally, the amount of the ligand-metal complex used can also be represented as a molar ratio of the substrate or reactant to the ligand-metal complex, and can represented by the term "S/C" or "substrate/complex."
The term "preformed" ligand-metal complex is recognized in the art as any form of a conjugated or coordinated metal adduct and ligand that has been isolated in a stable form, wherein a stoichiometric ratio exists between the metal adduct and ligand. The ratio of metal adduct to ligand is typically a fixed stoichiometric ratio, wherein the ligand-metal complex may be accompanied by counterions or may be present as a solvate, thus stabilizing and enabling the isolability of said complex. A preformed ligand-metal complex may or may not be isolable under open atmosphere, but often is handled under an inert atmosphere using methods known in the art. The preformed ligand-metal complex is typically stored for use, and then added to a solvent along with a substrate or reactant and optional additives for reaction with said substrate or reactant. One skilled in the art using methods known in the literature can prepare and isolate the preformed catalysts described herein. Moreover, a preformed ligand-metal complex includes those ligand-metal complexes that may be obtained as an in situ byproduct precipitated from a reaction mixture, isolated and stored in a stable form, then subsequently used as a "preformed" ligand-metal complex in a later reaction. For example, DMF may be incorporated into the stable preformed catalyst, as in [(5)-P-Phos RuCI2(DMF)T], resulting from the coordination of DMF with the metal adduct during the formation of the complex. A convention utilized herein to denote a preformed catalyst is the "/"denotation, used to indicate the ligand/[metal adduct].
Preformed catalysts not otherwise formed may also be purchased from commercial vendors. Preformed catalysts disclosed and used herein include, and are not limited to, (S)-P-PhOsZ[RuCI2(DMF)2], (S)-XyI-P-PhOsZ[RuCI2(DMF)2], (Λ)-MeBoPhoz/[RuCI2(DMF)2], (S)-P-Phos/[Ru(benzene)CI]CI, (Λ)-Xyl-P-Phos/[Ru(p-cymene)CI]CI, (S)-PhanePhos/[Rh(COD)]BF4, (/?)-PhanePhos/[Rh(COD)]BF4, (S)-P-PhosZ[Ir(COD)]CI, (S)-Xyl-P-PhosZ[Ir(COD)Cl], (/?)-iPr-PHOX/[lr(COD)]BArF, (/?)-Ph-PHOX/[Ir(COD)]BArF, (Λ)-MeOXyl-PhanePhos/[Rh(COD)]BF4, (Λ)-An-PhanePhos/[Rh(COD)]BF4, (Λ)-iPr-PhanePhos/[Rh(COD)]BF4, (Λ)-Xyl-P-Phos/[RuCI2(DMF)2]; (S)-PhanePhosZ[RuCl2(DMF)2], (7?)-Xyl-PhanePhosZ[RuCl2(DMF)2], (S)-MeBoPhOzZ[RuCl2(DMF)2], (#,)-Tol-BinapZ[RuCl(p-cymene)]CI,
(S;-Binap/[RuCI(p-cymene)]CI and
Figure imgf000105_0001
and, where not specifically stated, enantiomers of these preformed catalysts therein. Synonymous with these designations is the interchangability of the descriptions, ie: [(S)-P-Phos RuCI2(DMF)2] can also be expressed as (S)-P-PhOsZ[RuCI2(DMF)2] without loss of meaning or effect.
Although examples of synthetic methods for preparing preformed ligand-metal complexes include various formation conditions, one skilled in the art would generally expect that a set of formation conditions are specific to each of said complexes. For example, a synthetic method for preparing a preformed (S)-PhanePhos/[Rh(COD)]BF4 ligand-metal complex includes the coordination of an (S)-PhanePhos ligand and metal adduct [Rh(COD)2]BF4, with loss of one (COD) group. When dimeric metal adducts are used, as in the case Of [Ir(COD)Cl]2 for preparation of the preformed catalyst, [(.S)-P-Phos Ir(COD)]CI, the general preparation is expected to take place using an (S)-P-Phos ligand and a set of formation conditions specific for [(S)-P-Phos Ir(COD)]CI. The term "/« situ" ligand-metal complex is recognized in the art as a means to prepare a ligand-metal complex by the addition of a metal adduct and a ligand to a solvent, either as a separate step, or in combination with the substrate, whereby the ligand-metal complex is formed in the reaction mixture. The metal adduct and ligand are typically mixed according to a stoichiometric ratio such that the combination will lead to the desired ligand-metal complex. In some cases, various analytical techniques are used to prove that the ligand-metal complex has indeed been formed. In other cases, the formation of the ligand-metal complex cannot be definitively proven. The ligand-metal complex formed in situ may also typically have accompanying, stabilizing counterions or may be present as a solvate, thus stabilizing said ligand-metal complex during the reaction. The ligand-metal complex formed in situ will perform in the same manner as a preformed ligand-metal complex, and have the same characteristics of a preformed ligand-metal complex, as stated above. A ligand-metal complex made in situ may also be prepared in a stable solvent and stored in solution until needed. A convention utilized herein to denote an "in situ" catalyst is the "&"notation, used to indicate a ligand&fmetal adduct] group. For example, use of the in situ ligand-metal complex
(i?)-Me-BoPhoz&(Ir(COD)CI]2, would involve pre-mixing (in an appropriate solvent) the ligand (7?)-Me-BoPhoz with the metal adduct [Ir(COD)CI]2 for a period of time to allow the active catalyst to form, then performing the reduction reaction with a suitable starting material and a hydrogen source. In some cases herein, for "in situ" ligand-metal complexes involving dimeric metal adducts, the complexes may also be denoted as "ligand&metal precursor" (see description below)
The term "metal adduct" is meant to denote the convenient, weighable, stable form of a metal with its stabilizing ligands and counterions as is understood by one of ordinary skill in the art. In some cases, metal adducts are most stable in a dimeric form, which upon disproportionation under a prescribed set of reaction conditions, leads to a monomeric form, which is referred to herein as a "metal precursor." An example of a dimeric metal adduct is [Ru(COD)(CF3COO)2J 2, which upon disproportionation leads to the metal precursor [Ru(COD)(CF3COO)2]. It is understood by one of ordinary skill in the art that the stoichiometry of the disproportionation is such that 1 equivalent dimeric metal adduct provides 2 equivalents of metal precursor.
As discussed more fully below, the reactions contemplated in the present invention include reactions that are enantioselective, diastereoselective, and/or regioselective. In addition, for chiral embodiments of the invention, the invention is considered to include pure enantiomers, racemic mixtures, as well as mixtures of enantiomers having 0.001 % to 99.99% enantiomeric excess. Furthermore, an enantioselective reaction is a reaction that hydrogenates an achiral reactant to a chiral product enriched in one enantiomer. Enantioselectivity is generally quantified as "enantiomeric excess" (e.e.) defined as follows:
% enantiomeric exess A (ee) = (% enantiomer A)-(% enantiomer B), where A and B are the enantiomers formed.
An enantioselective reaction yields a product with an e.e. in a range of from about 5% e.e. to about 99% e.e., or in a range of from about 30% e.e. to about 99% e.e., or in a range of from about 60% e.e. to about 99% e.e., or in a range of from about 70% e.e. to about 99% e.e., or in a range of from about 80% e.e. to about 99% e.e. The term "substantially pure" means, within the scope of the present invention, an isomeric mixture which includes an enantiomerically enriched form of the enantiomer, wherein the mixture is substantially free of the opposite enantiomer. In this context, substantially pure means the opposite enantiomer may be an amount in a range of about less than 25% of the mixture, about less than 10 %, about less than 5 %, about less than 2 % or about less than 1 % of the mixture.
An enantiomerically enriched form of the S-enantiomer isolated by HPLC from a racemic mixture may be determined according to the formula:
(% area S enantiomer) % e.e. of S enantiomer = 100 X
(% area S enantiomer) + (% area R enantiomer)
An enantiomerically enriched form of the R-enantiomer isolated by HPLC from a racemic mixture may be determined according to the formula:
(% area R enantiomer) % e.e. of R enantiomer = 100 X
(% area S enantiomer) + (% area R enantiomer)
Furthermore, compounds of the present invention may have at least one crystalline, polymorph or amorphous form. The plurality of such forms is included in the scope of the invention. In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents (e.g., organic esters such as ethanolate and the like). The plurality of such solvates are also intended to be encompassed within the scope of this invention.
During any of the processes for preparation of the compounds of the present invention, it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991 . The protecting groups may be removed at a convenient subsequent stage using methods known from the art.
Discussion of the Invention
In the asymmetric, homogeneous hydrogenation reactions of Scheme C and Scheme D, in accordance with the following examples, the substrate Compound Cl and Compound Dl were reacted with a ligand-metal complex, wherein the ligand-metal complex consists essentially of a Iigand and a metal adduct. The following examples illustrate various embodiments of the ligands, metal adducts, the ligand-metal complexes thus formed, other additives and reaction temperature and pressure conditions used in accordance with said embodiments of the present invention.
Screening Examples Screening of various complexes of ligands conjugated with various metal adducts was performed to identify a suitable ligand-metal complex for the asymmetric hydrogenation of substrate Compound Cl and Compound Dl. The screening consisted of reacting substrate Compound Cl and Compound Dl with a series of preformed and in situ formed ligand-metal complexes. In addition, certain reaction conditions were optimized (such as solvent, additive, temperature and pressure and the like) in the hydrogenation of substrate Compounds Cl and Dl. Ligands referred to throughout the specification and used in the following examples include those shown below: Ligand Elements
Figure imgf000109_0001
BoPhoz Ligand Family
(R/S)-MeBoPhoz Rb is Me, Ra is Ph
(R/S)-Et-BoPhoz Rb is Et, Ra is Ph
(R7S)-iPr-BoPhoz Rb is i-Pr, Ra is Ph
(R/S)-Bn-BoPhoz Rb is Bn, Ra is Ph
(R7S)-Ph-BoPhoz Rb is Ph, Ra is Ph
(R/S)-Phenethyl-(R/S)-BoPhoz Rb is (R/S)- l -phenyl-ethyl, Ra is Ph
(S)-Ethyl-Naphthyl-(R/S)-BoPhoz Rb is ( I S)- I -naphth- 1 -yl-ethyl, Ra is Ph
Xyl-(R/S)-Me-BoPhoz Rb is Me, Ra is 3,5-Me2-C6H3 pFPh-(R/S)-Me-BoPhoz Rb is Me, Ra is 4-F-Ph
PFPh-(R/S-Et-BoPhoz Rb is Et, Ra is 4-F-Ph
PFPh-(R/S)-Bn-BoPhoz Rb is Bn. Ra is 4-F-Ph
PCy-(R/S)-BoPhoz Rb is Me, Ra is Cyclohexyl
CF3Ph-(R/S)-Me-BoPhoz Rb is Me, Ra is 4-CF3-C6H4
2,4,6-F3Ph-(R/S)-Me-BoPhoz Rb is Me, Ra is 2,4,5-F3-Ph
Binol-(R/S)-Me-BoPhoz Rb is Me, Ra is Binol
P(R/S,R/S)-Binol-(R/S,S/R)-Me-BoPhoz Ra and Rb are taken together to form
(R/S,R/S)-Binol
Fe
^^— PPh2 DPPF
1Bu2 Fe ^-P1Bu2 DtBPF Ligand Elements
Figure imgf000110_0001
PHOX Ligand Family
(R7S)-iPr-PHOX. R is iPr (R/S)-Ph-PHOX. R is Ph
Figure imgf000110_0002
(R)-Phos Ligand Family
(R)-P-Phos Ar is Ph
(R)-Xyl-P-Phos. Ar is 3,5-Me2-C6H3
(R)-Tol-P-Phos. Ar is X-Me-C6Ha
Figure imgf000110_0003
(S)-Phos Ligand Family
(S)-P-Phos Ar is Ph
(S)-Xyl-P-Phos. Ar is 3,5-Me2-C6H3 (S)-Tol-P-Phos. Ar is x-Me-C6H4
Figure imgf000110_0004
(R)-Phanephos Ligand Family
(R)-Phanephos Ra is Ph
(R)-Xyl-Phanephos. Ra is XyI: 3,5-Me2-C6H3 (R)-An-Phanephos.. Ra is 4-0Me-Ph Ligand Elements
(R)-iPr-PhanePhos Ra is iPr
(R)-MeOXyl-Phanephos Ra is MeOXyI: 3,5-Me2-4-OMe-C6H2
Figure imgf000111_0001
(S)-Phanephos Ligand Family
(S)-Xyl-Phanephos Ra is XyI: 3,5-Me2-C6H3
(S)-An-Phanephos Ra is 4-OMe-Ph
(S)-iPr-PhanePhos Ra is iPr
(S)-MeOXyl-Phanephos Ra is MeOXyI : 3,5-Me2^-OMe-C6H2
(/?,Λ)-Me-Duphos
Figure imgf000111_0002
(R)-Binap Ligand Family
(R)-Binap Ar is Ph
(R)-Tol-Binap Ar is 4-Me-C6H4
(R)-Xyl-Binap Ar is 3,5-Me2-C6H3
Figure imgf000111_0003
(S)-Binap Ligand Family
(S)-Binap Ar is Ph
(S)-Tol-Binap Ar is 4-Me-C6H4
(S)-Xyl-Binap Ar is 3,5-Me2-C6H3
General Information. 1 H NMR spectra were acquired at 300 MHz on a Bruker Avance- 300 spectrometer in CDCI3 unless indicated otherwise, using Me4Si as an internal standard. NMR abbreviations used: s. singlet; d, doublet; dd, doublet of doublets; t, triplet; m, multiplet; br, broad. Normal-phase preparative chromatography was performed on an lsco Combiflash Separation System Sg 100c equipped with a Biotage FLASH Si 4OM silica gel cartridge (KP-SiI Silica, 32-63 μ, 60 A; 4 x 15 cm) eluting at 35 mL/min with detection at 254 nm. Optical rotations were measured on a Perkin-EImer 241 polarimeter. Electrospray (ES) mass spectra were obtained on a Micromass Platform LC single quadrupole mass spectrometer in the positive mode. Elemental analysis and Karl Fischer water analysis were determined by Quantitative Technologies Inc., Whitehouse, NJ. When the percent e.e. is determined by HPLC (using Diacel ChiralPak AD-H column at 35 0C, 1 mL/min, 80:20 eluent ratio of Hexane: IPA after derivatization to the methyl ester), the resulting standard error for percent e.e. is about 2-3 % of the HPLC peak area. For derivatization to the methyl ester 0.1 M reactions: a 50 μL reaction sample (2 mg substrate/product, 0.005 mmol,) was treated in an HPLC vial with 50 μL of 2 M TMSCHN2 in Et2O (0.1 mmol) and MeOH ( 1 .5 mL).
Synthetic Examples
The terms used in describing the invention are commonly used and known to those skilled in the art. When used herein, the following abbreviations have the indicated meanings: General Synthetic Methods
Representative compounds of the present invention can be synthesized in accordance with the general synthetic methods described below and are illustrated more particularly in the schemes that follow. Since the schemes are illustrations whereby intermediate and target compounds of the present invention may be prepared, the invention should not be construed as being limited by the chemical reactions and conditions expressed. Additional representative compounds and stereoisomers, racemic mixtures, diastereomers and enantiomers thereof can be synthesized using the intermediates prepared in accordance with these schemes and other materials, compounds and reagents known to those skilled in the art. All such compounds, stereoisomers, racemic mixtures, diastereomers and enantiomers thereof are intended to be encompassed within the scope of the present invention. The preparation of the various starting materials used in the schemes is well within the skill of persons versed in the art.
Abbreviations used in the instant specification, particularly the Schemes and Examples, are as follows:
Abbreviation Meaning
Acac acetyl-acetone
AcOH acetic acid
Bn Benzyl
Boc /e/7-butoxycarbonyl
COD Cyclooctadiene
Conv Conversion
Cpd Compound
PCy cyclohexyl substituted on phosphorous
DCE 1 ,2-dichloroethane
DCM Dichloromethane
DIPEA N,N-diisopropylethylamine
DMF yV.jV-dimethylformamide d.r. diastereomeric ratio
EDC vV-ethyl-yV-dimethylaminopropylcarbodiimide hydrochloride e.e enantiomeric excess
Et Ethyl
Et2O diethyl ether
Et3N Triethylamine
EtOAc ethyl acetate
EtOH Ethanol d/hr/min day(s)/hour(s)/minute(s)
HCI hydrochloric acid
Hex Hexane
ICP inductively coupled plasma i-Pr Isopropyl
Ir Iridium
1HNMR proton nuclear magnetic resonance Abbreviation Meaning
HOBt 1 -hydroxybenzotriazole
HPLC high performance liquid chromatography
IPA 2-propanol
M molarity (mmole/mL)
Me Methyl
MeOH Methanol
MeCN Acetonitrile
NaHMDS sodium hexamethyldisilylamide
NaOH sodium hydroxide
NH4OH ammonium hydroxide
ND not determined
OTf Triflate
P pressure (in either PSIG or bar)
Pd/C palladium on carbon
Ph Phenyl
PH acidity/basicity on litmus paper
PSIG pound per square inch - gauge
Rh Rhodium
RP-HPLC reverse phase high performance liquid chromatography
RT/rt/r.t. room temperature
Ru Ruthenium
SDS sodium dodecasulfate
T temperature (in 0C)
TEA Triethylamine
TFA trifluoroacetic acid
THF Tetrahydrofuran
TMS Tetramethylsilane
ToI Toluene
XyI xylene (1 ,4-Me2-Ph)
Synthetic Example 1
Ru Adduct Complex Hydrogenation of Compound Cl Various basic-screening, preformed Ru adduct complexes were reacted with Compound Cl (82 mg, 0.2 mmol) in a 50: 1 substrate: complex ratio in various solvents (3 mL) at a temperature of about 500C, under H2 pressure of about 360 psig (25 bar) for a period of about 16 to about 18 hours. The percent conversion and e.e. were determined by HPLC (210 nm).
Table 1
Entry Complex Solvent Conv e.e.
1 (5)-P-Phos/[RuCI2(DMF)2] MeOH 6 <5
2 0S)-P-Phos/[RuCI2(DMF)2] DCE <5 ND
3 (.S)-XyI-P-PhOsZ[RuCI2(DMF)2] MeOH 6 8 (S)
4 (Λ)-Me-BoPhoz/[RuCI2(DMF)2] MeOH 8 23 (S)
5 (5)-P-Phos/[Ru(benzene)CI]CI MeOH 8 15 (S)
6 (S>P-Phos/[Ru(benzene)CI]Cl DCE <5 ND
7 (tf)-Xyl-P-Phos/[Ru(p-cymene)CI]CI MeOH <5 ND
8 (#)-Xyl-P-Phos/[Ru(p-cymene)Cl]CI DCE 10 59 (R) The results of Synthetic Example 1 show that the conversion and e.e. are dependent on both the solvent and ligand chosen. The reaction also may need to be run at a higher temperature in order to obtain improved percent conversion and e.e.
Synthetic Example 2 Rh-BoPhoz Hydrogenation of Compound Cl Various Rh-BoPhoz complexes formed in situ from ligand and [Rh(COD)2]OTf were reacted with Compound Cl (82 mg, 0.2 mmol) in a 50: 1 substratexomplex ratio in various solvents (3 mL) at a temperature of about 500C, under H2 pressure of about 360 psig (25 bar) for a period of about 16 to about 18 hours. The percent conversion and e.e. were determined by HPLC (210 nm). Table 2
Entry Ligand Solvent Conv e.e.
1 (R)-Me-BoPhoz MeOH 15 41 (S)
2 CF3Ph-(R)-Me-BoPhOZ MeOH 14 37 (S)
3 (R)-iPr-BoPhoz MeOH 13 45 (S)
4 (S)-Binol-(R)-Me-BoPhoz MeOH 6 7 (S)
5 (R)-Me-BoPhoz DCE 8 >90 (S)
14 Entry Ligand Solvent Conv e.e.
6 CF3Ph-(R)-Me-BoPhOZ DCE 7 77 (S)
7 (R)-Me-BoPhoz THF 10 80 (S)
8 CF3Ph-(R)-Me-BoPhOZ THF 10 85 (S)
Generally, the enantioselectivity obtained in aprotic solvents (such as THF and DCE) was improved over MeOH, even though MeOH provided improved conversion for a given complex. However, the low reactivity for conversion of the substrate may be attributable to coordination of the quinoline ring nitrogen atom to the complex.
Synthetic Example 3
Phanephos-Rh Hydrogenation of Compound Cl
A preformed (S)-PhanePhos/[Rh(COD)]BF4 complex was reacted with Compound Cl (82 mg, 0.2 mmol) in a 50: 1 substratexomplex ratio with various acid additives in MeOH (3 niL) at a temperature of about 500C, under H2 pressure of about 360 psig (25 bar) for a period of about 16 to about 18 hrs. The percent conversion and e.e. were determined by HPLC (210 nm).
Table 3
Entry Additive (Eq) Conv e.e.
1 TsOH (I Eq.) 27 67 (R)
2 TsOH (0.2 Eq.) 16 77 (R)
3 AcOH ( I Eq.) 13 67 (R)
4 AcOH (0.2 Eq.) 14 64 (R)
5 HBF4 (I Eq.) 37 75 (R)
6 HBF4 (I Eq.) 25 85 (R)
7 No Additive 14 <5
Generally, percent conversion obtained (compared to a reference Entry 7) was improved (see Entries 1 , 5, and 6) by the use of an additive (in a range of from about 0 Eq to about 1.2 Eq) to reduce the coordinative effect of the quinoline ring nitrogen atom on the complex. The improvement to conversion and enantioselectivity was achieved by the optional use of an additive to reduce the coordinative effect of the quinoline ring nitrogen atom.
Synthetic Example 4 Ir-ligand Complex Hydrogenation of Compound Cl
For Entries 1 -10, as shown in Table 4 below, various preformed P-Phos-Iridium and Phox-Iridium complexes were reacted with Compound Cl (82 mg, 0.2 mmol) in a 50: 1 substratexomplex ratio with various acid additives in either MeOH or DCE (3 mL) at a temperature of about 500C, under Hj pressure of about 360 psig (25 bar) for a period of about 16 to about 18 hours. The percent conversion and e.e. were determined by HPLC (210 nm).
Table 4
Entry Ligand Solvent Conv e.e.
1 (S)-P-Phos/[lr(COD)]CI MeOH 5 ND
2 (S)-P-Phos/[Ir(COD)]CI DCE 7 >90 (S)
(S)-Xyl-P-Phos/[Ir(COD)]CI MeOH 26 45 (S)
4 (S)-Xyl-P-Phos/[Ir(COD)]CI DCE 27 90 (S)
5 (R)-iPr-PHOX/[Ir(COD)]BArF MeOH 66 70 (S)
6 (R)-iPr-PHOX/[lr(COD)]BArF DCE 0 ND
7 (R)-Ph-PHOX/[Ir(COD)]BArF MeOH 19 68 (S)
8 (R)-Ph-PHOX/[Ir(COD)]BArF DCE 0 ND
9 (R)-Me-BoPhoz/[Ir(COD)CI]2 MeOH 24 19 (S)
10 (R)-Me-BoPhoz/[Ir(COD)Cl]2 DCE 88 95 (S)
Generally, the use of iridium complexes compared to rhodium complexes (see
Entry 3 , Table 4 compared to Entry 3, Table 1 ) provided an improved conversion and e.e
However, the conversion and e.e. results wen ; solvent-sensitive.
Synthetic I Example 5
Ir-ligand Complex Hydrogenation of Compound Cl A preformed (7?)-iPr-PHOX/[lr(COD)]BArF complex was reacted with Compound Cl (82 mg, 0.2 mmol) in a 50: 1 substratexomplex ratio in various solvents (3 mL) at various temperatures (0C) and under various H2 pressures (psig) for a period of about 16 to about 18 hours. The percent conversion and e.e. were determined by HPLC (210 nm).
Table 5 Entry Solvent Temp Pressure Conv e.e.
I MeOH 50 360 66 70 (S)
2 EtOH 50 360 30 65 (S)
-> iPrOH 50 360 23 34 (S)
4 MeOH 70 360 37 55 (S)
5 EtOH 70 360 44 61 (S)
6 MeOH 50 70 <5 —
7 MeOH 50 145 29 75 (S)
5 For use with a (/?)-iPr-PHOX/[Ir(COD)]BArF complex, lower alcohol solvents gave appreciable conversions and e.e. at a reaction temperature of greater than 50 0C and reaction pressures of greater than 145 psig.
Synthetic Example 6 Hydrogenation of Compound Dl
I O Various preformed Ru-ligand complexes were reacted with Compound Dl (82 mg, 0.2 mmol) in a 100: 1 substrateicomplex ratio with various additives in MeOH (2 mL) at a temperature of about 600C, under H2 pressure of about 430 psig (30 bar) for a period of about 20 hours.
The percent conversion e.e. were determined by HPLC (using Diacel ChiralPak 15 AD-H column at 35 0C, 1 mL/min, 80:20 eluent ratio of Hexane: IPA after derivatization to the methyl ester).
Table 6 Entry Complex Additive Conv e.e.
1 (7?>Xyl-P-Phos/[RuCI2(DMF)2] 0.5 Eq. Et3N >99 15 (R)
2 (7?;-PhanePhos/[RuCI2(DMF)2] 0.5 Eq. Et3N ND 58 (S)
3 (S;-PhanePhos/[RuCI2(DMF)2] 0.5 Eq. Et3N 99 64 (R) Entry Complex Additive Conv e.e.
4 (/?>Xyl-PhanePhos/[RuCl2(DMF)2] 0.5 Eq. Et3N >99 82 rø
5 (5;-Xyl-PhanePhos/[RuCI2(DMF)2] 0.5 Eq. Et3N 99 82 (R)
6 (5;-Me-BoPhoz/[RuCI2(DMF)2] 0.5 Eq. Et3N >99 5 (5)
7 (/?>Tol-Binap/[RuCI(/?-cymene)]CI 0.5 Eq. Et3N 94 5 (5)
8 (5;-Tol-Binap/[RuCIO-cymene)]Cl 0.5 Eq. Et3N ND 5 (R)
Entries 5 & 6 refer to use of a ligand in combination with a metal adduct as described in Ohta T, Takaya H, Kitamura M, Nagai K and Noyori R, J. Org. Chem. 1987, 52, 3176, under reaction conditions representative of the present invention.
Generally, Ru metal adducts and (R,S)-Xyl-P-Phos complexes in the presence of the additive Et3N led to high conversion but with a low e.e.
Synthetic Example 7 Iridium and Rhodium Complex Hydrogenation of Compound Cl
Various preformed iridium and rhodium complexes were reacted with Compound Cl (82 mg, 0.2 mmol) in a 50: 1 substrate:complex ratio in MeOH (3 mL) at a temperature of about 500C, under H2 pressure of about 360 psig (25 bar) for a period of about 16- 18 hours. The percent conversion and e.e. were determined by HPLC (210 nm).
Table 7
Entry Complex Additive Conv e.e.
1 (7?)-An-Phanephos/[Rh(COD)]BF4 1 Eq HBF4 13 47 (5)
2 (tf)-Xyl-Phanephos/[Rh(COD)]BF4 1 Eq HBF4 15 47 (5)
3 (0)-MeDuPhos/[Rh(COD)]BF4 1 Eq HBF4 12 10 (5)
4 (5)-P-Phos/[Ir(COD)CI] 1 Eq HBF4 14 -80(5)
5 (5)-Xyl-P-Phos/[Ir(COD)CI] 1 Eq HBF4 22 -83% (S)
6 (5)-Phanephos/[Rh(COD)]BF4 1 Eq HBF4 16 46 (R)
7 (5)-Phanephos/[Rh(COD)]BF4 No additive 21 W (R)
8 (tf)-iPr-PHOX/[[r(COD)]BF4 No additive 18 78 (5)
The use of HBF4 in the presence of iridium and rhodium complexes enhanced enantioselectivity when the reaction was run in 1 MeOH.
18 Synthetic Example 8 Rhodium Hydrogenation of Compound Cl
Various rhodium complexes, formed in situ from various ligands (0.005 mmol) and the metal adduct [Rh(ethylene)2CI]2 (0.002 mmol) by stirring in solvent (2 mL) at room temperature, were reacted with a solution of Compound Cl (82 mg, 0.2 mmol in I mL solvent) in a 50: 1 substratexomplex ratio in solvent (1 mL), with an optional HBF4 ( 1 equivalent) additive at a temperature of about 500C, under H2 pressure of about 360 psig (25 bar) for a period of about 16-18 hours. The percent conversion and e.e. were determined by HPLC (210 nm). Table 8
Entry Ligand Solvent Conv e.e.
I (R)-Me-BoPhoz MeOH 7 ND
2 (R)-Me-BoPhoz DCE 87 95.5 (S)
3 (R)-Me-BoPhoz MeOH + HBF4 3 ND
4 (R)-Me-BoPhoz DCE + HBF4 14 80 (5)
5 (R)-Phenethyl-(S)-BoPhoz DCE 40 79 (R)
6 (R)-Phenethyl-(R)-BoPhoz DCE 68 90 (Λ)
7 (R)-Phanephos DCE 58 79 (S)
8 (R)-Xyl-P-Phos DCE < 5 ND
9 (R)-Me-BoPhoz DCE (700C) 78 90 (S)
The results of Synthetic Example 8, show that conversion and enantioselectivity provided by certain and ligand metal complexes are sensitive to the solvent. For example, Table 8, Entry 1 shows that MeOH provides a low conversion and e.e. for a rhodium adduct and Me-BoPhoz ligand complex compared to the aforementioned iridium and rhodium PhanePhos complexes. Also, Table 8, Entry 2 shows that DCE provides a desirable conversion and e.e. for a rhodium adduct and Me-BoPhoz ligand complex compared to iridium and rhodium PhanePhos complexes.
Further, unlike the iridium and rhodium PhanePhos complexes, the use of an additive such as HBF4 for a rhodium adduct and (R)-Me-BoPhoz ligand complex results in low conversion and e.e. Synthetic Example 9 Rhodium Hydrogenation of Compound Cl
Various rhodium complexes, formed in situ from various ligands (0.005 mmol) listed in Table 9 and [Rh(ethylene)?(acac)] (0.004 mmol) by stirring in solvent (2 mL) at room temperature for a period of about 30 minutes, were reacted with a solution of Compound Cl (82 mg, 0.2 mmol in 1 mL solvent) in a 50: 1 substratexomplex ratio in solvent (1 mL) at a temperature of about 500C, under H2 pressure of about 360 psig (25 bar) for a period of about 16- 18 hours. The percent conversion and e.e. were determined by HPLC (210 nm). Note: acac is a counter ion used to stabilze the metal by supporting a negative charge.
Table 9 Entry Ligand Solvent Conv e.e.
1 (R)-Me-BoPhoz i-PrOH 55 68 (5)
2 (R)-Me-BoPhoz DCE 33 93 (5)
3 (R)-Xyl-P-Phos i-PrOH < 2 ND
4 (R)-Xyl-P-Phos DCE 13 16 (R)
The results of Synthetic Example 9, show that the conversion and enantioselectiveity provided by certain ligand-solvent combinations are sensitive to the metal adduct (relative to Synthetic Example 8) used.
Synthetic Example 10
[Rh(CO)2(acac)] Hydrogenation of Compound Cl
Various rhodium complexes, formed in situ from various ligands (0.005 mmol) and [Rh(CO)2(acac)] (0.004 mmol) by stirring in solvent (2 mL) at room temperature for a period of about 30 minutes, were reacted with a solution of Compound Cl (82 mg, 0.2 mmol in I mL solvent) in a 50: 1 substratexomplex ratio in solvent ( 1 mL) at a temperature of about 500C, under H2 pressure of about 360 psig (25 bar) for a period of about 16-18 hours. The percent conversion and e.e. were determined by HPLC (210 nm). Table 10
Entry Ligand Solvent Conv e.e.
1 (/?)-Me-BoPhoz i-PrOH 12 20 (5)
2 (tf)-Me-BoPhoz DCE 10 80 (5)
3 (Λ)-Xyl-P-Phos i-PrOH < 2 ND
4 (Λ)-Xyl-P-Phos DCE < 2 ND
The results of Synthetic Example 10, also show that the conversion and enantioselectiveity provided by certain ligand-solvent combinations are sensitive to the metal adduct used (relative to Examples 8 and 9).
5 Synthetic Example 1 I
[Ir(COD)CI]2 Hydrogenation of Compound Cl
Various iridium complexes, formed in situ from various ligands (0.005 mmol) and [Ir(COD)CI]2 (0.002 mmol) by stirring in solvent (2 mL) at room temperature for a period of about 30 minutes, were reacted with a solution of Compound Cl (82 mg; 0.2 I O mmol in I mL solvent) in a 50: 1 substratexomplex ratio in solvent ( I mL) with an optional HBF4 ( I Equivalent) additive at various temperatures (0C), under H2 pressure of about 360 psig (25 bar) for a period of about 16- 18 hours.
For Entries 1 - 1 5, the percent conversion and e.e. were determined by HPLC (210 nm). For Entries 16-20, the percent conversion and e.e. were determined by NMR as 15 discussed in Synthetic Example 13 and shown in Table 13.
Table 1 1
Entry Ligand Solvent Temp. Conv. e.e.
1 (Λ)-Me-BoPhoz MeOH 50 24 19 (5)
2 (Λ)-Me-BoPhoz MeOH + HBF4 50 19 73 (5)
3 (Λ)-Me-BoPhoz DCE 50 88 95 (5)
4 (Λ)-Me-BoPhoz DCE + HBF4 50 40 80 (S)
5 (5)-Me-BoPhoz DCE 50 85 93 (R)
6 (Λ)-Bn-BoPhoz DCE 50 87 95.5 (5)
7 3,4-diCIPh-(7?)-Me-BoPhoz DCE 50 86 93 (5) Entry Ligand Solven Temp. Con v. e.e.
8 PCy-(Λ)-Me-BoPhoz DCE 50 < 5 ND
9 Xyl-(/?)-Me-BoPhoz DCE 50 94 94 (5)
10 (Λ)-Phenethyl-(S)- DCE 50 69 35 m Me-BoPhoz
1 1 (Λ)-Phenethyl-(S)- DCE 50 10 82 (5) Me-BoPhoz
12 (5)-Binol-(/?)-Me-BoPhoz DCE 50 32 80 (5)
13 (fl)-Binol-(Λ)-Me-BoPhoz DCE 50 25 90 (5)
14 (7?)-Ph-BoPhoz DCE 50 92 57 (5)
15 (7?)-Phanephos DCE 50 < 5 ND
16 (Λ)-Me-BoPhoz THF 50 60 >95 (5)
17 (7?)-Me-BoPhoz toluene 50 90 91 (5)
18 (tf)-Me-BoPhoz EtOAc 50 75 94 (5)
19 (φ-Me-BoPhoz DCE 70 100 93 (S)
20 m-Me-BoPhoz DCE 90 100 92 (5)
The iridium complexes generated in situ by reacting [Ir(COD)CI]2 (0.5 Eq.) and Me-BoPhoz ( 1 .25 Eq.) were highly selective in aprotic solvents giving consistently > 90% ee. In MeOH, the addition Of HBF4 caused an increase in enantioselectivity (from 19% to 73% ee, Table 1 1 , Entries 1 and 2). In DCE, the addition of HBF4 caused a decrease in both activity and enantioselectivity (Table 1 1 , Entries 3 and 4).
Comparatively, the iridium (7?)-Me-BoPhoz complex was tested in non- chlorinated aprotic solvents (Table 1 1 , Entries 16-18) to provide various conversion and enantioselectivity results.
Synthetic Example 12 (/?)-Me-BoPhoz &[Ir(COD)CI]2 Hydrogenation of Compound Cl
An (7?)-Me-BoPhoz A[Ir(COD)CI]2 complex, formed in situ from the ligand (0.005 mmol) and [Ir(COD)CI]2 adduct (0.002 mmol) by stirring in solvent (2 mL) at room temperature for a period of about 30 minutes, was reacted with a solution of Compound Cl (82 mg, 0.2 mmol in 1 mL solvent) in a 50: 1 substrate:complex ratio in various solvents (1 mL) at various temperatures for a period of about 18 hours. The percent conversion and e.e. were determined by HPLCa (210 nm) and NMRb.
The percent conversion were determined by HPLCa (210 nm) and NMRb and e.e. was determined by HPLC.
Table 12
Entry Solvent Temp Cpd Clb Cpd C2b Cpd C2a e.e. (%)
(%) (%) (%)
1I T THHFF 5500 4400 40 46 >95(S)
22 i t toolluueennee 5500 1100 62 80 91 (S)
3 -* ! E EttOOAAcc 5500 2255 50 62 94 (S)
4 4 I D DCCEE 7700 -- 75 90 93 (S)
55 I D DCCEE 9900 - 75 90 92 (S)
The results of the Synthetic Example 12 show that NMR can be used to supplement the HPLC analysis for conversion to the desired enantiomer
Synthetic Example 13
(7?)-Me-BoPhoz &[lr(COD)Cl]2 Hydrogenation of Compound Cl Various concentrations of the (/?)-Me-BoPhoz &[Ir(COD)Cl]2 complex, formed in situ from the (R)-Me-BoPhoz ligand (0.0105 mmol) and [Ir(COD)CI]2 adduct (0.04 mmol) by stirring in DCE (8 mL) at room temperature for a period of about 30 minutes and then taken to 0.001 M volume with DCE, were reacted with a solution of Compound Cl ( 1 mmol in 1 mL DCE) in various substratexomplex ratios at a temperature of about 90 0C, under H? pressure of about 360 psig (25 bar) for a period of about 18 hours. The percent conversion was determined by HPLCa and 1H NMRb.
Table 13
Entry Cone. (M) S/C Cpd Clb Cpd C2b Cpd C2a e.e. (%)
(%) (%) (%)
5a 0.25 50/1 - 70 82 91 (S)
5b 0.25 100/1 9 62 75 90 (S)
5c 0.5 100/1 6 64 79 90 (S)
5d 0.5 200/1 35 36 43 88 (S) The results of the Synthetic Example 13 show that varying the substrate to complex ratio for Entry 5, Table 12 resulted in a reduced conversion without a substantial loss of e.e.
Synthetic Example 14 Rh-ligand Complex Hydrogenation of Compound Dl
Various preformed Rh-ligand complexes were reacted with Compound Dl (82 mg, 0.2 mmol) in a 100: 1 substrateicomplex ratio in MeOH (2 mL) at a temperature of about 600C, under H2 pressure of about 430 psig (30 bar) for a period of about 20 hours.
The percent conversion and e.e. were determined by HPLC (using Diacel ChiralPak AD-H column at 35 0C, 1 mL/min, 80:20 eluent ratio of Hexane: IPA after derivatization to the methyl ester).
Table 14 Entry Complex Conv e.e.
1 (/?;-PhanePhos/[Rh(COD)]BF4 >99 63 (S)
2 (/?;-MeOXyl-PhanePhos/[Rh(COD)]BF4 30 63 (S)
3 (Λ>An-PhanePhos/[Rh(COD)]BF4 >99 60 (S)
4 (S>iPr-PhanePhos/[Rh(COD)]BF4 >99 14 (R)
The results of Synthetic Example 14 show a high conversion rate with an average e.e. of at least 50% provided by a rhodium metal adduct for the acid Compound Dl. Entry 4, Table 14 shows that each enantiomer of the complex provides the opposite enantiomer of Compound D2.
Synthetic Example 15 Rh-BoPhoz Hydrogenation of Compound Dl
The Rh-BoPhoz complex formed in situ by the coordination of a PCy-(R)- Me-BoPhoz ligand&[Rh(COD)2]OTf was reacted with Compound Dl (82 mg, 0.2 mmol) in a 100: 1 substratexomplex ratio in various solvents (2 mL) at a temperature of about 600C, under H2 pressure of about 430 psig (30 bar) for a period of about 20 hours. The percent conversion (>99 %) and e.e. (30 % (S) enantiomer) were determined by HPLC (210 nm). Synthetic Example 16 Rh-PhanePhos Hydrogenation of Compound Dl
Various Rh-PhanePhos complexes that were preformed (Entry 1 ) or prepared in situ (Entries 2-4) from the PhanePhos ligand and [Rh(COD)2]BF4 or [RJi(COD)2]OTf metal adducts by stirring in MeOH (I mL) at room temperature were reacted with
Compound Dl (82 mg, 0.2 mmol) in a 100: 1 substratexomplex ratio and the optionally present additive HBF4 (in molar equivalents) in MeOH (2 mL) at a temperature of about 600C, under H2 pressure of about 430 psig (30 bar) for a period of about 20 hours.
The percent conversion and e.e. were determined by HPLC (using Diacel ChiralPak AD-H column at 35 0C, 1 mL/min, 80:20 eluent ratio of Hexane: IPA after derivatization to the methyl ester).
Table 15
Entry Complex HBF4 Conv e.e
1 (tfj-PhanePhos/[Rh(COD)]BF4 None >99 63 (S)
2 (φ-PhanePhos&[Rh(COD)2]OTf I Eq >94 40 (S)
3 (S>Xyl-PhanePhos &[Rh(COD)2]OTf None 96 67 (R)
4 (S;-Xyl-PhanePhos&[Rh(COD)2]OTf 1 Eq 81 40 (R)
In Table 15, Entries 2-4 further demonstrate that in situ formation is an effective means to prepare the ligand-metal complex and that addition Of HBF4 reduces the conversion and e.e.
Synthetic Example 17 Ru-PhanePhos Hydrogenation of Compound Dl
Various Ru-PhanePhos complexes (preformed) with a solvate with DMF (0.002 mmol) were reacted with Compound Dl (82 mg, 0.2 mmol) in a 100: 1 substratexomplex ratio in the solvent MeOH (2 mL) and the additive Et3N (0.1 mmol) at a temperature of about 600C, under H2 pressure of about 430 psig (30 bar) for a period of about 20 hours.
The percent conversion was determined by Η"NMR on the dried crude reaction mixture and the percent e.e. was determined by HPLC (using Diacel ChiralPak AD-H column at 35 0C, 1 mL/min, 80:20 eluent ratio of Hexane: IPA after derivatization to the methyl ester Compound C3).
Table 16
Entry Complex Conv e.e.
1 (5)-PhanePhos/[RuCl2(DMF)2] >99 58 (R)
2 (/?>PhanePhos/[RuCl2(DMF)2] >99 58(5)
3 (/?j-Xyl-PhanePhos/[RuCI2(DMF)2] >99 83(5;
4 (/?;-Xyl-PhanePhos/[RuCI2(DMF)2] >99 82-85 (S)
5 (5i;-Xyl-PhanePhos/[RuCI2(DMF)2] >99 S2(R)
Comparing Entries 1 and 2 and Entries 4 and 5 in Table 16 show that each stereospecific complex provides the opposite enantiomer of Compound D2.
Synthetic Example 18
(7?;-Xyl-PhanePhos/[RuCI2(DMF)2] Hydrogenation of Compound Dl
A 0"?)-Xyl-PhanePhos/[RuCl2(DMF)2] complex (0.002 mmol) was reacted with Compound Dl (0.25 M) in various substratexomplex ratios in MeOH and Et3N (0.5 Eq compared to Compound Dl) at various temperatures and H2 pressures for a period of about 20 hours.
The percent conversion was determined by 1FTNMR on the dried crude reaction mixture and the percent e.e. was determined by HPLC (using Diacel ChiralPak AD-H column at 35 0C, I mL/min, 80:20 eluent ratio of Hexane: IPA after derivatization to the methyl ester).
Table 17 Entry S/C P (bar) T (0C) Conv (%) e.e. (%)
1 250 30 60 >99 81(5)
2 500 30 60 >99 84(5)
3 250 30 40 >99 83(5)
4 500 30 40 >99 84(5)
5 250 10 40 >99 85(5) Entry S/C P (bar) T (0C) Conv (%) e.e. (%) 6 500 10 40 >99 85 (5;
The set of reaction conditions shown in Table 17 (using various substratexomplex ratios, pressures and temperatures) optimized the conversion and e.e. percentages using the (/?)-Xyl-PhanePhos/[RuCI2(DMF)2] complex.
Synthetic Example 19 Xyl-PhanePhos/[RuCI2(DMF)2] Transfer Hydrogenation of
Compound Dl
Stereoisomeric Xyl-PhanePhos/[RuCl2(DMF)2] complexes were reacted with Compound D2 (82 mg, 0.2 mmol) in a 100: 1 substratexomplex ratio in DCE (3 niL) with formic acid HCO2H (30 Eq excess to Compound Dl) and Et3N (in a molar equivalence ratio with HCO2H) at a temperature of about 6O0C for a period of about 24 hours.
The percent conversion and e.e. were determined by HPLC (using Diacel ChiralPak AD-H column at 35 0C, 1 mL/min, 80:20 eluent ratio of Hexane: IPA after derivatization to the methyl ester).
Table 18
Entry Complex HCOOH/Et3N Conv (%) e.e. (%)
1 (Λ;-Xyl-PhanePhos/[RuCI2(DMF)2] 1 : 1 40 58 (5)
2 (Sj-Xyl-PhanePhos/[RuCI2(DMF)2] 5:2 27 42 (R) The results of Synthetic Example 19 for substrate Compound Dl show moderate activity and selectivity when HCOOHZEt3N was used as the hydrogen source.
Synthetic Example 20 Enrichment of Compound Dl and Salt Forms Thereof
Reaction mixtures from Synthetic Example 18 were combined, neutralised and extracted in DCM ( 1.5 g). The average e.e obtained was 84.5%. Recrystallization from DCM/MTBE at -20 0C precipitated the undersired enantiomer to afford an enriched e.e for the desired enantiomer in the mother liquor. The desired enantiomer was isolated after evaporation of the mother liquor in 97% e.e. and 70% yield. The ratio of DCM:MTBE is important; DCM dissolves the enantiomeric mixture and addition of MTBE precipitates the undesired enantiomer. The ratio of the mixture may be from 1 : 1 to 1 :3.
The free base form solid obtained from the mother liquiour was redissolved in an excess of DCM/MTBE and treated with cyclohexylamine to obtain a salt of Compound D3. Other salts (from Et3N, JPr2-NH) of Compound D3 were tested and found to be also very soluble in DCM/Hexane and DCM/MTBE solvent mixtures.
Synthetic Example 21
(/?;-Xyl-PhanePhos/[RuCl2(DMF)2] Asymmetric Hydrogenation of Compound Dl
The (^)-Xyl-PhanePhos/[RuCI2(DMF)2] complex (0.25 M) was reacted with Compound Dl (0.25 M) in various substratexomplex ratios in MeOH (3 mL) with Et3N (0.5 Eq to Compound Dl) at various temperatures and H2 pressure for time periods of- about 20 hours. The percent conversion was determined by 1 HNMR on the dried crude reaction mixture and the percent e.e. was determined by HPLC (using Diacel ChiralPak AD-H column at 35 0C, 1 mL/min, 80:20 eluent ratio of Hexane:IPA after derivatization to the methyl ester).
Table 19
Entry S/C P (bar) T (0C) Conv (%) e.e. (%)
1 500 10 40 99 85 (S)
2 1000 10 60 66 73 (5)
3 2000 10 60 19 64 (5)
4 500 3 60 94 82 (5)
5 1000 3 60 93 78 (5)
6 2000 3 60 11 56 (5) The results of Synthetic Example 21 show that reaction conditions include a lower
HT gas pressure and a higher termperature. Entry I in Table 19 above corresponds to Entry 6 in Table 17 at a reaction time of about 4 hours. Entries 3 and 6 show the upper limit of the substratexomplex ratio using reaction conditions shown for the (R)-Xy\- PhanePhos/[RuCl2(DMF)2] complex. Entries 4 to 6 show the lower limit of the H2 gas pressure using the reaction conditions shown.
Synthetic Example 22 (/?)-Xyl-PhanePhos Hydrogenation of Compound Dl
Various Ru-PhanePhos complexes were reacted with Compound Dl in a 100: 1 substrate:complex ratio. The Ru-precursor (0.002 mrnol), (/?)-Xyl-PhanePhos (0.002 mmol) and Compound Dl (82 mg, 0.2 mmol) were loaded in a glass lined reaction chamber. The chamber was sealed and purged with nitrogen, then MeOH ( I mL) was injected. The resulting mixture was stirred at r.t. for 20-30 min, then MeOH ( 1 mL) was injected with an optional Et3N additive (0.5 Eq to Compound Dl), followed by hydrogen purge. The reaction was run at a temperature of about 400C, under H2 pressure of about 145 psig (10 bar) for a period of about 20 hours.
The percent conversion was determined by 1 HNMR on the dried crude reaction mixture and the percent e.e. was determined by HPLC (using Diacel ChiralPak AD-H column at 35 0C, 1 mL/min, 80:20 eluent ratio of HexaneMPA after derivatization to the methyl ester).
Table 20
Entry Complex Additive Conv e.e. (%)
(%)
1 (/?;-Xyl-PhanePhos/[RuCI2(DMF)2] 0.5 Eq >99 82-85 (S) Et3N
2 W-XyI- - 99 87 (S) PhanePhos&[Ru(CODXCF3COO)2]2
3 W-XyI- - 99 87 (S) PhanePhos&[Ru(COD)(methylallyl)2]
The (7?)-Xyl-PhanePhos ligand was tested in combination with other ruthenium metal adducts paired with various counterions by generating the complex in situ and were found to provide satisfactory conversion and e.e. Synthetic Example 23 (/?)-Xyl-PhanePhos Hydrogenation of Compound Dl
The preformed (7?;-Xyl-PhanePhos/[RuCl2(DMF)2] complex in Table 21a was paired with various additives and reacted with Compound Dl ( 196 mg, 0.5 mmol, 0.25 M) in a 500: 1 substratexomplex ratio at varying temperatures in MeOH ( I mL), under H? pressure of about 145 psig ( I O bar) for a period of about 4 hours to about 20 hours.
The in situ formed (/?;-Xyl-PhanePhos&[Ru(COD)(CF3COO)2]2 in Table 21 b and (/?,)-Xyl-PhanePhos&[Ru(COD)(methylallyl)2] complex in Table 21 c were prepared by loading the Ru metal adduct, the (7?)-XylPhanePhos ligand and Compound Dl in a glass liner. The liner was placed in the reactor. The reactor was sealed and purged with nitrogen, then MeOH ( 1 mL) was injected and the resulting mixture was stirred at r.t. for 20-30 min, followed by injection of MeOH ( 1 mL) (with or without additive).
The percent conversion was determined by 1HNMR on the dried crude reaction mixture; the percent e.e. was determined using Diacel ChiralPak AD-H column (35 0C), 1 mL/min, 80:20 eluent ratio of Hexane:IPA after derivatization to the methyl ester.
Table 21 a Entry Additive T (0C) Conv (%) e.e. (%)
Table 20 , No additive 40 99 85 (S)
Entry 1
1 0.5 Eq Et3N 40 99 $5 (S)
2 0.5 Eq Et3N 25 99 89-90 (S)
1 Eq Et3N 25 88 87 (S)
4 1 Eq. CH3COOH 25 2 ND
Table 21 b
Entry Additive T (0C) Conv (%) e.e. (%)
5 I Eq. HBF4-Et2O 40 16 71 (5)
6 I M HCI Et2O 40 3 ND
7 1 Eq. CF3COOH 25 73 90.5 (S)
8 1 Eq. CH3COOH 40 99 88 (5)
9 No additive 25 99 89 (5) Entry Additive T (0C) Conv (%) e.e. (%)
10 I Eq. CH3COOH 25 98 89-90 (S)
1 1 0.2 Eq. CH3COOH 25 93 90 (S)
12 0.5 Eq. Et3N 25 22 90 (S)
Table 21 c
Entry Additive T ( 0C) Conv (%) e.e. (%)
13 1 Eq. HBF4-Et2O 40 24 84 rø
14 I M HCI Et2O 40 13 Sl (S)
15 I Eq- CF3COOH 40 99 85 (5;
16 I Eq- CF3COOH 25 52 90.5 (S)
17 I Eq- CH3COOH 40 99 86 (5;
18 I Eq- CH3COOH 25 70 90 (5)
19 0.5 Eq. Et3N 25 1 1 ND
The various combinations shown in Table 21a and Table 21 b indicate that a variety of additives provide satisfactiory conversion and e.e.
While HCI ( I M Et2O) and HBF4. Et2O led to low conversion and partial deprotection of the Boc group (3- 15%) (Table 21 b, Entries 5, 6, 13 and 14), the
CH3COOH and CF3COOH additives led to full conversion and an e.e. of at least 85% (Table 21 b, Entries 8, 15 and 17).
Reaction conditions in Table 21 b considered combinations of Ru-precursor, the amount and nature of the additive and the temperature. Each of these factors in combination have an influence on both the amount of conversion and enantioselectivity. The (7?;-Xyl-PhanePhos/[RuCI?(DMF)2] complex led to full conversion and higher e.e. at 25 0C when using 0.5 Eq. Et3N. The use of more Et3N or CH3COOH led to lower conversion. When no additive was used, the reaction was slightly slower, reaching full conversion in approximately 8 hrs. When the in situ formed (/?;-Xyl-PhanePhos&[Ru(COD)(CF3COO)2]2 and (R)-
Xyl-PhanePhos&[Ru(COD)(methylallyl)2] complexes were employed, the enantioselectivity obtained was 90% (Table 21 b, Entry 8, compare with Entry 10). At S/C 500, the amount Of CH3COOH as an additive shows that there might be an influence on the activity of the complex (Table 21 b, Entries 9-1 1 ). The nature of the additive had an effect on the complex activity (Table 21 b, Entries 7, 9-12). Ru-systems that led to full conversion and approximately 90% e.e at S/C 500/1 , 25 0C and I O bar are shown in Table 21 b, Entries 2, 9 and 10 and Table 21c, Entry 17).
Synthetic Example 24 (/?)-Xyl-PhanePhos Hydrogenation of Compound Dl
Compound Dl (0.5 mmol) and a preformed C/?j-Xyl-PhanePhos/[RuCI2(DMF)2] complex (0.001 mmol) in a S/C ratio of 500: 1 in various solvents (2 itiL) with no additive was reacted at 40 0C, 10 bar ( 145 psig) H2, over a period of about 20 hrs.
The percent conversion was determined by 1HNMR on the dried crude reaction mixture; the percent e.e. was determined using Diacel ChiralPak AD-H column (35 0C), 1 mL/min, 80:20 ratio of Hexane:lPA after derivatization to the methyl ester.
Table 22
Entry Solvent Conv (%) e.e. (%)
1 MeOH >99 85 (S)
2 EtOH 44 84 (5)
*> IPA 35 75 (S)
4 MeOH/DCE 1/1 63 83 (S)
5 DCE 26 83 (S)
6 THF IO 72 (S)
7 ToI 5 83 (S)
8 EtOAc 19 83 (S) As shown in Table 22, unsaturated acid Compound Dl was fully hydrogenated to the corresponding D3 (S-acid, in approximately 90% e.e), via asymmetric hydrogenation in the presence of a (tf;-Xyl-PhanePhos/[RuCI2(DMF)2] or a (R)-Xy\- PhanePhos&[Ru(COD)(CF3COO)2]2 complex, at S/C 500/1 using in methanol, at 10 bar hydrogen pressure and room temperature. Synthetic Example 25 (/?)-Xyl-PhanePhos Hydrogenation of Compound Dl
Compound Dl (0.2 mmol, 79mg, 0.1 M) and the preformed (R)-XyI- PhanePhos/[RuCI2(DMF)2] complex in Table 25a (0.0002 mmol) in a S/C ratio of 1000: 1 in MeOH (2 mL) with various additives was reacted at 400C, 10 bar (145 psig) H2, over a period of about 20 hrs.
The percent conversion was determined by 1HNMR on the dried crude reaction mixture and the percent e.e. was determined using Diacel ChiralPak AD-H column (35 0C), 1 mL/min, 80:20 ratio of Hexane:IPA after derivatization to the methyl ester. Ligand-metal complex stock solutions (in situ) of a (R)-XyU
PhanePhos&[Ru(CODXCF3COO)2]2 complex in Table 25b and a (R)-Xy\- PhanePhos&[Ru(COD)(methylallyl)2] complex in Table 25c were generated by stirring the ruthenium adduct with the chiral phosphine ligand (0.0002 mmol/mL) in MeOH under N2 for 30-40 min at r.t. A solution of the complex (1 mL) was injected into the reactor, followed by CH3COOH (0.5 mL), the stock solution in MeOH, then MeOH (0.5 mL). The preparation of Entry 14 is detailed in Synthetic Example 27.
Table 23a Entry Additive Conv (%) e.e. (%)
1 No additive 4 ND
2 0.1 Eq- Et3N 66 82 (5;
3 0.25 Eq. Et3N 5 ND
4 0.5 Eq. Et3N 47 86 (5;
5 0.75 Eq. Et3N 3 ND
6 1 Eq. Et3N 2 ND
7 1.2 Eq. Et3N 17 77 (5;
Table 23b
Entry Additive Conv (%) e.e. (%)
8 No additive 5 ND
9 0.1 Eq. CH3COOH 93 86 Entry Additive Conv (%) e.e. (%)
I O 0. 25 Eq. CH3COOH 50 87
1 1 0.5 Eq. CH3COOH 98 87
12 0.75 Eq. CH3COOH 79 87
13 1 Eq. CH3COOH 4 ND
14 1.2 Eq. CH3COOH 99 88
Table 23c
Entry Additive Conv (%) e.e. (%)
15 No additive 30 87
16 0.1 Eq- CH3COOH 33 68
17 O. 25 Eq. CH3COOH 4 ND
18 0.5 Eq. CH3COOH 86 86
19 0.75 Eq. CH3COOH 23 85
20 1 Eq. CH3COOH 3 ND
21 1.2 Eq. CH3COOH 79 82
Synthetic Example 26
(/?)-Xyl-PhanePhos Hydrogenation of Compound Dl Compound Dl (2 mmol, I M) and preformed (R)-Xy\- PhanePhos[[Ru(COD)(CF3COO)2] (0.0002 mmol) in a S/C ratio of 1000: 1 in MeOH (2 mL) with additive CH3COOH (1.2 Eq., 0.5mL stock solution in MeOH), was reacted at 40 0C, 10 bar (145 psig) H2, over a period of about 20 hrs.
The percent conversion was determined by 1HlMMR on the dried crude reaction mixture and the percent e.e. were determined using Diacel ChiralPak AD-H column (35 0C), 1 mL/min, 80:20 ratio of Hexane:lPA after derivatization to the methyl ester.
Ligand-metal complex stock solutions (for use in situ) were generated by stirring the ruthenium precursor with the chiral phosphine ligand (0.002 mmol/mL) in MeOH under N2 for 2 hrs at 55 0C, then stirred with 1 .2 eq. Of CH3COOH (with respect to the starting material). The corresponding volume of complex stock solution was injected into the reactor, followed by CH3COOH (0.5 mL) stock solution in MeOH, then MeOH (0.5 mL).
Table 24 Entry T (0C) P (bar) Conv. (%) e.e. (%)
1 40 10 99.5 92 (S)
2 50 I O 99.7 89 (5;
50 3 99 82 (5;
Synthetic Example 27 (7?)-Xyl-PhanePhos Hydrogenation of Compound Dl
Compound Dl ( I M) and preformed (/?;-Xyl-PhanePhos/[Ru(COD)(CF3COO)2] (0.0002 mmol) in a S/C ratio of 1000: 1 in MeOH (2 mL) with additive CH3COOH (1.2 Eq., 0.5mL stock solution in MeOH), was reacted in a stand alone Parr vessel at 40 0C, 10 bar ( 145 psig) H2, over a period of about 20 hrs. The percent conversion and the percent e.e. were determined using Diacel
ChiralPak AD-H column (35 0C), I mL/min, 80:20 ratio of Hexane:IPA after derivatization to the methyl ester.
A ligand-metal complex stock solution was generated by stirring the ruthenium precursor with the chiral phosphine ligand in half of the total volume of MeOH under N? for 2 hrs at 55 0C, then stirred while cooling with 1.2 eq. Of CH3COOH (with respect to the starting material). This solution was injected to the starting material and the Schlenk flask was rinsed with the remaining solvent.
Table 25 Entry Cpd Dl (g) Time (h) P (bar) Conv. (%) e.e. (%)
I 1.58 17 I O 99.5 86(S)
2 1.58 16 3 90 82 (S)
3 1.58 24 98 81 (5;
4 1.58 40 98.5 79 (5;
5 3.17 17 10 99.5 89 (5; Synthetic Example 28
Recrystallization/Extraction of the crude acetic acid salt of Compound D3
The reaction products from Table 24, Entries 1 -3 were combined and crude 5 product Compound D3 (2.6 g) in the acetate salt form was obtained with the following composition: 0.8% starting material, 91% (83% e.e.) of Compound D3 and 8% of the (<xR) isomer Compound D2. Since both forms of the product (the free acid and the acetate salt) presented similar solubility, the crude acetate quinolinium salts (Table 24) were examined. The MTBE/Hexane and DCM/MTBE/Hexane solvent combinations led I O to the isolation of the product in 80% yield and >98 % e.e. (Table 26, Entries 6 and 8).
Table 26
Entry Solvent T (X) P re
1 IPA RT No 83 NA
2 IPA -20 No 83 NA
3 IPA/MTBE -20 No 83 NA
4 DCM/Hexane 60 Yes 99 10
5 MTBE 60 Yes 84 NA
6 MTBE/Hexane (1 :2) 60 Yes 98.3 80
7 MTBE/Hexane ( 1 : 1 ) 60 Yes 98 70
8 DCM:MTBE:Hex r.t. Yes 98.7 80
( 1 :5:5)
9 toluene r.t. Yes 91 NA
When the results from Table 26 were applied to the combined reaction products from Table 25, the product Compound D3 generated (5 g, >98% e.e.) was used as the starting material for diastereoselective hydrogenation of the quinoline ring.
15 Synthetic Example 29
Pd/C Catalyzed Hydrogenation of Compound D3 Et3N salt
Initial solvent screening in the Pd/C catalyzed diastereoselective hydrogenation of the Compound D3 Et3N salt was performed using I O%Pd/C (vv/w, dry basis) at 60 0C, 3 bar H2. The percent conversion and the percent e.e. were determined using Diacel ChiralPak AD-H column (35 0C), 1 mL/min, 80:20 ratio of Hexane:lPA after derivatization to the methyl ester.
Table 27 Entry Solvent Conv. (%) D4/D5 (ratio)
I MeOH 64 28/21
2 EtOH 73 33/30
Figure imgf000138_0001
4 Toluene 99 49/40
5 THF 96 44/44
6 DCE 79 35/30
7 EtOAc 85 37/34
8 MTBE 51 19/18 Synthetic Example 30
[Ir(COD)CI]2 Homogeneous Diastereoselective Hydrogenation of
Compound D3
[Ir(COD)CI]2 (0.004 mmol), various ligand stereoisomers (0.0044 mmol) and Compound D3 (0.2 mmol, 80 mg) in a S/C ratio of 50: 1 were reacted in toluene (3 mL) with 0.1 Eq. I2 (0.02 mmol, 5 mg), 50 0C, 25 bar hydrogen over a period of about 20 hrs.
The percent conversion and the percent e.e. were determined using Diacel ChiralPak AD-H column (35 0C), 1 mL/min, 80:20 eluent ratio of Hexane:IPA after derivatization to the methyl ester or by I H NMR estimations on the crude dried product.
The [Ir(COD)CI]2 adduct and various ligands were stirred in 1 mL solvent under N2, r.t. for a period of 30 min, followed by addition of stock solutions of I2 and substrate in toluene.
Table 28
Entry Ligand D3 (%) D4/D5 (d.r.) D4+D5 (%)
I (Λ)-Me-BoPhoz 47 28/72 82 Entry Ligand D3 (%) D4/D5 (d.r.) D4+D5 (%)
2 (S)-Me-BoPhoz 40 33/67 83
(tf)-Xyl-P-Phos 53 45/55 81
4 (S)-Xyl-P-Phos 50 50/50 77
5 (tf)-Xyl-PhanePhos 95 ND ND
6 (S)-Xyl-PhanePhos 95 ND ND
Synthetic Example 31
Me-BoPHoz/[Ir(COD)CI]2 Homogeneous Diastereoselective Hydrogenation of Compound D3
[Ir(COD)Cl]2 (0.004 mmol), various ligand stereoisomers (0.0044 mmol) and Compound D3 (0.2 mmol, 80 mg) in a S/C ratio of 50: 1 were reacted in various solvents (3 mL) with 0.1 Eq. I2 (0.02 mmol, 5 mg) at 50 0C and 25 bar hydrogen over a period of about 20 hrs.
The percent conversion and the percent e.e. were determined using either Diacel ChiralPak AD-H column (35 0C), 1 mL/min, 80:20 eluent ratio of Hexane:IPA after
I O derivatization to the methyl ester or by 1HNMR estimations on the crude dried product.
The [Ir(COD)CIJ2 adduct and the ligand were stirred in I mL solvent under NT, r.t. for a period of 30 min, followed by addition of stock solutions of I2 and substrate in the indicated solvent.
Table 29
Entry Ligand Solvent Additive D3 (%) D4/D5 (d.r.) D4+D5 (%)
1 (R)-Me- toluene None 47 28/72 82 BoPhoz
2 (S)-Me- toluene None 40 33/67 83 BoPhoz
3 (R)-Me- THF None 41/59 >99 BoPhoz
4 (S)-Me- THF None 46/54 >99 BoPhoz
5 (R)-Me- EtOAc None 28/72 >99 BoPhoz Entry Ligand Solvent Additive D3 (%) D4/D5 (d.r.) D4+D5 (%)
(S)-Me- EtOAc None 29/71 >99 BoPhoz
(Λ)-Me- DCE None 92 ND ND BoPhoz
(S)-Me- DCE None 92 ND ND BoPhoz
(R)-Me- EtOAc 0.2 Eq. Kl 25/75 >99 BoPhoz
10 (S)-Me- EtOAc 0.2 Eq. Kl 26/74 >99 BoPhoz
I l (R)-Me- EtOAc 1 .2 Eq. 98 ND ND BoPhoz Et3N
12 (S)-Me- EtOAc 1 .2 Eq. 98 ND ND BoPhoz Et3N
Synthetic Example 32
[Ir(COD)CI]2 Homogeneous Diastereoselective Hydrogenation of
Compound D3
[Ir(COD)CI]2 (0.004 mmol), various ligand stereoisomers (0.0044 mmol) and Compound D3 (0.2 mmol, 80 mg) in a S/C ratio of 50: 1 were reacted in EtOAc (3 mL) with 0.1 Eq. I2 (0.02 mmol, 5 mg) at 50 0C and 25 bar hydrogen over a period of about 20 hrs.
The percent conversion and the percent e.e. were determined using either Diacel ChiralPak AD-H column (35 "C), 1 mL/min, 80:20 eluent ratio of Hexane:IPA after derivatization to the methyl ester or by I H NMR estimations on the crude dried product.
The [Ir(COD)CI]: adduct and the ligand were stirred in I mL solvent under N2, r.t. for a period of 30 min, followed by addition of stock solutions of I2 and substrate in EtOAc.
Table 30
Entry Ligand D3 (%) D4/D5 (d.r.) D4+D5 (%)
(/?)-Me-BoPhoz 28/72 >99 Entry Ligand D3 (%) D4/D5 (d.r.) D4+D5 (%)
2 (S)-Me-BoPhOZ ND 29/71 >99
3 OR)-XyI-P-PhOS 4 38/62 >99
4 (S)-Xyl-P-Phos 4 38/62 >99
5 (Λ)-P-Phos 22 38/62 95
Figure imgf000141_0001
7 (S)-Tol-P-Phos 13 31/69 95
8 (Λ)-Xyl-Binap 74 50/50 47
9 (S)-Xyl-Binap 73 50/50 45
10 (tf)-Xyl-PhanePhos 83 31/69 ND
1 1 (S)-Xyl-PhanePhos 90 ND ND
12 (Λ)-PhanePhos 90 ND ND
1 3 (S)-PhanePhos 86 27/73 ND
Synthetic Example 33
[Ir(COD)CI]2 Homogeneous Diastereoselective Hydrogenation of
Compound C3
Metal precursor [Ir(COD)CI] (0.004 mmol), various ligand stereoisomers (0.0044 mmol) and Compound C3 (0.2 mmol, 83 mg) in a S/C ratio of 50: 1 were each reacted in EtOAc (3 mL) with 0.1 Eq. I2 (0.02 mmol, 5 mg) at 50 0C and 25 bar hydrogen over a period of about 18 hrs.
The percent conversion and the percent e.e. were determined using Diacel ChiralPak AD-H column (35 0C), 1 mL/min, 80:20 eluent ratio of Hexane:IPA after derivatization to the methyl ester.
The [Ir(COD)CI] 2 adduct and the ligand were stirred in 1 mL solvent under N2, r.t. for a period of 30 min, followed by addition of stock solutions of I2 and substrate in EtOAc.
Table 31
Entry Ligand C3 (%) C4/C5 (d.r.)
1 (Λ)-Me-BoPhoz <l 50/48 Entry Ligand C3 (%) C4/C5 (d.r.)
2 (S)-Me-BoPhOZ < 1 50/48
3 (tf)-Xyl-P-Phos 3 50/50
4 (S)-XyI-P-PhOS 12 52/48
5 (Λ)-Xyl-PhanePhos 76 50/50
6 (S)-Xyl-PhanePhos 82 47/53
Synthetic Example 34
[Ir(COD)CI]2 Homogeneous Diastereoselective Hydrogenation of
Compound C3
Metal precursor [Ir(COD)CI] (0.004 mmol), various ligand stereoisomers (0.0044 mmol) and Compound C3 (0.2 mmol, 83 mg) in a S/C ratio of 50: 1 were reacted in various solvents (3 mL) with 0.1 Eq. h (0.02 mmol, 5 mg) at 50 0C and 25 bar hydrogen over a period of about 18 to 20 hrs.
The percent conversion and the percent e.e. were determined using Diacel ChiralPak AD-H column (35 0C), I mL/min, 80:20 eluent ratio of Hexane:IPA after derivatization to the methyl ester.
The [Ir(COD)CI] 2 adduct and the ligand were stirred in 1 mL solvent under N2, r.t. for a period of 30 min, followed by addition of stock solutions of I2 and substrate in the indicated solvent.
Table 32
Entry Ligand Solvent C3 (%) C4/C5 (d.r.)
I (/?)-Me-BoPhoz EtOAc < 1 50/48
2 (S)-Me-BoPhoz EtOAc < 1 50/48
3 (Λ)-Me-BoPhoz THF 17 51/49
4 (S)-Me-BoPhOZ THF 2 52/48
5 OK)-Me-BoPhOz toluene 58 50/50
6 (S)-Me-BoPhOz toluene 58 50/50
7 (7?)-Me-BoPhoz DCE 88 50/50
8 (S)-Me-BoPhoz DCE 88 50/50 Entry Ligand Solvent C3 (%) C4/C5 (d.r.)
9 (Λ)-Me-BoPhoz MeOH 92 50/50
10 (5)-Me-BoPhoz MeOH 92 50/50
Synthetic Example 35
[Ir(COD)CI]? Homogeneous Diastereoselective Hydrogenation of
Compound C3
Metal precursor [Ir(COD)CI] (0.004 mmol), various ligand stereoisomers (0.0044 mmol) and Compound C3 (0.2 mmol, 83 mg) in a S/C ratio of 50: 1 were reacted in EtOAc (3 mL) with 0.1 Eq. I2 (0.02 mmol, 5 mg) at 50 0C and 25 bar hydrogen over a period of about 18 to 20 hrs.
The percent conversion and the percent e.e. were determined using Diacel ChiralPak AD-H column (35 0C), 1 mL/min, 80:20 eluent ratio of HexaneMPA after derivatization to the methyl ester.
The [Ir(COD)CI]2 adduct and the ligand were stirred in I mL solvent under N2, r.t. for a period of 30 min, followed by addition of stock solutions of I2 and substrate in EtOAc.
Table 33
Entry Ligand C3 (%) C4/C5 (d.r.)
1 None 98 ND
2 (Λ)-Me-BoPhoz < 1 50/48
3 (S)-Me-BoPhOZ <1 50/48
4 (Λ)-Phenethyl-(S)-BoPhoz 23 48/52
5 (S)-Ethyl-Naphthyl-(/?)-BoPhoz 6 49/51
6 (tf)-Et-BoPhoz 1 48/51
7 (7?)-iPr-BoPhoz I 49/50
8 (tf)-Ph-BoPhoz 16 49/51
9 PCy-(Λ)-Me-BoPhoz 75 48/52
I O 2,4,6-F3Ph-(Λ)-Me-BoPhoz 31 49/51
1 1 Xyl-(Λ)-Me-BoPhoz 2 48/51 Entry Ligand C3 (%) C4/C5 (d.r.)
12 pFPh-(7?)-Me-BoPhoz 1 49/50
13 pFPh-(/?)-Et-BoPhoz 78 50/50
14 pFPh-(/?)-Bn-BoPhoz 2 49/51
1 5 (S)-Binol-(/?)-Me-BoPhoz 10 50/50
16 (7?)-Binol-(7?)-Me-BoPhoz 1 48/52
17 DtBPF 94 ND
1 8 DPPF 29 49/51
Synthetic Example 36
One Pot (Λ)-Me-BoPhoz&[lr(COD)CI]2 Catalyzed Hydrogenation of Compound Cl
Figure imgf000144_0001
A one-pot reaction was developed wherein Compound Cl was reacted with an in situ formed (#)-Me-BoPhoz&[Ir(COD)Cl]2 ligand-metal complex at a S/C ratio of 50/1 in the solvent DCE, under 25 bar H2 at a temperature of 70 0C over a period of 24 hrs to provide Compound C3 (75% conversion, 96% e.e.) followed by the direct addition of 10% iodine. The foregoing reaction mixture was recharged under 25 bar H? at a temperature of 70 0C over a period of 48 hrs to provide an isomeric mixture of Compound C4 (43%) and Compound C5 (45%).
Synthetic Example 37
One Pot (7?)-Me-BoPhoz&[lr(COD)CI]2 Catalyzed Hydrogenation of Compound Dl
Figure imgf000145_0001
D6, (αR.βS) isomer D7, (αR.βR) isomer
A one-pot reaction was developed wherein Compound Dl was reacted with an in situ formed (7?)-Me-BoPhoz&[lr(COD)CI]2 ligand-metal complex at a S/C ratio of 50/1 in the solvent THF, under 25 bar H2 at a temperature of 70 0C over a period of 24 hrs to provide Compound D3 (51 % conversion, 65% e.e.) followed by the direct addition of 10% iodine. The foregoing reaction mixture was recharged under 25 bar H2 at a temperature of 70 0C over a period of 60 hrs to provide an isomeric mixture of Compound D4 (35%) and Compound D5 (50%) and the (α^)-isomers Compound D6 and Compound D7 ( 14% combined).
Synthetic Example 38 (7?)-Xyl-PhanePhos Hydrogenation of Compound Dl
The [Ru(COD)(CF3COO)2] metal precursor (0.004 mmol, 1.74 mg) and the (Λ)-Xyl-PhanePhos ligand (0.0044 mmol, 3.1 mg) (S/C 1000/1) were loaded in a 5 mL Schlenk tube. The tube was evacuated by performing three vacuum/nitrogen refill cycles and 2 mL anhydrous, degassed MeOH was injected. The resulting mixture was stirred at 55 0C for 2 hrs. After 2 hrs, the tube was taken out of the heating bath and glacial CH3COOH (undegassed)(l .2 eq. to substrate, 4.8 mmol, 0.275 mL) was injected. The resulting solution was stirred while cooling down (approximately 10 min).
The solid substrate Compound Dl (4 mmol, 1 .58 g) was loaded in a 25 mL Parr container, the Parr vessel sealed, and purged ten times with hydrogen. The pressure was released and a solution of the ligand-metal complex was injected via the injection port of the Parr vessel. The Schlenk tube was rinsed with 2 mL MeOH (degassed, anhydrous, 4 x 0.5 mL portions) and injected quickly via the injection port. The resulting mixture was purged five times without stirring and 10 times with stirring. The reaction mixture was stirred at 10 bar H2 and 4O 0C. The reaction was sampled after 17 hrs and analyzed by HPLC, after in situ conversion to the methyl ester Compound C2: >99.5% conversion and 86% e.e.
Compound D2 was converted to the corresponding methyl ester Compound C2 (for 0.1 M reactions) by in situ derivatization: a 50 μL reaction sample (2 mg substrate/product, 0.005 mmol,) was treated in an HPLC vial with 50 μL of 2 M TMSCHM2 in Et2O (0.1 mmol) and MeOH (1 .5 mL), then analyzed directly by the aforementioned chiral HPLC method; LC/MS (ES+) m/z 399.3 (M+ 1 );
The crude reaction mixture was treated with Et3N (4.8 mmol, 0.5 mL), the solvent was evaporated and the product extracted with DCM/sat'd NH4CI (aq). The DCM extracts were dried over Na2SO4, filtered and solvent evaporated to provide an off-white solid ( 1 .52 g, 96%): 1KNMR (CDCI3): free acid form. The solid was taken up in toluene (30 mL) and stirred, wherein a fine solid formed immediately after addition of toluene. The mother liquor was sampled and analyzed by HPLC after conversion to methyl ester: 91% e.e. The mixture was left stirring at r.t. for greater than 48 hours. Sampling of the mother liquor after conversion to methyl ester showed 99% e.e. The reaction mixture was filtered and the filtrate was evaporated to provide Compound D3 (1.13 g, 75% isolated yield with respect to the crude, 1.52 g) as a brown solid.
HPLC: >99% e.e.; 1H NMR (CDCI3): free acid form + residual toluene; mp 60- 70 0C; 1 H NMR (400 MHz, CDCI3) δ 10.9 (br m, I H), 8.86 (s, I H), 8.07 (m, 2H), 7.82 (m, I H), 7.66 (m, I H), 7.55 (m, 1 H), 4.04 (m, 2 H), 3.55 (m, I H), 2.9-2.4 (m, 4H), 1.9- 1.5 (m, 3H), 1.45 (s, 9H), 1.3-1.0 (m, 4H); 13C NMR ( 100 MHz, CDCI3) δ 174.47, 154.84, 150.05, 145.79, 137.20, 135.01 , 129.54, 128.12, 127.66, 127.07, 79.42, 43.70 (br), 42.55, 42.29, 36.72, 33.27, 32.59, 31.42, 28.43; Anal. Calcd for C23H30N2O4: C, 69.32; H, 7.59, N, 7.03. Found: C, 69.58; H, 7.92; N, 6.68.
Synthetic Example 39
(/?)-Xyl-PhanePhos Hydrogenation of Compound Dl and Enantiomeric Enrichment.
The [Ru(COD)(CF3COO)2] metal precursor (0.004 mmol, 1 .74 mg) and the (Λ)-Xyl-PhanePhos ligand (0.0044 mmol, 3.1 mg) (S/C 1000/1 ) were loaded in a 5 mL Schlenk tube. The tube was evacuated by performing three vacuum/nitrogen refill cycles and 2 mL anhydrous, degassed MeOH was injected. The resulting mixture was stirred at 55 0C for 2 hrs. After 2 hrs, the tube was taken out of the heating bath and glacial CH3COOH (undegassed)( 1.2 eq. to substrate, 4.8 mmol, 0.275 mL) was injected. The resulting solution was stirred while cooling down (approximately 10 min). The solid substrate Dl (4 mmol, 1 .58 g) was loaded in a 25 mL Parr container, the Parr vessel sealed, then purged ten times with hydrogen. The pressure was released and the complex solution was injected via the injection port of the Parr vessel. The Schlenk tube was rinsed with 2mL MeOH (degassed, anhydrous, 4x0.5 mL portions) and injected quickly via the injection port. The resulting mixture was purged five times without stirring and 10 times with stirring. The reaction mixture was stirred at 3 bar H2 and 40 0C. The reaction was sampled after 16, 24 and 48 and analyzed by HPLC, after in situ conversion to the methyl ester: 16 hrs: 90% conversion, 82% e.e.; 24 hrs: 98% conversion 81% e.e.; 40 hrs: 98.5% conversion and 79% e.e.
The solvent was evaporated and 1.43 g of a brown sticky solid was obtained. To this solid, a mixture of DCM:Hexane:MTBE in a ratio of 10 mL:50 mL:50 mL was added and the mixture stirred at r.t. Upon stirring, the sticky solid went into the solvent as a fine solid. The mother liquor was sampled and analyzed by HPLC after conversion to methyl ester: 1.5% Compound Dl, 98.5% product D3, 97.8% e.e. The reaction mixture was filtered, solid washed with 2x5 mL hexane and the filtrate was evaporated. 1.14 g (80% isolated yield with respect to the crude solid, 1 43g) off-white solid D3 was obtained: HPLC: 1.6% Compound Dl, 98.4% conversion, 97.8 % e.e.; 1H NMR (CDCI3): free acid form, 94% product Compound D3, 6% Compound Dl.
Synthetic Example 40
(Λ)-Xyl-PhanePhos Hydrogenation of Compound Dl and Enantiomeric Enrichment
The [Ru(COD)(CF3COO)2] metal precursor(0.008 mmol, 3.5 mg) and the (Λ)-Xyl-PhanePhos ligand (0.0088 mmol, 6.1 mg) (S/C = 1000/1 ) were loaded in a 5 mL Schlenk tube. The tube was evacuated by performing three vacuum/nitrogen refill cycles and 4mL anhydrous, degassed was MeOH injected. The resulting mixture was stirred at 55 0C for 2 hrs. After 2 hrs, the tube was taken out of the heating bath and glacial
CH3COOH (undegassed)(l .2 eq. to substrate, 9.6 mmol, 0.550 mL) was injected. The resulting solution was stirred while cooling down (approximately l Omin). The solid Compound Dl (8 mmol, 3.17 g) was loaded in a 50 mL Parr container, the Parr vessel sealed, then purged ten times with hydrogen. The pressure was released and the complex solution was injected via the injection port of the Parr vessel. The Schlenk tube was rinsed with 4 mL MeOH (degassed, anhydrous, 4x 1 mL portions) and injected quickly via the injection port. The resulting mixture was purged five times without stirring and 10 times with stirring. The reaction mixture was stirred at 10 bar H2 and 40 0C. The reaction was sampled after 17 hrs and analyzed by HPLC, after in situ conversion to the methyl ester: >99.5% conversion and 87% e.e. The crude reaction mixture was transferred to a 500 mL round bottom flask and solvent evaporated, with the formation of a brown sticky solid. The flask was fitted with an air reflux condenser and lowered in an oil bath at 60 0C and the solid dissolved in 20 mL MTBE (solvents added from the top of the reflux condenser). To this solution, 60 mL hexane was added and a sticky solid formed at the bottom of the flask. Small portions of MTBE and Hexane were added alternately until a fine solid started forming, with concomitant analysis of mother liquor aliquots. The final amounts of solvents were: 100 mL MTBE: 10OmL hexane (analysis of this mother liquor by HPLC after conversion to methyl ester: 98% e.e). The reaction mixture was filtered hot and the solid washed with hot hexane (20 mL). After solvent evaporation, Compound D3 (2.5 g, 80% yield) was obtained as an off-white solid.
Synthetic Example 41
Pd/C Catalyzed Diastereoselective Hydrogenation of Compound C3
Figure imgf000149_0001
Solvent screening in the heterogeneous Pd/C catalyzed diastereoselective hydrogenation of Compound C3 (0.2 mmol, 0. 1 M) in various solvents was performed using 10%Pd/C (w/w, dry basis) at 60 0C, 3 bar H2, over a period of about 1 8-20 hrs.
The percent conversion and the percent diastereomeric ratio (d.r.) were determined using Diacel ChiralPak AD-H column (35 0C), 1 mL/min, 80:20 ratio of Hexane:IPA after derivatization to the methyl ester and by 1 HlMMR. The by-product Compound 33a overlapped with Compound C4 by HPLC. Table 34
Entry Solvent C3 (%) (C4+33a)/C5 C3/(C4+C5)/33a (ratio % by HPLC) (ratio % by NMR)
1 MeOH 90 6/4 88/12/0
2 EtOH 21 44/35 6/77/17
3 /-PrOH <1 55/45 0/90/10
4 1 -BuOH <1 55/45 0/89/1 1
5 Tolene < 1 55/45 0/87/13
6 THF < l 56/44 0/80/20
7 EtOAc < l 56/44 0/88/12
8 DCE < l 89/10 8/92/0
Synthetic Example 42
Pd/C Catalyzed Diastereoselective Hydrogenation of Compound
D3
Figure imgf000150_0001
Solvent screening in the heterogeneous Pd/C catalyzed diastereoselective hydrogenation of Compound D3 (0.2 mmol, O. I M) in various solvents was performed using 10%Pd/C (w/w, dry basis) at 60 0C, 3 bar H2, over a period of about 1 8-20 hrs.
The percent conversion and the percent diastereomeric ratio (d.r.) were determined using Diacel ChiralPak AD-H column (35 0C), 1 mL/min, 80:20 ratio of Hexane:lPA after derivatization to the methyl ester and by 1 HNMR. The by-product Compound 34a overlapped with Compound D4 by H PLC.
Table 35
Entry Solvent D3 (%) (D4+34a)/D5 D3/(D4+D5)/34a (ratio % by HPLC) (ratio % by NMR)
MeOH 14 46/40 0/89/10 Entry Solvent D3 (%) (D4+34a)/D5 D3/(D4+D5)/34a (ratio % by HPLC) (ratio % by NMR)
2 EtOH 14 46/40 0/90/10 3 /-PrOH 50 27/23 23/61/16 4 1 -BuOH < l 53/47 0/78/32 5 toluene <1 49/51 0/79/31 6 THF 17 38/45 2/90/8 7 EtOAc 61 20/19 30/51/19 8 DCE 35 47/18 10/35/55
Synthetic Example 44
Pd/C Catalyzed Diastereoselective Hydrogenation of Compound D3
Compound D2 (0.2 mmol, 0.1 M) in MeOH was reacted with 10%Pd/C (w/w, dry basis) at 60 0C, 3 bar H?, over a period of about 18-20 hrs.
The percent conversion and the percent diastereomeric ratio (d.r.) were determined using Diacel ChiralPak AD-H column (35 0C), 1 mL/min, 80:20 ratio of Hexane:IPA after derivatization to the methyl ester and by 1 HNMR. The by-product Compound 33a overlapped with Compound D4 by HPLC.
Table 36
Entry Catalyst Cat. D3 (%) (D4+34a)/D5 D3/(D4+D5)/34a Loading (ratio % by (ratio % by
(%, w/w) HPLC) NMR)
I 10% Pd/C 10 14 46/40 0/89/10
2 10% Pd/C 10 6 52/42 0/81/19
3 10%Pd/C 10 <1 56/44 0/75/25
4 5% Pd/C 20 <1 87/13 0/27/73
5 4%Pd- 20 <1 56/44 0/72/28 l%Pt/C
6 5% Pt/C 20 <1 59/40 0/84/16
7 5% Ir/ 20 77 14/9 51/33/16 CaCO3 Entry Catalyst Cat. D3 (%) (D4+34a)/D5 D3/(D4+D5)/34a
Loading (ratio % by (ratio % by
(%, w/w) HPLC) NMR)
5% Rh/C 20 <1 90/10 0/15/85 5% Rh/C 20 <1 96/4 0/9/91
Synthetic Example 45
Pd/C Catalyzed Diastereoselective Hydrogenation of Compound D3 and Compound C3
Temperature and pressure optimization screening in the Pd/C catalyzed diastereoselective hydrogenation of Compound D2 (0.2 mmol, 0. I M) in MeOH was performed using 10%Pd/C (w/w, dry basis) at 60 0C, 3 bar H2, over a period of about 16 hrs.
The percent conversion and the percent diastereomeric ratio (d.r.) were determined using Diacel ChiralPak AD-H column (35 0C), 1 mL/min, 80:20 ratio of
I O Hexane:IPA after derivatization to the methyl ester and by 1HNMR. The byproduct Compound 34a overlapped with Compound D4 by HPLC.
Entries 9 and 10 were performed using Compound C3 in IPA, wherein the analysis by HPLC and NMR were based on the corresponding Me ester product Compounds C3, C4, C5 and 33a.
15 Table 37
Entry T (X) P (bar) D3 (%) (D4+34a)/D5 D3/(D4+D5)/34a (ratio % by (ratio % by HPLC) NMR)
1 30 77 13/10 53/44/3
2 40 3 40 32/28 13/80/7
60 3 14 46/40 0/89/10
4 80 3 0 68/32 0/52/48
5 30 10 0 52/48 0/89/10
6 40 10 0 54/46 0/95/5
7 30 25 0 53/47 0/93/7 Entry T (0C) P (bar) D3 (%) (D4+34a)/D5 D3/(D4+D5)/34a (ratio % by (ratio % by HPLC) NMR)
8 40 25 0 53/47 0/97/3
9 60 3 C3 <] 55/45 0/90/10
10 30 25 C3: 72 16/12 55/39/6
Synthetic Example 45
Pd/C Catalyzed Diastereoselective Hydrogenation of Compound
D3
Additive/pH optimization in the Pd/C catalyzed diastereoselective hydrogenation of Compound D2 (0.2 mmol, 0.1 M) in MeOH, using various additives was performed using I O%Pd/C (w/w, dry basis) at 40 0C, 10 bar H^, over a period of about 18 hrs.
The percent conversion and the percent diastereomeric ratio (d.r.) were determined using Diacel ChiralPak AD-H column (35 0C), 1 mL/min, 80:20 ratio of Hexane:lPA after derivatization to the methyl ester and by 1HMMR. The by-product Compound 34a overlapped with Compound D4 by HPLC.
Table 38
Entry Additive Eq. D3 (%) (D4+34a)/D5 D3/(D4+D5)/34a (to D3) (ratio % by (ratio % by HPLC) NMR)
1 None NA 0 54/46 0/95/5
2 Et3N 0.2 0 51/49 0/90/10
3 Et3N 0.5 0 50/50 0/95/5
4 Et3N 0.75 0 49/51 0/99.5/0.5
5 Et3N 1 .2 0 49/51 0/97/3
6 CH3COOH 0.2 0 54/46 0/88/12
7 CH3COOH 0.5 0 55/45 0/83/17
8 CH3COOH 0.75 0 55/45 0/84/16
9 CH3COOH 1.2 0 55/45 0/79/21 Synthetic Example 46
Pd/C Catalyzed Diastereoselective Hydrogenation of Compound D3
Additive optimization in the Pd/C catalyzed diastereoselective hydrogenation of Compound D3 (0.2 mmol, 0.1 M) in MeOH, using various additives was performed using 10%Pd/C (w/w, dry basis) at 40 0C, 10 bar H2, over a period of about 20 hrs. The additive is present in a stoichiometric ratio (Eq.) with Compound D3 as shown in Table 39/
The percent conversion and the percent diastereomeric ratio (d.r.) were determined using Diacel ChiralPak AD-H column (35 0C), 1 mL/min, 80:20 ratio of Hexane:lPA after derivatization to the methyl ester and by 1HNMR.
Table 39
Entry Additive Eq. D3 (%) (D4+34a)/D5 D3/(D4+D5)/34a (ratio % by (ratio % by HPLC) NMR)
1 Et3N 0.75 0 49/51 0/99.5/0.5
2 IPr2NH 0.75 0 50/50 0/99.3/0.7
3 Cy2NH 0.75 0 50/50 0/95.5/4.5
4 W-Ph-EtNH2 0.75 0 47/53 0/95/5
5 OS)-Ph-EtNH2 0.75 0 48/52 0/94/6
6 KOH 0.75 0 50/50 0/98/2
7 K2CO3 0.75 0 53/47 0/98/2
8 CH3COOH 0.2 0 54/46 0/88/12
9 (7?)-Camph-SO3H 0.2 0 55/45 0/83/17
10 (S)-Camph-SO3H 0.2 0 54/46 0/87/13
Synthetic Example 47
Pd/C Catalyzed Diastereoselective Hydrogenation of Compound D3
Concentration optimization in the Pd/C catalyzed diastereoselective hydrogenation of Compound D3 (0.2 mmol, 0.1 M) in MeOH (2 mL), using Et3N as an additive (0.75 Eq. Et3N:Compound D3) was performed using 10%Pd/C (w/vv, dry basis) at 40 0C, 10 bar H2, over a period of about 20 hrs.
The percent conversion and the percent diastereomeric ratio (d.r.) were determined using Diacel ChiralPak AD-H column (35 0C), 1 mL/min, 80:20 ratio of Hexane:IPA after derivatization to the methyl ester and by 1HNMR.
Table 40
Entry D3 (mmol/ag) D3 (%) (D4+34a)/D5 D3/(D4+D5)/34a (ratio % by (ratio % by HPLC) NMR)
1 0.1 0 49/51 0/99.5/0.5
2 0.25 0 49/51 ND
0.5 0 49/51 0/98/2
4 0.75 0 49/51 0/99.5/0.5
5 1 0 49/51 0/99.5/0.5
6 l/a1.6 0 49/51 0/96/4
Synthetic Example 48
Pd/C Catalyzed Diastereoselective Hydrogenation of Compound D3
Solid substrate Compound D3 (4 mmol, 1.6 g), 10% Pd/C ( 10% w/w to substrate on dry basis, 64.78% H2O, 460 mg), MeOH (4 mL) and Et3N (3 mmol, 0.42 mL) were loaded in a 25 mL Parr container, which was sealed and purged ten times with hydrogen without stirring and 10 times with stirring. The reaction mixture was stirred at 10 bar H2 and 40 0C. The reaction was sampled after 4 hrs and analyzed by HPLC, after in situ conversion to the methyl ester: >99.5% conversion and a ratio of Compound D4:Compound D5, 1/1 d.r. The reaction was stopped, the reaction mixture filtered and the Pd catalyst washed with 20 mL methanol. This crude solution was acidified with CH3COOH (8.8. mmol, 0.5mL), the solvent was evaporated and the product extracted with DCM from DCM/sat'd NH4CI. The DCM extracts were dried over Na2SO4, filtered and the solvent evaporated to dryness to afford 1.55g white solid as a mixture of Compounds D4 and D5 (96% isolated yield): 1H NMR showed some residual CH3COOH, DCM and 4% byproduct Compound 34a.
Synthetic Example 49
Pd/C Catalyzed Diastereoselective Hydrogenation of Compound C3
Compound C3 (1.4 mmol, 0.6 g), 10% Pd/C ( 10% w/w to substrate on dry basis, 64.78% H2O, 130 mg), /-PrOH ( 1.5 mL) and Et3N ( 1.05 mmol, 0.145 mL) were loaded in a glass liner, which was placed in the hydrogenation reactor. The reactor was sealed, purged five times with nitrogen, five times with hydrogen without stirring and five times with hydrogen while stirring. The reaction mixture was stirred at 40 0C, 10 bar H2. After the reaction was complete, the reaction mixture was filtered and the Pd catalyst washed with 20 mL methanol. The solvent and Et3N were removed under high vacuum and the crude reaction mixture (0.6 g) was analyzed by HPLC and 1 H NMR. HPLC: full conversion, 1/1 Compound C4:Compound C5, 1 % byproduct Compound 33a. 1HNMR (CDCI3): 2% byproduct Compound 33a.
Synthetic Example SO (tf)-Me-BoPhoz&[Ir(COD)CI]2 Hydrogenation of Compound Cl
An [Ir(COD)Cl]2 adduct (0.002 mmol, 1 .3 mg) and (Λ)-Me-BoPhoz ligand (0.005 mmol, 3.1 mg) were loaded in a glass liner. Theliner was placed in a hydrogenation reactor which was sealed and purged with nitrogen. DCE (2mL, anhydrous, degassed) was injected via the injection port and the mixture stirred under nitrogen for 30 min at room temperature. After 30 min, 1 mL stock solution of Compound Cl in DCE was injected via the injection port (0.2 mmol/mL, 82 mg substrate stock solution was prepared under nitrogen, using anhydrous, degassed DCE), followed by the injection of 1 mL DCE (anhydrous, degassed). The resulting mixture was purged five times with hydrogen without stirring and five times with hydrogen while stirring. The reaction mixture was stirred at 70 0C, 25 bar H2 for 18 hrs. The crude reaction mixture was analyzed for conversion and e.e. by HPLC and showed 93% conversion and 93% e.e. in Compound C3. Synthetic Example 51 Esterification of Compound D2 to Compound Cl
Compound D2 (0.06 mmol, 0.025 g) was loaded in a 10 mL Schlenk tube. The tube was evacuated via three vacuum/nitrogen cycles, and 3 mL anhydrous MeOH and 0.5 mL anhydrous DCM were injected. The resulting solution was cooled in an ice-water bath and TMSCHN2 (0.18 mol, 0.09 mL 2 M solution in Et2O) was injected slowly. The solution was stirred while warming to room temperature (approximately 2 hrs). The solvent was removed under high vacuum and the resulting crude analyzed by 1HNMR and chiral HPLC, which showed full conversion to the methyl ester Compound C3. Synthetic Example 52
Esterification of Compound D3 to Compound C3
Compound D3 (0.10 g, 0.25 mmol) was dissolved in acetonitrile (9 mL) and treated with 1 -hydroxybenzotriazole (0.034 g, 0.25 mmol), dicyclohexylcarbodiimide (0.1 1 g, 0.53 mmol), and methanol (200 μL, 4.9 mmol) at rt. The reaction mixture was stirred for 4 hrs, filtered thru 0.45 μm filter, washed with acetonitrile (3 x 3 mL), concentrated in vacuo, and dissolved in dichloromethane. This solution was washed with saturated sodium bicarbonate solution (2 x 25 mL), water (2 x 25 mL), and brine (2 x 25 mL); dried over anhydrous sodium sulfate; filtered; and concentrated in vacuo. The resulting solid was dissolved in boiling heptane. The resulting suspension was reduced in volume (~ I mL), filtered and allowed to crystallize, yielding Compound C3 as a white solid (0.080 g, 77%), pure by LC/MS and 1H-NMR.
Synthetic Example 53
Preparation of 4-(3-methoxycarbonyl-2-quinolin-3-yl-allyl)- piperidine-1 -carboxylic acid tert-butyl ester Compound Cl To a 4 neck, 5 L flask, equipped with a Teflon-coated thermocouple, reflux condenser, mechanical stirrer, and a nitrogen inlet was charged the potassium salt of methyl malonate (320.9 g, 2.056 mol), MgCI2 (92.9 g, 0.976 mol), and THF (1 .25 L). The suspension was heated at 50 0C for 5 hrs, and cooled to rt.
To a separate three-neck 1 L flask, equipped with a mechanical stirrer, nitrogen inlet, teflon covered thermocouple, and septum, was added carbonyl diimidazole, (CDl, 333.4 g, 2.056 mol) portionwise over 10 min to a cooled solution of 4-carboxymethyl- piperidine-1 -carboxylic acid tert-butyl ester Compound Fl (250.0 g, 1.028 mol) in THF (1.25 L) at 0 0C. The mixture was allowed to warm to rt and stirred for 1.5 h to to provide an acylimidazole intermediate. The solution of the acylimidazole was transferred into the ambient temperature suspension of methyl malonate and MgCI2 and the resulting mixture was stirred for 12 h at rt. The resulting thick white suspension was diluted with EtOAc (1 L), transferred to a separatory funnel and washed twice with saturated NaHSO4 (2 L). The aqueous phases were combined and extracted with EtOAc (1 L). The combined organic extracts were washed twice with saturated NaHCO3 (500 mL). The combined bicarbonate extracts were back extracted with EtOAc (2 L) and the combined organic extracts were dried over Na2SO4, filtered, and concentrated under reduced pressure affording 290 g of crude product as a yellow oil which crystallized upon standing over 5 hrs. Purification by chromatography on silica gel (200-400 mesh, 1.25 kg, gradient elution with 4L of hexanes. 4 L of 20% EtOAc/hexanes, and 8 L of 40% EtOAc/hexanes) afforded the 4-(3- methoxycarbonyl-2-oxo-propyl)-piperidine-l -carboxylic acid /er/-butyl ester Compound F2 (272.1 g, 88%) as a pale-yellow oil which crystallized on standing.
1H NMR (300 MHz, CDCI3) δ 4.05 (br s, 2 H), 3.74 (s, 3 H), 3.43 (s, 2 H), 2.79- 2.65 (t, J = 12.4 Hz , 2 H), 2.47 (d, J = 6.7 Hz, 2 H), 2.10-1.95 (m, 1 H), 1.7- 1.6 (d, J = 12.7 Hz, 2 H), 1.44 (s, 9H), 1.18-1.02 (m, 2H); 13C NMR (75 MHz, CDCI3) (ppm) 201 .7, 167.7, 154.9, 90.4, 79.6, 52.6, 49.8, 49.6, 43.8, 42.3, 31.9, 31.7, 28.7; LC/MS (ES+) m/z 300.2 (M+ 1 ); Anal. Calcd for Ci5H25NO5: C, 60.18; H, 8.42; N, 4.68. Found: C, 60.32; H, 8.15; N, 4.59.
To a four-neck, 5 L flask equipped with a mechanical stirrer, Teflon-coated thermocouple, an addition funnel, and a nitrogen inlet, was charged sodium hydride (60% in mineral oil, 30.0 g, 0.752 mol) and toluene (450 mL). The suspension was cooled to an internal temperature of-5 0C and a solution of Compound F2 ( 150.0 g, 0.501 mol) in toluene ( 1200 mL) was added dropwise at such a rate as to maintain the internal temperature below -3 0C during the addition. Once addition was complete the mixture was aged for 40 min at 0 0C, followed by sequential dropvvise addition of diisopropylethylamine (436.3 mL, 2.505 mol), followed by trifluoromethanesulfonic anhydride ( 1 18.7 mL, 0.706 mol), maintaining the internal temperature below 5 0C during the addition. After the addition was complete, the mixture was allowed to warm to rt and stirred for 1 h. The mixture was cooled to 0 0C, quenched with saturated brine (1.5 L), diluted with EtOAc (1 L), and the two phases were separated. The organic extract was washed with water (1 L) followed by re-extraction of the combined aqueous phases with EtOAc (1 L). The combined organic extracts were dried over Na2SO4, filtered, and concentrated affording a (Z)-4-(3-methoxycarbonyl-2-trifluoromethanesulfonyloxy- allyl)-piperidine- 1 -carboxylic acid tert-butyl ester Compound F3 (287 g) as a red-brown oily solid. The material was judged satisfactory for use in the next reaction step by 1H NMR analysis. The signal for the vinyl proton appears at ~6.0 ppm in the E-isomer and at 5.88 ppm in the Z-isomer.
1H NMR (300 MHz, CDCI3) δ 5.88 (s, I H) 4.1 (br s, 2H), 3.78 (s, 3H), 2.61 -2.78 (t, J = 12.6 Hz, 2H), 2.31 (m, 2H), 1178 (m, I H), 1.65-1.77 (d, J = 12.8 Hz, 2H), 1.45 (s, 9H), 1.20 (m, 2H), 0.80- 1.30 (residual diisopropylethylamine); 13C NMR (CDCI3, 75 MHz) (ppm) 162.8, 157.0, 154.8, 1 13.2, 79.8, 54.9, 52.3, 41.9, 33.7, 31.7, 29.9, 28.6; HPLC Method A: (Phenomenex Jupiter: 5 urn, C- 18, 300 A, 4.6 x 250 mm, 29 0C) H2O)CH3CN 90: 10 to 10:90 in 15 min, hold at 90: 10 for 2 min. Flow rate: 1.5 mL min" 1, UV detection: 220 nm, H2O buffered with 0.025% TFA. Retention time: 15.39 min.
To a suspension of quinoline-3-boronic acid ( 130.0 g, 0.752 mol), Compound F3 (216.1 g, 0.501 mol) and bistriphenylphosphine palladium dichloride ( 17.5 g, 0.025 mol) in THF ( 1 .2 L) was added 2 M Na2CO3 ( 160 mL, 0.32 mol). The mixture was heated to 40 0C and monitored for completion by HPLC analysis. After 7 hrs the reaction was judged complete (>97% conversion by HPLC) and the mixture was filtered and diluted with EtOAc (1 L). The mixture was washed with NaHCO3 (2 x 2 L) and 0.5 M NaOH (2 x 2 L). The combined aqueous phases were extracted with EtOAc (1 L) and the combined organic extracts were dried over Na2SO,), filtered and concentrated under reduced pressure and afforded a crude brown oil (200 g). Purification by chromatography on silica gel (1 kg, 70-230 mesh, gradient elution with 4 L of hexanes, 4 L of 10% EtOAc/hexanes, 2 L of 40% EtOAc/hexanes, and 100% EtOAc afforded a dark brown oily solid. The oily solid was triturated with hexanes (150 mL) and collected by filtration affording the title Compound Cl, which was 96% pure by HPLC analysis (139.1 g, 67%, mp 1 19-124 0C). NMR analysis indicated lower purity in the aromatic region (15% impurity). The olefin was the Z-isomer as determined by nuclear
Overhauser effect (nθe) studies (Z-isomer vinyl proton resonance at 6.05 ppm, E-isomer at 6.28 ppm).
1H NMR (300 MHz, CDCI3) 5 8.71 (d, J= 2.2 Hz, I H), 8.10 (d, J = 8.4 Hz, I H), 7.96 (d, J = 2.2 Hz, I H), 7.81 (d, J= 8.4 Hz, I H), 7.72 (td, J = 7.0, 1.3 Hz, I H), 7.56 (td, J= 7.0, 1.3 Hz, IH), 6.05 (s, I H), 4.01 (br s, 2H), 3.47 (s, 3H), 2.59 (br s, 2H), 2.51 (d, J = 7.0 Hz, 2H), 1.70-1.60 (m, 2H), 1.42 (s, 10 H), 1 .20-1.03 (m, 2H); 13C NMR (CDCI3, 75 MHz) (ppm) 165.89, 154.91 , 154.19, 149.97, 147.72, 133.81 , 132.68, 129.95, 129.56, 128.23, 127.14, 120.33, 51.53, 47.74, 44.0 (br), 34.00, 32.10, 28.64; HPLC Method A: retention time: 1 1 .21 min; LC/MS (ES+) m/z 41 1 .2 (M+ 1 ); Anal. Calcd for C24H30N2O4: C, 70.22; H, 7.37; N, 6.82. Found: C, 69.87; H, 7.56; N, 6.58.
Synthetic Example 54 HPLC Identification of Compounds C4, C5, 54a and 54b
Figure imgf000160_0001
54a, (αR.βS) isomer 54b, (αR,βR) isomer
A racemic mixture of Compounds C4, C5, 54a and 54b (323 g, 0.775 mol) was purified by sequential chiral chromatography. The elution order using a Chiralpak AD® column is reversed when using a Chiralcel OD column. The racemic mixture eluted as a 1/1/1/1 ratio of Compounds 54b, 54a, C5 and C4.
Compound 54b and Compound C5 were separated from Compound 54a and Compound C4, using a Chiralcel OD® column ( 1 10 mm I. D. dynamic axial compression (DAC) column filled with 2000 g of 20 μm Chiralcel OD® (Daicel); temperature of eluent: 28 °C; column wall temperature: 30 0C; eluent: methanol; flow rate: 750 mL/min). The sample was prepared by dissolving the racemic mixture (5.8 g) in 200 mL of the eluent (29 mg/mL) and injected at a rate of 3.6 runs per hour (20.9 g of the mixture per hour). The purification was complete after 15 h of continuous chromatography (56 injections).
Compound 54a was separated from Compound C4 using a Chiralpak® AD column (1 10 mm l.D. DAC filled with 2000 g of Chiralpak AD®; temperature of eluent: 38 0C; temperature of column wall: 40 0C; eluent: acetonitrile (750 mL/min), ethanol (rinsing plug); injection amount: 4 g/ 250 mL of eluent; capacity: 3.5 runs/h at 14 g/h).
From this procedure there was isolated Compound C4 (65 g; 20% yield; 96.1% pure by chiral HPLC; 0.68, 1 .87, 1 .35 % of Compounds C5, 54a and 54b, respectively) was isolated. Samples of the other fractions were also obtained in similar purity, but no attempt was made to maximize the quantity of them in this purification. Chiral HPLC Method A: Chiralpak AD®: (5 μm, 150 mm x 4.6 mm), isocratic ethanol, ambient, flow rate: 1 .0 mL min" 1, UV detection: 254 nm, retention times: Compounds 54b, 54a, C5 and C4, 5.5 min, 6.0 min, 7.5 min and 8.5 min, respectively.
Synthetic Example 55
Preparation of Dihydrochloride Salt Compound C6 by HCI Deprotection of Compound C4
Figure imgf000161_0001
A 3-L three-neck round bottom flask, equipped with magnetic stirrer and argon inlet, was charged with Compound C4 (55.22 g, 33 mmol), methoxybenzene (1.44 mL, 13.3 mmol), and 1 ,4-dioxane (880 mL). The mixture was treated with 4 M hydrogen chloride in dioxane (883 mL, 3.53 mol) to give a clear solution that became hazy and deposited a thick red oil that was difficult to stir. A spatula was used to loosen the red oil. After 4 hrs, additional 4 M HCI/dioxane (90 mL, 0.36 mol) was added and the reaction stirred for an additional 7 h until complete by LC/MS. The solvent was removed in vacuo at 45 0C to afford a solid that was triturated with ethyl ether ( I L), collected by filtration, and washed with ethyl ether (= 0.5-1 L). The isolated light pink solid was dried in vacuum oven (55-60 0C) for 6 h to give (3S,3'-S)-4-piperidin-4-yl-3-( 1 ,2,3,4- tetrahydroquinolin-3-yl)-butyric acid methyl ester dihydrochloride salt Compound C6 (50.87 g, 98%).
1 H NMR (300 MHz, DMSO-D6) δ 7.2-6.8 (m, 4H), 3.58 (s, 3H), 3.33-3.21 (m, 3H), 3.0-2.4 (m, 6H), 2.33-2.26 (m, I H), 2.04 (m, 2H), 1 .82-1.76 (m, 2H), 1.59 (m, I H), 1.4- 1.1 (m, 4H); HPLC (Thermo Betabasic®-C-I 8, 4.6 x 150 mm, ambient, H2OiCH3CN 95:5 to 5:95 in 12 min, H2O and acetonitrile buffered with 0.1 % TFA, flow rate: 1.5 mL min" 1, UV detection: 210 nm, 254 nm) >99% area, retention time: 4.85 min: ; LC/MS (ES+) m/z 317.3 (M+ 1 ); Anal. Calcd for C9H28N2O2^ HCI-0.35 H2O-0.60 C4H,0O: Q. 57.30; H, 7.98; N, 6.24; Cl, 15.81 . Found: C, 56.94; H, 8.13; N, 6.70; Cl, 15.77. Karl Fisher Titration Calcd: 1.41 %. Found: 1.39 % (w/w).
Synthetic Example 56 Preparation of Compound C7
Figure imgf000162_0001
A 200 mL single neck round bottom flask equipped with magnetic stirrer and argon inlet, was charged with a slurry/solution of (35,3'5)-4-piperidin-4-yl-3-(l , 2,3,4- tetrahydroquinolin-3-yl)-butyric acid methyl ester dihydrochloride salt Compound C6 (29.5 g, 75.8 mmol), acid Compound C7 (20.23 g, 83.3 mmol), 1 -hydroxybenzotriazole hydrate (5.89 g, 37.9 mmol) and dimethylformamide (295 mL). The reaction mixture was purged with an argon stream ( 15-20 min) and chilled in an ice bath and l -(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI, 15.98 g, 83.3 mmol) was added in one portion. Diisopropylethylamine (39.64 mL, 227 mmol) was added in a dropwise fashion. The reaction mixture was stirred for 60 min, removed from ice/water bath, and stirred at rt for 17 hrs until the reaction was complete. The reaction mixture was poured into saturated sodium bicarbonate (3 L) andextracted with ethyl acetate (4 x 750 mL). The combined organic phases were washed with saturated ammonium chloride (2 x 500 mL) and brine (3 x 500 mL), dried (MgSO4 and Na2SO4) and concentrated to give crude amide product (35.4 g). The crude product was dissolved in dichloromethane and loaded onto an Analogix® column (2 runs - SiO2 - 220 g) and eluted (linear gradient, dichloromethane to 1 :6:3:90 NH4OH/IPA/EtOH/dichloromethane) to give a crude Compound C8 (4.1 g), followed by pure Compound C8 (31.7 g). The mixed fractions were dissolved in dichloromethane and loaded onto an Isco® column (SiO2 - 120 g) and eluted (linear gradient, dichloromethane to 1.5:6:3:89.5
NH4θH/IPA/EtOH/dichloromethane) to give additional product (2.7 g). The product from each purification was combined and concentrated from chloroform to provide the title Compound C8 (34.4 g, 83% yield).
1H NMR (300 MHz, DMSO-D6) δ 7.00 (m, IH), 6.84-6.80 (m, 2H), 6.42-6.38 (m, 2H), 6.28-6.23 (m, 2H), 5.60 (br s, I H), 4.35 (br d, J= 13 Hz, I H), 3.82 (br d, J = 13 Hz, I H), 3.59 (s, 3H), 3.3-3.1 (m, 3H), 3.0-2.8 (m, 2H), 2.7-2.4 (m, 10H), 2.29-2.27 (m, I H), 1.98 (m, I H), 1.8-1.4 (m, 6H), 1.30 (m, I H), 1.14 (m, I H), 0.88 (m, 2H); HPLC: (Agilent Eclipse® XDB-C 18, 3.0 x 150 mm, 45 0C, A:B 85: 15 to 15:85 in 27 min, (A) 1 O mM ammonium acetate/H2O (B) 10 mM ammonium acetate/(H2θ:acetonitrile, 1 :9, flow rate: 0.6 mL min" 1, UV detection: 220 - 400 nm), >99% area, retention time: 21.3 min: LC/MS (ES+) m/z 505.4 (M+ 1 ); Anal. Calcd for C30H40N4O3-O^ CHCI3-0.25 H2O: C, 65.56; H, 7.40; N, 10.06; Cl, 7.64. Found: C, 65.70; H, 7.42; N, 10.09; Cl, 7.89; residue after ignition: < 0.10%; Karl Fisher Titration Calcd: 0.81 %. Found: 0.87 % (w/w). Synthetic Example 57
(3S,3'S)-4-[ 1 -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-3-( l ,2,3,4-tetrahydroquinolin-3-yl)- butyric acid Formula (Ia)
Figure imgf000164_0001
A I -L one-neck round bottom flask, equipped with magnetic stirrer and argon inlet, was charged with Compound C8 (34.44 g, 62.8 mmol), methanol ( 138 mL, 3.40 mol), and 3 M sodium hydroxide solution (62.8 mL, 188 mmol). Argon was bubbled through the mixture to remove oxygen (30 min) and the reaction mixture was stirred at rt ( 18 hrs) and then concentrated to remove methanol. The oily aqueous residue was diluted with water (700 mL) and the pH was adjusted to 6.5 with 2 M hydrochloric acid (~2 N, ~ l 00 mL) and sodium hydroxide ( 1 N) to give a white slurry. The slurry was extracted with dichloromethane (3 x 300 mL). The resulting turbid solution of combined organics was diluted with THF, dried (Na2SO4) and concentrated to give the title compound of Formula (Ia) (34.7 g, 97%) mixed with THF (-0.75 eq).
1 H NMR (300 MHz, DMSO-D6) δ 7.05 (d, J = 7 Hz, I H), 6.84-6.80 (m, 2H), 6.43-6.37 (m, 2H), 6.29 (d, J = 7 Hz, I H), 5.63 (br s, I H), 4.35 (br d, J = 13 Hz, I H), 3.82 (br d, J = 13 Hz, 1 H), 3.2-3. 1 (m, 3H), 3.0-2.8 (m, 2H), 2.7-2.4 (m, 9H), 2.34-2.1 3 (m, 2H), 1 .97 (m, I H), 1 .8- 1 .4 (m, 6H), 1 .19 (m, I H), 1 .14 (m, I H), 0.87 (m, 2H); HPLC (Agilent Eclipse® XDB-C 1 8, 3.0 x 1 50 mm, 45 0C, A:B 85: 15 to 15:85 in 27 min, (A) 10 mM ammonium acetate/H2θ (B) 10 mM ammonium acetate/(H2θ:acetonitrile, 1 :9, flow rate: 0.6 mL min' 1 , UV detection: 220 - 400 nm), >98% area, retention time: 1 1 .9 min; LC/MS (ES+) m/z 491 .2 (M+ 1 ); Anal. Calcd for C29H38N4O3-OJS THF-0.05 DCM - 0.45 H2O: C, 69.10; H, 8.14; N, 10.06; Cl, 0.64. Found: C, 68.73; H, 7.68; N, 9.85; Cl, 0.65. Residue after Ignition: <0.10 %. Karl Fisher Titration Calcd: 1 .46%. Found: 1 .28 % (w/w). Synthetic Example 58
(3S,3'S)-4-[ 1 -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-3-( l ,2,3,4-tetrahydroquinolin-3-yl)- butyric acid hydrochloride salt Formula (Ia) The compound of Formula (Ia) (41.15 g, 74.85 mmol) was dissolved in water
(617 mL), I M aqueous hydrogen chloride ( 15O mL, 1 50 mmol), and acetonitrile (93 tτ)L). The resulting solution was syringe filtered (0.45 μm, Nylon) into six-600 mL lyophilization bottles and frozen. These bottles were lyophilized for 5 days to give the desired compound of Formula (Ia) as an HCI salt (40.5 g, 92%) mp 146- 148 0C (decomposition); HPLC (Agilent Eclipse® XDB-C I 8, 3.0 x 150 mm, 45 0C, A:B 95:5 to 25:75 in 27 min, (A) 10 mM ammonium acetate/H2O (B) 10 mM ammonium acetate/(H2O:acetonitrile, 1 :9), flow rate: 0.6 mL min 1, UV detection: 220 - 400 nm), >98% area, retention time: 1 5.9 min: LC/MS (ES+) m/z 491.2 (M+ 1 ); Anal. Calcd for C29H38N4O3^.2 HCI- I H2O: C, 59.15; H, 7.22; N, 9.51 ; Cl, 13.25. Found: C, 59.55; H, 7.47; N, 9.55; Cl, 13.75. Residue after Ignition: <0. 10 %. Karl Fisher Titration Calcd: 3.06%. Found: 3.36 % (w/w).
Additional Data for Chiral HPLC analysis for Compound C3 Chiral HPLC Method B: Chiralpak AD-H: (4.6 x 250 mm), isocratic hexane:IPA 80:20, 23 0C, flow rate: 1 .0 mL min' 1, UV detection: 254 nm, retention time: 16.5 min for Compound C3, 26.6 min for 7?-isomer Compound C2, 9 min for Compound Cl .
Additional NMR and Optical Rotation Data for Compound C3 1H NMR (300 MHz, CDCI3) δ 8.80 (s, I H), 8. 10 (m, I H), 7.90 (m, I H), 7.80 (m, I H), 7.70 (m, I H), 7.50 (m, 1 H), 4.00 (m, 2 H), 3.55 (s, 3H), 3.45 (m, 2H), 2.70 (m, I H), 2.50 (m, 2H), 1.80 (m, 2H), 1.60 (m, 1 H), 1 .40 (s, 9H), 1 .3-1 .0 (m, 4H); LC/MS (ES+) m/z: 413.25 (M+ 1 ); Anal. Calcd for C24H32N2O4-O^ H2O: C, 69.27; H, 7.85, N, 6.73. Found: C, 69.08; H, 7.72; N, 6.35; [α]D 23 = -23.18 °, c 0.48, MeOH. Synthetic Example 59
(R)-Me-BoPhoz/[Rh(ethylene)2CI]2 Hydrogenation of Compound Cl
A (7?)-Me-BoPhoz ligand (6.7 mg, 0.01 1 mmol) and a [Rh(ethylene)2CI]2 metal addiict ( 1.9 mg, 0.005 mmol) were loaded in a glass liner, which was placed in the hydrogenation reactor. The reactor was sealed and purged with nitrogen. Dichloroethane (DCE, I mL, anhydrous, degassed) was injected via the injection port and the mixture stirred under nitrogen for 30 min at rt to form in situ the (R)- Me-BoPhoz/[Rh(ethylene)2CI]2 complex (0.01 mmol, S/C 100/1 ). After 30 min, Compound Cl (410 mg, 1 mmol) in DCE (4 mL) was injected via the injection port. The substrate stock solution was prepared under nitrogen, using anhydrous, degassed DCE. The resulting mixture was purged five times with hydrogen without stirring and five times with hydrogen while stirring. The reaction mixture was stirred at 60 0C, 30 bar H2 for 16 hrs. The crude reaction mixture was analyzed for conversion and ee by chiral HPLC Method B and showed 97% conversion and 93% e.e. in Compound C3. Chiral HPLC Method B: Chiralpak AD-H (4.6 x 250 mm), isocratic hexane:lPA 80:20, 35 0C, flow rate: 1.0 mL min" 1, UV detection: 210 and 254 nm, retention times: 13.2 min for Compound C3, 25.9 min for the 7?-isomer Compound C2, 9.6 min for Compound Cl. Flash chromatograph (2 cm diameter, 30-35% ethyl acetate in heptane) afforded pure Compound C3 (276 mg, 67%) by NMR and LC/MS.
Synthetic Example 60 Re-aromatization of Compound C4 to Compound C3
Figure imgf000166_0001
A solution of Compound C5 (21.6 g, 51 .9 mmol) was dissolved in dry toluene (420 mL) and 10% Pd/C (1 1.3 g) was carefully added. The reaction was brought to a gentle reflux under air. The reaction was refluxed for 6 h and left overnight at room temperature. After another 5 h of reflux, additional 10% Pd/C (2.0 g) was added as a slurry in toluene (20 mL). The reaction mixture was refluxed for an additional 1 h, left at rt overnight, filtered through Celite®, washed several times with toluene, and evaporated. The resulting yellow oil was solidified upon evaporation over the weekend to give an off- white solid ( 19.4 g) (85-90% pure by NMR and LC). The solid was recrystallized once from heptane (100 m L) to give Compound C3 (15.8 g, 74%, mp 90-102 0C) as an off- white solid. Chiral HPLC (Chiralpak AD-H (4.6 x 150 mm), isocratic hexane:IPA 80:20, 35 0C, flow rate: 1 .0 mL min" 1, UV detection: 210 and 254 nm, retention times: 7 min for Compound C3, 10 min for /?-isomer Compound C2, 5.5 min for Compound Cl): 99% Compound C3, 0.56% ^-isomer Compound C5; Anal. Calcd for C24H32N2O4: C, 69.88; H, 7.82, N, 6.79. Found: C, 69.87; H, 7.98; N, 6.79. Palladium 169 ppm by ICP.
Synthetic Example 61 Achiral Hydrogenation of Compound C3
Figure imgf000167_0001
A sample of Compound C3 (48 mg, 0.12 mmol), water (90 mg), and 10% palladium on carbon (50 mg) in methanol was hydrogenated in a Parr apparatus at 53 psig for 28 hrs. After filtration through Celite® and evaporation, the residue was purified on silica gel (elution with 30% ethyl acetate and (0.1% triethylamine in heptane) yielding Compound C4 and Compound C5 (35 mg, 70%), as a mixture of isomers. HPLC Analysis was performed using Chiral HPLC Method A showing 45% of Compound C5 and 45% of Compound C4.
Synthetic Example 62
Preparation of Compound Gl Camphanic Amide from Compound C5 for X-ray Determination of Absolute Configuration of
Structure
Figure imgf000168_0001
Figure imgf000168_0002
( IS)-(-)-camphanoyl chloride
62a, (αS,βR) isomer
Figure imgf000168_0003
A bis-(-)-(S)-camphanic acid amide Compound Gl of (2.S,3'/?)-4-Piperidin-4-yl- 3-( r,2',3',4'-tetrahydroqιιinolin-3'-yl)-butyric acid ethyl ster (C5) was prepared by the following procedure:
(25,3'Λ)-4-Piperidin-4-yl-3-( r,2',3',4'-tetrahydroquinolin-3'-yl)-butyric acid methyl ester Compound C5 (4.50 g, 10.8 mmol) was dissolved in dioxane (45 mL), and treated with anisole (few drops) and 4 N hydrogen chloride in dioxane (45 mL). After 2 hrs, the reaction mixture was evaporated to give a crude solid (4.5 g). A portion of the solid (2.9 g) was partitioned between saturated sodium carbonate solution (25 mL) and ethyl acetate (25 mL). The organic layer was dried (IsIa2SO*)) and evaporated to yield (S)- methyl 4-(piperidin-4-yl)-3-((R)- l ,2,3,4-tetrahydroquinolin-3-yl)butanoate Compound 62a (2.06 g, 93%, LC/MS: consistent).
Compound 62a (162 mg, 0.51 mmol) was dissolved in dichloromethane ( I O mL) under nitrogen and treated with triethylamine (0.21 mL, 1 .5 mmol) and (-)-(S)-camphanic acid chloride (277 mg, 1 .28 mmol) at 0 0C and stirred for 1.5 hrs. The reaction mixture was poured into saturated sodium bicarbonate solution (25 mL), extracted with dichloromethane (3 x 25 mL), washed with brine (25 mL), dried (MgSO<i) and evaporated. The residue was dissolved in dichloromethane and applied to a flash column (2 cm diameter, gradient elution with 30-35% ethyl acetate in heptane) affording the bisamide Compound Gl as a colorless oil, which later turned to a solid (234 mg, 68%).
LC/MS (ES+) m/z 611.0 (M+ 1 ); 1 H NMR (300 MHz, CDCI3) δ 7.2-7.1 (m, 4 H), 4.6-4.2 (m, 3H), 3.67 (s, 3H), 3.2-2.8 (m, 3H), 2.6- 1 .6 (m, 14H), 1 .22 (s, 3H), 1 .18 (s, 3H), 1.10 (s, 6H), 1 .00 (s, 6H), 1.5-0.8 (m, 5H), 0.88 (t, J = 7 Hz, 2H); Anal. Calcd for C39H52N2O8: C, 69.21 ; H, 7.74, N, 4.14. Found: C, 69.44; H, 7.94; N, 4.02. A small sample of Compound Gl (23 mg) was dissolved in methanol (3 mL) and water was added dropwise until just cloudy. A small amount of methanol was added to clarify and the sample was left to slowly evaporate with a slightly vented aluminum foil cap. When the first solid came out after I day, methanol was added to dissolve again and the evaporation was repeated. Crystals formed after 5 days (mp 122- 1 32 0C), and were examined by single-crystal X-ray diffraction.
Synthetic Example 63 Preparation of Compound Dl from Compound Cl
Compound Cl ( 16.67 g, 40.6 mmol, >99% Z-isomer by NMR) was dissolved in THF (48 mL) and methanol (64 mL). To this solution was added LiOH (8.2 g, 200 mmol) dissolved in water (64 mL). The mixture was stirred at room temperature for 1 .5 hrs. The progress of the reaction was monitored by HPLC. The reaction was quenched with 1 M HCI (95% of theory, 190 mL) to pH 7 on litmus paper, and concentrated on a rotary evaporator at 27 0C. A final amount of 1 M HCI was added ( 10 mL) with stirring and the solid was collected by filtration, washed with water (2x50 mL) to afford the acid, which was air-dried, then vacuum dried (60 0C) overnight. The brown solid ( 15 g) was an E/Z mixture of ~10:90 by HPLC. This material was recrystallized from isopropanol (200 mL) by heating to reflux to dissolve the material, allowing the material to cool to ambient temperature and aging for 1 -2 h. The white solid was isolated by filtration and washed with ice cold IPA to afford Compound Dl ( 10.96 g, 68%, m.p. 21 5.9-216.9 0C). The compound was 98.3% pure Z-isomer by HPLC (R1 6.868 min). The (E)-isomer was present ( 1.62% at R1 6.654 min) (HPLC conditions: Agilent Eclipse, 5 urn, C-8, 4.6 mm x 150 mm , CH3CN:H2O, 0.1 % TFA gradient elution from 10:90 to 90: 10 in 12 min, hold 90: 10 for 2 min., flow 1 .3 mL/min, UV at 254 nm.
5 LC/MS (ES+) m/z 397 (M+ 1 ); 1H NMR (300 MHz, CDCI3) δ 8.76 (d, J = 2.1 Hz,
1 H), 8.02 (m, 1 H), 7.82 (d, J = 8.1 Hz, 1 H), 7.67 (t, J = 7.2 Hz, 1 H), 7.55 (t, J = 7.5 Hz, I H), 6.35 (br s, I H), 6.09 (s, I H), 4.00 (br m, 2H), 2.51 (m, 4H), 1 .61 (d, J = 12.6 Hz, 2H), 1 .43 (m, 10H), 1 .13 (m, 2H); 13C NMR (300 MHz, CDCI3) ppm 168.1 , 154.7, 152. 1 , 149.7, 146.0, 134.4, 132.7, 128.0, 127.9, 127.5, 127. 1 , 121 .5, 79.4, 47.1 , 43.5, 10 33.9, 31 .8, 28.4; Anal. Calcd for C23H28N2O4: C, 69.67; H, 7. 12, N, 7.07. Found: C, 69.63; H, 7.19; N, 7.06. Palladium: 74 ppm by ICP, ash <0. 1 %.
While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, it will be understood that the practice of the invention encompasses all of the usual variations, adaptations and I 5 modifications as come within the scope of the following claims and their equivalents.
Throughout this application, various publications are cited. These publications are hereby incorporated by reference in their entirety into this application to describe more fully the state of the art to which this invention pertains.

Claims

What is claimed is:
A process for preparing a compound of Formula (1) and Formula (II):
Figure imgf000171_0001
Formula (I) Formula (II) wherein α represents a chiral carbon chain atom;
W is selected from the group consisting of -Co-6alkyl(Rι), -C|.6alkyl(R|a),
-Co.6alkyl-aryl(Rι,R8), -Co.6alkyl-heterocyclyl(R|,R8), -Co^alkoxy(Rι), -Co-6alkoxy-aryl(R|,R8), and -Co-6alkoxy-heterocyclyl(R|,R8),
Ri is selected from the group consisting of hydrogen, -N(R4):, -N(R4)(R5), -N(R4)(R6), -heterocyclyl(Rg) and -heteroaryl(R8);
Rιa is selected from the group consisting of -C(R4X=N-R4), -C(=N-R4)-N(R4)2, -C(=N-RJ)-N(R4)(R6), -C(=N-R4)-N(R4)-C(=O)-R4,
Figure imgf000171_0002
-C(=N-R4)-N(R4)-CO2-R4, -C(=N-R4)-N(R4)-SO2-Ci.8alkyl(R7) and -C(=N-R4)-N(R4)-SO2-N(R4)2;
R4 is selected from the group consisting of hydrogen and -C|.8alkyl(R7);
Rs is selected from the group consisting of -C^O)-R4, -C(=O)-N(R4)2,
-C(=O)-cycloalkyl(R8), -C(=O)-heterocyclyl(R8), -C(=O)-aryl(R8), -C(=O)-heteroaryl(R8), -C(=O)-N(R4)-cycloalkyl(R8), -Cl=O)-N(R4)^yI(R8), -CO2-R4, -CO2-cycloalkyl(R8), -CO2-aryl(R8), -C(R4X=N-R4), -C(=N-R4)-N(R4)2, -C(=N-R4)-N(R4)(R6), -C(=N-R4)-N(R4)-C(=O)-R4, -C(=N-R4)-N(R4)-C(=O)-N(R4)2, -C(=N-R4)-N(R4)-CO2-R4, -C(=N-R4)-N(R4)-SO2-C|.8alkyl(R7), -C(=N-R4)-N(R4)-SO2-N(R4)2, -N(R4K(R4X=N-R4), -N(R4)-C(=N-R4)-N(R4)2, -N(R4)-C(=N-R4)-N(R4)(R6), -N(R4)-C(=N-R4)-N(R4)-C(=O)-R4,
-N(R4)-C(=N-R4)-N(R4)-C(=O)-N(R4)2, -N(R4)-C(=N-R4)-N(R4)-CO2-R4, -N(R4)-C(=N-R4)-N(R4)-Sθ2-C|.salkyl(R7), -N(R4)-C(=N-R4)-N(R4)-SO2-N(R4)2, -SO2-C|.8alkyl(R7), -SCVN^h,
-SO2-cycloalkyl(R8) and -SO2-aryl(R8); Rδ is selected from the group consisting of -cycIoalkyl(Rs), -heterocyclyl(R8),
-aryl(Rs) and -heteroaryl(R8); R7 is one to two substituents independently selected from the group consisting of hydrogen, -C|.8alkoxy(R9), -NH2, -NH-C,.8alkyl(R9), -N(C|.8alkyl(R9))2,
-C(O)H1 -C(O)-C|.8alkyl(R9), -C(O)-NH2, -C(=O)-NH-C|.8alkyl(R9), -C(O)-N(C,.8alkyl(R9))2, -C(O)-NH-aryl(R,0), -C(0)-cycloalkyl(R,0), -C(=0)-heterocyclyl(R,o), -C(=0)-aryl(Rιo), -C(=O)-heteroaryl(R,0), -CO2H, -CO2-C1.salkyl(R9), -CO2-aryl(R,0), -C(^NH)-NH2, -SH, -S-C,.8alkyl(R9), -S-C|.salkyl-S-C,.8alkyl(R9); -S-C,.8alkyl-C,.8alkoxy(R9);
-S-C|.salkyl-NH-C|.8alkyl(R9), -SO2-C|.8alkyl(R9), -SO2-NH2, -SO2-NH-C|.8alkyl(R9), -SO2-N(C|.8alkyl(R9))2, -SO2-aryl(R|0), cyano, (halo)|.3, hydroxy, nitro, oxo, -cycloalkyl(Rιo), -heterocyclyl(Rιo), -aryl(Rιo) and -heteroaryl(Rιo); R8 is selected from the group consisting of hydrogen, -C|.salkyl(R9), -C(=O)H,
-C(O)-C|.8alkyl(R9), -C(O)-NH2, -C(=O)-NH-C,.8alkyl(R9), -C(0)-N(C,.8alkyl(R9))2, -C(0)-NH-aryl(R,o), -C(0)-cycloalkyl(R10), -C(0)-heterocyclyl(Rio), -C(0)-aryl(R,o), -C(0)-heteroaryl(R,o), -CO2H, -CO2-C,.8alkyl(R9), -CO2-aryl(R,0), -C(=NH)-NH2, -SO2-C|.8alkyl(R9), -SO2-NH2, -SO2-NH-C,.8alkyl(R9),
-SO2-N(C|.8alkyl(R9))2, -SO2-aryl(R|0), -cycloalkyl(R,0) and -aryl(R,0) when attached to a nitrogen atom; and, wherein R8 is one to four substituents independently selected from the group consisting of hydrogen, -C|.8alkyl(R9), -C|.8alkoxy(R9), -O-cycloalkyl(Rιo), -O-aryl(Rιo), -C(O)H, -C(O)-C,.8alkyl(R9),
-C(O)-NH2, -C(O)-NH-C|.8alkyl(R9), -C(=O)-N(C,.8alkyl(R9))2, -C(=0)-NH-aryl(R|0), -C(-0)-cycloalkyl(Rio); -C(=0)-heterocyclyl(Rio); -C(=O)-aryl(R|0), -C(=O)-heteroaryl(R,0), -CO2H, -Cθ2-C|.8alkyl(R9), -C02-aryl(R,o), -Q=NH)-NH2, -SO2-Ci.8alkyl(R9), -SO2-NH2, -SO2-NH-C|.8alkyl(R9), -SO2-N(C|.8alkyl(R9))2) -S02-aryl(R,o), -SH, -S-C|.8alkyl(R9), -S-C|.8alkyl-S-Ci.8alkyl(R9), -S-C|.8alkyl-C|.8alkoxy(R9),
-S-C|.8alkyl-NH-C,.8alkyl(R9), -NH2, -NH-C,.8alkyl(R9), -N(C|.galkyl(R9))2, cyano, halo, hydroxy, nitro, oxo, -cycloalkyl(Rιo), -heterocyclyl(Rιo), -aryl(Rιo) and -heteroaryl(Rιo) when attached to a carbon atom; R9 is selected from the group consisting of hydrogen, -C|_salkoxy, -NH2,
-NH-C,.8alkyl, -N(C|.8alkyl)2, -C(=O)H, -Q=O)-NH2, -C(=O)-NH-C,.8alkyl, -Q=O)-N(C,.8alkyl)2, -CO2H, -COs-Csalkyl, -SO2-C, .salkyl, -SO2-NH2, -SO2-NH-C ,.salkyl, -SO2-N(C,.8alkyl)2, cyano, (halo)ι-3, hydroxy, nitro and oxo; Rio is selected from the group consisting of hydrogen, -Ci-salkyl, -Q=O)H,
-C(=O)-C|.8alkyl, -C(=0)-NH2, -C(=O)-NH-C,.salkyl, -C(=O)-N(C|.salkyl)2, -CO2H, -CO2- C,.4alkyl, -SO2-C|.8alkyl, -SO2-NH2, -SO2-NH-Ci_salkyl and -SO?-N(C|.8alkyl)2 when attached to a nitrogen atom; and, wherein Rio is one to four substituents independently selected from the group consisting of hydrogen, -C|.8alkyl, -C|.8alkoxy, -C(=0)H, -C(=O)-C,.8alkyl, -Q=O)-NH2, -Q=O)-NH-C|.8alkyl, -Q=O)-N(C,.8alkyl)2, -CO2H, -CO2- C,.4alkyl, -SO2-C,.salkyl, -SO2-NH2, -SO.-NH-Csalkyl, -SO2-N(C ,.8alkyl)2, -NH2, -NH-C,.8alkyl, -N(C|.8alkyl)2, cyano, halo, hydroxy, nitro and oxo when attached to a carbon atom; R2 is selected from the group consisting of -cycloalkyl(R8), -heterocyclyl(Rg),
-aryl(R8) and -heteroaryl(R8), wherein β represents a chiral carbon ring member atom of -cycloalkyl(R8) and -heterocyclyl(Rs); q is O, 1 ,
2 or 3; and Z is selected from the group consisting of hydroxy and -O-Ci.galkyl; comprising the steps of:
Step 1 . reacting a Compound Al, wherein PG is a C|_4alkoxycarbonyl protecting group such as Boc, with a first hydrogen source, a first ligand-metal complex consisting essentially of a first ligand conjugated with a first metal adduct, in a first solvent in the presence of an optional first additive at an elevated first temperature and an elevated first pressure to provide a substantially pure Compound A2 or a substantially pure Compound A3:
Figure imgf000174_0001
.
Step 2. optionally converting Compound A2 or Compound A3, each wherein Z is hydroxy, to a Compound A2 or Compound A3, each wherein Z is -O-Csalkyl;
Step 3. optionally hydrogenating Compound A2 or Compound A3, wherein R2 is selected from the group consisting of -aryl(Rg) and -heteroaryl(Rs), with a second hydrogen source and a hydrogenation agent in a second solvent at an elevated second temperature and an elevated second pressure to provide an isomericmixture comprising a Compound A4, Compound A5, Compound A6 and Compound A7, wherein R2 is selected from the group consisting of -cycloalkyl(R8) and -heterocyclyl(Rs):
Figure imgf000175_0001
A6, (αS, βS) isomer
A7, (αS, βR) isomer . and Step 4. when any of Compound A4, Compound A5, Compound A6 or
Compound A7, wherein Z is hydroxy, are present, converting each such compound into the corresponding Compound A4, Compound A5, Compound A6 or Compound A7, wherein Z is -0-Cι.salkyl; Step 5. separating each of Compound A2, Compound A3, Compound A4, Compound A5, Compound A6 and Compound A7, each wherein Z is
-O-Cι-8alkyl, from the isomeric mixture;
Step 6. deprotecting the compound selected from Compound A2 to Compound A7, each wherein Z is -O-C|.8alkyl, to provide a corresponding compound respectively selected from Compound A8 to a Compound A13:
A2, (αR) isomer A3, (αS) isomer A4, (αR.βR) isomer A5, (αR.βS) isomer A6, (αS.βS) isomer
Figure imgf000176_0001
A7, (αS.βR) isomer AlO, (αR.βR) isomer Al l , (αR.βS) isomer A12, (αS.βS) isomer A13, (αS,βR) isomer .
Step 7. reacting the compound selected from Compound A8 to Compound A13, each wherein Z is -0-Cι-salkyl, with a Compound A14 to provide a corresponding compound respectively selected from Compound A15 to a Compound A20 of Formula (I):
A8, (αR) isomer A9, (αS) isomer AlO, (αR,βR) isomer Al l , (αR,βS) isomer
Figure imgf000176_0002
A12, (αS,βS) isomer A18, (αR,βS) isomer A13, (αS,βR) isomer A19, (αS,βS) isomer A20, (αS,βR) isomer . ancj
Step 8. converting the compound selected from Compound A15 to Compound A20, each wherein Z is -O-Cj.8alkyl, to a Compound A15 to Compound A20, each wherein Z is hydroxy, of Formula (I).
A process of claim 1 further comprising the following step:
Step 5a. dehydrogenating Compound A7, wherein Z is -O-C|.8alkyl and R2 is selected from -cycloalkyl(R8) or -heterocyclyl(R8), to Compound A3, wherein Z is -O-C|.8alkyl and R2 is selected from -aryl(R8) or -heteroaryl(Rs), and then repeating Step 3 using said dehydrogenated Compound A3 as the starting material.
3. The process of Claim 1 , wherein the first ligand is selected from the group consisting of (./?)-PhanePhos, (S)-PhanePhos, (Λ)-An-PhanePhos, (5)-An-PhanePhos,
(/?)-Xyl-PhanePhos, (5)-Xyl-PhanePhos, (7?)-MeOXyl-PhanePhos, (5)-MeOXyl-PhanePhos, (Λ)-iPr-PhanePhos, (S)-iPr-PhanePhos, (Λ,/?)-Me-DuPhos, (.S,S)-Me-DuPhos, (Λ)-P-Phos, (S)-P-Phos, (i?)-Xyl-P-Phos, OS)-Xyl-P-Phos, W-Ph-PHOX, (S)-Ph-PHOX, (Λ)-iPr-PHOX, (S)-JPr-PHOX, (/?)-Me-BoPhoz, (5)-Me-BoPhoz,
CF3Ph-(Λ>Me-BoPhoz, CF3Ph-(SJ-Me-BoPhOZ, (/?)-Phenethyl-(7?)-Me-BoPhoz, (i?)-Phenethyl-(5)-Me-BoPhoz, 3,4-diCI-Ph-(/?)-Me-BoPhoz, 3,4-diCI-Ph-(5)-Me-BoPhoz, Xyl-(/?)-Me-BoPhoz, Xyl-(.S)-Me-BoPhoz, (Λ)-Binol-(7?)-Me-BoPhoz, (Λ)-Binol-(5)-Me-BoPhpz, (5)-Binol-(S)-Me-BoPhoz,
(5)-Binol-(/?)-Me-BoPhoz, PCy-(/?)-Me-BoPhoz, PCy-(5)-Me-BoPhoz, (Λ)-iPr-BoPhoz, (.S)-iPr-BoPhoz, (Λ)-Et-BoPhoz, (S)-Et-BoPhoz, (Λ)-Phenethyl-(5)-BoPhoz, (Λ)-Phenethyl-(Λ)-BoPhoz, (S)-Phenethyl-(Λ)-BoPhoz, (5)-Phenethyl-(5)-BoPhoz, (Λ)-Ph-BoPhoz, (5)-Ph-BoPhoz, (/?)-Bn-BoPhoz and (5)-Bn-BoPhoz, and the first metal adduct is selected from the group consisting of [Rh(COD)2]BF,!, [Rh(COD)2]OTf, [Rh(ethylene)2CI]2, [Rh(ethylene)2(acac)], [Rh(CO)2(acac)]9 [Rh(COD)CI]2, [Rh(COD)(acac)], [Ru(COD)(CF3COO)2]2, [Ru(COD)(CH3COO)2], [Ru(COD)(methylallyl)2], [Ru(benzene)CI2]2, [Ru(p-cymene)CI2]2,
[Ru(mesitylene)CI2]2, [Ir(COD)CI]2, [Ir(COD)]BF4 and [Ir(COD)2]BArF.
4. The process of Claim I , wherein the first ligand metal complex is selected from the group consisting of (Λ)-An-Phanephos/[Rh(COD)]BF4, (/?)-Binol-(Λ)-Me-BoPhoz&[Ir(COD)CI]2, (#)-Bn-BoPhoz&[Ir(COD)CI]2) (7?)-Et-BoPhoz&[lr(COD)CI]2, (tf)-iPr-BoPhoz&[lr(COD)CI]2, (Λ)-iPr-BoPhoz&[Rh(COD)2]OTf, (Λ)-iPr-PHOX/[lr(COD)]BArF, (#)-iPr-PHOX/[Ir(COD)]BF4, (7?)-Me-BoPhoz&[Ir(COD)CI]2) (Λ)-Me-BoPhoz«&[Rh(CO)2(acac)], (/?)-Me-BoPhoz&[Rh(COD)2]OTf, (/?)-Me-BoPhoz&[Rh(ethylene)2(acac)]! (/?)-Me-BoPhoz&[Rh(ethylene)2CI]2) (Λ)-Me-BoPhoz/[RuCl2(DMF)2], (Λ;-MeOXyl-PhanePhos/[Rh(COD)]BF4,
(Λ)-Phanephos&[lr(COD)CI]2, (Λ>PhanePhos/[Rh(COD)]BF4, (φ-PhanePhos/[Rh(COD)2]OTf, (Λ)-Phanephos&[Rh(ethylene)2Cl]2; (Λ;-PhanePhos/[RuCI2(DMF)2], (Λ)-Ph-BoPhoz&[Ir(COD)Cl]2, (/?)-Phenethyl-(/?)-BoPhoz&[Rh(ethylene)2CI]2, (/?)-Phenethyl-(S>BoPhoz&[Ir(COD)Cl]2,
(Λ)-Phenethyl-(5)-BoPhoz&[Rh(ethylene)2CI]2,
(Λ)-Phenethyl-(5)-Me-BoPhoz&[Ir(COD)CI]2, (#)-Ph-PHOX/[Ir(COD)]BArF, (Λ)-P-Phos&[Ir(COD)Cl]2, (Λ;-Tol-Binap/[RuCI(p-cymene)]CI, (Λ)-Xyl-Binap&[Ir(COD)CI]2, (Λ)-Xyl-PhanePhos&[lr(COD)CI]2) (tf)-Xyl-Phanephos/[Rh(COD)]BF4;
(Λ;-Xyl-PhanePhos&[Ru(COD)(CF3COO)2]2;
(Λ;-Xyl-PhanePhos&[Ru(COD)(methylallyl)2],
(/?;-Xyl-PhanePhos/[RuCI2(DMF)2], (Λ)-Xyl-P-Phos&[Ir(COD)CI]:,
(/.)-Xyl-P-Phos&[Rh(CO)2(acac)], (Λ)-Xyl-P-Phos&[Rh(ethylene)2(acac)], (Λ)-Xyl-P-Phos&[Rh(ethylene)2CI]2, (Λ)-Xyl-P-Phos/[Ru(p-cymene)CI]Cl,
(Λ>Xyl-P-Phos/[RuCl2(DMF)2], (7?,i?)-MeDuPhos/[Rh(COD)]BF4,
C1S)-BInOl-(^)-Me-BoPhOZa[Ir(COD)Cl]2,
(5)-Binol-(/?)-Me-BoPhoz&[Rh(COD)2]OTf,
(lS)-Ethyl-Naphthyl-(7?)-BoPhoz&[lr(COD)CI]2, (5;-iPr-PhanePhos/[Rh(COD)]BF4, (5)-Me-BoPhoz&[Ir(COD)CI]2,
(5;-Me-BoPhoz/[RuCI2(DMF)2], (S)-PhanePhos&[Ir(COD)CI]2,
(S)-Phanephos/[Rh(COD)]BF4, (5;-PhanePhos/[RuCI2(DMF)2],
(S)-P-Phos/[Ir(COD)CI], (S)-P-Phos&[Ir(COD)CI]2,
(5)-P-Phos/[Ru(benzene)CI]CI, (5)-P-Phos/[RuCl2(DMF)2], (,S;-Tol-Binap/[RuCl(p-cymene)]Cl, (5)-Tol-P-Phos&[Ir(COD)CI]2,
(5)-Xyl-Binap&[lr(COD)Cl]2, (S)-Xyl-PhanePhos&[[r(COD)CI]2, (S;-Xyl-PhanePhos&[Rh(COD)2]OTf, (5;-Xyl-PhanePhos/[RuCI2(DMF)2], (5)-Xyl-P-Phos/[lr(COD)Cl], (S)-Xyl-P-Phos&[Ir(COD)CI]2, (S)-Xyl-P-Phos/[RuCI2(DMF)2], 2,4,6-F3Ph-(Λ)-Me-BoPhoz&[Ir(COD)CI]2, 3,4-diCIPh-(J?)-Me-BoPhoz&[Ir(COD)CI]2, CF3Ph-(/?)-Me-BoPhoz&[Rh(COD)2]OTf, DPPF&[lr(COD)CI]2)
DtBPF&[lr(COD)CI]2, PCy-(/?)-Me-BoPhoz&[lr(COD)CI]2, PCy-(/?)-Me-BoPhoz&[Rh(COD)2]OTf, pFPh-(/?)-Bn-BoPhoz&[Ir(COD)CI]2; pFPh-(/?)-Et-BoPhoz&[lr(COD)CI]2) pFPh-(/?)-Me-BoPhoz&[Ir(COD)CI]2 and Xyl-(/?)-Me-BoPhoz&[Ir(COD)CI]2.
5. The process of Claim I , wherein the first hydrogen source is selected from gaseous hydrogen or an excess of formic acid; wherein the first solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA, THF, toluene, EtOAc, 2- propanol and DMF and mixtures thereof; and, wherein the optional first additive is selected from the group consisting of AcOH, Et3N, HBF4, HBF4 etherate, HCI, HCI etherate, CF3COOH, CH3COOH and TsOH, and, when present, is in an amount up to about 1 .2 Eq.
6. The process of Claim 1 , wherein the first temperature is in a range of from about 25 0C to about 90 0C, or is in a range of from about 50 0C to about 90 0C; and, wherein the first pressure is in a range of from about 3 bar to about 30 bar, or is in a range of from about 25 bar to about 30 bar.
7. The process of Claim 1 , wherein, when Z is hydroxy for Compound Al, the first ligand is selected from the group consisting of (/?)-Xyl-PhanePhos,
(SJ-Xyl-PhanePhos, (Λ>PhanePhos, (S>PhanePhos, (φ-An-PhanePhos, (Sj-An-PhanePhos, (7?)-Me-BoPhoz, (S)-Me-BoPhoz, (tf)-MeOXyl-PhanePhos, (5>MeOXyl-PhanePhos, (Λ)-iPr-PhanePhos,
(5)-iPr-PhanePhos, PCy-(Λ)-Me-BoPhoz and PCy-(5)-Me-BoPhoz, the first metal adduct is selected from the group consisting Of [Rh(COD)2]BF4, [Rh(COD)2]OTf, [Rh(ethylene)2CI]2, [Rh(ethylene)2(acac)], [Rh(CO)2(acac)]s [Rh(COD)CI]2, [Rh(COD)(acac)], [RU(COD)(CF3COO)2I2JRU(COD)(CH3COO)2], [Ru(COD)(methylallyl)2], [Ru(benzene)CI2]2, [Ru(p-cymene)CI2]2, [Ru(mesitylene)CI2]2, [Ir(COD)Cl]2, [Ir(COD)2]BF4 and [Ir(C0D)2]BArFj the first temperature is in a range of from about 25 0C to about 70 0C, and the first pressure is in a range of from about 3 bar to about 30 bar.
8. The process of Claim 1 , wherein, when Z is hydroxy for Compound Al, the first ligand-metal complex is selected from the group consisting of (7?;-An-PhanePhos/[Rh(COD)]BF4, (fl)-Me-BoPhoz &[lr(COD)CI]2, (/?>MeOXyl-PhanePhos/[Rh(COD)]BF4, (Λ;-PhanePhos/[Rh(COD)]BF4, (/?;-PhanePhos &[Rh(COD)2]OTf, (Λ;-PhanePhos/[RuCl2(DMF)2],
(Λ;-Tol-Binap/[RuCI(p-cymene)]CI, (/y-Xyl-PhanePhos &[Ru(COD)(CF3COO)2]2; (Λ>Xyl-PhanePhos &[Ru(COD)(methylallyl)2], (7?;-Xyl-PhanePhos/[RuCI2(DMF)2]; (/?;-Xyl-P-Phos/[RuCI2(DMF)2]) (5;-iPr-PhanePhos/[Rh(COD)]BF4) (5;-Me-BoPhoz/[RuCl2(DMF)2], (S;-PhanePhos/[RuCI2(DMF)2], (SJ-Tol-Binap/[RuCI(/?-cymene)]CI,
(S;-Xyl-PhanePhos A[Rh(COD)2]OTf and (5>Xyl-PhanePhos/[RuCI2(DMF)2].
9. The process of Claim 1 , wherein, when Z is hydroxy for Compound Al, the first ligand is selected from the group consisting of (Λ)-Xyl-PhanePhos,
(S;-Xyl-PhanePhos, (φ-PhanePhos, (Sj-PhanePhos, (φ-An-PhanePhos, (S;-An-PhanePhos, (/?)-MeOXyl-PhanePhos and (5;-MeOXyl-PhanePhos, and the first metal adduct is selected from the group consisting of [Rh(COD)2]BF4, [Rh(COD)2]OTf, [Ru(COD)(CF3COO)2I2, [Ru(COD)(methylallyl)2] and [Ru(benzene)CI2]2.
10. The process of Claim 1 , wherein, when Z is -O-C|.8alkyl for Compound Al, the first ligand is selected from the group consisting of (Λ)-PhanePhos, (5)-PhanePhos, (tf)-An-PhanePhos, (.S)-An-PhanePhos, (Λ)-Xyl-PhanePhos, (5)-Xyl-PhanePhos, (tf)-MeOXyl-PhanePhos, (5)-MeOXyl-PhanePhos, (Z?)-iPr-PhanePhos, (5)-iPr-PhanePhos, (Λ,Λ)-Me-DuPhos, (S,S)-Me-DuPhos, (Λ)-P-Phos, (S)-P-Phos, (Λ)-Xyl-P-Phos, (S)-Xyl-P-Phos, W-Ph-PHOX, (S)-Ph-PHOX, (Λ)-iPr-PHOX, (S)-iPr-PHOX, (Λ)-Me-BoPhoz, (S)-Me-BoPhoz, CF3Ph-W-Me-BoPhOZ5 CF3Ph-(^-Me-BoPhOz, 5 CK)-Phenethyl-(S)-Me-BoPhoz, 3,4-diCI-Ph-(Λ)-Me-BoPhoz,
3,4-diCI-Ph-(S)-Me-BoPhoz, Xyl-(/?)-Me-BoPhoz, Xyl-(S)-Me-BoPhoz, (Λ)-Binol-(Λ)-Me-BoPhoz, (Λ)-Binol-(S)-Me-BoPhoz, (S)-Binol-(S)-Me-BoPhoz, (S)-BinoI-(Λ)-Me-BoPhoz, PCy-(Λ)-Me-BoPhoz, PCy-(S)-Me-BoPhoz, (Λ)-iPr-BoPhoz, I O (S)-iPr-BoPhoz, (Λ)-Et-BoPhoz, (5)-Et-BoPhoz,
(y?)-Phenethyl-(5)-BoPhoz, (/?)-Phenethyl-(Λ)-BoPhoz, (5)-Phenethyl-(/?)-BoPhoz, (5>Phenethyl-(S)-BoPhoz, (i?)-Ph-BoPhoz, (S)-Ph-BoPhoz, (7?)-Bn-BoPhoz and (S)-Bn-BoPhoz, the first metal adduct is selected from the group consisting of [Ir(COD)2]BArF, 15 [Ir(COD)2]BF4, [Ir(COD)CI]2, [Rh(ethylene)2CI]2, [Rh(ethylene)2(acac)]2,
[Rh(COD)CI]2, and [RIi(CODXaCaC)], the first solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA, THF, toluene, EtOAc, DMF, and mixtures thereof, the optional first additive is selected from the group consisting Of Et3N, HBF4, 0 CH3COOH and TsOH, and, when present, is in an amount up to about 1.2
Eq., the first temperature is in a range of from about 50 0C to about 70 0C, and the first pressure is in a range of from about 10 bar to about 30 bar.
1 1. The process of Claim 1 , wherein, when Z is -O-C|.salkyl for Compound Al, the 5 first ligand-metal complex is selected from the group consisting of
(Λ)-An-Phanephos/[ Rh(COD)]BF4, (Λ)-Binol-(Λ)-Me-BoPhoz&[Ir(COD)CI]2, (#)-Bn-BoPhoz&[Ir(COD)CI]2, (J?)-iPr-BoPhoz&[Rh(COD)2]OTf, (/?)-iPr-PHOX/[Ir(COD)]BArF, (/?)-iPr-PHOX/[Ir(COD)]BF4) (tf)-Me-BoPhoz&[Ir(COD)CI]2, (Λ)-Me-BoPhoz&[Rh(CO)2(acac)], 30 (#)-Me-BoPhoz&[Rh(COD)2]OTf, (/?)-Me-BoPhoz&[Rh(ethylene)2(acac)], (/?)-Me-BoPhoz &[Rh(ethylene)2CI]2, (^)-Me-BoPhOZZ[RuCI2(DMF)2], (Λ)-Phanephos&[Ir(COD)CI]2, (#)-Phanephos&[Rh(ethylene)2Cl]2, (i?)-Ph-BoPhoz&[lr(COD)CI]2, (Λ)-Phenethyl-(/?)-BoPhoz&[Rh(ethylene)2CI]2, (^)-Phenethyl-(5)-BoPhoz&[Rh(ethylene)2CI]2; (7?)-Phenethyl-(5)-Me-BoPhoz&[lr(COD)CI]2, (Λ)-Ph-PHOX/[Ir(COD)]BArF,
(Λ)-Xyl-Phanephos/[Rh(COD)]BF4, (Λ)-Xyl-P-Phos&[Rh(CO)2(acac)], (Λ)-Xyl-P-Phos&[Rh(ethylene)2(acac)], (Λ)-Xyl-P-Phos&[Rh(ethylene)2CI]2, (Λ)-Xyl-P-Phos/[Ru(p-cymene)CI]Cl, (Λ,Λ)-MeDuPhos/[Rh(COD)]BF4, (5)-Binol-(7?)-Me-BoPhoz&[lr(COD)CI]2, (S)-Binol-(R)-Me-BoPhoz&[Rh(COD)2]OTf, (S)-Me-BoPhoz&[Ir(COD)CI]2,
(5)-PhanePhos/[Rh(COD)]BF4, (S)-P-Phos/[Ir(COD)]CI, (5)-P-Phos&[Ir(COD)CI]2> (5)-P-Phos/[Ru(benzene)Cl]CI, (S)-P-Phos/[RuCI2(DMF)2], (5)-Xyl-P-Phos/[Ir(COD)]CI, (5)-Xyl-P-Phos&[lr(COD)CI]2, (5)-Xyl-P-Phos/[RuCI2(DMF)2], 3,4-diCIPh-(/?)-Me-BoPhoz&[lr(COD)CI]2,
CF3Ph-(R)-Me-BoPhoz&[Rh(COD)2]OTf, PCy-(/?)-Me-BoPhoz&[Ir(COD)CI]2 and Xyl-(Λ)-Me-BoPhoz&[Ir(COD)CI]2.
12. The process of Claim I , wherein, when Z is -O-C|.8alkyl for Compound Al, the first ligand is selected from the group consisting of (Λ)-Me-BoPhoz, (.S)-Me-BoPhOz, 3,4-diCI-Ph-(Λ)-Me-BoPhoz,
3,4-diCI-Ph-(5)-Me-BoPhoz, Xyl-(tf)-Me-BoPhoz, Xyl-(5)-Me-BoPhoz, (/?)-Bn-BoPhoz and (5)-Bn-BoPhoz, the first metal adduct is selected from the group consisting of [Ir(COD)CI]2 and
[Ir(COD)2]BArF) the first solvent is selected from the group consisting of MeOH, DCE, THF, toluene, EtOAc, IPA, and mixtures thereof, the optional first additive is HBF4, and, when present, is in an amount up to about
1.2 Eq., the first temperature is in a range of from about 50 0C to about 90 0C, and the first pressure is from about 25 bar to about 30 bar.
13. The process of Claim 1 , wherein, when R2 is selected from -aryl(Rg) and -heteroaryl(Rs) for Compound A2 or Compound A3, the second hydrogen source is gaseous hydrogen, the hydrogenation agent is selected from either 10% Pd/C or a second ligand- metal complex, wherein the second ligand-metal complex consists essentially of a second ligand and an [Ir(COD)Cl]2 metal adduct combined with iodine in an amount up to about O. I Eq., wherein 10% Pd/C is present in a range of weight % of from about 5% weight/weight (w/vv) to about 20% (w/w), and wherein the second ligand is selected from the group consisting of (i?)-PhanePhos, (S)-PhanePhos, (Λ)-An-PhanePhos, (S>An-PhanePhos, (Λ)-Xyl-PhanePhos, (5)-Xyl-PhanePhos, (J?)-MeOXyl-PhanePhos, (S)-MeOXyl-PhanePhos, (Λ)-iPr-PhanePhos, (SyiPr-PhanePhos, CO)-Me-DuPhOs, (5,^)-Me-DuPhOS, (Λ)-P-Phos, (5>P-Phos,
(Λ)-Xyl-P-Phos, (5)-Xyl-P-Phos, (Λ)-Tol-P-Phos, (5>Tol-P-Phos, (7?;-Ph-PH0X, (.S)-Ph-PHOX, (7?)-iPr-PH0X, (5>iPr-PHOX, OK)-Me-BoPhoz, (S)-Me-BoPhoz, CF3Ph-(7?)-Me-BoPhoz,
Figure imgf000183_0001
(i?)-Phenethyl-(Λ)-Me-BoPhoz, (Λ)-Phenethyl-(5)-Me-BoPhoz, (5>Ethyl-Napthyl-(Λ)-Me-BoPhoz,
3,4-diCl-Ph-(/?)-Me-BoPhoz, 3,4-diCI-Ph-(S)-Me-BoPhoz, (7?)-2,4,6-F3Ph-(/?)-Me-BoPhoz, (#)-2,4,6-F3Ph-(S>Me-BoPhoz, (5)-2,4,6-F3Ph-(50-Me-BoPhoz, (5)-2,4;6-F3Ph-(7?)-Me-BoPhoz, Xyl-(7?)-Me-BoPhoz, Xyl-(5)-Me-BoPhoz, (j*?)-Binol-(Λ)-Me-BoPhoz, (Λ)-Binol-(5)-Me-BoPhoz, (5)-Binol-(5)-Me-BoPhoz,
(5)-Binol-(/?)-Me-BoPhoz, PCy-(tf)-Me-BoPhoz, pFPh-(/?)-Me-BoPhoz, pFPh-(5)-Me-BoPhoz, (Λ)-Et-BoPhoz, (5)-Et-BoPhoz, pFPh-(7?)-Et-BoPhoz, pFPh-(S)-Et-BoPhoz, (Λ)-iPr-BoPhoz, (5)-iPr-BoPhoz, (Λ)-Et-BoPhoz, (5>Et-BoPhoz, (Λ)-Phenethyl-(5}-BoPhoz, (Λ)-Phenethyl-(7?)-BoPhoz,
(5)-Phenethyl-(/?)-BoPhoz, (5>Phenethyl-(S)-BoPhoz, (/?)-Ph-BoPhoz, (S)-Ph-BoPhOZ, (/?)-Bn-BoPhoz, (S)-Bn-BoPhoz, pFPh-(/?)-Bn-BoPhoz, pFPh-(5)-Bn-BoPhoz, (Λ)-Xyl-Binap, (S)-Xyl-Binap and DPPF, and the second solvent is selected from the group consisting of MeOH, DCE, EtOH,
IPA, THF, toluene, EtOAc, 1-BuOH and MTBE and mixtures thereof, the optional second additive is selected from the group consisting Of Et3N,
JPr2-NH, Cy2NH, (Λ)-Ph-ethyl-NH2, (S)-Ph-ethyl-NH2, KI, KOH, K2CO3,
(/?/5)-camphorsulfonic acid and CH3COOH, and, when present, is in an amount up to about 1.2 Eq., the second temperature is in a range of from about 30 0C to about 80 0C, or is in a range of from about 40 0C to about 60 0C, and the second pressure is in a range of from about 3 bar to about 25 bar, or is in a range of from about 10 bar to about 25 bar, or is in a range of from about 3 bar to about 10 bar.
14. The process of Claim 1 , wherein, when Z is hydroxy and R2 is selected from -aryl(Rs) and -heteroaryl(Rs) for Compound A2 or Compound A3, the second ligand-metal complex is selected from the group consisting of (Λ)-Me-BoPhoz&[Ir(COD)CI]2, (Λ)-PhanePhos&[Ir(COD)Cl]2, (/?)-P-Phos&[Ir(COD)CI]2; (^)-Xyl-Binap&[Ir(COD)CI]2, (tf)-Xyl-PhanePhos&[Ir(COD)Cl]2, (Λ)-Xyl-P-Phos&[Ir(COD)CI]2) (5)-Me-BoPhoz&[Ir(COD)Cl]2, (S)-PhanePhos&[Ir(COD)CI]2,
(5)-P-Phos&[Ir(COD)Cl]2, (5)-Tol-P-Phos&[Ir(COD)CI]2, (5>Xyl-Binap&[lr(COD)CI]2, (5)-Xyl-PhanePhos&[Ir(COD)CI]2 and (5)-Xyl-P-Phos&[Ir(COD)Cl]2.
15. The process of Claim 1 , wherein, when Z is -O-C|.8alkyl and R2 is selected from -aryl(Rs) and -heteroaryl(Rs) for Compound A2 or Compound A3, the second ligand-metal complex is selected from the group consisting of (Λ)-Binol-(Λ)-Me-BoPhoz&[Ir(COD)CI]2, (7?)-Et-BoPhoz&[Ir(COD)CI]2, (Ze)-JPr-BOPhOZ(SL[Ir(COD)CI]21
Figure imgf000184_0001
(/?)-Ph-BoPhoz&[Ir(COD)CI]2, (Λ)-Phenethyl-(5)-BoPhoz&[Ir(COD)CI]2, (/?)-Xyl-PhanePhos&[Ir(COD)CI]2, (Λ)-Xyl-P-Phos&[Ir(COD)CI]2, (S)-Binol-(/?)-Me-BoPhoz&[lr(COD)Cl]2)
(5)-Ethyl-Naphthyl-(/?)-BoPhoz&[Ir(COD)CI]2, (S)-Me-BoPhoz&[lr(COD)CI]2, (5)-Xyl-PhanePhos&[Ir(COD)CI]2, (5)-Xyl-P-Phos&[lr(COD)Cl]2, 2,4,6-F3Ph-(Λ)-Me-BoPhoz&[Ir(COD)CI]2, DPPF&[Ir(COD)CI]2, DtBPF&[Ir(COD)CI]2, PCy-(/?)-Me-BoPhoz&[Ir(COD)Cl]2, pFPh-(/?)-Bn-BoPhoz&[Ir(COD)CI]2, pFPh-(7?)-Et-BoPhoz&[Ir(COD)CI]2; pFPh-(Λ)-Me-BoPhoz&[Ir(COD)CI]2 and Xyl-(Λ)-Me-BoPhoz&[Ir(COD)Cl]2.
16. The process of Claim 1 , wherein, when R2 is selected from -aryl(Rg) and -heteroaryl(Rs) for Compound A2 or Compound A3, the second hydrogen source is gaseous hydrogen,
10% Pd/C is present in a range of weight % of from about 5% (w/vv) to about
20% (w/w), the second solvent is selected from the group consisting of MeOH, DCE, EtOH',.
IPA, THF, toluene, EtOAc, 1 -BuOH and MTBE and mixtures thereof, the optional second additive is selected from the group consisting Of Et3N, iPr2-NH, Cy2NH, (Λ)-Ph-ethyl-NH2, (5>Ph-ethyl-NH2, Kl, KOH, K2CO3, (/?/S)-camphorsulfonic acid and CH3COOH, and, when present, is in an amount up to about 1.2 Eq., the second temperature is in a range of from about 30 0C to about 80 0C, or is in a range of from about 40 0C to about 60 0C, and the second pressure is in a range of from about 3 bar to about 25 bar, or is in a range of from about 10 bar to about 25 bar, or is in a range of from about 3 bar to about 10 bar.
17. The process of Claim 1 , wherein, when R2 is selected from -aryl(Rs) and -heteroaryl(Rg) for Compound A2 or Compound A3, the second ligand-metal complex consists essentially of a second ligand and an [Ir(COD)CI]2 second metal adduct combined with iodine in an amount up to about 0.1 Eq., the second ligand is selected from the group consisting of (/?)-PhanePhos, (S)-PhanePhos, (Λ)-An-PhanePhos, (S)-An-PhanePhos, (/?)-Xyl-PhanePhos, (S)-Xy)-PhanePhos, (Λ)-MeOXyl-PhanePhos, (5)-MeOXyl-PhanePhos, (7?,J?)-Me-DuPhos, (5,S)-Me-DuPhOS, (Λ)-P-Phos, (S)-P-PhOs, (Λ)-Xyl-P-Phos, (S)-Xyl-P-Phos, (Λ)-Tol-P-Phos, (S)-Tol-P-Phos, (/ΪJ-Ph-PHOX, (S)-Ph-PHOX, (Λ)-iPr-PHOX, (S)-iPr-PHOX, (tf)-Me-BoPhoz, (S)-Me-BoPhoz, CF3Ph-(/?j-Me-BoPhoz,
CF3Ph-(S>Me-BoPhoz, (7?)-Phenethyl-(/?)-Me-BoPhoz, (Λ)-Phenethyl-(S)-Me-BoPhoz, (S)-Ethyl-Napthyl-(/?)-Me-BoPhoz, 3,4-diCI-Ph-(/?)-Me-BoPhoz, 3,4-diCI-Ph-(S)-Me-BoPhoz, (/?)-2,4,6-F3Ph-(Λ)-Me-BoPhoz, (/?)-2,4,6-F3Ph-(S)-Me-BoPhoz, (S)-2,4,6-F3Ph-(S)-Me-BoPhoz, (S)-2,4,6-F3Ph-(#)-Me-BoPhoz,
Xyl-(/?)-Me-BoPhoz, Xyl-(S)-Me-BoPhoz, (7?)-Binol-(/?)-Me-BoPhoz, (7?)-Binol-(S)-Me-BoPhoz, (S)-Binol-(S)-Me-BoPhoz, (S)-Binol-(Λ)-Me-BoPhoz, PCy-(Λ)-Me-BoPhoz, pFPh-(/?)-Me-BoPhoz, pFPh-(S)-Me-BoPhoz, (Λ)-Et-BoPhoz, (S)-Et-BoPhoz, pFPh-(/?)-Et-BoPhoz, pFPh-(S)-Et-BoPhoz, (Z?)-iPr-BoPhoz,
(5)-iPr-BoPhoz, (Λ)-Phenethyl-(5)-BoPhoz, (Λ)-Phenethyl-(Λ)-BoPhoz, (S)-Phenethyl-(/?)-BoPhoz, (S)-Phenethyl-(S)-BoPhoz, (Λ)-Ph-BoPhoz, (S)-Ph-BoPhOz, (Λ)-Bn-BoPhoz, (S)-Bn-BoPhoz, pFPh-(7?)-Bn-BoPhoz, pFPh-(S)-Bn-BoPhoz, (7?)-Xyl-Binap, (S)-Xyl-Binap and DPPF, the second solvent is selected from the group consisting of MeOH, DCE, EtOH,
IPA, THF, toluene, EtOAc, 1-BuOH and MTBE and mixtures thereof, the optional second additive is selected from the group consisting Of Et3N, iPr2-NH, Cy2NH, (Λ)-Ph-ethyl-NH2, (S)-Ph-ethyl-NH2, KI, KOH, K2CO3, (Λ/S)-camphorsulfonic acid and CH3COOH, and, when present, is in an amount up to about 1.2 Eq., the second temperature is in a range of from about 30 0C to about 80 0C, or is in a range of from about 40 0C to about 60 0C, and the second pressure is in a range of from about 3 bar to about 25 bar, or is in a range of from about 10 bar to about 25 bar, or is in a range of from about 3 bar to about 10 bar.
18. A process for preparing a compound of Formula (Ia) and intermediates thereof:
Figure imgf000187_0001
Formula (Ia) comprising the steps of:
Step 1. reacting a Compound Cl with a first hydrogen source, a first ligand- metal complex consisting essentially of a first ligand conjugated with a first metal adduct, in a first solvent in the presence of an optional first additive at an elevated first temperature and an elevated first pressure to provide a substantially pure Compound C3:
Figure imgf000187_0002
Step 2. reacting Compound C3 with a second hydrogen source and a hydrogenation agent in a second solvent in the presence of an optional second additive at an elevated second temperature and an elevated second pressure to provide an isomeric mixture of a Compound C4 and Compound C5:
Figure imgf000187_0003
Step 3. separating each of Compound C4 and Compound C5 from the isomeric mixture; Step 4. optionally dehydrogenating Compound C5 to Compound C3, and then repeating Step 2 using said dehydrogenated Compound C3 as the starting material;
Step 5. deprotecting the Compound C4 to provide a Compound C6:
C4, (αS,βS) isomer
Figure imgf000188_0001
Step 6. reacting Compound C6 with a Compound C7 to provide a Compound C8:
C6, (αS.βS) isomer
Figure imgf000188_0002
Step 7. converting Compound C8 to the compound of Formula (Ia).
19. A process for making a substantially pure Compound Cl comprising the step of: reacting a Compound Cl with a first hydrogen source, a first ligand-metal complex consisting essentially of a first ligand conjugated with a first metal adduct, in a first solvent in the presence of an optional first additive at an elevated first temperature and an elevated first pressure to provide a substantially pure Compound C2.
Figure imgf000188_0003
20. The process of Claim 18, wherein the first hydrogen source is selected from gaseous hydrogen or an excess of formic acid, the first ligand is selected from the group consisting of (/?)-PhanePhos,
(5)-PhanePhos, (tf)-An-PhanePhos, (5>An-PhanePhos, (Λ)-Xyl-PhanePhos, (S)-XyI-PhanePhos, (tf)-MeOXyl-PhanePhos, (S)-MeOXyl-PhanePhos, (/?)-iPr-PhanePhos, (S)-iPr-PhanePhos, (/?,Λ)-Me-DuPhos, (S,S)-Me-DuPhos, (Λ)-P-Phos, (5)-P-Phos, (Λ)-Xy I-P-Phos, (S)-Xyl-P-Phos, W-Ph-PHOX, (S)-Ph-PHOX,
(Λ)-iPr-PHOX, (S>i Pr-PHOX, (/?)-Me-BoPhoz, (5)-Me-BoPhoz, CF3Ph-(Λ;-Me-BoPhoz, CF3Ph-(S;-Me-BoPhoz, (7?)-Phenethyl-(/?)-Me-BoPhoz, (/?)-Phenethyl-(5)-Me-BoPhoz, 3,4-diCI-Ph-(/?)-Me-BoPhoz, 3,4-diCI-Ph-(5)-Me-BoPhoz, XyI-(^)-Me-BoPhOZ, Xyl-(5)-Me-BoPhoz, (Λ)-Binol-(/?)-Me-BoPhoz,
(Λ)-Binol-(S)-Me-BoPhoz, (S)-Binol-(S)-Me-BoPhoz, (5)-Binol-(/?)-Me-BoPhoz, PCy-(Λ)-Me-BoPhoz, PCy-(5)-Me-BoPhoz, (Λ)-iPr-BoPhoz, (5)-iPr-BoPhoz, (7?)-Phenethyl-(5)-BoPhoz, (Λ)-Phenethyl-(/?)-BoPhoz, (5)-Phenethyl-(/?)-BoPhoz, (S)-Phenethyl-(S)-BoPhoz, (Λ)-Ph-BoPhoz, (5)-Ph-BoPhoz,
(Λ)-Bn-BoPhoz and (5)-Bn-BoPhoz, the first metal adduct is selected from the group consisting of [Rh(COD)2]BF4, [Rh(COD)2]OTf, [Rh(ethylene)2CI]2, [Rh(ethylene)2(acac)]5 [Rh(C0)2(acac)], [Rh(COD)(acac)], [Ru(COD)(CF3COO)2]2, [Ru(COD)(methylallyl)2], [Ru(benzene)CI2]2, [Ru(p-cymene)CI2]2,
[Ir(COD)CI]2, [Ir(COD)2]BF4 and [lr(COD)2]BArF, the first solvent is selected from the group consisting of MeOH, EtOH, IPA, DCE, THF, toluene, EtOAc, DMF and mixtures thereof, the optional first additive is selected from the group consisting of AcOH, Et3N,
HBF4, HBF4 etherate, HCI, HCI etherate, CF3COOH, CH3COOH and
TsOH, and, when present, is in an amount up to about 1.2 Eq., the first temperature is in a range of from about 25 0C to about 70 0C, the first pressure is in a range of from about 3 bar to about 30 bar, the second hydrogen source is gaseous hydrogen, the hydrogenation agent is selected from either 10% Pd/C or a second ligand- metal complex, wherein the second ligand-metal complex consists essentially of a second ligand and an [Ir(COD)CI]2 metal adduct combined with iodine in an amount up to about 0.1 Eq., wherein 10% Pd/C is present in a range of weight % of from about 5% (w/w) to about 20% (w/w), and wherein the second ligand is selected from the group consisting of (/?)-P-Phos, (S)-P-PhOS, (Λ)-Xyl-P-Phos, (S)-Xyl-P-Phos, (S)-Tol-P-Phos,
(tf)-Me-BoPhoz, (S)-Me-BoPhoz, (tf)-Xyl-Binap and (S)-Xyl-Binap, the second solvent is selected from the group consisting of MeOH, DCE, EtOH,
IPA, THF, toluene, EtOAc and MTBE and mixtures thereof, the optional second additive is selected from the group consisting Of Et3N, iPr2-NH, Cy2NH, (tf)-Ph-ethyl-NH2, (5)-Ph-ethyl-NH2, Kl, KOH, K2CO3,
(/?/5)-camphorsulfonic acid and CH3COOH, and, when present, is in an amount up to about 1 .2 Eq., the second temperature is in a range of from about 40 0C to about 60 0C, and the second pressure is in a range of from about 3 bar to about 25 bar, or is in a range of from about 10 bar to about 25 bar, or is in a range of from about 3 bar to about I O bar.
21. The process of Claim 20, wherein the first hydrogen source is gaseous hydrogen; the first ligand-metal complex is (#)-Me-BoPhoz&[Ir(COD)Cl]2; the first solvent is DCE; the first temperature is about 70 0C; the first pressure is about 25 bar; the second hydrogen source is gaseous hydrogen; and the hydrogenation agent is selected from either 10% Pd/C or a second ligand- metal complex, wherein, when the hydrogenation agent is a second ligand-metal complex selected from (7?)-Me-BoPhoz&[Ir(COD)CI]2 combined with iodine in an amount of about 0.1 Eq., then the second solvent is EtOAc; the second temperature is about 50 0C; and the second pressure is about 25 bar; and, wherein, when the hydrogenation agent is selected from 10% Pd/C in an amount of about 10% (w/w); the second solvent is IPA; the optional second additive is Et3N in an amount of about 0.75 Eq.; the second temperature is about 40 0C; and, the second pressure is about 10 bar.
22. The process of Claim 18, further comprising the steps:
Step I . reacting a Compound Dl with a first hydrogen source, a first ligand- metal complex consisting essentially of a first ligand conjugated with a first metal adduct, in a first solvent in the presence of an optional first additive at an elevated first temperature and an elevated first pressure to provide a substantially pure Compound D3:
Figure imgf000191_0001
Step 2. optionally converting the Compound D3 hydroxy group to provide Compound C3 having a -O-Ci-salkyl group, and carrying forward Compound C3 according to Step 2 of Claim 18;
Step 3. reacting Compound D3 with a second hydrogen source and a hydrogenation agent in a second solvent in the presence of an optional second additive at an elevated second temperature and an elevated second pressure to provide an isomeric mixture of a Compound D4 and Compound D5:
Figure imgf000192_0001
and
Step 4. converting the hydroxy group in the isomeric mixture of Compound D4 and Compound D5 to an -0-Cι-salkyl group to provide an isomeric mixture of Compound C4 and Compound C5; and carrying forward the isomeric mixture of Compound C4 and Compound C5 according to Step 3 of Claim 18.
23. A process for making a substantially pure Compound D2 comprising the step of: reacting a Compound Dl with a first hydrogen source, a first ligand-metal complex consisting essentially of a first ligand conjugated with a first metal adduct, in a first solvent in the presence of an optional first additive at an elevated first temperature and an elevated first pressure to provide a substantially pure Compound D2:
Figure imgf000192_0002
24. The process of Claims 22, wherein the first hydrogen source is selected from gaseous hydrogen or an excess of formic acid, the first ligand is selected from the group consisting of (7?)-Xyl-PhanePhos,
(Sj-Xyl-PhanePhos, (φ-PhanePhos, (5>PhanePhos, (i?>An-PhanePhos, (S>An-PhanePhos, (Λ)-MeOXyl-PhanePhos, (S,)-MeOXyl-PhanePhos,
PCy-(/?)-Me-BoPhoz and PCy-(S)-Me-BoPhoz, the first metal adduct is selected from the group consisting of [RJi(COD)2]BF4,
[RJi(COD)2]OTf, [Ru(COD)(CF3COO)2I2, [Ru(COD)(methylallyl)2], [Ru(benzene)CI2]2 and [Ir(COD)Cl]2, the first solvent is selected from the group consisting of MeOH, EtOH, IPA, DCE,
THF, toluene, EtOAc, DMF and mixtures thereof, the optional first additive is selected from the group consisting of AcOH, Et3N,
HBF4, HBF4 etherate, HCI, HCI etherate, CF3COOH, CH3COOH and TsOH, and, when present, is in an amount up to about 1.2 Eq., the first temperature is in a range of from about 25 0C to about 70 0C, the first pressure is in a range of from about 3 bar to about 30 bar, the second hydrogen source is gaseous hydrogen, the hydrogenation agent is selected from either 10% Pd/C or a second ligand- metal complex, wherein the second ligand-metal complex consists essentially of a second ligand and an [Ir(COD)CI]2 metal adduct combined with iodine in an amount up to about O. I Eq., wherein 10% Pd/C is present in a range of weight % of from about 5% (w/w) to about 20% (w/w), and wherein the second ligand is selected from the group consisting of (/?)-P-Phos,
OS)-P-Phos, (φ-Xyl-P-Phos, (S)-Xyl-P-Phos, (5)-Tol-P-Phos,
(/?)-Me-BoPhoz, (S)-Me-BoPhoz, (Λ)-Xyl-Binap and (5)-Xyl-Binap, the second solvent is selected from the group consisting of MeOH, DCE, EtOH, IPA, THF, toluene, EtOAc and MTBE and mixtures thereof, the optional second additive is selected from the group consisting Of Et3N, iPr2-NH, Cy2NH, (Λ)-Ph-ethyl-NH2, (S)-Ph-ethyl-NH2, KI, KOH, K2CO3,
(/?/5)-camphorsulfonic acid and CH3COOH, and, when present, is in an amount up to about 1.2 Eq., the second temperature is in a range of from about 40 0C to about 60 0C, and the second pressure is in a range of from about 3 bar to about 25 bar, or is in a range of from about 10 bar to about 25 bar, or is in a range of from about 3 bar to about 10 bar.
25. The process of Claim 24, wherein 5 the first hydrogen source is gaseous hydrogen; the first ligand-metal complex is C/?;-Xyl-PhanePhos&[Ru(COD)(CF3COO)2]2; the first solvent is MeOH; the first temperature is about 40 0C; the first pressure is about 10 bar; I O the second hydrogen source is gaseous hydrogen; and the hydrogenation agent is selected from either 10% Pd/C or a second ligand- metal complex, wherein, when the hydrogenation agent is a second ligand-metal complex selected from (/?)-Me-BoPhoz&[lr(COD)CI]2 combined with iodine in an amount 15 of about 0.1 Eq., then the second solvent is EtOAc; the second temperature is about 50 0C; and the second pressure is about 25 bar; and, wherein, when the hydrogenation agent is selected from 10% Pd/C in an amount of about 10% (w/w); the second solvent is MeOH; the optional second additive is Et3N in an amount of about 0.75 Eq.; the second temperature is 0 about 40 0C; and, the second pressure is about 10 bar.
26. The process of Claim 1 , wherein the process provides an enantiomer or diastereomer of a compound of Formula (I) or a compound of Formula (II) selected from the group consisting of: β-[ l -[[3-[(l ,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]phenyl]acetyl]-4- piperidinyl]-3-quinolinepropanoic acid,
3-(l -{2-[3-(5-hydroxy-l ,4,5,6-tetrahydro-pyrimidin-2-ylamino)-phenyl]- acetyl}-piperidin-4-yl)-3-quinolin-3-yl-propionic acid methyl ester, β-[ I -[ 1 -oxo-4-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2-yl)butyl]-4-piperidinyl]- 3-quinolinepropanoic acid, 3-quinolin-3-yl-3-[ 1 -(4-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl-butyryl)- piperidin-4-yl]-propionic acid methyl ester,
3-[ i -(4-5,6,7, 8-tetrahydro-[ 1 ,8]naphthyridin-2-yl-butyryl)-piperidin-4-yl]-3- ( l ,2,3,4-tetrahydro-quinolin-3-yl)-propionic acid,
(3/?*,3'5'*)-3-[l -(4-5,6,7,8-tetrahydro-[ l !8]naphthyridin-2-yl-butyryl)- piperidin-4-yl]-3-(l ,2,3,4-tetrahydro-quinolin-3-yl)-propionic acid,
(3Λ*,3'Λ*)-3-[ l -(4-5,6,7,8-tetrahydro-[1 ,8]naphthyridin-2-yl-butyryl)- piperidin-4-yl]-3-(l ,2,3,4-tetrahydro-quinolin-3-yl)-propionic acid,
(35*,3'/?*)-3-[l -(4-5,6)7,8-tetrahydro-[ l )8]naphthyridin-2-yl-butyryl)- piperidin-4-yl]-3-(l ,2,3,4-tetrahydro-quinolin-3-yl)-propionic acid,
(3S'*,3'S'*)-3-[l -(4-5,6,7, 8-tetrahydro-[ 1 , 8]naphthyridin-2-yl-butyryl)-piperidin- 4-yl]-3-( l ,2,3,4-tetrahydro-quinolin-3-yl)-propionic acid,
3-[ 1 -(4-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl-butyryl)-piperidin-4-yl]-3- ( l ,2,3,4-tetrahydro-quinolin-3-yl)-propionic acid methyl ester, β-[2-[ 1 -[3-[( 1 ,4,5,6-tetrahydro-2-pyrimidinyl)amino]benzoyl]-4- piperidinyl]ethyl]-3-pyridinepropanoic acid,
3-pyridin-3-yl-5-{ 1 -[3-( 1 ,4,5,6-tetrahydro-pyrimidin-2-ylamino)-benzoyl]- piperidin-4-yl}-pentanoic acid methyl ester, β-[2-[ l -[3-[(l ,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]-4- piperidinyl]ethyl]-3-pyridinepropanoic acid,
5-{ l -[3-(5-hydroxy-l ,4,5,6-tetrahydro-pyrimidin-2-ylamino)-benzoyi]- piperidin-4-yl}-3-pyridin-3-yl-pentanoic acid methyl ester, β-[2-[ 1 -[ I -oxo-3-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2-yl)propy l]-4- piperidinyl]ethyl]-3-pyridinepropanoic acid,
3-pyridin-3-yl-5-[ 1 -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl-propionyl)- piperidin-4-yl]-pentanoic acid methyl ester, β-[2-[ I -[ 1 -oxo-4-(2-pyridinylamino)butyl]-4-piperidinyl]ethyl]-3- pyridinepropanoic acid,
3-pyridin-3-yl-5-{ l -[4-(pyridin-2-ylamino)-butyryl]-piperidin-4-yl}-pentanoic acid methyl ester,
6-methoxy-β-[2-[ 1 -[3-[( 1 ,4,5,6-tetrahydro-5-hydroxy-2- pyrimidinyl)amino]benzoyl]-4-piperidinyl]ethyl]-3-pyridinepropanoic acid,
5-{ l -[3-(5-hydroxy- 1 ,4,5, 6-tetrahydro-pyrimidin-2-ylamino)-benzoyl]- piperidin-4-yl}-3-(6-methoxy-pyridin-3-yl)-pentanoic acid methyl ester, β-( 1 ,3-benzodioxol-5-yl)- 1 -[ 1 -oxo-3-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2- yl)propyl]-4-piperidinebutanoic acid, 3-benzo[ 1 ,3]dioxol-5-yl-4-[ 1 -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid methyl ester, β-[2-[ 1 -[3-[( 1 ,4,5,6-tetrahydro-2-pyrimidinyl)amino]benzoyl]-4- piperidinyl]ethyl]-3-quinolinepropanoic acid,
3-quinolin-3-yl-5-{ l-[3-(l ,4,5,6-tetrahydro-pyrimidin-2-ylamino)-benzoyl]- piperidin-4-yl}-pentanoic acid methyl ester,
1 -[ 1 -oxo-3-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2-yl)propyl]-β-phenyl-4- piperidinebutanoic acid,
3-phenyl-4-[ 1 -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl-propionyl)- piperidin-4-yl]-butyric acid methyl ester, β-( 1 ,3-benzodioxol-5-yl)- 1 -[ 1 -oxo-3-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2- yl)propyl]-4-piperidinepropanoic acid,
3-benzo[ l ,3]dioxol-5-yl-3-[l-(3-5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-propionic acid methyl ester, β-( 1 ,3-benzodioxol-5-yl)- 1 -[ 1 -oxo-4-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2- yl)butyl]-4-piperidinepropanoic acid,
3-benzo[ l ,3]dioxol-5-yl-3-[ l-(4-5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2-yl- butyryl)-piperidin-4-yl]-propionic acid methyl ester, β-(l ,3-benzodioxol-5-yl)-l-[(5,6,7,8-tetrahydro- l ,8-naphthyridin-2-yl)acetyl]- 4-piperidinepropanoic acid,
3-benzo[ 1 ,3]dioxol-5-yl-3-[ l-(2-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl- acetyl)-piperidin-4-yl]-propionic acid methyl ester,
6-methoxy-β-[ 1 -[ 1 -oxo-4-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2-yl)butyl]-4- piperidinyl]-3-pyridinepropanoic acid,
3-(6-methoxy-pyridin-3-yl)-3-[ l -(4-5,6,7, 8-tetrahydro-[l ,8]naphthyridin-2-yl- butyryl)-piperidin-4-yl]-propionic acid methyl ester,
3-(2-methyl- 1 , 4,5,6-tetrahydro-pyrimidin-5-yl)-4-[ ] -(3-5,6,7, 8-tetrahydro- [ 1 ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-butyric acid,
3-(2-methyl- 1 , 4,5,6-tetrahydro-pyrimidin-5-yl)-4-[ l -(3-5,6,7, 8-tetrahydro- [ l ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-butyric acid methyl ester,
4-[l -(3-5,6,7,8-tetrahydro-[l ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-3- ( l ,2,3,4-tetrahydro-quinolin-3-yl)-butyric acid,
(3Λ,3'/?)-4-[ l -(3-5,6,7,8-tetrahydro-[l ,8]naphthyridin-2-yl-propionyl)- piperidin-4-yl]-3-(l ,2,3,4-tetrahydro-quinolin-3-yl)-butyric acid,
(3i"?,3'/?)-4-[ l -(3-5,6,7,8-tetrahydro-[l ,8]naphthyridin-2-yl-propionyl)- piperidin-4-yl]-3-(l ,2,3,4-tetrahydro-quinolin-3-yl)-butyric acid methyl ester, (3Λ,3'S)-4-[ l -(3-5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2-yl-propionyl)- piperidin-4-yl]-3-( 1 ,2,3,4-tetrahydro-quinolin-3-yl)-butyric acid,
(3/?,3'5)-4-[ l -(3-5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2-yl-propionyl)- piperidin-4-yl]-3-( l ,2,3,4-tetrahydro-quinolin-3-yl)-butyric acid methyl ester,
(3ιS,3'Λ)-4-[ l-(3-5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2-yl-propionyl)- piperidin-4-yl]-3-( l ,2,3,4-tetrahydro-quinolin-3-yl)-butyric acid,
(35,3'/?)-4-[ l-(3-5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2-yl-propionyl)- piperidin-4-yl]-3-( l ,2,3,4-tetrahydro-quinoIin-3-yl)-butyric acid methyl ester,
(35,3 'S)-4-[l -(3-5, 6,7, 8-tetrahydro-[ l ,8]naphthyridin-2-yl-propionyl)-piperidin- 4-yl]-3-( 1 ,2,3,4-tetrahydro-quinolin-3-yl)-butyric acid,
(3S,3'5)-4-[ I -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl-propionyl)-piperidin- 4-yl]-3-(l ,2,3,4-tetrahydro-quinolin-3-yl)-butyric acid methyl ester,
4-[ 1 -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-3- ( l ,2,3,4-tetrahydro-quinolin-3-yl)-butyric acid methyl ester, β-( 1 ,3-benzodioxol-5-yl)- 1 -[ 1 -oxo-3-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2- yl)propyl]-4-piperidinepentanoic acid,
3-benzo[ 1 ,3]dioxol-5-yl-5-[ 1 -(3-5,6,7, 8-tetrahydro-[ 1 ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-pentanoic acid methyl ester,
6-methoxy-β-[2-[ 1 -[ 1 -oxo-3-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2-y l)propy I]- 4-piperidinyl]ethyl]-3-pyridinepropanoic acid,
3-(6-methoxy-pyridin-3-yl)-5-[l -(3-5,6,7,8-tetrahydro-[l ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-pentanoic acid methyl ester,
(35r*)-3-(6-methoxy-pyridin-3-yl)-5-[ I -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin- 2-yl-propionyl)-piperidin-4-yl]-pentanoic acid,
(3/?*)-3-(6-methoxy-pyridin-3-yl)-5-[l -(3-5,6,7,8-tetrahydro-[l ,8]naphthyridin- 2-yl-propionyl)-piperidin-4-yl]-pentanoic acid, β-[2-[ l -[l -oxo-4-(2-pyridinylamino)butyl]-4-piperidinyl]ethyl]-3- quinolinepropanoic acid,
5-{ l -[4-(pyridin-2-ylamino)-butyryl]-piperidin-4-yl}-3-quinolin-3-yl-pentanoic acid methyl ester, β-( l ,3-benzodioxol-5-yl)-l -[l -oxo-4-(2-pyridinylamino)butyl]-4- piperidinepentanoic acid,
3-benzo[ l ,3]dioxol-5-yl-5-{ l -[4-(pyridin-2-ylamino)-butyryl]-piperidin-4-yl}- pentanoic acid methyl ester, β-( l ,3-benzodioxol-5-yl)-l -[ l -oxo-4-(2-pyridinylamino)butyl]-4- piperidinepropanoic acid, 3-benzo[ l ,3]dioxol-5-yl-3-{ l -[4-(pyridin-2-ylamino)-butyryl]-piperidin-4-yl}- propionic acid methyl ester,
6-methoxy-β-[2-[ l-[ l -oxo-4-(2-pyridinylamino)butyl]-4-piperidinyl]ethyl]-3- pyridinepropanoic acid,
3-(6-methoxy-pyridin-3-yl)-5-{ l-[4-(pyridin-2-ylamino)-butyryl]-piperidin-4- yl}-pentanoic acid methyl ester, β-( 1 ,3-benzodioxol-5-yl)- 1 -[ 1 -oxo-4-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2- yl)butyl]-4-piperidinebutanoic acid,
3-benzo[ 1 ,3]dioxol-5-yl-4-[ I -(4-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl- butyryl)-piperidin-4-yl]-butyric acid methyl ester, β-( 1 ,3-benzodioxol-5-yl)- 1 -[3-[( 1 ,4,5,6-tetrahydro-5-hydroxy-2- pyrimidinyl)amino]benzoyl]-4-piperidinebutanoic acid,
3-benzo[l ,3]dioxol-5-yl-4-{ l -[3-(5-hydroxy-l ,4,5,6-tetrahydro-pyrimidin-2- ylamino)-benzoyl]-piperidin-4-yl}-butyric acid methyl ester,
6-methoxy-β-[[ 1 -[ 1 -oxo-3-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2-yl)propy l]-4- piperidinyl]methyl]-3-pyridinepropanoic acid,
3-(6-methoxy-pyridin-3-yl)-4-[ l -(3-5,6,7, 8-tetrahydro-[l ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid methyl ester.
(3i?*)-3-(6-methoxy-pyridin-3-yl)-4-[l -(3-5,6,7,8-tetrahydro-[l ,8]naphthyridin- 2-yl-propionyl)-piperidin-4-yl]-butyric acid,
(35'*)-3-(6-methoxy-pyridin-3-yl)-4-[ l -(3-5,6,7,8-tetrahydro-[l ,8]naphthyridin- 2-yl-propionyl)-piperidin-4-yl]-butyric acid, β-[[ 1 -[ 1 -oxo-4-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2-yl)butyl]-4- piperidinyl]methyl]-3-quinolinepropanoic acid,
3-quinolin-3-yl-4-[ l -(4-5,6,7,8-tetrahydro-[l ,8]naphthyridin-2-yl-butyryl)- piperidin-4-yl]-butyric acid methyl ester, β-(3-fluorophenyl)-l -[ l -oxo-3-(5,6,7,8-tetrahydro-l ,8-naphthyridin-2- yl)propyl]-4-piperidinebutanoic acid,
3-(3-fluoro-phenyl)-4-[ ] -(3-5,6,7, 8-tetrahydro-[ 1 ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid methyl ester,
(3/?*)-3-(3-fluoro-phenyl)-4-[l -(3-5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid,
(35*)-3-(3-fluoro-phenyl)-4-[ 1 -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid, β-(3-fluorophenyl)-l -[ l -oxo-4-(5,6,7,8-tetrahydro-l ,8-naphthyridin-2-yl)butyl]- 4-piperidinebutanoic acid, 3-(3-fluoro-phenyl)-4-[ l -(4-5,6,7,8-tetrahydro-[l ,8]naphthyridin-2-yl-butyryl)- piperidin-4-yl]-butyric acid methyl ester, β-[[ 1 -[ 1 -oxo-3-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2-yl)propy l]-4- piperidinyl]methyl]-3-quinolinepropanoic acid,
3-quinolin-3-yl-4-[ 1 -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl-propionyl)- piperidin-4-yl]-butyric acid methyl ester, β-(4-fluorophenyl)- 1 -[ 1 -oxo-3-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2- yl)propyl]-4-piperidinebutanoic acid,
3-(4-fluoro-phenyl)-4-[l -(3-5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid methyl ester, β-(4-f!uorophenyl)- 1 -[ 1 -oxo-4-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2-yl)butyl]- 4-piperidinebutanoic acid,
3-(4-fluoro-phenyl)-4-[ l -(4-5,6,7, 8-tetrahydro-[ l ,8]naphthyridin-2-yl-butyryl)- piperidin-4-yl]-butyric acid methyl ester,
2-methyl-β-[[ l-[l -oxo-3-(5,6,7,8-tetrahydro-l ,8-naphthyridin-2-yl)propyl]-4- piperidinyl]methyl]-5-pyrimidinepropanoic acid,
3-(2-methyl-pyrimidin-5-yl)-4-[ ] -(3-5,6,7, 8-tetrahydro-[l ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid methyl ester, β-(2,3-dihydro-6-benzofuranyl)- 1 -[ 1 -oxo-3-(5,6,7,8-tetrahydro- 1 ,8- naphthyridin-2-yl)propyl]-4-piperidinebυtanoic acid,
3-(2,3-dihydro-benzofuran-6-yl)-4-[ 1 -(3-5,6,7,8-tetrahydro-[l ,8]naphthyridin- 2-yl-propionyl)-piperidin-4-yl]-butyric acid methyl ester,
(S^^S^^-dihydro-benzofuran-o-yO^-tl^S-S^J^-tetrahydro- [ 1 ,8]naphthyπdin-2-yl-propionyl)-piperidin-4-yl]-butyric acid,
(3tf*)-3-(2,3-dihydro-benzofuran-6-yl)-4-[ l -(3-5,6,7,8-tetrahydro- [ 1 ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-bιιtyric acid, β-(3,5-difluorophenyl)-l -[ l -oxo-3-(5,6,7,8-tetrahydro-l ,8-naphthyridin-2- yl)propyl]-4-piperidinebutanoic acid,
3-(3,5-difluoro-phenyl)-4-[ 1 -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid methyl ester, β-(3,5-difluorophenyl)-l -[l -oxo-4-(5,6,7,8-tetrahydro-l ,8-naphthyridin-2- yl)butyl]-4-piperidinebutanoic acid,
3-(3,5-difluoro-phenyl)-4-[l-(4-5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2-yl- butyryl)-piperidin-4-yl]-butyric acid methyl ester,
1 -[ 1 -oxo-3-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2-yl)propyl]-β-[3- (trifluoromethyl)phenyl]-4-piperidinebutanoic acid, 4-[ 1 -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-3- (3-trifluoromethyl-phenyl)-butyric acid methyl ester, l -[ l -oxo-3-(5,6,7,8-tetrahydro-l ,8-naphthyridin-2-yl)propyl]-β-[4- (trifluoromethoxy)phenyl]-4-piperidinebutanoic acid,
4-[ l -(3-5,6,7,8-tetrahydro-[l ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-3- (4-trifluoromethoxy-phenyl)-butyric acid methyl ester, β-(2-fluoro[ 1 , 1 '-biphenyl]-4-yl)- 1 -[ 1 -oxo-3-(5,6,7,8-tetrahydro- 1 ,8- naphthyridin-2-yl)propyl]-4-piperidinebutanoic acid,
3-(2-fluoro-biphenyl-4-yl)-4-[l -(3-5,6,7, 8-tetrahydro-[l ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid methyl ester, β-(3-fluoro-4-methoxyphenyl)-l -[ l -oxo-3-(5,6,7,8-tetrahydro-l ,8-naphthyridin- 2-yl)propyl]-4-piperidinebutanoic acid,
3-(3-fluoro-4-methoxy-phenyl)-4-[l -(3-5,6,7, 8-tetrahydro-[l ,8]naphthyridin-2- yl-propionyl)-piperidin-4-yl]-butyric acid methyl ester, l -[ l -oxo-3-(5,6,7,8-tetrahydro-l ,8-naphthyridin-2-yl)propyl]-β-(4- phenoxyphenyl)-4-piperidinebutanoic acid,
3-(4-phenoxy-phenyl)-4-[ l-(3-5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid methyl ester, β-[[ l-[ l -oxo-3-(5,6,7,8-tetrahydro-l ,8-naphthyridin-2-yl)propyl]-4- piperidinyl]methyl]-4-isoquinolinepropanoic acid,
3-isoqui noli n-4-yl-4-[l -(3-5, 6,7, 8-tetrahydro-[ 1 ,8] naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid methyl ester, β-[[l -[ l -oxo-3-(5,6,7,8-tetrahydro-l ,8-naphthyridin-2-yl)propyl]-4- piperidinyl]methyl]-3-pyridinepropanoic acid,
3-pyridin-3-yl-4-[ 1 -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl-propionyl)- piperidin-4-yl]-butyric acid methyl ester, β-(2,3-dihydro-5-benzofuranyl)-l-[ l -oxo-3-(5,6,7,8-tetrahydro-l ,8- naphthyridin-2-yl)propyl]-4-piperidinebutanoic acid,
3-(2,3-dihydro-benzofuran-5-yl)-4-[ 1 -(3-5,6,7, 8-tetrahydro-[ 1 ,8]naphthyridin- 2-yl-propionyl)-piperidin-4-yl]-butyric acid methyl ester,
2,4-dimethoxy-β-[[ l -[l -oxo-3-(5,6,7,8-tetrahydro-l ,8-naphthyridin-2- yl)propyl]-4-piperidinyl]methyl]-5-pyrimidinepropanoic acid,
3-(2,4-dimethoxy-pyrimidin-5-yl)-4-[ l -(3-5,6,7,8-tetrahydro-[l ,8]naphthyridin- 2-yl-propionyl)-piperidin-4-yl]-butyric acid methyl ester,
2-methoxy-β-[[ I -[ I -oxo-3-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2-yl)propyl]-4- piperidinyl]methyl]-5-pyrimidinepropanoic acid, 3-(2-methoxy-pyrimidin-5-yl)-4-[ I -(3-5,6,7, 8-tetrahydro-[ 1 ,8]naphthyridin-2- yl-propionyl)-piperidin-4-yl]-butyric acid methyl ester, β-[2-[ l -[3-[( l ,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]-4- piperidinyl]ethyl]-3-quinolinepropanoic acid,
5-{ 1 -[3-(5-hydroxy- 1 ,4,5,6-tetrahydro-pyrimidin-2-ylamino)-benzoyl]- piperidin-4-yl}-3-quinolin-3-yl-pentanoic acid methyl ester, β-[2-[ 1 -[3-[(3,4,5,6-tetrahydro-2-pyridinyl)amino]benzoyl]-4- piperidinyl]ethyl]-3-quinolinepropanoic acid,
3-quinolin-3-yl-5-{ l -[3-(3,4,5,6-tetrahydro-pyridin-2-ylamino)-benzoyl]- piperidin-4-yl}-pentanoic acid methyl ester, β-[2-[ 1 -[ 1 -oxo-3-(5,6,7,8-tetrahydro-l ,8-naphthyridin-2-yl)propyl)-4- piperidinyl]ethyl]-3-quinolinepropanoic acid,
3-quinolin-3-yl-5-[l -(3-5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2-yl-propionyl)- piperidin-4-yl]-pentanoic acid methyl ester, β-[2-[ 1 -[ 1 -oxo-3-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2-yl)propyl]-4- piperidinyl]ethyl]-3-quinolinepropanoic acid,
3-quinolin-3-yl-5-[l -(3-5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2-yl-propionyl)-- piperidin-4-yl]-pentanoic acid methyl ester, β-( 1 ,3-benzodioxol-5-yl)- 1 -[3-[(3,4,5,6-tetrahydro-2-pyridinyl)amino]benzoyl]- 4-piperidinepentanoic acid,
3-benzo[ l ,3]dioxol-5-yl-5-{ l -[3-(3,4,5,6-tetrahydro-pyridin-2-ylamino)- benzoyl]-piperidin-4-yl }-pentanoic acid methyl ester, β-( l ,3-benzodioxol-5-yl)-l -[3-[(l ,4,5,6-tetrahydro-5-hydroxy-2- pyrimidinyl)amino]benzoyl]-4-piperidinepentanoic acid,
3-benzo[ 1 ,3]dioxol-5-yl-5-{ I -[3-(5-hydroxy- 1 ,4,5,6-tetrahydro-pyrimidin-2- ylamino)-benzoyl]-piperidin-4-yl}-pentanoic acid methyl ester, β-( l ,3-benzodioxol-5-yl)-l -[(5,6,7,8-tetrahydro-l ,8-naphthyridin-2-yl)acetyl]- 4-piperidinepentanoic acid,
3-benzo[ l ,3]dioxol-5-yl-5-[l-(2-5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2-yl- acetyl)-piperidin-4-yl]-pentanoic acid methyl ester, β-(2-naphthalenyl)- 1 -[ 1 -oxo-3-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2- yl)propyl]-4-piperidinebutanoic acid,
3-naphthalen-2-yl-4-[ 1 -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl-propionyl)- piperidin-4-yl]-butyric acid methyl ester,
(3S'*)-3-naphthalen-2-yl-4-[ 1 -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid, (3Λ*)-3-naphthalen-2-yl-4-[ l -(3-5,6,7,8-tetrahydro-[1 ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid,
3-[ 1 -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-4- (5,6,7,8-tetrahydro-quinolin-3-yl)-butyric acid,
3-[ 1 -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-4- (5,6,7,8-tetrahydro-quinolin-3-yl)-butyric acid methyl ester,
5,6,7,8-tetrahydro-β-[ I -[ 1 -oxo-4-(5,6,7;8-tetrahydro- 1 ,8-naphthyridin-2- yl)butyl]-4-piperidinyl]-3-quinolinepropanoic acid,
5,6,7,8-tetrahydro-β-[ 1 -[ 1 -oxo-4-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2- yl)butyl]-4-piperidinyl]-3-quinolinepropanoic acid,
5,6,7,8-tetrahydro-β-[ I -[ 1 -oxo-4-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2- yl)butyl]-4-piperidinyl]-3-quinolinepropanoic acid,
3-[l -(4-5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2-yl-butyryl)-piperidin-4-yl]-3- (5,6,7,8-tetrahydro-quinolin-3-yl)-propionic acid methyl ester,
3-(3-methoxy-phenyl)-4-[ 1 -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid,
3-(3-methoxy-phenyl)-4-[ 1 -(3-5,6,7, 8-tetrahydro-[ 1 ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid methyl ester,
3-(4-methoxy-phenyl)-4-[ 1 -(3-5,6,7, 8-tetrahydro-[ 1 ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid,
3-(4-methoxy-phenyl)-4-[ l -(3-5,6,7, 8-tetrahydro-[ 1 , 8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid methyl ester,
3-(tetrahydro-furan-3-yl)-4-[l -(3-5,6,7, 8-tetrahydro-[ l ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid,
3-(tetrahydro-furan-3-yl)-4-[l -(3-5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid methyl ester,
4-[ 1 -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-3- thiophen-2-yl-butyric acid,
4-[ l-(3-5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-3- thiophen-2-yl-butyric acid methyl ester,
3-(2,3-dihydro-benzo[ l ,4]dioxin-6-yl)-4-[ l-(3-5,6,7,8-tetrahydro- [ 1 ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-butyric acid,
3-(2,3-dihydro-benzo[ l ,4]dioxin-6-yl)-4-[l -(3-5,6,7,8-tetrahydro- [ l ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-butyric acid methyl ester,
3-(3-methylsulfanyl-phenyl)-4-[l -(3-5,6,7, 8-tetrahydro-[ l , 8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid, 3-(3-methylsulfanyl-phenyl)-4-[ 1 -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid methyl ester, jV-methy I- 1 ,2,3,4-tetrahydro-β-[[ 1 -[ 1 -oxo-3-(5,6,7,8-tetrahydro- 1 ,8- naphthyridin-2-yl)propyl]-4-piperidinyl]methyl]-3-quinolinepropanoic acid,
3-( 1 -methyl- 1 ,2,3,4-tetrahydro-quinolin-3-yl)-4-[ 1 -(3-5,6,7, 8-tetrahydro- [ l ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-butyric acid methyl ester,
3-(3-dimemylamino-phenyl)-4-[ l -(3-5,6,7,8-tetrahydro-[l ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid,
3-(3-dimethylamino-phenyl)-4-[l -(3-5,6,7,8-tetrahydro-[l ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid methyl ester,
3-(4-hydroxy-3-methoxy-phenyl)-4-[ 1 -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin- 2-yl-propionyl)-piperidin-4-yl]-butyric acid,
3-(4-hydroxy-3-methoxy-phenyl)-4-[ 1 -(3-5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin- 2-yl-propionyl)-piperidin-4-yl]-butyric acid methyl ester,
(3S*)-3-(4-hydroxy-3-methoxy-phenyl)-4-[ l-(3-5,6,7,8-tetrahydro- [ 1 ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-butyric acid,
4-{ l -[3-(4,5-dihydro-l H-imidazol-2-ylamino)-benzoyl]-piperidin-4-yl}-3-(3- fluoro-phenyl)-butyric acid,
4-{ l -[3-(4,5-dihydro-l H-imidazol-2-ylamino)-benzoyl]-piperidin-4-yl}-3-(3- fluoro-phenyl)-butyric acid methyl ester,
3-(3-ethylamino-phenyl)-4-[ 1 -(3-5,6,7, 8-tetrahydro-[ 1 ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-bυtyric acid,
3-(3-ethylamino-phenyl)-4-[l -(3-5,6,7, 8-tetrahydro-[l ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid methyl ester,
3-(3-methylamino-phenyl)-4-[l -(3-5,6,7,8-tetrahydro-[l ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid,
3-(3-methylamino-phenyl)-4-[l -(3-5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2-yl- propionyl)-piperidin-4-yl]-butyric acid methyl ester,
3-(2,3-dihydro-benzofuran-6-yl)-3-[l -(4-5,6,7,8-tetrahydro-[l ,8]naphthyridin- 2-yl-butyryl)-piperidin-4-yl]-propionic acid,
3-(2,3-dihydro-benzofuran-6-yl)-3-[l-(4-5,6,7,8-tetrahydro-[ l ,8]naphthyridin- 2-yl-butyryl)-piperidin-4-yl]-propionic acid methyl ester,
3-(3-fluoro-phenyl)-4-{ 1 -[3-(5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl)- propyl]-piperidin-4-yl}-butyric acid,
3-(3-fluoro-phenyl)-4-{ 1 -[3-(5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl)- propyl]-piperidin-4-yl}-butyric acid methyl ester, 3-(2,3-dihydro-benzofuran-6-yl)-3-[ l -4-(5,6,7,8-tetrahydro-l ,8-naphthyridin-2- yl)butyl]-4-piperidinyl]-propanoic acid,
3-(2,3-dihydro-benzofuran-6-yl)-3-[ 1 -4-(5,6,7,8-tetrahydro- 1 ,8-naphthyridin-2- yl)butyl]-4-piperidinyl]-propanoic acid methyl ester,
3-{4-[2-(2-bromo-ethoxy)-ethoxy]-3-methoxy-phenyl}-4-[ l -(3-5,6,7,8- tetrahydro-[l ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-butyric acid,
3-{4-[2-(2-bromo-ethoxy)-ethoxy]-3-methoxy-phenyl}-4-[ l -(3-5,6,7,8- tetrahydro-[l ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-butyric acid methyl ester,
3-{4-[2-(2-acetylsulfanyl-ethoxy)-ethoxy]-3-methoxy-phenyl}-4-[l -(3-5,6,7,8- tetrahydro-[l ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-butyric acid,
3-{4-[2-(2-acetylsulfanyl-ethoxy)-ethoxy]-3-methoxy-phenyl}-4-[l-(3-5,6,7,8- tetrahydro-[l ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-butyric acid methyl ester,
3-{4-[2-(2-mercapto-ethoxy)-ethoxy]-3-methoxy-phenyl) -4-[ l -(3-5,6,7,8- tetrahydro-[l ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-butyric acid,
3-{4-[2-(2-mercapto-ethoxy)-ethoxy]-3-methoxy-phenyl}-4-[l -(3-5,6,7,8- tetrahydro-[l ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-butyric acid methyl ester,
3-(4- {2-[2-(2-chloro-ethoxy)-ethoxy]-ethoxy}-3-methoxy-phenyl)-4-[l -(3-
5,6,7,8-tetrahydro-[l ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-butyric acid,
3-(4-{2-[2-(2-chloro-ethoxy)-ethoxy]-ethoxy}-3-methoxy-phenyl)-4-[ l -(3- 5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-butyric acid methyl ester,
3-(4-{2-[2-(2-mercapto-ethoxy)-ethoxy]-ethoxy}-3-methoxy-phenyl)-4-[ l-(3-
5,6,7,8-tetrahydro-[ l,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-butyric acid,
3-(4-{2-[2-(2-mercapto-ethoxy)-ethoxy]-ethoxy}-3-methoxy-phenyl)-4-[ l-(3- 5,6,7,8-tetrahydro-[ ] ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-butyric acid methyl ester,
3-(4-{2-[2-(2-acetylsulfanyl-ethoxy)-ethoxy]-ethoxy}-3-methoxy-phenyl)-4-[ l - (3-5,6,7,8-tetrahydro-[l ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-butyric acid methyl ester, and
3-(4-{2-[2-(2-acetylsulfanyl-ethoxy)-ethoxy]-ethoxy}-3-methoxy-phenyl)-4-[ l-
(3-5,6,7,8-tetrahydro-[l ,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-butyric acid.
27. A Compound Al of claim 1 selected from the group consisting of:
(Z)-4-(3-methoxycarbonyl-2-quinolin-3-yl-allyl)-piperidine- l -carboxylic acid tert-butyl ester, and
(Z)-4-(3-carboxy-2-quinolin-3-yl-allyl)-piperidine- 1 -carboxylic acid tert-butyl ester.
28. A process for preparing the (Z)-4-(3-methoxycarbonyl-2-quinolin-3-yl-allyl)- piperidine-1 -carboxylic acid tert-butyl ester of Claim 27, comprising the steps: Step 1 . reacting a first mixture of a Compound Fl and carbonyl diimidazole in tetrahydrofuran;
Step 2. reacting the first mixture with the potassium salt of methyl malonate and MgCh in tetrahydrofuran to provide a Compound F2:
Figure imgf000205_0001
Step 3. reacting Compound F2 with trifluoromethanesulfonic anhydride in a
I O second mixture with sodium hydride and yV,N-diisopropylethylamine in toluene to provide a (Z)-isomer Compound F3:
Figure imgf000205_0002
Step 4. reacting Compound F3 with quinoline-3-boronic acid and bistriphenylphosphine palladium dichloride in a third mixture with 2 M Na2CO3 in tetrahydrofuran to provide (Z)-4-(3-methoxycarbonyl-2- quinolin-3-yl-allyl)-piperidtne- 1 -carboxylic acid tert-butyl ester:
Figure imgf000206_0001
PCT/US2008/012294 2007-10-30 2008-10-30 Enantioselective process for preparing a substituted alkanoic acid WO2009058314A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA2703876A CA2703876A1 (en) 2007-10-30 2008-10-30 Enantioselective process for preparing a substituted alkanoic acid
EP08846194.2A EP2217569B1 (en) 2007-10-30 2008-10-30 Enantioselective process for preparing a substituted alkanoic acid
ES08846194.2T ES2474165T3 (en) 2007-10-30 2008-10-30 Enantioselective process to prepare a substituted alkanoic acid
JP2010532054A JP2011519340A (en) 2007-10-30 2008-10-30 Enantioselective Process for the Preparation of Substituted Alkanoic Acids This US Patent Regular Application is filed on US Patent Provisional Application No. 61 / 001,004 filed October 30, 2007, and filed February 29, 2008. Claims the right to US Provisional Patent Application No. 61 / 067,842.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US100407P 2007-10-30 2007-10-30
US61/001,004 2007-10-30
US6784208P 2008-02-29 2008-02-29
US61/067,842 2008-02-29

Publications (1)

Publication Number Publication Date
WO2009058314A1 true WO2009058314A1 (en) 2009-05-07

Family

ID=40591362

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/012294 WO2009058314A1 (en) 2007-10-30 2008-10-30 Enantioselective process for preparing a substituted alkanoic acid

Country Status (6)

Country Link
US (1) US8680278B2 (en)
EP (1) EP2217569B1 (en)
JP (1) JP2011519340A (en)
CA (1) CA2703876A1 (en)
ES (1) ES2474165T3 (en)
WO (1) WO2009058314A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105061263A (en) * 2015-08-11 2015-11-18 苏州楚凯药业有限公司 Preparation method of NEP (neutral endopeptidase) inhibitor intermediate
US10875848B2 (en) 2018-10-10 2020-12-29 Forma Therapeutics, Inc. Inhibiting fatty acid synthase (FASN)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0060717A1 (en) * 1981-03-17 1982-09-22 BP Chemicals Limited Process for the production of methyl acetate by esterifying methanol with acetic acid
US20040077684A1 (en) 2002-08-16 2004-04-22 Bart De Corte Piperidinyl compounds that selectively bind integrins
US20040224986A1 (en) * 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465664B1 (en) * 1999-09-15 2002-10-15 Massachusetts Institute Of Technology Asymmetric 1,4-reductions of and 1,4-additions to enoates and related systems
TW200602293A (en) * 2004-04-05 2006-01-16 Merck & Co Inc Process for the preparation of enantiomerically enriched beta amino acid derivatives
JP2008505163A (en) * 2004-07-05 2008-02-21 ソルヴィーアス　アクチェンゲゼルシャフト 1,1-diphosphinoferrocene having an achiral or chiral group at the 2,2 'position
DE602006017064D1 (en) * 2005-05-20 2010-11-04 Reddy S Lab Eu Ltd Dr ASYMMETRIC HYDROGENATION FOR THE PREPARATION OF DIPHENYL ALANINE DERIVATIVES

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0060717A1 (en) * 1981-03-17 1982-09-22 BP Chemicals Limited Process for the production of methyl acetate by esterifying methanol with acetic acid
US20040077684A1 (en) 2002-08-16 2004-04-22 Bart De Corte Piperidinyl compounds that selectively bind integrins
US20040224986A1 (en) * 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHURCH T.L. ET AL.: "Iridium Catalysts for the Asymmetric Hydrogenation of Olefins with Nontraditional Functional Substituents", COORD CHEM REV, vol. 252, 25 September 2007 (2007-09-25), pages 513 - 531, XP022500953 *
DE CORTE BL; KINNEY WA; LIU L, GHOSH S; BRUNNER L; HOEKSTRA WJ; SANTULLI RJ; TUMAN RW; BAKER J; BUMS C; PROOST JC, BIOORG. MED. CHEM. LETT., vol. 14, 2004, pages 5227
SCHREMS M.G. ET AL.: "Iridium-Catalyzed Asymmetric Hydrogenation of Unfunctionalized Tetrasubstituted Olefins", ANGEW. CHEM. INT. ED., vol. 46, 21 September 2007 (2007-09-21), pages 8274 - 8276, XP008135942 *
See also references of EP2217569A4 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105061263A (en) * 2015-08-11 2015-11-18 苏州楚凯药业有限公司 Preparation method of NEP (neutral endopeptidase) inhibitor intermediate
CN105061263B (en) * 2015-08-11 2017-03-15 苏州楚凯药业有限公司 A kind of preparation method of nep inhibitor intermediate
US10875848B2 (en) 2018-10-10 2020-12-29 Forma Therapeutics, Inc. Inhibiting fatty acid synthase (FASN)
US11299484B2 (en) 2018-10-10 2022-04-12 Forma Therapeutics, Inc. Inhibiting fatty acid synthase (FASN)

Also Published As

Publication number Publication date
ES2474165T3 (en) 2014-07-08
US8680278B2 (en) 2014-03-25
CA2703876A1 (en) 2009-05-07
EP2217569B1 (en) 2014-04-16
EP2217569A1 (en) 2010-08-18
JP2011519340A (en) 2011-07-07
US20090124804A1 (en) 2009-05-14
EP2217569A4 (en) 2012-04-25

Similar Documents

Publication Publication Date Title
JP7121794B2 (en) Process for preparing pyrrolidine compounds
JP5279789B2 (en) Method for producing chiral propionic acid derivative
EP2029541B1 (en) Process for preparation of enantiomerically enriched cyclic beta-aryl or heteroaryl carboxylic acids
JP3878703B2 (en) Chiral ruthenium complex, process for its preparation, and process for enantioselective transfer hydrogenation of prochiral ketones
CN114315917A (en) Chiral ferrocene PNNO tetradentate ligand and application thereof in asymmetric hydrogenation reaction
JP5372771B2 (en) process
WO2009058314A1 (en) Enantioselective process for preparing a substituted alkanoic acid
DK2958893T3 (en) Asymmetric synthesis of a substituted pyrrolidine-2-carboxamide
Fabra et al. Surface-enhanced stereoselectivity in Mukaiyama aldol reactions catalyzed by clay-supported bis (oxazoline)–copper complexes
KR100306964B1 (en) Process for producing an optically active diamine hexanone derivative
JP4703925B2 (en) Electronically tuned ligand
MX2007007820A (en) Process for transition metal-catalyzed asymmetric hydrogenation of acrylic acid derivatives, and a novel catalyst system for asymmetric transition metal catalysis.
JP2008169201A (en) Novel optically biaryl phosphorus compound and method for producing the same
JP4861317B2 (en) A method for producing an enantiomer of a 2,3-diaminopropionic acid derivative.
WO2011018445A2 (en) Process for the preparation of (r)-2-phenyl propionic acid derivatives
JP2002508345A (en) Asymmetric hydrogenation
CN108290910A (en) N, N- bis- (2- dialkyl phosphines ethyl) amine-borane complex and its manufacturing methods and using the amine as the manufacturing method of the ruthenium complex of ligand
CN110357923B (en) Diaminodiphosphine tetradentate ligand, ruthenium complex thereof, and preparation methods and applications of diamido diphosphine tetradentate ligand and ruthenium complex
US6414187B1 (en) Asymmetric hydrogenation
WO2009030626A1 (en) New phosphine-phosphite ligands
León García et al. Double asymmetric hydrogenation of conjugated dienes: a self-breeding chirality route for C2 symmetric 1, 4-diols
US7015320B2 (en) Process for the manufacture of optically active 3-substituted lactams by asymmetric hydrogenation of 3-alkylidenelactams
CN114426511A (en) Method for preparing chiral spiro [2.4] heptane compounds through palladium-catalyzed asymmetric cycloaddition reaction
CN113717092A (en) Preparation method of trifluoromethyl-containing 3-substituted-2-indolinone compound
WO2009027729A1 (en) Paracyclophane-based ligands, their preparation and use in catalysis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08846194

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2703876

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010532054

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008846194

Country of ref document: EP